Title,URL,Text,POS_Tags,Named_Entities,entities,resolved_entities
Muscle loss on Ozempic: Antibody treatment may help prevent decline,https://www.medicalnewstoday.com/articles/novel-antibody-help-prevent-bone-muscle-loss-glp-1-drugs-ozempic-wegovy,"Studies suggest that weight loss induced by glucagon-like peptide-1 (GLP-1) drugs can also cause a decline in muscle mass and bone mineral density, similar to that observed in aging. A new study published in the Journal of Cachexia, Sarcopenia, and Muscle suggests that the antibody bimagrumab is effective in increasing muscle mass and bone density in a mouse model of muscle and bone loss. These findings suggest that bimagrumab could potentially help preserve not only muscle mass, as shown by previous research, but also help prevent bone loss in individuals using GLP-1 drugs for weight loss. The study’s author, Frederik Duch Bromer, a researcher at Aarhus University, Denmark, said, “Since the rise of incretin therapies like Wegovy and Mounjaro, scientists have been searching for ways to counteract the loss of muscle and bone mass often accompanying rapid weight loss. Our research shows that bimagrumab can mitigate even more severe muscle and bone loss than what typically occurs with weight loss therapies.” “As bimagrumab is now being repurposed to help preserve lean mass during weight loss, its ability to protect bone as well is especially relevant given the large number of people using these treatments,” Bromer told Medical News Today. A loss of muscle mass and a decline in bone density are common features of aging that often occur together. The loss of muscle mass and strength with aging is referred to as sarcopenia, whereas the decrease in bone mass and bone mineral density is referred to as osteoporosis. Besides old age, limited physical activity can also lead to muscle loss and osteoporosis. While medications are available for the treatment of osteoporosis, there is a lack of approved treatments for muscle loss. One of the categories of drugs currently under investigation for the treatment of muscle loss includes drugs that inhibit the activation of the activin receptor or the signaling pathway activated by this receptor. Inhibition of the activin signaling pathway leads to increased muscle mass and bone formation and enhanced blood cell formation. The antibody bimagrumab is an example of one such drug that binds to the activin receptors to inhibit the activation of the activin signaling pathway. Similar to other inhibitors of the activin signaling pathway, animal and clinical studies have shown that bimagrumab can increase muscle mass and lean body mass. The use of GLP-1 receptor agonists is associated with muscle mass loss and a decline in bone density. Currently, bimagrumab is being investigated in a clinical trial to evaluate its ability to prevent muscle loss in individuals using Wegovy, a type of GLP-1 drug. Bones and muscles not only cooperate with each other during movements, but muscles also release small proteins called myokines that impact bone health. However, it is not known whether bimagrumab can also simultaneously improve bone health along with increasing muscle mass. In the present study, researchers examined whether bimagrumab could improve bone health and increase muscle mass simultaneously. The inhibitors of the activin signaling pathway can also lead to an increase in blood cell production and potentially increase the risk of blood clots. Hence, it is essential to assess the risk of blood clots due to bimagrumab before it can be considered for preventing muscle and bone loss. In the present study, the researchers assessed the impact of bimagrumab on muscle and bone mass in healthy and immobilized mice, with the latter serving as a model of bone and muscle loss. To simulate the simultaneous loss of muscle mass and bone density, the researchers injected a group of mice with botulinum toxin into the quadriceps and the gastrocnemius, the major muscles of the hindlimb. The botulinum toxin causes paralysis of the hindlimb muscles, resulting in immobilization of the animal, followed by muscle mass loss and a decline in bone density. The healthy and immobilized mice in the bimagrumab group received two weekly antibody injections over 21 days, whereas those in the control groups received an injection of the vehicle. After 21 days, the mice in all groups were euthanized, and the muscles and bones in the right hindlimb were removed and evaluated. The researchers found that bimagrumab increased muscle mass, the size of muscle fibers, and bone mineral density in the hindlimb of both free-moving and immobilized mice. Bimagrumab also promoted new bone formation, including at the end of the thigh bone or femur, which is prone to fracture in older individuals. The scientists observed that the increase in muscle mass and bone mineral density was smaller in the immobilized mice, likely due to the potent action of botulinum toxin. Yet, these results demonstrate that bimagrumab could potentially help increase muscle mass and bone density in individuals at risk of sarcopenia and osteoporosis. The researchers also examined the impact of bimagrumab on blood cell formation at two and seven days after the injection of the antibody. Bimagrumab did not have an impact on blood cell formation or any other related factors, suggesting its safety for preserving muscle and bone mass in patients using GLP-1 drugs. However, more research and larger clinical trials will be needed to determine its effectiveness and safety. “While our study focused on a model of muscle and bone loss, it did not specifically examine bone loss related to obesity. Since weight loss drugs are mainly used by people with obesity, it is essential to explore how bimagrumab interacts with bone affected by obesity,” Bromer added.","[('Studies', 'NOUN'), ('suggest', 'VERB'), ('that', 'SCONJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('induced', 'VERB'), ('by', 'ADP'), ('glucagon', 'NOUN'), ('-', 'PUNCT'), ('like', 'ADJ'), ('peptide-1', 'PROPN'), ('(', 'PUNCT'), ('GLP-1', 'PROPN'), (')', 'PUNCT'), ('drugs', 'NOUN'), ('can', 'AUX'), ('also', 'ADV'), ('cause', 'VERB'), ('a', 'DET'), ('decline', 'NOUN'), ('in', 'ADP'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('mineral', 'NOUN'), ('density', 'NOUN'), (',', 'PUNCT'), ('similar', 'ADJ'), ('to', 'ADP'), ('that', 'PRON'), ('observed', 'VERB'), ('in', 'ADP'), ('aging', 'NOUN'), ('.', 'PUNCT'), ('A', 'DET'), ('new', 'ADJ'), ('study', 'NOUN'), ('published', 'VERB'), ('in', 'ADP'), ('the', 'DET'), ('Journal', 'PROPN'), ('of', 'ADP'), ('Cachexia', 'PROPN'), (',', 'PUNCT'), ('Sarcopenia', 'PROPN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('Muscle', 'PROPN'), ('suggests', 'VERB'), ('that', 'SCONJ'), ('the', 'DET'), ('antibody', 'NOUN'), ('bimagrumab', 'NOUN'), ('is', 'AUX'), ('effective', 'ADJ'), ('in', 'ADP'), ('increasing', 'VERB'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('density', 'NOUN'), ('in', 'ADP'), ('a', 'DET'), ('mouse', 'NOUN'), ('model', 'NOUN'), ('of', 'ADP'), ('muscle', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('These', 'DET'), ('findings', 'NOUN'), ('suggest', 'VERB'), ('that', 'SCONJ'), ('bimagrumab', 'NOUN'), ('could', 'AUX'), ('potentially', 'ADV'), ('help', 'VERB'), ('preserve', 'VERB'), ('not', 'PART'), ('only', 'ADV'), ('muscle', 'PROPN'), ('mass', 'PROPN'), (',', 'PUNCT'), ('as', 'SCONJ'), ('shown', 'VERB'), ('by', 'ADP'), ('previous', 'ADJ'), ('research', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('also', 'ADV'), ('help', 'VERB'), ('prevent', 'VERB'), ('bone', 'NOUN'), ('loss', 'NOUN'), ('in', 'ADP'), ('individuals', 'NOUN'), ('using', 'VERB'), ('GLP-1', 'PROPN'), ('drugs', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('study', 'NOUN'), ('’s', 'PART'), ('author', 'NOUN'), (',', 'PUNCT'), ('Frederik', 'PROPN'), ('Duch', 'PROPN'), ('Bromer', 'PROPN'), (',', 'PUNCT'), ('a', 'DET'), ('researcher', 'NOUN'), ('at', 'ADP'), ('Aarhus', 'PROPN'), ('University', 'PROPN'), (',', 'PUNCT'), ('Denmark', 'PROPN'), (',', 'PUNCT'), ('said', 'VERB'), (',', 'PUNCT'), ('“', 'PUNCT'), ('Since', 'SCONJ'), ('the', 'DET'), ('rise', 'NOUN'), ('of', 'ADP'), ('incretin', 'ADJ'), ('therapies', 'NOUN'), ('like', 'ADP'), ('Wegovy', 'PROPN'), ('and', 'CCONJ'), ('Mounjaro', 'PROPN'), (',', 'PUNCT'), ('scientists', 'NOUN'), ('have', 'AUX'), ('been', 'AUX'), ('searching', 'VERB'), ('for', 'ADP'), ('ways', 'NOUN'), ('to', 'PART'), ('counteract', 'VERB'), ('the', 'DET'), ('loss', 'NOUN'), ('of', 'ADP'), ('muscle', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('mass', 'NOUN'), ('often', 'ADV'), ('accompanying', 'VERB'), ('rapid', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('Our', 'PRON'), ('research', 'NOUN'), ('shows', 'VERB'), ('that', 'SCONJ'), ('bimagrumab', 'PROPN'), ('can', 'AUX'), ('mitigate', 'VERB'), ('even', 'ADV'), ('more', 'ADV'), ('severe', 'ADJ'), ('muscle', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('loss', 'NOUN'), ('than', 'ADP'), ('what', 'PRON'), ('typically', 'ADV'), ('occurs', 'VERB'), ('with', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('therapies', 'NOUN'), ('.', 'PUNCT'), ('”', 'PUNCT'), ('“', 'PUNCT'), ('As', 'SCONJ'), ('bimagrumab', 'NOUN'), ('is', 'AUX'), ('now', 'ADV'), ('being', 'AUX'), ('repurposed', 'VERB'), ('to', 'PART'), ('help', 'VERB'), ('preserve', 'VERB'), ('lean', 'ADJ'), ('mass', 'NOUN'), ('during', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('its', 'PRON'), ('ability', 'NOUN'), ('to', 'PART'), ('protect', 'VERB'), ('bone', 'NOUN'), ('as', 'ADV'), ('well', 'ADV'), ('is', 'AUX'), ('especially', 'ADV'), ('relevant', 'ADJ'), ('given', 'VERB'), ('the', 'DET'), ('large', 'ADJ'), ('number', 'NOUN'), ('of', 'ADP'), ('people', 'NOUN'), ('using', 'VERB'), ('these', 'DET'), ('treatments', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Bromer', 'PROPN'), ('told', 'VERB'), ('Medical', 'PROPN'), ('News', 'PROPN'), ('Today', 'NOUN'), ('.', 'PUNCT'), ('A', 'DET'), ('loss', 'NOUN'), ('of', 'ADP'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('a', 'DET'), ('decline', 'NOUN'), ('in', 'ADP'), ('bone', 'NOUN'), ('density', 'NOUN'), ('are', 'AUX'), ('common', 'ADJ'), ('features', 'NOUN'), ('of', 'ADP'), ('aging', 'NOUN'), ('that', 'PRON'), ('often', 'ADV'), ('occur', 'VERB'), ('together', 'ADV'), ('.', 'PUNCT'), ('The', 'DET'), ('loss', 'NOUN'), ('of', 'ADP'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('strength', 'NOUN'), ('with', 'ADP'), ('aging', 'NOUN'), ('is', 'AUX'), ('referred', 'VERB'), ('to', 'ADP'), ('as', 'ADP'), ('sarcopenia', 'PROPN'), (',', 'PUNCT'), ('whereas', 'SCONJ'), ('the', 'DET'), ('decrease', 'NOUN'), ('in', 'ADP'), ('bone', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('mineral', 'NOUN'), ('density', 'NOUN'), ('is', 'AUX'), ('referred', 'VERB'), ('to', 'ADP'), ('as', 'ADP'), ('osteoporosis', 'NOUN'), ('.', 'PUNCT'), ('Besides', 'SCONJ'), ('old', 'ADJ'), ('age', 'NOUN'), (',', 'PUNCT'), ('limited', 'ADJ'), ('physical', 'ADJ'), ('activity', 'NOUN'), ('can', 'AUX'), ('also', 'ADV'), ('lead', 'VERB'), ('to', 'ADP'), ('muscle', 'NOUN'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('osteoporosis', 'NOUN'), ('.', 'PUNCT'), ('While', 'SCONJ'), ('medications', 'NOUN'), ('are', 'AUX'), ('available', 'ADJ'), ('for', 'ADP'), ('the', 'DET'), ('treatment', 'NOUN'), ('of', 'ADP'), ('osteoporosis', 'NOUN'), (',', 'PUNCT'), ('there', 'PRON'), ('is', 'VERB'), ('a', 'DET'), ('lack', 'NOUN'), ('of', 'ADP'), ('approved', 'VERB'), ('treatments', 'NOUN'), ('for', 'ADP'), ('muscle', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('One', 'NUM'), ('of', 'ADP'), ('the', 'DET'), ('categories', 'NOUN'), ('of', 'ADP'), ('drugs', 'NOUN'), ('currently', 'ADV'), ('under', 'ADP'), ('investigation', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('treatment', 'NOUN'), ('of', 'ADP'), ('muscle', 'NOUN'), ('loss', 'NOUN'), ('includes', 'VERB'), ('drugs', 'NOUN'), ('that', 'PRON'), ('inhibit', 'VERB'), ('the', 'DET'), ('activation', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('activin', 'NOUN'), ('receptor', 'NOUN'), ('or', 'CCONJ'), ('the', 'DET'), ('signaling', 'VERB'), ('pathway', 'NOUN'), ('activated', 'VERB'), ('by', 'ADP'), ('this', 'DET'), ('receptor', 'NOUN'), ('.', 'PUNCT'), ('Inhibition', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('activin', 'NOUN'), ('signaling', 'VERB'), ('pathway', 'NOUN'), ('leads', 'VERB'), ('to', 'ADP'), ('increased', 'VERB'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('formation', 'NOUN'), ('and', 'CCONJ'), ('enhanced', 'VERB'), ('blood', 'NOUN'), ('cell', 'NOUN'), ('formation', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('antibody', 'NOUN'), ('bimagrumab', 'NOUN'), ('is', 'AUX'), ('an', 'DET'), ('example', 'NOUN'), ('of', 'ADP'), ('one', 'NUM'), ('such', 'ADJ'), ('drug', 'NOUN'), ('that', 'PRON'), ('binds', 'VERB'), ('to', 'ADP'), ('the', 'DET'), ('activin', 'NOUN'), ('receptors', 'NOUN'), ('to', 'PART'), ('inhibit', 'VERB'), ('the', 'DET'), ('activation', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('activin', 'NOUN'), ('signaling', 'VERB'), ('pathway', 'NOUN'), ('.', 'PUNCT'), ('Similar', 'ADJ'), ('to', 'ADP'), ('other', 'ADJ'), ('inhibitors', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('activin', 'NOUN'), ('signaling', 'VERB'), ('pathway', 'NOUN'), (',', 'PUNCT'), ('animal', 'NOUN'), ('and', 'CCONJ'), ('clinical', 'ADJ'), ('studies', 'NOUN'), ('have', 'AUX'), ('shown', 'VERB'), ('that', 'SCONJ'), ('bimagrumab', 'NOUN'), ('can', 'AUX'), ('increase', 'VERB'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('lean', 'ADJ'), ('body', 'NOUN'), ('mass', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('use', 'NOUN'), ('of', 'ADP'), ('GLP-1', 'PROPN'), ('receptor', 'NOUN'), ('agonists', 'NOUN'), ('is', 'AUX'), ('associated', 'VERB'), ('with', 'ADP'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('a', 'DET'), ('decline', 'NOUN'), ('in', 'ADP'), ('bone', 'NOUN'), ('density', 'NOUN'), ('.', 'PUNCT'), ('Currently', 'ADV'), (',', 'PUNCT'), ('bimagrumab', 'PROPN'), ('is', 'AUX'), ('being', 'AUX'), ('investigated', 'VERB'), ('in', 'ADP'), ('a', 'DET'), ('clinical', 'ADJ'), ('trial', 'NOUN'), ('to', 'PART'), ('evaluate', 'VERB'), ('its', 'PRON'), ('ability', 'NOUN'), ('to', 'PART'), ('prevent', 'VERB'), ('muscle', 'NOUN'), ('loss', 'NOUN'), ('in', 'ADP'), ('individuals', 'NOUN'), ('using', 'VERB'), ('Wegovy', 'PROPN'), (',', 'PUNCT'), ('a', 'DET'), ('type', 'NOUN'), ('of', 'ADP'), ('GLP-1', 'PROPN'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Bones', 'NOUN'), ('and', 'CCONJ'), ('muscles', 'NOUN'), ('not', 'PART'), ('only', 'ADV'), ('cooperate', 'VERB'), ('with', 'ADP'), ('each', 'DET'), ('other', 'ADJ'), ('during', 'ADP'), ('movements', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('muscles', 'NOUN'), ('also', 'ADV'), ('release', 'VERB'), ('small', 'ADJ'), ('proteins', 'NOUN'), ('called', 'VERB'), ('myokines', 'NOUN'), ('that', 'PRON'), ('impact', 'NOUN'), ('bone', 'NOUN'), ('health', 'NOUN'), ('.', 'PUNCT'), ('However', 'ADV'), (',', 'PUNCT'), ('it', 'PRON'), ('is', 'AUX'), ('not', 'PART'), ('known', 'VERB'), ('whether', 'SCONJ'), ('bimagrumab', 'NOUN'), ('can', 'AUX'), ('also', 'ADV'), ('simultaneously', 'ADV'), ('improve', 'VERB'), ('bone', 'NOUN'), ('health', 'NOUN'), ('along', 'ADP'), ('with', 'ADP'), ('increasing', 'VERB'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('the', 'DET'), ('present', 'ADJ'), ('study', 'NOUN'), (',', 'PUNCT'), ('researchers', 'NOUN'), ('examined', 'VERB'), ('whether', 'SCONJ'), ('bimagrumab', 'NOUN'), ('could', 'AUX'), ('improve', 'VERB'), ('bone', 'NOUN'), ('health', 'NOUN'), ('and', 'CCONJ'), ('increase', 'VERB'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('simultaneously', 'ADV'), ('.', 'PUNCT'), ('The', 'DET'), ('inhibitors', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('activin', 'NOUN'), ('signaling', 'VERB'), ('pathway', 'NOUN'), ('can', 'AUX'), ('also', 'ADV'), ('lead', 'VERB'), ('to', 'ADP'), ('an', 'DET'), ('increase', 'NOUN'), ('in', 'ADP'), ('blood', 'NOUN'), ('cell', 'NOUN'), ('production', 'NOUN'), ('and', 'CCONJ'), ('potentially', 'ADV'), ('increase', 'VERB'), ('the', 'DET'), ('risk', 'NOUN'), ('of', 'ADP'), ('blood', 'NOUN'), ('clots', 'NOUN'), ('.', 'PUNCT'), ('Hence', 'ADV'), (',', 'PUNCT'), ('it', 'PRON'), ('is', 'AUX'), ('essential', 'ADJ'), ('to', 'PART'), ('assess', 'VERB'), ('the', 'DET'), ('risk', 'NOUN'), ('of', 'ADP'), ('blood', 'NOUN'), ('clots', 'NOUN'), ('due', 'ADP'), ('to', 'ADP'), ('bimagrumab', 'NOUN'), ('before', 'SCONJ'), ('it', 'PRON'), ('can', 'AUX'), ('be', 'AUX'), ('considered', 'VERB'), ('for', 'ADP'), ('preventing', 'VERB'), ('muscle', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('the', 'DET'), ('present', 'ADJ'), ('study', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('researchers', 'NOUN'), ('assessed', 'VERB'), ('the', 'DET'), ('impact', 'NOUN'), ('of', 'ADP'), ('bimagrumab', 'NOUN'), ('on', 'ADP'), ('muscle', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('mass', 'NOUN'), ('in', 'ADP'), ('healthy', 'ADJ'), ('and', 'CCONJ'), ('immobilized', 'ADJ'), ('mice', 'NOUN'), (',', 'PUNCT'), ('with', 'ADP'), ('the', 'DET'), ('latter', 'ADJ'), ('serving', 'VERB'), ('as', 'ADP'), ('a', 'DET'), ('model', 'NOUN'), ('of', 'ADP'), ('bone', 'NOUN'), ('and', 'CCONJ'), ('muscle', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('To', 'PART'), ('simulate', 'VERB'), ('the', 'DET'), ('simultaneous', 'ADJ'), ('loss', 'NOUN'), ('of', 'ADP'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('density', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('researchers', 'NOUN'), ('injected', 'VERB'), ('a', 'DET'), ('group', 'NOUN'), ('of', 'ADP'), ('mice', 'NOUN'), ('with', 'ADP'), ('botulinum', 'ADJ'), ('toxin', 'NOUN'), ('into', 'ADP'), ('the', 'DET'), ('quadriceps', 'NOUN'), ('and', 'CCONJ'), ('the', 'DET'), ('gastrocnemius', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('major', 'ADJ'), ('muscles', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('hindlimb', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('botulinum', 'ADJ'), ('toxin', 'NOUN'), ('causes', 'VERB'), ('paralysis', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('hindlimb', 'NOUN'), ('muscles', 'NOUN'), (',', 'PUNCT'), ('resulting', 'VERB'), ('in', 'ADP'), ('immobilization', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('animal', 'NOUN'), (',', 'PUNCT'), ('followed', 'VERB'), ('by', 'ADP'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('a', 'DET'), ('decline', 'NOUN'), ('in', 'ADP'), ('bone', 'NOUN'), ('density', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('healthy', 'ADJ'), ('and', 'CCONJ'), ('immobilized', 'VERB'), ('mice', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('bimagrumab', 'NOUN'), ('group', 'NOUN'), ('received', 'VERB'), ('two', 'NUM'), ('weekly', 'ADJ'), ('antibody', 'NOUN'), ('injections', 'NOUN'), ('over', 'ADP'), ('21', 'NUM'), ('days', 'NOUN'), (',', 'PUNCT'), ('whereas', 'SCONJ'), ('those', 'PRON'), ('in', 'ADP'), ('the', 'DET'), ('control', 'NOUN'), ('groups', 'NOUN'), ('received', 'VERB'), ('an', 'DET'), ('injection', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('vehicle', 'NOUN'), ('.', 'PUNCT'), ('After', 'ADP'), ('21', 'NUM'), ('days', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('mice', 'NOUN'), ('in', 'ADP'), ('all', 'DET'), ('groups', 'NOUN'), ('were', 'AUX'), ('euthanized', 'VERB'), (',', 'PUNCT'), ('and', 'CCONJ'), ('the', 'DET'), ('muscles', 'NOUN'), ('and', 'CCONJ'), ('bones', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('right', 'ADJ'), ('hindlimb', 'NOUN'), ('were', 'AUX'), ('removed', 'VERB'), ('and', 'CCONJ'), ('evaluated', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('researchers', 'NOUN'), ('found', 'VERB'), ('that', 'SCONJ'), ('bimagrumab', 'PROPN'), ('increased', 'PROPN'), ('muscle', 'PROPN'), ('mass', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('size', 'NOUN'), ('of', 'ADP'), ('muscle', 'NOUN'), ('fibers', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('mineral', 'NOUN'), ('density', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('hindlimb', 'NOUN'), ('of', 'ADP'), ('both', 'DET'), ('free', 'ADV'), ('-', 'PUNCT'), ('moving', 'VERB'), ('and', 'CCONJ'), ('immobilized', 'VERB'), ('mice', 'NOUN'), ('.', 'PUNCT'), ('Bimagrumab', 'PROPN'), ('also', 'ADV'), ('promoted', 'VERB'), ('new', 'ADJ'), ('bone', 'NOUN'), ('formation', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('at', 'ADP'), ('the', 'DET'), ('end', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('thigh', 'NOUN'), ('bone', 'NOUN'), ('or', 'CCONJ'), ('femur', 'NOUN'), (',', 'PUNCT'), ('which', 'PRON'), ('is', 'AUX'), ('prone', 'ADJ'), ('to', 'PART'), ('fracture', 'VERB'), ('in', 'ADP'), ('older', 'ADJ'), ('individuals', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('scientists', 'NOUN'), ('observed', 'VERB'), ('that', 'SCONJ'), ('the', 'DET'), ('increase', 'NOUN'), ('in', 'ADP'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('mineral', 'NOUN'), ('density', 'NOUN'), ('was', 'AUX'), ('smaller', 'ADJ'), ('in', 'ADP'), ('the', 'DET'), ('immobilized', 'ADJ'), ('mice', 'NOUN'), (',', 'PUNCT'), ('likely', 'ADJ'), ('due', 'ADP'), ('to', 'ADP'), ('the', 'DET'), ('potent', 'ADJ'), ('action', 'NOUN'), ('of', 'ADP'), ('botulinum', 'ADJ'), ('toxin', 'NOUN'), ('.', 'PUNCT'), ('Yet', 'ADV'), (',', 'PUNCT'), ('these', 'DET'), ('results', 'NOUN'), ('demonstrate', 'VERB'), ('that', 'SCONJ'), ('bimagrumab', 'NOUN'), ('could', 'AUX'), ('potentially', 'ADV'), ('help', 'VERB'), ('increase', 'VERB'), ('muscle', 'NOUN'), ('mass', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('density', 'NOUN'), ('in', 'ADP'), ('individuals', 'NOUN'), ('at', 'ADP'), ('risk', 'NOUN'), ('of', 'ADP'), ('sarcopenia', 'PROPN'), ('and', 'CCONJ'), ('osteoporosis', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('researchers', 'NOUN'), ('also', 'ADV'), ('examined', 'VERB'), ('the', 'DET'), ('impact', 'NOUN'), ('of', 'ADP'), ('bimagrumab', 'NOUN'), ('on', 'ADP'), ('blood', 'NOUN'), ('cell', 'NOUN'), ('formation', 'NOUN'), ('at', 'ADP'), ('two', 'NUM'), ('and', 'CCONJ'), ('seven', 'NUM'), ('days', 'NOUN'), ('after', 'ADP'), ('the', 'DET'), ('injection', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('antibody', 'NOUN'), ('.', 'PUNCT'), ('Bimagrumab', 'PROPN'), ('did', 'AUX'), ('not', 'PART'), ('have', 'VERB'), ('an', 'DET'), ('impact', 'NOUN'), ('on', 'ADP'), ('blood', 'NOUN'), ('cell', 'NOUN'), ('formation', 'NOUN'), ('or', 'CCONJ'), ('any', 'DET'), ('other', 'ADJ'), ('related', 'ADJ'), ('factors', 'NOUN'), (',', 'PUNCT'), ('suggesting', 'VERB'), ('its', 'PRON'), ('safety', 'NOUN'), ('for', 'ADP'), ('preserving', 'VERB'), ('muscle', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('mass', 'NOUN'), ('in', 'ADP'), ('patients', 'NOUN'), ('using', 'VERB'), ('GLP-1', 'PROPN'), ('drugs', 'NOUN'), ('.', 'PUNCT'), ('However', 'ADV'), (',', 'PUNCT'), ('more', 'ADJ'), ('research', 'NOUN'), ('and', 'CCONJ'), ('larger', 'ADJ'), ('clinical', 'ADJ'), ('trials', 'NOUN'), ('will', 'AUX'), ('be', 'AUX'), ('needed', 'VERB'), ('to', 'PART'), ('determine', 'VERB'), ('its', 'PRON'), ('effectiveness', 'NOUN'), ('and', 'CCONJ'), ('safety', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('While', 'SCONJ'), ('our', 'PRON'), ('study', 'NOUN'), ('focused', 'VERB'), ('on', 'ADP'), ('a', 'DET'), ('model', 'NOUN'), ('of', 'ADP'), ('muscle', 'NOUN'), ('and', 'CCONJ'), ('bone', 'NOUN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('it', 'PRON'), ('did', 'AUX'), ('not', 'PART'), ('specifically', 'ADV'), ('examine', 'VERB'), ('bone', 'NOUN'), ('loss', 'NOUN'), ('related', 'VERB'), ('to', 'ADP'), ('obesity', 'NOUN'), ('.', 'PUNCT'), ('Since', 'SCONJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drugs', 'NOUN'), ('are', 'AUX'), ('mainly', 'ADV'), ('used', 'VERB'), ('by', 'ADP'), ('people', 'NOUN'), ('with', 'ADP'), ('obesity', 'NOUN'), (',', 'PUNCT'), ('it', 'PRON'), ('is', 'AUX'), ('essential', 'ADJ'), ('to', 'PART'), ('explore', 'VERB'), ('how', 'SCONJ'), ('bimagrumab', 'NOUN'), ('interacts', 'NOUN'), ('with', 'ADP'), ('bone', 'NOUN'), ('affected', 'VERB'), ('by', 'ADP'), ('obesity', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Bromer', 'PROPN'), ('added', 'VERB'), ('.', 'PUNCT')]","[('the Journal of Cachexia', 'ORG'), ('Sarcopenia', 'GPE'), ('Muscle', 'PERSON'), ('bimagrumab', 'PERSON'), ('GLP-1', 'ORG'), ('Frederik Duch Bromer', 'PERSON'), ('Aarhus University', 'ORG'), ('Denmark', 'GPE'), ('Wegovy', 'ORG'), ('Mounjaro', 'PERSON'), ('bimagrumab', 'PERSON'), ('bimagrumab', 'PERSON'), ('Medical News', 'ORG'), ('Today', 'DATE'), ('One', 'CARDINAL'), ('one', 'CARDINAL'), ('bimagrumab', 'PERSON'), ('GLP-1', 'LOC'), ('bimagrumab', 'PERSON'), ('Wegovy', 'ORG'), ('GLP-1', 'LOC'), ('bimagrumab', 'PERSON'), ('bimagrumab', 'PERSON'), ('bimagrumab', 'PERSON'), ('two', 'CARDINAL'), ('weekly', 'DATE'), ('21 days', 'DATE'), ('21 days', 'DATE'), ('bimagrumab', 'PERSON'), ('Bimagrumab', 'PERSON'), ('bimagrumab', 'PERSON'), ('two and seven days', 'DATE'), ('Bimagrumab', 'PERSON'), ('GLP-1', 'PERSON')]","['the Journal of Cachexia', 'Sarcopenia', 'Muscle', 'bimagrumab', 'GLP-1', 'Frederik Duch Bromer', 'Aarhus University', 'Denmark', 'Wegovy', 'Mounjaro', 'bimagrumab', 'bimagrumab', 'Medical News', 'Today', 'One', 'one', 'bimagrumab', 'GLP-1', 'bimagrumab', 'Wegovy', 'GLP-1', 'bimagrumab', 'bimagrumab', 'bimagrumab', 'two', 'weekly', '21 days', '21 days', 'bimagrumab', 'Bimagrumab', 'bimagrumab', 'two and seven days', 'Bimagrumab', 'GLP-1']","['the Journal of Cachexia', 'Sarcopenia', 'Muscle', 'bimagrumab', 'GLP-1', 'Frederik Duch Bromer', 'Aarhus University', 'Denmark', 'Wegovy', 'Mounjaro', 'bimagrumab', 'bimagrumab', 'Medical News', 'Today', 'One', 'One', 'bimagrumab', 'GLP-1', 'bimagrumab', 'Wegovy', 'GLP-1', 'bimagrumab', 'bimagrumab', 'bimagrumab', 'two', 'weekly', '21 days', '21 days', 'bimagrumab', 'bimagrumab', 'bimagrumab', 'two and seven days', 'bimagrumab', 'GLP-1']"
Denmark Ozempic card to Trump Greenland threat - Trump Greenland threat Denmark may halt Ozempic obesity drug - India Today,https://www.indiatoday.in/world/story/donald-trump-greenland-tariff-threat-denmark-ozempic-weight-loss-drug-legos-2673180-2025-02-01,"Listen to Story If US President Donald Trump is indeed serious about his threat to acquire Greenland, the autonomous Danish territory, it may well affect the weight-loss journey of millions of obese Americans. Puzzled? The equation is simple. Denmark, despite having a population smaller than New York, has several trump cards up its sleeve, with the foremost being curbing or halting the exports of the popular weight-loss drug Ozempic and kids' favourite Lego toys. Ever since Trump won the US presidential election, the Republican has on several occasions floated the idea of buying Greenland. He has only escalated the pitch after taking over as US President last month, threatening punitive tariffs and even hinting at military action to take control of the strategically important island. However, Danish Prime Minister Mette Frederiksen, in a fiery phone call with Trump, made it clear that Greenland was ""not for sale"", the BBC reported. DENMARK TARIFF THREAT MAY HURT WAISTLINES OF AMERICANS The issue has threatened the possibility of an all-out trade war between the US and its NATO ally. However, it may turn out to be a pain in the waistlines of millions of Americans. In the past two years, the drugs Ozempic and Wegovy, made by Danish pharma giant Novo Nordisk, have revolutionised obesity and diabetes treatment in the United States - which has one of the highest obesity rates in the world. In fact, CDC data shows that in 23 American states, more than one in three adults (35%) has obesity. A study in the Journal of the American Medical Association has revealed that between 2021 and 2023, the number of Ozempic prescriptions in the US has jumped by 400 per cent. In the backdrop of this, if Trump does go on with steep tariffs on Denmark, it could jack up the prices of Ozempic and Wegovy. Presently, Americans have to shell out nearly $1,000 for each packet of Ozempic (without discounts or insurance). For Wegovy, it is $1,300 per package. The price of the drugs is already higher in the US than in other countries. Additionally, data by Trading Economics shows that the US imported medicines, vaccines and antibiotics worth $5.7 billion from ""pharma state"" Denmark in 2023. Even if the US wants to make such drugs from scratch, it doesn't have the resources as the active ingredient for Ozempic and Wegovy, called semaglutide, is made in Denmark. The widely popular Lego Group, the world's largest toymaker, is also based in Denmark. Besides, Denmark is also the leading supplier of hearing aids to America. Thus, even if Trump decides to go on with his tariff threats, there is no shortage of economic leverage for Denmark to hurt the United States.Published By: Abhishek DePublished On: Feb 1, 2025Must Watch","[('Listen', 'VERB'), ('to', 'ADP'), ('Story', 'PROPN'), ('If', 'SCONJ'), ('US', 'PROPN'), ('President', 'PROPN'), ('Donald', 'PROPN'), ('Trump', 'PROPN'), ('is', 'AUX'), ('indeed', 'ADV'), ('serious', 'ADJ'), ('about', 'ADP'), ('his', 'PRON'), ('threat', 'NOUN'), ('to', 'PART'), ('acquire', 'VERB'), ('Greenland', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('autonomous', 'ADJ'), ('Danish', 'ADJ'), ('territory', 'NOUN'), (',', 'PUNCT'), ('it', 'PRON'), ('may', 'AUX'), ('well', 'ADV'), ('affect', 'VERB'), ('the', 'DET'), ('weight', 'NOUN'), ('-', 'PUNCT'), ('loss', 'NOUN'), ('journey', 'NOUN'), ('of', 'ADP'), ('millions', 'NOUN'), ('of', 'ADP'), ('obese', 'ADJ'), ('Americans', 'PROPN'), ('.', 'PUNCT'), ('Puzzled', 'VERB'), ('?', 'PUNCT'), ('The', 'DET'), ('equation', 'NOUN'), ('is', 'AUX'), ('simple', 'ADJ'), ('.', 'PUNCT'), ('Denmark', 'PROPN'), (',', 'PUNCT'), ('despite', 'SCONJ'), ('having', 'VERB'), ('a', 'DET'), ('population', 'NOUN'), ('smaller', 'ADJ'), ('than', 'ADP'), ('New', 'PROPN'), ('York', 'PROPN'), (',', 'PUNCT'), ('has', 'VERB'), ('several', 'ADJ'), ('trump', 'NOUN'), ('cards', 'NOUN'), ('up', 'ADP'), ('its', 'PRON'), ('sleeve', 'NOUN'), (',', 'PUNCT'), ('with', 'ADP'), ('the', 'DET'), ('foremost', 'ADJ'), ('being', 'AUX'), ('curbing', 'VERB'), ('or', 'CCONJ'), ('halting', 'VERB'), ('the', 'DET'), ('exports', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('popular', 'ADJ'), ('weight', 'NOUN'), ('-', 'PUNCT'), ('loss', 'NOUN'), ('drug', 'NOUN'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('kids', 'NOUN'), (""'"", 'PART'), ('favourite', 'ADJ'), ('Lego', 'PROPN'), ('toys', 'NOUN'), ('.', 'PUNCT'), ('Ever', 'ADV'), ('since', 'SCONJ'), ('Trump', 'PROPN'), ('won', 'VERB'), ('the', 'DET'), ('US', 'PROPN'), ('presidential', 'ADJ'), ('election', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('Republican', 'PROPN'), ('has', 'AUX'), ('on', 'ADP'), ('several', 'ADJ'), ('occasions', 'NOUN'), ('floated', 'VERB'), ('the', 'DET'), ('idea', 'NOUN'), ('of', 'ADP'), ('buying', 'VERB'), ('Greenland', 'PROPN'), ('.', 'PUNCT'), ('He', 'PRON'), ('has', 'AUX'), ('only', 'ADV'), ('escalated', 'VERB'), ('the', 'DET'), ('pitch', 'NOUN'), ('after', 'ADP'), ('taking', 'VERB'), ('over', 'ADP'), ('as', 'ADP'), ('US', 'PROPN'), ('President', 'PROPN'), ('last', 'ADJ'), ('month', 'NOUN'), (',', 'PUNCT'), ('threatening', 'VERB'), ('punitive', 'ADJ'), ('tariffs', 'NOUN'), ('and', 'CCONJ'), ('even', 'ADV'), ('hinting', 'VERB'), ('at', 'ADP'), ('military', 'ADJ'), ('action', 'NOUN'), ('to', 'PART'), ('take', 'VERB'), ('control', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('strategically', 'ADV'), ('important', 'ADJ'), ('island', 'NOUN'), ('.', 'PUNCT'), ('However', 'ADV'), (',', 'PUNCT'), ('Danish', 'ADJ'), ('Prime', 'PROPN'), ('Minister', 'PROPN'), ('Mette', 'PROPN'), ('Frederiksen', 'PROPN'), (',', 'PUNCT'), ('in', 'ADP'), ('a', 'DET'), ('fiery', 'ADJ'), ('phone', 'NOUN'), ('call', 'NOUN'), ('with', 'ADP'), ('Trump', 'PROPN'), (',', 'PUNCT'), ('made', 'VERB'), ('it', 'PRON'), ('clear', 'ADJ'), ('that', 'SCONJ'), ('Greenland', 'PROPN'), ('was', 'AUX'), ('""', 'PUNCT'), ('not', 'PART'), ('for', 'ADP'), ('sale', 'NOUN'), ('""', 'PUNCT'), (',', 'PUNCT'), ('the', 'DET'), ('BBC', 'PROPN'), ('reported', 'VERB'), ('.', 'PUNCT'), ('DENMARK', 'VERB'), ('TARIFF', 'NOUN'), ('THREAT', 'NOUN'), ('MAY', 'AUX'), ('HURT', 'VERB'), ('WAISTLINES', 'NOUN'), ('OF', 'ADP'), ('AMERICANS', 'NOUN'), ('The', 'DET'), ('issue', 'NOUN'), ('has', 'AUX'), ('threatened', 'VERB'), ('the', 'DET'), ('possibility', 'NOUN'), ('of', 'ADP'), ('an', 'DET'), ('all', 'ADV'), ('-', 'PUNCT'), ('out', 'ADJ'), ('trade', 'NOUN'), ('war', 'NOUN'), ('between', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('and', 'CCONJ'), ('its', 'PRON'), ('NATO', 'PROPN'), ('ally', 'NOUN'), ('.', 'PUNCT'), ('However', 'ADV'), (',', 'PUNCT'), ('it', 'PRON'), ('may', 'AUX'), ('turn', 'VERB'), ('out', 'ADP'), ('to', 'PART'), ('be', 'AUX'), ('a', 'DET'), ('pain', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('waistlines', 'NOUN'), ('of', 'ADP'), ('millions', 'NOUN'), ('of', 'ADP'), ('Americans', 'PROPN'), ('.', 'PUNCT'), ('In', 'ADP'), ('the', 'DET'), ('past', 'ADJ'), ('two', 'NUM'), ('years', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('drugs', 'NOUN'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), (',', 'PUNCT'), ('made', 'VERB'), ('by', 'ADP'), ('Danish', 'ADJ'), ('pharma', 'NOUN'), ('giant', 'NOUN'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), (',', 'PUNCT'), ('have', 'AUX'), ('revolutionised', 'VERB'), ('obesity', 'NOUN'), ('and', 'CCONJ'), ('diabetes', 'VERB'), ('treatment', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('United', 'PROPN'), ('States', 'PROPN'), ('-', 'PUNCT'), ('which', 'PRON'), ('has', 'VERB'), ('one', 'NUM'), ('of', 'ADP'), ('the', 'DET'), ('highest', 'ADJ'), ('obesity', 'NOUN'), ('rates', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('world', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('fact', 'NOUN'), (',', 'PUNCT'), ('CDC', 'PROPN'), ('data', 'NOUN'), ('shows', 'VERB'), ('that', 'SCONJ'), ('in', 'ADP'), ('23', 'NUM'), ('American', 'ADJ'), ('states', 'NOUN'), (',', 'PUNCT'), ('more', 'ADJ'), ('than', 'ADP'), ('one', 'NUM'), ('in', 'ADP'), ('three', 'NUM'), ('adults', 'NOUN'), ('(', 'PUNCT'), ('35', 'NUM'), ('%', 'NOUN'), (')', 'PUNCT'), ('has', 'VERB'), ('obesity', 'NOUN'), ('.', 'PUNCT'), ('A', 'DET'), ('study', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('Journal', 'PROPN'), ('of', 'ADP'), ('the', 'DET'), ('American', 'PROPN'), ('Medical', 'PROPN'), ('Association', 'PROPN'), ('has', 'AUX'), ('revealed', 'VERB'), ('that', 'SCONJ'), ('between', 'ADP'), ('2021', 'NUM'), ('and', 'CCONJ'), ('2023', 'NUM'), (',', 'PUNCT'), ('the', 'DET'), ('number', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('prescriptions', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('has', 'AUX'), ('jumped', 'VERB'), ('by', 'ADP'), ('400', 'NUM'), ('per', 'ADP'), ('cent', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('the', 'DET'), ('backdrop', 'NOUN'), ('of', 'ADP'), ('this', 'PRON'), (',', 'PUNCT'), ('if', 'SCONJ'), ('Trump', 'PROPN'), ('does', 'AUX'), ('go', 'VERB'), ('on', 'ADP'), ('with', 'ADP'), ('steep', 'ADJ'), ('tariffs', 'NOUN'), ('on', 'ADP'), ('Denmark', 'PROPN'), (',', 'PUNCT'), ('it', 'PRON'), ('could', 'AUX'), ('jack', 'VERB'), ('up', 'ADP'), ('the', 'DET'), ('prices', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), ('.', 'PUNCT'), ('Presently', 'ADV'), (',', 'PUNCT'), ('Americans', 'PROPN'), ('have', 'VERB'), ('to', 'PART'), ('shell', 'VERB'), ('out', 'ADP'), ('nearly', 'ADV'), ('$', 'SYM'), ('1,000', 'NUM'), ('for', 'ADP'), ('each', 'DET'), ('packet', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('(', 'PUNCT'), ('without', 'ADP'), ('discounts', 'NOUN'), ('or', 'CCONJ'), ('insurance', 'NOUN'), (')', 'PUNCT'), ('.', 'PUNCT'), ('For', 'ADP'), ('Wegovy', 'PROPN'), (',', 'PUNCT'), ('it', 'PRON'), ('is', 'AUX'), ('$', 'SYM'), ('1,300', 'NUM'), ('per', 'ADP'), ('package', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('price', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drugs', 'NOUN'), ('is', 'AUX'), ('already', 'ADV'), ('higher', 'ADJ'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('than', 'ADP'), ('in', 'ADP'), ('other', 'ADJ'), ('countries', 'NOUN'), ('.', 'PUNCT'), ('Additionally', 'ADV'), (',', 'PUNCT'), ('data', 'NOUN'), ('by', 'ADP'), ('Trading', 'PROPN'), ('Economics', 'PROPN'), ('shows', 'VERB'), ('that', 'SCONJ'), ('the', 'DET'), ('US', 'PROPN'), ('imported', 'VERB'), ('medicines', 'NOUN'), (',', 'PUNCT'), ('vaccines', 'NOUN'), ('and', 'CCONJ'), ('antibiotics', 'NOUN'), ('worth', 'ADJ'), ('$', 'SYM'), ('5.7', 'NUM'), ('billion', 'NUM'), ('from', 'ADP'), ('""', 'PUNCT'), ('pharma', 'PROPN'), ('state', 'NOUN'), ('""', 'PUNCT'), ('Denmark', 'PROPN'), ('in', 'ADP'), ('2023', 'NUM'), ('.', 'PUNCT'), ('Even', 'ADV'), ('if', 'SCONJ'), ('the', 'DET'), ('US', 'PROPN'), ('wants', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('such', 'ADJ'), ('drugs', 'NOUN'), ('from', 'ADP'), ('scratch', 'NOUN'), (',', 'PUNCT'), ('it', 'PRON'), ('does', 'AUX'), (""n't"", 'PART'), ('have', 'VERB'), ('the', 'DET'), ('resources', 'NOUN'), ('as', 'ADP'), ('the', 'DET'), ('active', 'ADJ'), ('ingredient', 'NOUN'), ('for', 'ADP'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), (',', 'PUNCT'), ('called', 'VERB'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('is', 'AUX'), ('made', 'VERB'), ('in', 'ADP'), ('Denmark', 'PROPN'), ('.', 'PUNCT'), ('The', 'DET'), ('widely', 'ADV'), ('popular', 'ADJ'), ('Lego', 'PROPN'), ('Group', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('world', 'NOUN'), (""'s"", 'PART'), ('largest', 'ADJ'), ('toymaker', 'NOUN'), (',', 'PUNCT'), ('is', 'AUX'), ('also', 'ADV'), ('based', 'VERB'), ('in', 'ADP'), ('Denmark', 'PROPN'), ('.', 'PUNCT'), ('Besides', 'ADV'), (',', 'PUNCT'), ('Denmark', 'PROPN'), ('is', 'AUX'), ('also', 'ADV'), ('the', 'DET'), ('leading', 'VERB'), ('supplier', 'NOUN'), ('of', 'ADP'), ('hearing', 'VERB'), ('aids', 'NOUN'), ('to', 'ADP'), ('America', 'PROPN'), ('.', 'PUNCT'), ('Thus', 'ADV'), (',', 'PUNCT'), ('even', 'ADV'), ('if', 'SCONJ'), ('Trump', 'PROPN'), ('decides', 'VERB'), ('to', 'PART'), ('go', 'VERB'), ('on', 'ADP'), ('with', 'ADP'), ('his', 'PRON'), ('tariff', 'NOUN'), ('threats', 'NOUN'), (',', 'PUNCT'), ('there', 'PRON'), ('is', 'VERB'), ('no', 'DET'), ('shortage', 'NOUN'), ('of', 'ADP'), ('economic', 'ADJ'), ('leverage', 'NOUN'), ('for', 'SCONJ'), ('Denmark', 'PROPN'), ('to', 'PART'), ('hurt', 'VERB'), ('the', 'DET'), ('United', 'PROPN'), ('States', 'PROPN'), ('.', 'PUNCT'), ('Published', 'VERB'), ('By', 'ADP'), (':', 'PUNCT'), ('Abhishek', 'PROPN'), ('DePublished', 'PROPN'), ('On', 'ADP'), (':', 'PUNCT'), ('Feb', 'PROPN'), ('1', 'NUM'), (',', 'PUNCT'), ('2025Must', 'NUM'), ('Watch', 'PROPN')]","[('Story', 'PERSON'), ('US', 'GPE'), ('Donald Trump', 'PERSON'), ('Greenland', 'GPE'), ('Danish', 'NORP'), ('millions', 'CARDINAL'), ('obese Americans', 'NORP'), ('Denmark', 'GPE'), ('New York', 'GPE'), ('Lego', 'PERSON'), ('Trump', 'PERSON'), ('US', 'GPE'), ('Republican', 'NORP'), ('Greenland', 'GPE'), ('US', 'GPE'), ('last month', 'DATE'), ('Danish', 'NORP'), ('Mette Frederiksen', 'PERSON'), ('Trump', 'PERSON'), ('Greenland', 'GPE'), ('BBC', 'ORG'), ('DENMARK TARIFF THREAT', 'PERSON'), ('US', 'GPE'), ('NATO', 'ORG'), ('millions', 'CARDINAL'), ('Americans', 'NORP'), ('the past two years', 'DATE'), ('Wegovy', 'ORG'), ('Danish', 'NORP'), ('Novo Nordisk', 'PERSON'), ('the United States', 'GPE'), ('one', 'CARDINAL'), ('CDC', 'ORG'), ('23', 'CARDINAL'), ('American', 'NORP'), ('more than one', 'CARDINAL'), ('three', 'CARDINAL'), ('35%', 'PERCENT'), ('the Journal of the American Medical Association', 'ORG'), ('between 2021 and 2023', 'DATE'), ('Ozempic', 'NORP'), ('US', 'GPE'), ('400 per cent', 'MONEY'), ('Trump', 'PERSON'), ('Denmark', 'GPE'), ('Ozempic', 'ORG'), ('Wegovy', 'ORG'), ('Americans', 'NORP'), ('nearly $1,000', 'MONEY'), ('Ozempic', 'GPE'), ('Wegovy', 'PERSON'), ('1,300', 'MONEY'), ('US', 'GPE'), ('Trading Economics', 'ORG'), ('US', 'GPE'), ('$5.7 billion', 'MONEY'), ('Denmark', 'GPE'), ('2023', 'DATE'), ('US', 'GPE'), ('Ozempic', 'ORG'), ('Wegovy', 'ORG'), ('Denmark', 'GPE'), ('Lego Group', 'ORG'), ('Denmark', 'GPE'), ('Denmark', 'GPE'), ('America', 'GPE'), ('Trump', 'PERSON'), ('Denmark', 'GPE'), ('the United States', 'GPE'), ('Abhishek DePublished', 'PERSON'), ('2025Must', 'CARDINAL')]","['Story', 'US', 'Donald Trump', 'Greenland', 'Danish', 'millions', 'obese Americans', 'Denmark', 'New York', 'Lego', 'Trump', 'US', 'Republican', 'Greenland', 'US', 'last month', 'Danish', 'Mette Frederiksen', 'Trump', 'Greenland', 'BBC', 'DENMARK TARIFF THREAT', 'US', 'NATO', 'millions', 'Americans', 'the past two years', 'Wegovy', 'Danish', 'Novo Nordisk', 'the United States', 'one', 'CDC', '23', 'American', 'more than one', 'three', '35%', 'the Journal of the American Medical Association', 'between 2021 and 2023', 'Ozempic', 'US', '400 per cent', 'Trump', 'Denmark', 'Ozempic', 'Wegovy', 'Americans', 'nearly $1,000', 'Ozempic', 'Wegovy', '1,300', 'US', 'Trading Economics', 'US', '$5.7 billion', 'Denmark', '2023', 'US', 'Ozempic', 'Wegovy', 'Denmark', 'Lego Group', 'Denmark', 'Denmark', 'America', 'Trump', 'Denmark', 'the United States', 'Abhishek DePublished', '2025Must']","['Story', 'US', 'Donald Trump', 'Greenland', 'Danish', 'millions', 'obese Americans', 'Denmark', 'New York', 'Lego', 'Trump', 'US', 'Republican', 'Greenland', 'US', 'last month', 'Danish', 'Mette Frederiksen', 'Trump', 'Greenland', 'BBC', 'DENMARK TARIFF THREAT', 'US', 'NATO', 'millions', 'Americans', 'the past two years', 'Wegovy', 'Danish', 'Novo Nordisk', 'the United States', 'One', 'CDC', '23', 'Americans', 'more than one', 'three', '35%', 'the Journal of the American Medical Association', 'between 2021 and 2023', 'Ozempic', 'US', '400 per cent', 'Trump', 'Denmark', 'Ozempic', 'Wegovy', 'Americans', 'nearly $1,000', 'Ozempic', 'Wegovy', '1,300', 'US', 'Trading Economics', 'US', '$5.7 billion', 'Denmark', '2023', 'US', 'Ozempic', 'Wegovy', 'Denmark', 'Lego Group', 'Denmark', 'Denmark', 'American', 'Trump', 'Denmark', 'the United States', 'Abhishek DePublished', '2025Must']"
"Shortage of Novo's Wegovy and Ozempic is resolved, FDA website shows",https://www.globalbankingandfinance.com/HEALTH-OBESITY-NOVO-0ba04163-5d5e-4266-a5ea-18a27bbac336,Take advantage of our newsletter subscription and stay informed on the go!,"[('Take', 'VERB'), ('advantage', 'NOUN'), ('of', 'ADP'), ('our', 'PRON'), ('newsletter', 'NOUN'), ('subscription', 'NOUN'), ('and', 'CCONJ'), ('stay', 'VERB'), ('informed', 'ADJ'), ('on', 'ADP'), ('the', 'DET'), ('go', 'NOUN'), ('!', 'PUNCT')]",[],[],[]
Ozempic blindness: New study flags unexpected side effect of weight loss drugs - The Times of India,https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/ozempic-blindness-new-study-flags-unexpected-side-effect-of-weight-loss-drugs/articleshow/118148954.cms,"The TOI Lifestyle Desk is a dynamic team of dedicated journalists who, with unwavering passion and commitment, sift through the pulse of the nation to curate a vibrant tapestry of lifestyle news for The Times of India readers. At the TOI Lifestyle Desk, we go beyond the obvious, delving into the extraordinary. Consider us your lifestyle companion, providing a daily dose of inspiration and information. Whether you're seeking the latest fashion trends, travel escapades, culinary delights, or wellness tips, the TOI Lifestyle Desk is your one-stop destination for an enriching lifestyle experience.Read More Kareena's best wedding looks â10 new animal species discovered for the first time in 2024 10 birds that eat meat and other animals 9 reasons why pumpkin seed is a superfood 8 Indian wildlife destinations visitors are most excited about 10 health benefits of chewing cloves daily 10 wild animals known for their friendly nature 10 quotes to inspire and motivate you How to make Oats Omelette for a quick dinner","[('The', 'DET'), ('TOI', 'PROPN'), ('Lifestyle', 'PROPN'), ('Desk', 'PROPN'), ('is', 'AUX'), ('a', 'DET'), ('dynamic', 'ADJ'), ('team', 'NOUN'), ('of', 'ADP'), ('dedicated', 'ADJ'), ('journalists', 'NOUN'), ('who', 'PRON'), (',', 'PUNCT'), ('with', 'ADP'), ('unwavering', 'VERB'), ('passion', 'NOUN'), ('and', 'CCONJ'), ('commitment', 'NOUN'), (',', 'PUNCT'), ('sift', 'VERB'), ('through', 'ADP'), ('the', 'DET'), ('pulse', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('nation', 'NOUN'), ('to', 'PART'), ('curate', 'VERB'), ('a', 'DET'), ('vibrant', 'ADJ'), ('tapestry', 'NOUN'), ('of', 'ADP'), ('lifestyle', 'NOUN'), ('news', 'NOUN'), ('for', 'ADP'), ('The', 'DET'), ('Times', 'PROPN'), ('of', 'ADP'), ('India', 'PROPN'), ('readers', 'NOUN'), ('.', 'PUNCT'), ('At', 'ADP'), ('the', 'DET'), ('TOI', 'PROPN'), ('Lifestyle', 'PROPN'), ('Desk', 'PROPN'), (',', 'PUNCT'), ('we', 'PRON'), ('go', 'VERB'), ('beyond', 'ADP'), ('the', 'DET'), ('obvious', 'ADJ'), (',', 'PUNCT'), ('delving', 'VERB'), ('into', 'ADP'), ('the', 'DET'), ('extraordinary', 'ADJ'), ('.', 'PUNCT'), ('Consider', 'VERB'), ('us', 'PRON'), ('your', 'PRON'), ('lifestyle', 'NOUN'), ('companion', 'NOUN'), (',', 'PUNCT'), ('providing', 'VERB'), ('a', 'DET'), ('daily', 'ADJ'), ('dose', 'NOUN'), ('of', 'ADP'), ('inspiration', 'NOUN'), ('and', 'CCONJ'), ('information', 'NOUN'), ('.', 'PUNCT'), ('Whether', 'SCONJ'), ('you', 'PRON'), (""'re"", 'AUX'), ('seeking', 'VERB'), ('the', 'DET'), ('latest', 'ADJ'), ('fashion', 'NOUN'), ('trends', 'NOUN'), (',', 'PUNCT'), ('travel', 'NOUN'), ('escapades', 'NOUN'), (',', 'PUNCT'), ('culinary', 'PROPN'), ('delights', 'NOUN'), (',', 'PUNCT'), ('or', 'CCONJ'), ('wellness', 'NOUN'), ('tips', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('TOI', 'PROPN'), ('Lifestyle', 'PROPN'), ('Desk', 'PROPN'), ('is', 'AUX'), ('your', 'PRON'), ('one', 'NUM'), ('-', 'PUNCT'), ('stop', 'NOUN'), ('destination', 'NOUN'), ('for', 'ADP'), ('an', 'DET'), ('enriching', 'VERB'), ('lifestyle', 'NOUN'), ('experience', 'NOUN'), ('.', 'PUNCT'), ('Read', 'VERB'), ('More', 'ADJ'), ('Kareena', 'PROPN'), (""'s"", 'PART'), ('best', 'ADJ'), ('wedding', 'NOUN'), ('looks', 'VERB'), ('â\x80\x8b10', 'ADP'), ('new', 'ADJ'), ('animal', 'NOUN'), ('species', 'NOUN'), ('discovered', 'VERB'), ('for', 'ADP'), ('the', 'DET'), ('first', 'ADJ'), ('time', 'NOUN'), ('in', 'ADP'), ('2024', 'NUM'), ('10', 'NUM'), ('birds', 'NOUN'), ('that', 'PRON'), ('eat', 'VERB'), ('meat', 'NOUN'), ('and', 'CCONJ'), ('other', 'ADJ'), ('animals', 'NOUN'), ('9', 'NUM'), ('reasons', 'NOUN'), ('why', 'SCONJ'), ('pumpkin', 'NOUN'), ('seed', 'NOUN'), ('is', 'AUX'), ('a', 'DET'), ('superfood', 'NOUN'), ('8', 'NUM'), ('Indian', 'ADJ'), ('wildlife', 'NOUN'), ('destinations', 'NOUN'), ('visitors', 'NOUN'), ('are', 'AUX'), ('most', 'ADV'), ('excited', 'ADJ'), ('about', 'ADP'), ('10', 'NUM'), ('health', 'NOUN'), ('benefits', 'NOUN'), ('of', 'ADP'), ('chewing', 'VERB'), ('cloves', 'VERB'), ('daily', 'ADV'), ('10', 'NUM'), ('wild', 'ADJ'), ('animals', 'NOUN'), ('known', 'VERB'), ('for', 'ADP'), ('their', 'PRON'), ('friendly', 'ADJ'), ('nature', 'NOUN'), ('10', 'NUM'), ('quotes', 'NOUN'), ('to', 'PART'), ('inspire', 'VERB'), ('and', 'CCONJ'), ('motivate', 'VERB'), ('you', 'PRON'), ('How', 'SCONJ'), ('to', 'PART'), ('make', 'VERB'), ('Oats', 'PROPN'), ('Omelette', 'PROPN'), ('for', 'ADP'), ('a', 'DET'), ('quick', 'ADJ'), ('dinner', 'NOUN')]","[('The TOI Lifestyle Desk', 'ORG'), ('The Times of India', 'ORG'), ('the TOI Lifestyle Desk', 'FAC'), ('daily', 'DATE'), ('the TOI Lifestyle Desk', 'ORG'), ('one', 'CARDINAL'), ('Kareena', 'ORG'), ('first', 'ORDINAL'), ('2024', 'DATE'), ('9', 'CARDINAL'), ('8', 'CARDINAL'), ('Indian', 'NORP'), ('about 10', 'CARDINAL'), ('daily', 'DATE'), ('10', 'CARDINAL'), ('10', 'CARDINAL')]","['The TOI Lifestyle Desk', 'The Times of India', 'the TOI Lifestyle Desk', 'daily', 'the TOI Lifestyle Desk', 'one', 'Kareena', 'first', '2024', '9', '8', 'Indian', 'about 10', 'daily', '10', '10']","['The TOI Lifestyle Desk', 'The Times of India', 'The TOI Lifestyle Desk', 'daily', 'The TOI Lifestyle Desk', 'One', 'Kareena', 'first', '2024', '9', '8', 'Indian', 'about 10', 'daily', '10', '10']"
"FDA Says Ozempic, Wegovy Shortage Resolved",https://www.drugtopics.com/view/fda-declares-shortage-of-ozempic-wegovy-resolved,"    Semaglutide has been in shortage since 2022 due to increased demand. The FDA has declared the shortage of semaglutide (Ozempic, Wegovy) has been resolved, confirming that the US supply of the prescription-only medications now meets or exceeds the current and projected demand. Semaglutide has been in shortage since March (Wegovy) and August (Ozempic) 2022 due to increased demand, according to the FDA.1,2 The FDA said that there may be intermittent and limited localized supply disruptions due to products moving through the supply chain. | Image Credit: Araki Illustrations | stock.adobe ""We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding current and projected nationwide demand. No one should have to compromise their health due to misinformation and reach for fake or illegitimate knockoff drugs that pose significant safety risks to patients,"" Dave Moore, executive vice president of US operations and global business development and president of Novo Nordisk Inc, said in a statement.1 ""Patient safety remains our top priority, and, in line with our purpose to improve lives and health, we continue to partner, educate, and advocate for expanded, affordable access to our medicines for those who need and rely on them."" In a letter addressed to Novo Nordisk, Jacqueline Corrigan-Curay, JD, MD, acting director for the CDC and FDA, stated, “As a result of this review, we conclude that the information and data Novo Nordisk has provided to the FDA demonstrate that Novo Nordisk’s supply is currently meeting or exceeding demand for its semaglutide injection products and that Novo Nordisk has developed reserves that it now holds in its finished product inventory in addition to significant units of semi-finished product, such that supply will meet or exceed projected demand.”3 The FDA said that there may be intermittent and limited localized supply disruptions due to products moving through the supply chain, but it will not take action against compounders violating the Food, Drug & Cosmetic Act for state-licensed pharmacy or physician compounding under section 503A and for outsourcing facilities under sections 503B until April 22, 2025, and May 22, 2025, respectively. The agency can still take action against any other violations of any other statutory or regulatory requirements, including addressing unsafe or substandard quality products.2 Previously, the FDA noted that semaglutide injections were in shortage on October 2, 2024, but that Novo Nordisk had reported all but on presentation. On December 19, 2024, the FDA updated that after all presentations were reported, the product was still in shortage and the agency would actively monitor the drug availability to determine if the demand and projected demand for each drug exceeded the available supply.3 The FDA also affirmed that dulaglutide injection (Trulicity) and liraglutide (Victoza, Saxenda) injection are still in drug shortage but have presentations available.2 FDA Approves Chenodiol for Treatment of Cerebrotendinous Xanthomatosis Ctexli is the first FDA-approved treatment for adults with cerebrotendinous xanthomatosis. How Pharmacy Matches Perfectly With Nutrition Known as “The Nutrition Pharmacist,” Sarah Gray, PharmD, GAICD, recently joined Drug Topics to discuss her dual profession within health care. Type 1 Diabetes Linked With Increased Dementia Risk A recent metanalysis found that patients with type 1 diabetes had a 50% higher chance of developing dementia. Episode 8: Stay in Sync with Innovations in Medication Decision Support Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space. FDA Accepts New Drug Application for Vatiquinone to Treat Friedreich Ataxia The FDA also granted priority review, with a Prescription Drug User Fee Act target action date of August 19, 2025. GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity ASC30, an investigational glucagon-like 1-peptide receptor agonist, demonstrates mean weight reductions from baseline of 4.3% and 6.3% for 2 separate cohorts. FDA Approves Chenodiol for Treatment of Cerebrotendinous Xanthomatosis Ctexli is the first FDA-approved treatment for adults with cerebrotendinous xanthomatosis. How Pharmacy Matches Perfectly With Nutrition Known as “The Nutrition Pharmacist,” Sarah Gray, PharmD, GAICD, recently joined Drug Topics to discuss her dual profession within health care. Type 1 Diabetes Linked With Increased Dementia Risk A recent metanalysis found that patients with type 1 diabetes had a 50% higher chance of developing dementia. Episode 8: Stay in Sync with Innovations in Medication Decision Support Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space. FDA Accepts New Drug Application for Vatiquinone to Treat Friedreich Ataxia The FDA also granted priority review, with a Prescription Drug User Fee Act target action date of August 19, 2025. GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity ASC30, an investigational glucagon-like 1-peptide receptor agonist, demonstrates mean weight reductions from baseline of 4.3% and 6.3% for 2 separate cohorts. 2 Commerce Drive Cranbury, NJ 08512 609-716-7777","[('    ', 'SPACE'), ('Semaglutide', 'PROPN'), ('has', 'AUX'), ('been', 'AUX'), ('in', 'ADP'), ('shortage', 'NOUN'), ('since', 'SCONJ'), ('2022', 'NUM'), ('due', 'ADP'), ('to', 'ADP'), ('increased', 'VERB'), ('demand', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('FDA', 'PROPN'), ('has', 'AUX'), ('declared', 'VERB'), ('the', 'DET'), ('shortage', 'NOUN'), ('of', 'ADP'), ('semaglutide', 'NOUN'), ('(', 'PUNCT'), ('Ozempic', 'PROPN'), (',', 'PUNCT'), ('Wegovy', 'PROPN'), (')', 'PUNCT'), ('has', 'AUX'), ('been', 'AUX'), ('resolved', 'VERB'), (',', 'PUNCT'), ('confirming', 'VERB'), ('that', 'SCONJ'), ('the', 'DET'), ('US', 'PROPN'), ('supply', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('prescription', 'NOUN'), ('-', 'PUNCT'), ('only', 'ADJ'), ('medications', 'NOUN'), ('now', 'ADV'), ('meets', 'VERB'), ('or', 'CCONJ'), ('exceeds', 'VERB'), ('the', 'DET'), ('current', 'ADJ'), ('and', 'CCONJ'), ('projected', 'ADJ'), ('demand', 'NOUN'), ('.', 'PUNCT'), ('Semaglutide', 'PROPN'), ('has', 'AUX'), ('been', 'AUX'), ('in', 'ADP'), ('shortage', 'NOUN'), ('since', 'SCONJ'), ('March', 'PROPN'), ('(', 'PUNCT'), ('Wegovy', 'PROPN'), (')', 'PUNCT'), ('and', 'CCONJ'), ('August', 'PROPN'), ('(', 'PUNCT'), ('Ozempic', 'PROPN'), (')', 'PUNCT'), ('2022', 'NUM'), ('due', 'ADP'), ('to', 'ADP'), ('increased', 'VERB'), ('demand', 'NOUN'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('the', 'DET'), ('FDA.1,2', 'NOUN'), ('The', 'DET'), ('FDA', 'PROPN'), ('said', 'VERB'), ('that', 'SCONJ'), ('there', 'PRON'), ('may', 'AUX'), ('be', 'AUX'), ('intermittent', 'ADJ'), ('and', 'CCONJ'), ('limited', 'VERB'), ('localized', 'ADJ'), ('supply', 'NOUN'), ('disruptions', 'NOUN'), ('due', 'ADJ'), ('to', 'ADP'), ('products', 'NOUN'), ('moving', 'VERB'), ('through', 'ADP'), ('the', 'DET'), ('supply', 'NOUN'), ('chain', 'NOUN'), ('.', 'PUNCT'), ('|', 'NOUN'), ('Image', 'PROPN'), ('Credit', 'PROPN'), (':', 'PUNCT'), ('Araki', 'PROPN'), ('Illustrations', 'PROPN'), ('|', 'VERB'), ('stock.adobe', 'VERB'), ('""', 'PUNCT'), ('We', 'PRON'), ('are', 'AUX'), ('pleased', 'ADJ'), ('the', 'DET'), ('FDA', 'PROPN'), ('has', 'AUX'), ('declared', 'VERB'), ('that', 'SCONJ'), ('supply', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('only', 'ADJ'), ('real', 'ADJ'), (',', 'PUNCT'), ('FDA', 'PROPN'), ('-', 'PUNCT'), ('approved', 'VERB'), ('semaglutide', 'ADJ'), ('medicines', 'NOUN'), ('is', 'AUX'), ('resolved', 'VERB'), (',', 'PUNCT'), ('affirming', 'VERB'), ('that', 'SCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('is', 'AUX'), ('meeting', 'VERB'), ('or', 'CCONJ'), ('exceeding', 'VERB'), ('current', 'ADJ'), ('and', 'CCONJ'), ('projected', 'VERB'), ('nationwide', 'ADJ'), ('demand', 'NOUN'), ('.', 'PUNCT'), ('No', 'DET'), ('one', 'NOUN'), ('should', 'AUX'), ('have', 'VERB'), ('to', 'PART'), ('compromise', 'VERB'), ('their', 'PRON'), ('health', 'NOUN'), ('due', 'ADP'), ('to', 'ADP'), ('misinformation', 'NOUN'), ('and', 'CCONJ'), ('reach', 'VERB'), ('for', 'ADP'), ('fake', 'ADJ'), ('or', 'CCONJ'), ('illegitimate', 'ADJ'), ('\xa0', 'SPACE'), ('knockoff', 'NOUN'), ('drugs', 'NOUN'), ('that', 'PRON'), ('pose', 'VERB'), ('significant', 'ADJ'), ('\xa0', 'SPACE'), ('safety', 'NOUN'), ('risks', 'NOUN'), ('to', 'ADP'), ('patients', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Dave', 'PROPN'), ('Moore', 'PROPN'), (',', 'PUNCT'), ('executive', 'ADJ'), ('vice', 'NOUN'), ('president', 'NOUN'), ('of', 'ADP'), ('US', 'PROPN'), ('operations', 'NOUN'), ('and', 'CCONJ'), ('global', 'ADJ'), ('business', 'NOUN'), ('development', 'NOUN'), ('and', 'CCONJ'), ('president', 'NOUN'), ('of', 'ADP'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('Inc', 'PROPN'), (',', 'PUNCT'), ('said', 'VERB'), ('in', 'ADP'), ('a', 'DET'), ('statement.1', 'PROPN'), ('""', 'PUNCT'), ('Patient', 'ADJ'), ('safety', 'NOUN'), ('remains', 'VERB'), ('our', 'PRON'), ('top', 'ADJ'), ('priority', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), (',', 'PUNCT'), ('in', 'ADP'), ('line', 'NOUN'), ('with', 'ADP'), ('our', 'PRON'), ('purpose', 'NOUN'), ('to', 'PART'), ('improve', 'VERB'), ('lives', 'NOUN'), ('and', 'CCONJ'), ('health', 'NOUN'), (',', 'PUNCT'), ('we', 'PRON'), ('continue', 'VERB'), ('to', 'PART'), ('partner', 'VERB'), (',', 'PUNCT'), ('educate', 'VERB'), (',', 'PUNCT'), ('and', 'CCONJ'), ('advocate', 'VERB'), ('for', 'ADP'), ('expanded', 'VERB'), (',', 'PUNCT'), ('affordable', 'ADJ'), ('access', 'NOUN'), ('to', 'ADP'), ('our', 'PRON'), ('medicines', 'NOUN'), ('for', 'ADP'), ('those', 'PRON'), ('who', 'PRON'), ('need', 'VERB'), ('and', 'CCONJ'), ('rely', 'VERB'), ('on', 'ADP'), ('them', 'PRON'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('In', 'ADP'), ('a', 'DET'), ('letter', 'NOUN'), ('addressed', 'VERB'), ('to', 'ADP'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), (',', 'PUNCT'), ('Jacqueline', 'PROPN'), ('Corrigan', 'PROPN'), ('-', 'PUNCT'), ('Curay', 'PROPN'), (',', 'PUNCT'), ('JD', 'PROPN'), (',', 'PUNCT'), ('MD', 'PROPN'), (',', 'PUNCT'), ('acting', 'NOUN'), ('director', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('CDC', 'PROPN'), ('and', 'CCONJ'), ('FDA', 'PROPN'), (',', 'PUNCT'), ('stated', 'VERB'), (',', 'PUNCT'), ('“', 'PUNCT'), ('As', 'ADP'), ('a', 'DET'), ('result', 'NOUN'), ('of', 'ADP'), ('this', 'DET'), ('review', 'NOUN'), (',', 'PUNCT'), ('we', 'PRON'), ('conclude', 'VERB'), ('that', 'SCONJ'), ('the', 'DET'), ('information', 'NOUN'), ('and', 'CCONJ'), ('data', 'NOUN'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('has', 'AUX'), ('provided', 'VERB'), ('to', 'ADP'), ('the', 'DET'), ('FDA', 'PROPN'), ('demonstrate', 'VERB'), ('that', 'SCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('’s', 'PART'), ('supply', 'NOUN'), ('is', 'AUX'), ('currently', 'ADV'), ('meeting', 'VERB'), ('or', 'CCONJ'), ('exceeding', 'VERB'), ('demand', 'NOUN'), ('for', 'ADP'), ('its', 'PRON'), ('semaglutide', 'ADJ'), ('injection', 'NOUN'), ('products', 'NOUN'), ('and', 'CCONJ'), ('that', 'SCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('has', 'AUX'), ('developed', 'VERB'), ('reserves', 'NOUN'), ('that', 'SCONJ'), ('it', 'PRON'), ('now', 'ADV'), ('holds', 'VERB'), ('in', 'ADP'), ('its', 'PRON'), ('finished', 'ADJ'), ('product', 'NOUN'), ('inventory', 'NOUN'), ('in', 'ADP'), ('addition', 'NOUN'), ('to', 'ADP'), ('significant', 'ADJ'), ('units', 'NOUN'), ('of', 'ADP'), ('semi', 'ADJ'), ('-', 'ADJ'), ('finished', 'ADJ'), ('product', 'NOUN'), (',', 'PUNCT'), ('such', 'ADJ'), ('that', 'SCONJ'), ('supply', 'NOUN'), ('will', 'AUX'), ('meet', 'VERB'), ('or', 'CCONJ'), ('exceed', 'VERB'), ('projected', 'VERB'), ('demand', 'NOUN'), ('.', 'PUNCT'), ('”3', 'PROPN'), ('The', 'DET'), ('FDA', 'PROPN'), ('said', 'VERB'), ('that', 'SCONJ'), ('there', 'PRON'), ('may', 'AUX'), ('be', 'AUX'), ('intermittent', 'ADJ'), ('and', 'CCONJ'), ('limited', 'VERB'), ('localized', 'ADJ'), ('supply', 'NOUN'), ('disruptions', 'NOUN'), ('due', 'ADJ'), ('to', 'ADP'), ('products', 'NOUN'), ('moving', 'VERB'), ('through', 'ADP'), ('the', 'DET'), ('supply', 'NOUN'), ('chain', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('it', 'PRON'), ('will', 'AUX'), ('not', 'PART'), ('take', 'VERB'), ('action', 'NOUN'), ('against', 'ADP'), ('compounders', 'NOUN'), ('violating', 'VERB'), ('the', 'DET'), ('Food', 'PROPN'), (',', 'PUNCT'), ('Drug', 'PROPN'), ('&', 'CCONJ'), ('Cosmetic', 'PROPN'), ('Act', 'PROPN'), ('for', 'ADP'), ('state', 'NOUN'), ('-', 'PUNCT'), ('licensed', 'VERB'), ('pharmacy', 'NOUN'), ('or', 'CCONJ'), ('physician', 'NOUN'), ('compounding', 'NOUN'), ('under', 'ADP'), ('section', 'NOUN'), ('503A', 'NUM'), ('and', 'CCONJ'), ('for', 'ADP'), ('outsourcing', 'ADJ'), ('facilities', 'NOUN'), ('under', 'ADP'), ('sections', 'NOUN'), ('503B', 'PROPN'), ('until', 'ADP'), ('April', 'PROPN'), ('22', 'NUM'), (',', 'PUNCT'), ('2025', 'NUM'), (',', 'PUNCT'), ('and', 'CCONJ'), ('May', 'PROPN'), ('22', 'NUM'), (',', 'PUNCT'), ('2025', 'NUM'), (',', 'PUNCT'), ('respectively', 'ADV'), ('.', 'PUNCT'), ('The', 'DET'), ('agency', 'NOUN'), ('can', 'AUX'), ('still', 'ADV'), ('take', 'VERB'), ('action', 'NOUN'), ('against', 'ADP'), ('any', 'DET'), ('other', 'ADJ'), ('violations', 'NOUN'), ('of', 'ADP'), ('any', 'DET'), ('other', 'ADJ'), ('statutory', 'ADJ'), ('or', 'CCONJ'), ('regulatory', 'ADJ'), ('requirements', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('addressing', 'VERB'), ('unsafe', 'ADJ'), ('or', 'CCONJ'), ('substandard', 'ADJ'), ('quality', 'NOUN'), ('products.2', 'NOUN'), ('Previously', 'ADV'), (',', 'PUNCT'), ('the', 'DET'), ('FDA', 'PROPN'), ('noted', 'VERB'), ('that', 'SCONJ'), ('semaglutide', 'ADJ'), ('injections', 'NOUN'), ('were', 'AUX'), ('in', 'ADP'), ('shortage', 'NOUN'), ('on', 'ADP'), ('October', 'PROPN'), ('2', 'NUM'), (',', 'PUNCT'), ('2024', 'NUM'), (',', 'PUNCT'), ('but', 'CCONJ'), ('that', 'SCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('had', 'AUX'), ('reported', 'VERB'), ('all', 'PRON'), ('but', 'CCONJ'), ('on', 'ADP'), ('presentation', 'NOUN'), ('.', 'PUNCT'), ('On', 'ADP'), ('December', 'PROPN'), ('19', 'NUM'), (',', 'PUNCT'), ('2024', 'NUM'), (',', 'PUNCT'), ('the', 'DET'), ('FDA', 'PROPN'), ('updated', 'VERB'), ('that', 'SCONJ'), ('after', 'SCONJ'), ('all', 'DET'), ('presentations', 'NOUN'), ('were', 'AUX'), ('reported', 'VERB'), (',', 'PUNCT'), ('the', 'DET'), ('product', 'NOUN'), ('was', 'AUX'), ('still', 'ADV'), ('in', 'ADP'), ('shortage', 'NOUN'), ('and', 'CCONJ'), ('the', 'DET'), ('agency', 'NOUN'), ('would', 'AUX'), ('actively', 'ADV'), ('monitor', 'VERB'), ('the', 'DET'), ('drug', 'NOUN'), ('availability', 'NOUN'), ('to', 'PART'), ('determine', 'VERB'), ('if', 'SCONJ'), ('the', 'DET'), ('demand', 'NOUN'), ('and', 'CCONJ'), ('projected', 'VERB'), ('demand', 'NOUN'), ('for', 'ADP'), ('each', 'DET'), ('drug', 'NOUN'), ('exceeded', 'VERB'), ('the', 'DET'), ('available', 'ADJ'), ('supply.3', 'NOUN'), ('The', 'DET'), ('FDA', 'PROPN'), ('also', 'ADV'), ('affirmed', 'VERB'), ('that', 'SCONJ'), ('dulaglutide', 'ADJ'), ('injection', 'NOUN'), ('(', 'PUNCT'), ('Trulicity', 'PROPN'), (')', 'PUNCT'), ('and', 'CCONJ'), ('liraglutide', 'PROPN'), ('(', 'PUNCT'), ('Victoza', 'PROPN'), (',', 'PUNCT'), ('Saxenda', 'PROPN'), (')', 'PUNCT'), ('injection', 'NOUN'), ('are', 'AUX'), ('still', 'ADV'), ('in', 'ADP'), ('drug', 'NOUN'), ('shortage', 'NOUN'), ('but', 'CCONJ'), ('have', 'VERB'), ('presentations', 'NOUN'), ('available.2', 'PROPN'), ('FDA', 'PROPN'), ('Approves', 'VERB'), ('Chenodiol', 'PROPN'), ('for', 'ADP'), ('Treatment', 'PROPN'), ('of', 'ADP'), ('Cerebrotendinous', 'PROPN'), ('Xanthomatosis', 'PROPN'), ('Ctexli', 'PROPN'), ('is', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('FDA', 'PROPN'), ('-', 'PUNCT'), ('approved', 'VERB'), ('treatment', 'NOUN'), ('for', 'ADP'), ('adults', 'NOUN'), ('with', 'ADP'), ('cerebrotendinous', 'ADJ'), ('xanthomatosis', 'NOUN'), ('.', 'PUNCT'), ('How', 'SCONJ'), ('Pharmacy', 'PROPN'), ('Matches', 'PROPN'), ('Perfectly', 'ADV'), ('With', 'ADP'), ('Nutrition', 'PROPN'), ('Known', 'PROPN'), ('as', 'ADP'), ('“', 'PUNCT'), ('The', 'DET'), ('Nutrition', 'PROPN'), ('Pharmacist', 'PROPN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Sarah', 'PROPN'), ('Gray', 'PROPN'), (',', 'PUNCT'), ('PharmD', 'PROPN'), (',', 'PUNCT'), ('GAICD', 'NOUN'), (',', 'PUNCT'), ('recently', 'ADV'), ('joined', 'VERB'), ('Drug', 'PROPN'), ('Topics', 'PROPN'), ('to', 'PART'), ('discuss', 'VERB'), ('her', 'PRON'), ('dual', 'ADJ'), ('profession', 'NOUN'), ('within', 'ADP'), ('health', 'NOUN'), ('care', 'NOUN'), ('.', 'PUNCT'), ('Type', 'NOUN'), ('1', 'NUM'), ('Diabetes', 'NOUN'), ('Linked', 'VERB'), ('With', 'ADP'), ('Increased', 'PROPN'), ('Dementia', 'PROPN'), ('Risk', 'NOUN'), ('A', 'DET'), ('recent', 'ADJ'), ('metanalysis', 'NOUN'), ('found', 'VERB'), ('that', 'SCONJ'), ('patients', 'NOUN'), ('with', 'ADP'), ('type', 'NOUN'), ('1', 'NUM'), ('diabetes', 'NOUN'), ('had', 'VERB'), ('a', 'DET'), ('50', 'NUM'), ('%', 'NOUN'), ('higher', 'ADJ'), ('chance', 'NOUN'), ('of', 'ADP'), ('developing', 'VERB'), ('dementia', 'NOUN'), ('.', 'PUNCT'), ('Episode', 'NOUN'), ('8', 'NUM'), (':', 'PUNCT'), ('Stay', 'VERB'), ('in', 'ADP'), ('Sync', 'PROPN'), ('with', 'ADP'), ('Innovations', 'PROPN'), ('in', 'ADP'), ('Medication', 'PROPN'), ('Decision', 'PROPN'), ('Support', 'PROPN'), ('Episode', 'PROPN'), ('8', 'NUM'), ('of', 'ADP'), ('Over', 'ADP'), ('the', 'DET'), ('Counter', 'PROPN'), ('discusses', 'VERB'), ('the', 'DET'), ('new', 'ADJ'), ('and', 'CCONJ'), ('exciting', 'ADJ'), ('modernizations', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('medication', 'NOUN'), ('decision', 'NOUN'), ('support', 'NOUN'), ('space', 'NOUN'), ('.', 'PUNCT'), ('FDA', 'PROPN'), ('Accepts', 'VERB'), ('New', 'PROPN'), ('Drug', 'PROPN'), ('Application', 'PROPN'), ('for', 'ADP'), ('Vatiquinone', 'PROPN'), ('to', 'PART'), ('Treat', 'VERB'), ('Friedreich', 'PROPN'), ('Ataxia', 'PROPN'), ('The', 'DET'), ('FDA', 'PROPN'), ('also', 'ADV'), ('granted', 'VERB'), ('priority', 'NOUN'), ('review', 'NOUN'), (',', 'PUNCT'), ('with', 'ADP'), ('a', 'DET'), ('Prescription', 'PROPN'), ('Drug', 'PROPN'), ('User', 'PROPN'), ('Fee', 'PROPN'), ('Act', 'PROPN'), ('target', 'NOUN'), ('action', 'NOUN'), ('date', 'NOUN'), ('of', 'ADP'), ('August', 'PROPN'), ('19', 'NUM'), (',', 'PUNCT'), ('2025', 'NUM'), ('.', 'PUNCT'), ('GLP-1', 'PROPN'), ('Oral', 'PROPN'), ('Tablet', 'PROPN'), ('Shows', 'VERB'), ('Favorable', 'PROPN'), ('Safety', 'PROPN'), ('Findings', 'PROPN'), ('in', 'ADP'), ('Patients', 'PROPN'), ('With', 'ADP'), ('Obesity', 'PROPN'), ('ASC30', 'PROPN'), (',', 'PUNCT'), ('an', 'DET'), ('investigational', 'ADJ'), ('glucagon', 'NOUN'), ('-', 'PUNCT'), ('like', 'ADJ'), ('1', 'NUM'), ('-', 'PUNCT'), ('peptide', 'NOUN'), ('receptor', 'NOUN'), ('agonist', 'NOUN'), (',', 'PUNCT'), ('demonstrates', 'VERB'), ('mean', 'ADJ'), ('weight', 'NOUN'), ('reductions', 'NOUN'), ('from', 'ADP'), ('baseline', 'NOUN'), ('of', 'ADP'), ('4.3', 'NUM'), ('%', 'NOUN'), ('and', 'CCONJ'), ('6.3', 'NUM'), ('%', 'NOUN'), ('for', 'ADP'), ('2', 'NUM'), ('separate', 'ADJ'), ('cohorts', 'NOUN'), ('.', 'PUNCT'), ('FDA', 'PROPN'), ('Approves', 'VERB'), ('Chenodiol', 'PROPN'), ('for', 'ADP'), ('Treatment', 'PROPN'), ('of', 'ADP'), ('Cerebrotendinous', 'PROPN'), ('Xanthomatosis', 'PROPN'), ('Ctexli', 'PROPN'), ('is', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('FDA', 'PROPN'), ('-', 'PUNCT'), ('approved', 'VERB'), ('treatment', 'NOUN'), ('for', 'ADP'), ('adults', 'NOUN'), ('with', 'ADP'), ('cerebrotendinous', 'ADJ'), ('xanthomatosis', 'NOUN'), ('.', 'PUNCT'), ('How', 'SCONJ'), ('Pharmacy', 'PROPN'), ('Matches', 'PROPN'), ('Perfectly', 'ADV'), ('With', 'ADP'), ('Nutrition', 'PROPN'), ('Known', 'PROPN'), ('as', 'ADP'), ('“', 'PUNCT'), ('The', 'DET'), ('Nutrition', 'PROPN'), ('Pharmacist', 'PROPN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Sarah', 'PROPN'), ('Gray', 'PROPN'), (',', 'PUNCT'), ('PharmD', 'PROPN'), (',', 'PUNCT'), ('GAICD', 'NOUN'), (',', 'PUNCT'), ('recently', 'ADV'), ('joined', 'VERB'), ('Drug', 'PROPN'), ('Topics', 'PROPN'), ('to', 'PART'), ('discuss', 'VERB'), ('her', 'PRON'), ('dual', 'ADJ'), ('profession', 'NOUN'), ('within', 'ADP'), ('health', 'NOUN'), ('care', 'NOUN'), ('.', 'PUNCT'), ('Type', 'NOUN'), ('1', 'NUM'), ('Diabetes', 'NOUN'), ('Linked', 'VERB'), ('With', 'ADP'), ('Increased', 'PROPN'), ('Dementia', 'PROPN'), ('Risk', 'NOUN'), ('A', 'DET'), ('recent', 'ADJ'), ('metanalysis', 'NOUN'), ('found', 'VERB'), ('that', 'SCONJ'), ('patients', 'NOUN'), ('with', 'ADP'), ('type', 'NOUN'), ('1', 'NUM'), ('diabetes', 'NOUN'), ('had', 'VERB'), ('a', 'DET'), ('50', 'NUM'), ('%', 'NOUN'), ('higher', 'ADJ'), ('chance', 'NOUN'), ('of', 'ADP'), ('developing', 'VERB'), ('dementia', 'NOUN'), ('.', 'PUNCT'), ('Episode', 'NOUN'), ('8', 'NUM'), (':', 'PUNCT'), ('Stay', 'VERB'), ('in', 'ADP'), ('Sync', 'PROPN'), ('with', 'ADP'), ('Innovations', 'PROPN'), ('in', 'ADP'), ('Medication', 'PROPN'), ('Decision', 'PROPN'), ('Support', 'PROPN'), ('Episode', 'PROPN'), ('8', 'NUM'), ('of', 'ADP'), ('Over', 'ADP'), ('the', 'DET'), ('Counter', 'PROPN'), ('discusses', 'VERB'), ('the', 'DET'), ('new', 'ADJ'), ('and', 'CCONJ'), ('exciting', 'ADJ'), ('modernizations', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('medication', 'NOUN'), ('decision', 'NOUN'), ('support', 'NOUN'), ('space', 'NOUN'), ('.', 'PUNCT'), ('FDA', 'PROPN'), ('Accepts', 'VERB'), ('New', 'PROPN'), ('Drug', 'PROPN'), ('Application', 'PROPN'), ('for', 'ADP'), ('Vatiquinone', 'PROPN'), ('to', 'PART'), ('Treat', 'VERB'), ('Friedreich', 'PROPN'), ('Ataxia', 'PROPN'), ('The', 'DET'), ('FDA', 'PROPN'), ('also', 'ADV'), ('granted', 'VERB'), ('priority', 'NOUN'), ('review', 'NOUN'), (',', 'PUNCT'), ('with', 'ADP'), ('a', 'DET'), ('Prescription', 'PROPN'), ('Drug', 'PROPN'), ('User', 'PROPN'), ('Fee', 'PROPN'), ('Act', 'PROPN'), ('target', 'NOUN'), ('action', 'NOUN'), ('date', 'NOUN'), ('of', 'ADP'), ('August', 'PROPN'), ('19', 'NUM'), (',', 'PUNCT'), ('2025', 'NUM'), ('.', 'PUNCT'), ('GLP-1', 'PROPN'), ('Oral', 'PROPN'), ('Tablet', 'PROPN'), ('Shows', 'VERB'), ('Favorable', 'PROPN'), ('Safety', 'PROPN'), ('Findings', 'PROPN'), ('in', 'ADP'), ('Patients', 'PROPN'), ('With', 'ADP'), ('Obesity', 'PROPN'), ('ASC30', 'PROPN'), (',', 'PUNCT'), ('an', 'DET'), ('investigational', 'ADJ'), ('glucagon', 'NOUN'), ('-', 'PUNCT'), ('like', 'ADJ'), ('1', 'NUM'), ('-', 'PUNCT'), ('peptide', 'NOUN'), ('receptor', 'NOUN'), ('agonist', 'NOUN'), (',', 'PUNCT'), ('demonstrates', 'VERB'), ('mean', 'ADJ'), ('weight', 'NOUN'), ('reductions', 'NOUN'), ('from', 'ADP'), ('baseline', 'NOUN'), ('of', 'ADP'), ('4.3', 'NUM'), ('%', 'NOUN'), ('and', 'CCONJ'), ('6.3', 'NUM'), ('%', 'NOUN'), ('for', 'ADP'), ('2', 'NUM'), ('separate', 'ADJ'), ('cohorts', 'NOUN'), ('.', 'PUNCT'), ('2', 'NUM'), ('Commerce', 'PROPN'), ('Drive', 'PROPN'), ('Cranbury', 'PROPN'), (',', 'PUNCT'), ('NJ', 'PROPN'), ('08512', 'NUM'), ('609', 'NUM'), ('-', 'SYM'), ('716', 'NUM'), ('-', 'SYM'), ('7777', 'NUM')]","[('2022', 'DATE'), ('FDA', 'ORG'), ('US', 'GPE'), ('March', 'DATE'), ('August', 'DATE'), ('2022', 'DATE'), ('FDA', 'ORG'), ('FDA', 'ORG'), ('FDA', 'ORG'), ('Novo Nordisk', 'PERSON'), ('Dave Moore', 'PERSON'), ('US', 'GPE'), ('Novo Nordisk Inc', 'ORG'), ('Novo Nordisk', 'PERSON'), ('Jacqueline Corrigan-Curay', 'PERSON'), ('JD', 'GPE'), ('MD', 'GPE'), ('CDC', 'ORG'), ('FDA', 'ORG'), ('Novo Nordisk', 'PERSON'), ('FDA', 'ORG'), ('Novo Nordisk’s', 'PERSON'), ('Novo Nordisk', 'PERSON'), ('FDA', 'ORG'), ('the Food, Drug & Cosmetic Act', 'ORG'), ('section 503A', 'LAW'), ('503B', 'CARDINAL'), ('April 22, 2025', 'DATE'), ('May 22, 2025', 'DATE'), ('FDA', 'ORG'), ('October 2, 2024', 'DATE'), ('Novo Nordisk', 'PERSON'), ('December 19, 2024', 'DATE'), ('FDA', 'ORG'), ('FDA', 'ORG'), ('Victoza', 'GPE'), ('Saxenda', 'PERSON'), ('FDA Approves Chenodiol for Treatment of Cerebrotendinous Xanthomatosis Ctexli', 'ORG'), ('first', 'ORDINAL'), ('FDA', 'ORG'), ('The Nutrition Pharmacist', 'WORK_OF_ART'), ('Sarah Gray', 'PERSON'), ('GAICD', 'PERSON'), ('Drug Topics', 'ORG'), ('1', 'CARDINAL'), ('1', 'CARDINAL'), ('50%', 'PERCENT'), ('Sync', 'ORG'), ('Innovations in Medication Decision Support', 'ORG'), ('Counter', 'PERSON'), ('FDA Accepts New Drug Application for Vatiquinone', 'ORG'), ('FDA', 'ORG'), ('August 19, 2025', 'DATE'), ('GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity ASC30', 'ORG'), ('1', 'CARDINAL'), ('4.3%', 'PERCENT'), ('6.3%', 'PERCENT'), ('2', 'CARDINAL'), ('FDA', 'ORG'), ('first', 'ORDINAL'), ('FDA', 'ORG'), ('The Nutrition Pharmacist', 'WORK_OF_ART'), ('Sarah Gray', 'PERSON'), ('GAICD', 'PERSON'), ('Drug Topics', 'ORG'), ('1', 'CARDINAL'), ('1', 'CARDINAL'), ('50%', 'PERCENT'), ('Sync', 'ORG'), ('Innovations in Medication Decision Support', 'ORG'), ('Counter', 'PERSON'), ('FDA Accepts New Drug Application for Vatiquinone', 'ORG'), ('FDA', 'ORG'), ('August 19, 2025', 'DATE'), ('GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity ASC30', 'ORG'), ('1', 'CARDINAL'), ('4.3%', 'PERCENT'), ('6.3%', 'PERCENT'), ('2', 'CARDINAL'), ('2', 'CARDINAL'), ('NJ', 'ORG'), ('609', 'CARDINAL')]","['2022', 'FDA', 'US', 'March', 'August', '2022', 'FDA', 'FDA', 'FDA', 'Novo Nordisk', 'Dave Moore', 'US', 'Novo Nordisk Inc', 'Novo Nordisk', 'Jacqueline Corrigan-Curay', 'JD', 'MD', 'CDC', 'FDA', 'Novo Nordisk', 'FDA', 'Novo Nordisk’s', 'Novo Nordisk', 'FDA', 'the Food, Drug & Cosmetic Act', 'section 503A', '503B', 'April 22, 2025', 'May 22, 2025', 'FDA', 'October 2, 2024', 'Novo Nordisk', 'December 19, 2024', 'FDA', 'FDA', 'Victoza', 'Saxenda', 'FDA Approves Chenodiol for Treatment of Cerebrotendinous Xanthomatosis Ctexli', 'first', 'FDA', 'The Nutrition Pharmacist', 'Sarah Gray', 'GAICD', 'Drug Topics', '1', '1', '50%', 'Sync', 'Innovations in Medication Decision Support', 'Counter', 'FDA Accepts New Drug Application for Vatiquinone', 'FDA', 'August 19, 2025', 'GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity ASC30', '1', '4.3%', '6.3%', '2', 'FDA', 'first', 'FDA', 'The Nutrition Pharmacist', 'Sarah Gray', 'GAICD', 'Drug Topics', '1', '1', '50%', 'Sync', 'Innovations in Medication Decision Support', 'Counter', 'FDA Accepts New Drug Application for Vatiquinone', 'FDA', 'August 19, 2025', 'GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity ASC30', '1', '4.3%', '6.3%', '2', '2', 'NJ', '609']","['2022', 'FDA', 'US', 'March', 'August', '2022', 'FDA', 'FDA', 'FDA', 'Novo Nordisk', 'Dave Moore', 'US', 'Novo Nordisk Inc', 'Novo Nordisk', 'Jacqueline Corrigan-Curay', 'JD', 'MD', 'CDC', 'FDA', 'Novo Nordisk', 'FDA', 'Novo Nordisk’s', 'Novo Nordisk', 'FDA', 'the Food, Drug & Cosmetic Act', 'section 503A', '503B', 'April 22, 2025', 'May 22, 2025', 'FDA', 'October 2, 2024', 'Novo Nordisk', 'December 19, 2024', 'FDA', 'FDA', 'Victoza', 'Saxenda', 'FDA Approves Chenodiol for Treatment of Cerebrotendinous Xanthomatosis Ctexli', 'first', 'FDA', 'The Nutrition Pharmacist', 'Sarah Gray', 'GAICD', 'Drug Topics', '1', '1', '50%', 'Sync', 'Innovations in Medication Decision Support', 'Counter', 'FDA Accepts New Drug Application for Vatiquinone', 'FDA', 'August 19, 2025', 'GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity ASC30', '1', '4.3%', '6.3%', '2', 'FDA', 'first', 'FDA', 'The Nutrition Pharmacist', 'Sarah Gray', 'GAICD', 'Drug Topics', '1', '1', '50%', 'Sync', 'Innovations in Medication Decision Support', 'Counter', 'FDA Accepts New Drug Application for Vatiquinone', 'FDA', 'August 19, 2025', 'GLP-1 Oral Tablet Shows Favorable Safety Findings in Patients With Obesity ASC30', '1', '4.3%', '6.3%', '2', '2', 'NJ', '609']"
"FDA says Ozempic, Wegovy shortage is over",https://endpts.com/fda-says-ozempic-wegovy-shortage-is-over/,"The FDA said Fri­day that the short­age of semaglu­tide, the main in­gre­di­ent in No­vo Nordisk’s GLP-1 drugs Ozem­pic and We­govy, has … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.","[('The', 'DET'), ('FDA', 'PROPN'), ('said', 'VERB'), ('Fri\xadday', 'PROPN'), ('that', 'SCONJ'), ('the', 'DET'), ('short\xadage', 'NOUN'), ('of', 'ADP'), ('semaglu\xadtide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('in\xadgre\xaddi\xadent', 'NOUN'), ('in', 'ADP'), ('No\xadvo', 'ADV'), ('Nordisk', 'PROPN'), ('’s', 'PART'), ('GLP-1', 'PROPN'), ('drugs', 'NOUN'), ('Ozem\xadpic', 'PROPN'), ('and', 'CCONJ'), ('We\xadgovy', 'PROPN'), (',', 'PUNCT'), ('has', 'AUX'), ('…', 'PUNCT'), ('Get', 'VERB'), ('free', 'ADJ'), ('access', 'NOUN'), ('to', 'ADP'), ('a', 'DET'), ('limited', 'ADJ'), ('number', 'NOUN'), ('of', 'ADP'), ('articles', 'NOUN'), (',', 'PUNCT'), ('plus', 'CCONJ'), ('choose', 'VERB'), ('newsletters', 'NOUN'), ('to', 'PART'), ('get', 'VERB'), ('straight', 'ADJ'), ('to', 'ADP'), ('your', 'PRON'), ('inbox', 'NOUN'), ('.', 'PUNCT')]","[('FDA', 'ORG'), ('Nordisk’s GLP-1', 'PERSON'), ('We\xadgovy', 'GPE')]","['FDA', 'Nordisk’s GLP-1', 'We\xadgovy']","['FDA', 'Nordisk’s GLP-1', 'We\xadgovy']"
FDA: Ozempic and Wegovy drug shortage is over,https://www.usatoday.com/story/money/2025/02/21/ozempic-wegovy-drug-shortage-is-over-fda/79428396007/,"The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper compounded versions of the wildly popular medications. In a statement, the FDA said it confirmed Novo Nordisk's ""stated product availability and manufacturing capacity"" of these prescription drugs meets or exceeds current and projected demand. The agency warned consumers and doctors might still experience ""limited localized supply disruptions"" as the products are shipped from drug factories to distributors to pharmacies. The Danish drugmaker Novo Nordisk said it has invested $6.5 billion this year in the United States to bolster drug production facilities that are operating 24/7, shipping Wegovy and Ozempic to wholesalers. Pharmaceutical giants that market lucrative weight-loss drugs have battled with firms that sell less expensive versions made by compounding pharmacies. The FDA allows compounding pharmacies to sell copies of drugs when the medications are in short supply. But compounding pharmacies face stiffer restrictions when a drug shortage is resolved. Need a break? Play the USA TODAY Daily Crossword Puzzle. Companies that market compounded drugs − combining, mixing or altering drug ingredients − have prospered amid shortages of the class of weight-loss medications, called GLP-1 (glucagon-like peptide-1) receptor agonists. Hims & Hers, which launched a Super Bowl ad touting its weight loss product offerings, markets a compounded version of semaglutide, the active ingredient in Ozempic and Wegovy. Shares of Hims & Hers plunged 17% in mid-morning trading after the FDA's announcement. The FDA said it won't take enforcement action against pharmacies or doctors that make compounded semaglutide due to the shortage before April 22. Facilities that compound, distribute or dispense semaglutide injections won't face enforcement action before May 22. In December, the FDA declared that Eli Lilly's weight loss and diabetes medication tirzepatide, sold under the brand names Mounjaro and Zepbound, was no longer in short supply. That meant pharmacies had to discontinue ""compounding, distributing or dispensing"" tirzepatide as of Feb 18. Suppliers that produce batches of the drug and sell to others have until March 19 to cease distribution. Compounding pharmacies are regulated by state boards of pharmacy and source ingredients are usually obtained from factories registered with the FDA. However, the federal agency doesn't verify the safety or effectiveness of compounding pharmacies.","[('The', 'DET'), ('Food', 'PROPN'), ('and', 'CCONJ'), ('Drug', 'PROPN'), ('Administration', 'PROPN'), ('on', 'ADP'), ('Friday', 'PROPN'), ('said', 'VERB'), ('the', 'DET'), ('shortage', 'NOUN'), ('of', 'ADP'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), (""'s"", 'PART'), ('weight', 'NOUN'), ('-', 'PUNCT'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('diabetes', 'NOUN'), ('drugs', 'NOUN'), ('Wegovy', 'PROPN'), ('and', 'CCONJ'), ('Ozempic', 'PROPN'), ('is', 'AUX'), ('resolved', 'VERB'), (',', 'PUNCT'), ('a', 'DET'), ('move', 'NOUN'), ('that', 'PRON'), ('could', 'AUX'), ('limit', 'VERB'), ('the', 'DET'), ('availability', 'NOUN'), ('of', 'ADP'), ('cheaper', 'ADJ'), ('compounded', 'VERB'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('wildly', 'ADV'), ('popular', 'ADJ'), ('medications', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('a', 'DET'), ('statement', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('FDA', 'PROPN'), ('said', 'VERB'), ('it', 'PRON'), ('confirmed', 'VERB'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), (""'s"", 'PART'), ('""', 'PUNCT'), ('stated', 'VERB'), ('product', 'NOUN'), ('availability', 'NOUN'), ('and', 'CCONJ'), ('manufacturing', 'NOUN'), ('capacity', 'NOUN'), ('""', 'PUNCT'), ('of', 'ADP'), ('these', 'DET'), ('prescription', 'NOUN'), ('drugs', 'NOUN'), ('meets', 'VERB'), ('or', 'CCONJ'), ('exceeds', 'VERB'), ('current', 'ADJ'), ('and', 'CCONJ'), ('projected', 'ADJ'), ('demand', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('agency', 'NOUN'), ('warned', 'VERB'), ('consumers', 'NOUN'), ('and', 'CCONJ'), ('doctors', 'NOUN'), ('might', 'AUX'), ('still', 'ADV'), ('experience', 'VERB'), ('""', 'PUNCT'), ('limited', 'ADJ'), ('localized', 'VERB'), ('supply', 'NOUN'), ('disruptions', 'NOUN'), ('""', 'PUNCT'), ('as', 'SCONJ'), ('the', 'DET'), ('products', 'NOUN'), ('are', 'AUX'), ('shipped', 'VERB'), ('from', 'ADP'), ('drug', 'NOUN'), ('factories', 'NOUN'), ('to', 'ADP'), ('distributors', 'NOUN'), ('to', 'ADP'), ('pharmacies', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('Danish', 'ADJ'), ('drugmaker', 'NOUN'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('said', 'VERB'), ('it', 'PRON'), ('has', 'AUX'), ('invested', 'VERB'), ('$', 'SYM'), ('6.5', 'NUM'), ('billion', 'NUM'), ('this', 'DET'), ('year', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('United', 'PROPN'), ('States', 'PROPN'), ('to', 'PART'), ('bolster', 'VERB'), ('drug', 'NOUN'), ('production', 'NOUN'), ('facilities', 'NOUN'), ('that', 'PRON'), ('are', 'AUX'), ('operating', 'VERB'), ('24/7', 'NUM'), (',', 'PUNCT'), ('shipping', 'VERB'), ('Wegovy', 'PROPN'), ('and', 'CCONJ'), ('Ozempic', 'PROPN'), ('to', 'ADP'), ('wholesalers', 'NOUN'), ('.', 'PUNCT'), ('Pharmaceutical', 'NOUN'), ('giants', 'NOUN'), ('that', 'PRON'), ('\xa0', 'SPACE'), ('market', 'NOUN'), ('lucrative', 'ADJ'), ('weight', 'NOUN'), ('-', 'PUNCT'), ('loss', 'NOUN'), ('drugs', 'NOUN'), ('have', 'AUX'), ('battled', 'VERB'), ('with', 'ADP'), ('firms', 'NOUN'), ('that', 'PRON'), ('sell', 'VERB'), ('less', 'ADV'), ('expensive', 'ADJ'), ('versions', 'NOUN'), ('\xa0', 'SPACE'), ('made', 'VERB'), ('by', 'ADP'), ('compounding', 'VERB'), ('pharmacies', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('FDA', 'PROPN'), ('allows', 'VERB'), ('compounding', 'VERB'), ('pharmacies', 'NOUN'), ('to', 'PART'), ('sell', 'VERB'), ('copies', 'NOUN'), ('of', 'ADP'), ('drugs', 'NOUN'), ('when', 'SCONJ'), ('the', 'DET'), ('medications', 'NOUN'), ('are', 'AUX'), ('in', 'ADP'), ('short', 'ADJ'), ('supply', 'NOUN'), ('.', 'PUNCT'), ('But', 'CCONJ'), ('compounding', 'VERB'), ('pharmacies', 'NOUN'), ('face', 'VERB'), ('stiffer', 'VERB'), ('restrictions', 'NOUN'), ('when', 'SCONJ'), ('a', 'DET'), ('drug', 'NOUN'), ('shortage', 'NOUN'), ('is', 'AUX'), ('resolved', 'VERB'), ('.', 'PUNCT'), ('Need', 'VERB'), ('a', 'DET'), ('break', 'NOUN'), ('?', 'PUNCT'), ('Play', 'VERB'), ('the', 'DET'), ('USA', 'PROPN'), ('TODAY', 'PROPN'), ('Daily', 'PROPN'), ('Crossword', 'PROPN'), ('Puzzle', 'PROPN'), ('.', 'PUNCT'), ('Companies', 'NOUN'), ('that', 'PRON'), ('market', 'NOUN'), ('compounded', 'VERB'), ('drugs', 'NOUN'), ('−', 'PROPN'), ('combining', 'VERB'), (',', 'PUNCT'), ('mixing', 'VERB'), ('or', 'CCONJ'), ('altering', 'VERB'), ('drug', 'NOUN'), ('ingredients', 'NOUN'), ('−', 'PROPN'), ('have', 'AUX'), ('prospered', 'VERB'), ('amid', 'ADP'), ('shortages', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('class', 'NOUN'), ('of', 'ADP'), ('\xa0', 'SPACE'), ('weight', 'NOUN'), ('-', 'PUNCT'), ('loss', 'NOUN'), ('medications', 'NOUN'), (',', 'PUNCT'), ('called', 'VERB'), ('GLP-1', 'PROPN'), ('(', 'PUNCT'), ('glucagon', 'NOUN'), ('-', 'PUNCT'), ('like', 'ADP'), ('peptide-1', 'NUM'), (')', 'PUNCT'), ('receptor', 'NOUN'), ('agonists', 'NOUN'), ('.', 'PUNCT'), ('Hims', 'PROPN'), ('&', 'CCONJ'), ('Hers', 'PROPN'), (',', 'PUNCT'), ('which', 'PRON'), ('launched', 'VERB'), ('a', 'DET'), ('Super', 'PROPN'), ('Bowl', 'PROPN'), ('ad', 'NOUN'), ('touting', 'VERB'), ('its', 'PRON'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('product', 'NOUN'), ('offerings', 'NOUN'), (',', 'PUNCT'), ('markets', 'VERB'), ('a', 'DET'), ('compounded', 'VERB'), ('version', 'NOUN'), ('of', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('active', 'ADJ'), ('ingredient', 'NOUN'), ('in', 'ADP'), ('\xa0', 'SPACE'), ('Ozempic', 'PROPN'), ('\xa0', 'SPACE'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), ('.', 'PUNCT'), ('Shares', 'NOUN'), ('of', 'ADP'), ('Hims', 'PROPN'), ('&', 'CCONJ'), ('Hers', 'PROPN'), ('plunged', 'VERB'), ('17', 'NUM'), ('%', 'NOUN'), ('in', 'ADP'), ('mid', 'ADJ'), ('-', 'NOUN'), ('morning', 'NOUN'), ('trading', 'NOUN'), ('after', 'ADP'), ('the', 'DET'), ('FDA', 'PROPN'), (""'s"", 'PART'), ('announcement', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('FDA', 'PROPN'), ('said', 'VERB'), ('it', 'PRON'), ('wo', 'AUX'), (""n't"", 'PART'), ('take', 'VERB'), ('enforcement', 'NOUN'), ('action', 'NOUN'), ('against', 'ADP'), ('pharmacies', 'NOUN'), ('or', 'CCONJ'), ('doctors', 'NOUN'), ('that', 'PRON'), ('make', 'VERB'), ('compounded', 'VERB'), ('semaglutide', 'NOUN'), ('due', 'ADP'), ('to', 'ADP'), ('the', 'DET'), ('shortage', 'NOUN'), ('before', 'ADP'), ('April', 'PROPN'), ('22', 'NUM'), ('.', 'PUNCT'), ('Facilities', 'NOUN'), ('that', 'PRON'), ('compound', 'VERB'), (',', 'PUNCT'), ('distribute', 'VERB'), ('or', 'CCONJ'), ('dispense', 'VERB'), ('semaglutide', 'NOUN'), ('injections', 'NOUN'), ('wo', 'AUX'), (""n't"", 'PART'), ('face', 'VERB'), ('enforcement', 'NOUN'), ('action', 'NOUN'), ('before', 'ADP'), ('May', 'PROPN'), ('22', 'NUM'), ('.', 'PUNCT'), ('In', 'ADP'), ('December', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('FDA', 'PROPN'), ('\xa0', 'SPACE'), ('declared', 'VERB'), ('that', 'SCONJ'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), (""'s"", 'PART'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('diabetes', 'VERB'), ('medication', 'NOUN'), ('tirzepatide', 'NOUN'), (',', 'PUNCT'), ('sold', 'VERB'), ('under', 'ADP'), ('the', 'DET'), ('brand', 'NOUN'), ('names', 'NOUN'), ('Mounjaro', 'PROPN'), ('and', 'CCONJ'), ('Zepbound', 'PROPN'), (',', 'PUNCT'), ('was', 'AUX'), ('\xa0', 'SPACE'), ('no', 'ADV'), ('longer', 'ADV'), ('in', 'ADP'), ('short', 'ADJ'), ('supply', 'NOUN'), ('.', 'PUNCT'), ('That', 'PRON'), ('meant', 'VERB'), ('pharmacies', 'NOUN'), ('had', 'VERB'), ('to', 'PART'), ('discontinue', 'VERB'), ('""', 'PUNCT'), ('compounding', 'NOUN'), (',', 'PUNCT'), ('distributing', 'VERB'), ('or', 'CCONJ'), ('dispensing', 'VERB'), ('""', 'PUNCT'), ('tirzepatide', 'NOUN'), ('as', 'ADP'), ('of', 'ADP'), ('Feb', 'PROPN'), ('18', 'NUM'), ('.', 'PUNCT'), ('Suppliers', 'NOUN'), ('that', 'PRON'), ('produce', 'VERB'), ('batches', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('and', 'CCONJ'), ('sell', 'VERB'), ('to', 'ADP'), ('others', 'NOUN'), ('have', 'VERB'), ('until', 'ADP'), ('\xa0', 'SPACE'), ('March', 'PROPN'), ('19', 'NUM'), ('\xa0', 'SPACE'), ('to', 'PART'), ('cease', 'VERB'), ('distribution', 'NOUN'), ('.', 'PUNCT'), ('Compounding', 'VERB'), ('pharmacies', 'NOUN'), ('are', 'AUX'), ('regulated', 'VERB'), ('by', 'ADP'), ('state', 'NOUN'), ('boards', 'NOUN'), ('of', 'ADP'), ('pharmacy', 'NOUN'), ('and', 'CCONJ'), ('source', 'NOUN'), ('ingredients', 'NOUN'), ('are', 'AUX'), ('usually', 'ADV'), ('obtained', 'VERB'), ('from', 'ADP'), ('factories', 'NOUN'), ('registered', 'VERB'), ('with', 'ADP'), ('the', 'DET'), ('FDA', 'PROPN'), ('.', 'PUNCT'), ('However', 'ADV'), (',', 'PUNCT'), ('the', 'DET'), ('federal', 'ADJ'), ('agency', 'NOUN'), ('does', 'AUX'), (""n't"", 'PART'), ('verify', 'VERB'), ('the', 'DET'), ('safety', 'NOUN'), ('or', 'CCONJ'), ('effectiveness', 'NOUN'), ('of', 'ADP'), ('compounding', 'VERB'), ('pharmacies', 'NOUN'), ('.', 'PUNCT')]","[('The Food and Drug Administration', 'ORG'), ('Friday', 'DATE'), (""Novo Nordisk's"", 'PERSON'), ('Wegovy and Ozempic', 'ORG'), ('FDA', 'ORG'), (""Novo Nordisk's"", 'PERSON'), ('Danish', 'NORP'), ('Novo Nordisk', 'PERSON'), ('$6.5 billion', 'MONEY'), ('this year', 'DATE'), ('the United States', 'GPE'), ('Wegovy and Ozempic', 'ORG'), ('FDA', 'ORG'), ('−', 'GPE'), ('−', 'GPE'), ('GLP-1', 'PERSON'), ('Hims & Hers', 'ORG'), ('Super Bowl', 'EVENT'), ('Wegovy', 'ORG'), ('Hims & Hers', 'ORG'), ('17%', 'PERCENT'), ('mid-morning', 'TIME'), ('FDA', 'ORG'), ('FDA', 'ORG'), ('April 22', 'DATE'), ('May 22', 'DATE'), ('December', 'DATE'), ('FDA', 'ORG'), (""Eli Lilly's"", 'ORG'), ('Mounjaro', 'PERSON'), ('Zepbound', 'PERSON'), ('Feb 18', 'DATE'), ('March 19', 'DATE'), ('FDA', 'ORG')]","['The Food and Drug Administration', 'Friday', ""Novo Nordisk's"", 'Wegovy and Ozempic', 'FDA', ""Novo Nordisk's"", 'Danish', 'Novo Nordisk', '$6.5 billion', 'this year', 'the United States', 'Wegovy and Ozempic', 'FDA', '−', '−', 'GLP-1', 'Hims & Hers', 'Super Bowl', 'Wegovy', 'Hims & Hers', '17%', 'mid-morning', 'FDA', 'FDA', 'April 22', 'May 22', 'December', 'FDA', ""Eli Lilly's"", 'Mounjaro', 'Zepbound', 'Feb 18', 'March 19', 'FDA']","['The Food and Drug Administration', 'Friday', 'Novo Nordisk’s', 'Wegovy and Ozempic', 'FDA', 'Novo Nordisk’s', 'Danish', 'Novo Nordisk', '$5.7 billion', 'this year', 'the United States', 'Wegovy and Ozempic', 'FDA', '−', '−', 'GLP-1', 'Hims & Hers', 'Super Bowl', 'Wegovy', 'Hims & Hers', '17%', 'mid-morning', 'FDA', 'FDA', 'April 22', 'May 22', 'December', 'FDA', ""Eli Lilly's"", 'Mounjaro', 'Zepbound', 'Feb 18', 'March 19', 'FDA']"
FDA declares end to Wegovy and Ozempic shortage - CBS News,https://www.cbsnews.com/news/fda-declares-end-to-wegovy-and-ozempic-shortage/,"                      Alexander Tin Edited By                       Nicole Brown Chau February 21, 2025 / 11:42 AM EST           / CBS News The Food and Drug Administration announced Friday it had officially declared an end to the nationwide shortage of Ozempic and Wegovy, medications used for diabetes and weight loss. The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency that all dosages of its semaglutide product had become fully available nationwide. The company said in a statement that it confirms the supply of the medications, which are prescription-only, ""now meets or exceeds both current and projected U.S. demand."" ""This update comes after ongoing dialogue with the FDA, and substantial efforts by Novo Nordisk to increase manufacturing capacity, including $6.5 billion dollars of investments in the U.S. this year alone,"" the drugmaker said. The FDA said that it will allow compounding pharmacies to continue to make copies of semaglutide for now, which they are usually allowed to do only while the drug is in shortage. That leeway will continue until April 22 for many pharmacies and May 22 for outsourcing facilities to ""avoid unnecessary disruption"" to patients, the agency said. This is similar to what the FDA has granted compounding pharmacies making copies of Eli Lilly's diabetes and weight loss drug tirzepatide, amid an ongoing lawsuit brought by outsourcing facilities disputing the FDA's decision to declare the shortage of that weight loss drug over. Some compounding pharmacies and outsourcing facilities have made millions making copies of semaglutide and tirzepatide during their shortages in recent years, amid a flurry of companies cashing in on demand for the drugs. The FDA is also facing calls to do more to crack down on counterfeits of the drugs, including from state attorneys general who urged the agency this week to stop illegal imports from overseas. ""Demand for the medications Mounjaro, Zepbound, Ozempic, and Wegovy (GLP-1 drugs) has skyrocketed, but supply shortages and high costs have created opportunities for wrongdoers to cash in and endanger consumers,"" they wrote. Alexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers federal public health agencies. © 2025 CBS Interactive Inc. All Rights Reserved.","[('                      ', 'SPACE'), ('Alexander', 'PROPN'), ('Tin', 'PROPN'), ('Edited', 'VERB'), ('By', 'ADP'), ('                      ', 'SPACE'), ('Nicole', 'PROPN'), ('Brown', 'PROPN'), ('Chau', 'PROPN'), ('February', 'PROPN'), ('21', 'NUM'), (',', 'PUNCT'), ('2025', 'NUM'), ('/', 'SYM'), ('11:42', 'NUM'), ('AM', 'PROPN'), ('EST', 'PROPN'), ('          ', 'SPACE'), ('/', 'SYM'), ('CBS', 'PROPN'), ('News', 'PROPN'), ('The', 'DET'), ('Food', 'PROPN'), ('and', 'CCONJ'), ('Drug', 'PROPN'), ('Administration', 'PROPN'), ('announced', 'VERB'), ('Friday', 'PROPN'), ('it', 'PRON'), ('had', 'AUX'), ('officially', 'ADV'), ('declared', 'VERB'), ('an', 'DET'), ('end', 'NOUN'), ('to', 'ADP'), ('the', 'DET'), ('nationwide', 'ADJ'), ('shortage', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), (',', 'PUNCT'), ('medications', 'NOUN'), ('used', 'VERB'), ('for', 'ADP'), ('diabetes', 'NOUN'), ('and', 'CCONJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('agency', 'NOUN'), ('first', 'ADV'), ('declared', 'VERB'), ('a', 'DET'), ('shortage', 'NOUN'), ('of', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('ingredient', 'NOUN'), ('used', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), (',', 'PUNCT'), ('in', 'ADP'), ('2022', 'NUM'), ('.', 'PUNCT'), ('The', 'DET'), ('FDA', 'PROPN'), (""'s"", 'PART'), ('announcement', 'NOUN'), ('comes', 'VERB'), ('months', 'NOUN'), ('after', 'ADP'), ('drugmaker', 'NOUN'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('told', 'VERB'), ('the', 'DET'), ('agency', 'NOUN'), ('that', 'SCONJ'), ('all', 'DET'), ('dosages', 'NOUN'), ('of', 'ADP'), ('its', 'PRON'), ('semaglutide', 'NOUN'), ('product', 'NOUN'), ('had', 'AUX'), ('become', 'VERB'), ('fully', 'ADV'), ('available', 'ADJ'), ('nationwide', 'ADV'), ('.', 'PUNCT'), ('The', 'DET'), ('company', 'NOUN'), ('said', 'VERB'), ('in', 'ADP'), ('a', 'DET'), ('statement', 'NOUN'), ('that', 'SCONJ'), ('it', 'PRON'), ('confirms', 'VERB'), ('the', 'DET'), ('supply', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('medications', 'NOUN'), (',', 'PUNCT'), ('which', 'PRON'), ('are', 'AUX'), ('prescription', 'NOUN'), ('-', 'PUNCT'), ('only', 'ADV'), (',', 'PUNCT'), ('""', 'PUNCT'), ('now', 'ADV'), ('meets', 'VERB'), ('or', 'CCONJ'), ('exceeds', 'VERB'), ('both', 'CCONJ'), ('current', 'ADJ'), ('and', 'CCONJ'), ('projected', 'VERB'), ('U.S.', 'PROPN'), ('demand', 'NOUN'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('""', 'PUNCT'), ('This', 'DET'), ('update', 'NOUN'), ('comes', 'VERB'), ('after', 'ADP'), ('ongoing', 'ADJ'), ('dialogue', 'NOUN'), ('with', 'ADP'), ('the', 'DET'), ('FDA', 'PROPN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('substantial', 'ADJ'), ('efforts', 'NOUN'), ('by', 'ADP'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('to', 'PART'), ('increase', 'VERB'), ('manufacturing', 'NOUN'), ('capacity', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('$', 'SYM'), ('6.5', 'NUM'), ('billion', 'NUM'), ('dollars', 'NOUN'), ('of', 'ADP'), ('investments', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('U.S.', 'PROPN'), ('this', 'DET'), ('year', 'NOUN'), ('alone', 'ADV'), (',', 'PUNCT'), ('""', 'PUNCT'), ('the', 'DET'), ('drugmaker', 'NOUN'), ('said', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('FDA', 'PROPN'), ('said', 'VERB'), ('that', 'SCONJ'), ('it', 'PRON'), ('will', 'AUX'), ('allow', 'VERB'), ('compounding', 'NOUN'), ('pharmacies', 'NOUN'), ('to', 'PART'), ('continue', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('copies', 'NOUN'), ('of', 'ADP'), ('semaglutide', 'NOUN'), ('for', 'ADP'), ('now', 'ADV'), (',', 'PUNCT'), ('which', 'PRON'), ('they', 'PRON'), ('are', 'AUX'), ('usually', 'ADV'), ('allowed', 'VERB'), ('to', 'PART'), ('do', 'VERB'), ('only', 'ADV'), ('while', 'SCONJ'), ('the', 'DET'), ('drug', 'NOUN'), ('is', 'AUX'), ('in', 'ADP'), ('shortage', 'NOUN'), ('.', 'PUNCT'), ('That', 'DET'), ('leeway', 'NOUN'), ('will', 'AUX'), ('continue', 'VERB'), ('until', 'ADP'), ('April', 'PROPN'), ('22', 'NUM'), ('for', 'ADP'), ('many', 'ADJ'), ('pharmacies', 'NOUN'), ('and', 'CCONJ'), ('May', 'PROPN'), ('22', 'NUM'), ('for', 'ADP'), ('outsourcing', 'VERB'), ('facilities', 'NOUN'), ('to', 'PART'), ('""', 'PUNCT'), ('avoid', 'VERB'), ('unnecessary', 'ADJ'), ('disruption', 'NOUN'), ('""', 'PUNCT'), ('to', 'ADP'), ('patients', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('agency', 'NOUN'), ('said', 'VERB'), ('.', 'PUNCT'), ('This', 'PRON'), ('is', 'AUX'), ('similar', 'ADJ'), ('to', 'ADP'), ('what', 'PRON'), ('the', 'DET'), ('FDA', 'PROPN'), ('has', 'AUX'), ('granted', 'VERB'), ('compounding', 'NOUN'), ('pharmacies', 'NOUN'), ('making', 'VERB'), ('copies', 'NOUN'), ('of', 'ADP'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), (""'s"", 'PART'), ('diabetes', 'NOUN'), ('and', 'CCONJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drug', 'NOUN'), ('tirzepatide', 'NOUN'), (',', 'PUNCT'), ('amid', 'ADP'), ('an', 'DET'), ('ongoing', 'ADJ'), ('lawsuit', 'NOUN'), ('brought', 'VERB'), ('by', 'ADP'), ('outsourcing', 'VERB'), ('facilities', 'NOUN'), ('disputing', 'VERB'), ('the', 'DET'), ('FDA', 'PROPN'), (""'s"", 'PART'), ('decision', 'NOUN'), ('to', 'PART'), ('declare', 'VERB'), ('the', 'DET'), ('shortage', 'NOUN'), ('of', 'ADP'), ('that', 'DET'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drug', 'NOUN'), ('over', 'ADP'), ('.', 'PUNCT'), ('Some', 'DET'), ('compounding', 'NOUN'), ('pharmacies', 'NOUN'), ('and', 'CCONJ'), ('outsourcing', 'VERB'), ('facilities', 'NOUN'), ('have', 'AUX'), ('made', 'VERB'), ('millions', 'NOUN'), ('making', 'VERB'), ('copies', 'NOUN'), ('of', 'ADP'), ('semaglutide', 'NOUN'), ('and', 'CCONJ'), ('tirzepatide', 'NOUN'), ('during', 'ADP'), ('their', 'PRON'), ('shortages', 'NOUN'), ('in', 'ADP'), ('recent', 'ADJ'), ('years', 'NOUN'), (',', 'PUNCT'), ('amid', 'ADP'), ('a', 'DET'), ('flurry', 'NOUN'), ('of', 'ADP'), ('companies', 'NOUN'), ('cashing', 'VERB'), ('in', 'ADP'), ('on', 'ADP'), ('demand', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('drugs', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('FDA', 'PROPN'), ('is', 'AUX'), ('also', 'ADV'), ('facing', 'VERB'), ('calls', 'NOUN'), ('to', 'PART'), ('do', 'VERB'), ('more', 'ADJ'), ('to', 'PART'), ('crack', 'VERB'), ('down', 'ADP'), ('on', 'ADP'), ('counterfeits', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drugs', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('from', 'ADP'), ('state', 'NOUN'), ('attorneys', 'NOUN'), ('general', 'NOUN'), ('who', 'PRON'), ('urged', 'VERB'), ('the', 'DET'), ('agency', 'NOUN'), ('this', 'DET'), ('week', 'NOUN'), ('to', 'PART'), ('stop', 'VERB'), ('illegal', 'ADJ'), ('imports', 'NOUN'), ('from', 'ADP'), ('overseas', 'ADV'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('Demand', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('medications', 'NOUN'), ('Mounjaro', 'PROPN'), (',', 'PUNCT'), ('Zepbound', 'PROPN'), (',', 'PUNCT'), ('Ozempic', 'PROPN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), ('(', 'PUNCT'), ('GLP-1', 'PROPN'), ('drugs', 'NOUN'), (')', 'PUNCT'), ('has', 'AUX'), ('skyrocketed', 'VERB'), (',', 'PUNCT'), ('but', 'CCONJ'), ('supply', 'NOUN'), ('shortages', 'NOUN'), ('and', 'CCONJ'), ('high', 'ADJ'), ('costs', 'NOUN'), ('have', 'AUX'), ('created', 'VERB'), ('opportunities', 'NOUN'), ('for', 'ADP'), ('wrongdoers', 'NOUN'), ('to', 'PART'), ('cash', 'VERB'), ('in', 'ADP'), ('and', 'CCONJ'), ('endanger', 'VERB'), ('consumers', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('they', 'PRON'), ('wrote', 'VERB'), ('.', 'PUNCT'), ('Alexander', 'PROPN'), ('Tin', 'PROPN'), ('is', 'AUX'), ('a', 'DET'), ('digital', 'ADJ'), ('reporter', 'NOUN'), ('for', 'ADP'), ('CBS', 'PROPN'), ('News', 'PROPN'), ('based', 'VERB'), ('in', 'ADP'), ('the', 'DET'), ('Washington', 'PROPN'), (',', 'PUNCT'), ('D.C.', 'PROPN'), ('bureau', 'NOUN'), ('.', 'PUNCT'), ('He', 'PRON'), ('covers', 'VERB'), ('federal', 'ADJ'), ('public', 'ADJ'), ('health', 'NOUN'), ('agencies', 'NOUN'), ('.', 'PUNCT'), ('©', 'NOUN'), ('2025', 'NUM'), ('CBS', 'PROPN'), ('Interactive', 'PROPN'), ('Inc.', 'PROPN'), ('All', 'DET'), ('Rights', 'PROPN'), ('Reserved', 'VERB'), ('.', 'PUNCT')]","[('Alexander Tin Edited', 'PERSON'), ('February 21, 2025', 'DATE'), ('11:42 AM EST', 'TIME'), ('The Food and Drug Administration', 'ORG'), ('Friday', 'DATE'), ('Ozempic', 'GPE'), ('Wegovy', 'ORG'), ('first', 'ORDINAL'), ('Wegovy', 'ORG'), ('2022', 'DATE'), ('FDA', 'ORG'), ('months', 'DATE'), ('Novo Nordisk', 'PERSON'), ('U.S.', 'GPE'), ('FDA', 'ORG'), ('Novo Nordisk', 'PERSON'), ('$6.5 billion dollars', 'MONEY'), ('U.S.', 'GPE'), ('this year', 'DATE'), ('FDA', 'ORG'), ('April 22', 'DATE'), ('May 22', 'DATE'), ('FDA', 'ORG'), (""Eli Lilly's"", 'ORG'), ('FDA', 'ORG'), ('millions', 'CARDINAL'), ('recent years', 'DATE'), ('FDA', 'ORG'), ('this week', 'DATE'), ('Mounjaro', 'PERSON'), ('Zepbound', 'GPE'), ('Ozempic', 'GPE'), ('Wegovy', 'PERSON'), ('Alexander Tin', 'PERSON'), ('CBS News', 'ORG'), ('Washington', 'GPE'), ('D.C.', 'GPE'), ('2025', 'DATE'), ('CBS Interactive Inc.', 'ORG')]","['Alexander Tin Edited', 'February 21, 2025', '11:42 AM EST', 'The Food and Drug Administration', 'Friday', 'Ozempic', 'Wegovy', 'first', 'Wegovy', '2022', 'FDA', 'months', 'Novo Nordisk', 'U.S.', 'FDA', 'Novo Nordisk', '$6.5 billion dollars', 'U.S.', 'this year', 'FDA', 'April 22', 'May 22', 'FDA', ""Eli Lilly's"", 'FDA', 'millions', 'recent years', 'FDA', 'this week', 'Mounjaro', 'Zepbound', 'Ozempic', 'Wegovy', 'Alexander Tin', 'CBS News', 'Washington', 'D.C.', '2025', 'CBS Interactive Inc.']","['Alexander Tin Edited', 'February 21, 2025', '11:42 AM EST', 'The Food and Drug Administration', 'Friday', 'Ozempic', 'Wegovy', 'first', 'Wegovy', '2022', 'FDA', 'months', 'Novo Nordisk', 'U.S.', 'FDA', 'Novo Nordisk', '$6.5 billion dollars', 'U.S.', 'this year', 'FDA', 'April 22', 'May 22', 'FDA', ""Eli Lilly's"", 'FDA', 'millions', 'recent years', 'FDA', 'this week', 'Mounjaro', 'Zepbound', 'Ozempic', 'Wegovy', 'Alexander Tin', 'CBS News', 'Washington', 'D.C.', '2025', 'CBS Interactive Inc.']"
"In Brazil's São Paulo, armed gangs on the hunt for something more sought-after than gold—Ozempic",https://theprint.in/world/in-brazils-sao-paulo-armed-gangs-on-the-hunt-for-something-more-sought-after-than-gold-ozempic/2504921/,"New Delhi: Ozempic is the new gold for thieves and armed gangs. In São Paulo, Brazil, armed robbers are targeting pharmacies in smash-and-grabs specifically for the ‘weight-loss’ drug that’s used to treat type-2 diabetes. Thieves looking to make a quick buck are cashing in on the growing demand for Ozempic and other semaglutide-based drugs like Wegovy and Saxenda among people who are convinced that they are miracle cures for weight loss.  This is especially true in Brazil, where body image is paramount but obesity is on the rise, according to a report in The New York Times. According to a health ministry study quoted in the report, in Brazil’s largest cities, obesity increased to 24 percent in 2023 from nearly 12 percent in 2006.  					Show Full Article New Delhi: Ozempic is the new gold for thieves and armed gangs. In São Paulo, Brazil, armed robbers are targeting pharmacies in smash-and-grabs specifically for the ‘weight-loss’ drug that’s used to treat type-2 diabetes. Thieves looking to make a quick buck are cashing in on the growing demand for Ozempic and other semaglutide-based drugs like Wegovy and Saxenda among people who are convinced that they are miracle cures for weight loss.  This is especially true in Brazil, where body image is paramount but obesity is on the rise, according to a report in The New York Times. According to a health ministry study quoted in the report, in Brazil’s largest cities, obesity increased to 24 percent in 2023 from nearly 12 percent in 2006.  					Show Full Article Thieves looking to make a quick buck are cashing in on the growing demand for Ozempic and other semaglutide-based drugs like Wegovy and Saxenda among people who are convinced that they are miracle cures for weight loss. This is especially true in Brazil, where body image is paramount but obesity is on the rise, according to a report in The New York Times. According to a health ministry study quoted in the report, in Brazil’s largest cities, obesity increased to 24 percent in 2023 from nearly 12 percent in 2006.  					Show Full Article This is especially true in Brazil, where body image is paramount but obesity is on the rise, according to a report in The New York Times. According to a health ministry study quoted in the report, in Brazil’s largest cities, obesity increased to 24 percent in 2023 from nearly 12 percent in 2006. An NYT analysis of the São Paulo State database showed that theft of Ozempic has risen in the last three years—from one incident in 2022 when four boxes of Ozempic were taken from a single drugstore to 18 in 2023 and 39 in 2024. “The wave of thefts began when social media started openly discussing the drug, particularly as celebrity and influencers showcased dramatic weight loss,” Renata Goncalves, head of a union of pharmacists in Sao Paulo, told the NYT. The desperation for the drug is real, and world over, the black market is thriving. Break-ins at pharmacies have also been reported in Michigan, US, and Santiago de Copostela, Spain.  In Brazil’s Rio de Janeiro, for instance, free Ozempic even became a campaign promise when the mayor actively advocated the drug for weight loss and promised to make it available for free. “Rio will be a city where there will be no more fat people; everyone will be taking Ozempic at family clinics,” the mayor said while seeking re-election last year. “This is the first time I’ve seen weight loss drugs actually targeted for theft,” Issa Shain, Police chief in Dearborn, Michigan, told the media. But the drugs are not cheap and are seen as a luxury item. In India, people are spending as much as Rs 80,000 on a six-month course or scouring the black market for a shot. There are fears that this trend will continue to rise. The patent for semaglutide, the main ingredient of the Ozempic drug, will expire in 2026 in a number of countries, including India, China and Brazil. Only then will manufacturers in these countries be able to market generic and cheaper versions of the drug. Also Read:  I was a pregnant penguin, see my before-after pics. 66-yr-old’s Ozempic to Mounjaro journey An NYT analysis of the São Paulo State database showed that theft of Ozempic has risen in the last three years—from one incident in 2022 when four boxes of Ozempic were taken from a single drugstore to 18 in 2023 and 39 in 2024. “The wave of thefts began when social media started openly discussing the drug, particularly as celebrity and influencers showcased dramatic weight loss,” Renata Goncalves, head of a union of pharmacists in Sao Paulo, told the NYT. The desperation for the drug is real, and world over, the black market is thriving. Break-ins at pharmacies have also been reported in Michigan, US, and Santiago de Copostela, Spain.  In Brazil’s Rio de Janeiro, for instance, free Ozempic even became a campaign promise when the mayor actively advocated the drug for weight loss and promised to make it available for free. “Rio will be a city where there will be no more fat people; everyone will be taking Ozempic at family clinics,” the mayor said while seeking re-election last year. “This is the first time I’ve seen weight loss drugs actually targeted for theft,” Issa Shain, Police chief in Dearborn, Michigan, told the media. But the drugs are not cheap and are seen as a luxury item. In India, people are spending as much as Rs 80,000 on a six-month course or scouring the black market for a shot. There are fears that this trend will continue to rise. The patent for semaglutide, the main ingredient of the Ozempic drug, will expire in 2026 in a number of countries, including India, China and Brazil. Only then will manufacturers in these countries be able to market generic and cheaper versions of the drug. Also Read:  I was a pregnant penguin, see my before-after pics. 66-yr-old’s Ozempic to Mounjaro journey “The wave of thefts began when social media started openly discussing the drug, particularly as celebrity and influencers showcased dramatic weight loss,” Renata Goncalves, head of a union of pharmacists in Sao Paulo, told the NYT. The desperation for the drug is real, and world over, the black market is thriving. Break-ins at pharmacies have also been reported in Michigan, US, and Santiago de Copostela, Spain.  In Brazil’s Rio de Janeiro, for instance, free Ozempic even became a campaign promise when the mayor actively advocated the drug for weight loss and promised to make it available for free. “Rio will be a city where there will be no more fat people; everyone will be taking Ozempic at family clinics,” the mayor said while seeking re-election last year. “This is the first time I’ve seen weight loss drugs actually targeted for theft,” Issa Shain, Police chief in Dearborn, Michigan, told the media. But the drugs are not cheap and are seen as a luxury item. In India, people are spending as much as Rs 80,000 on a six-month course or scouring the black market for a shot. There are fears that this trend will continue to rise. The patent for semaglutide, the main ingredient of the Ozempic drug, will expire in 2026 in a number of countries, including India, China and Brazil. Only then will manufacturers in these countries be able to market generic and cheaper versions of the drug. Also Read:  I was a pregnant penguin, see my before-after pics. 66-yr-old’s Ozempic to Mounjaro journey The desperation for the drug is real, and world over, the black market is thriving. Break-ins at pharmacies have also been reported in Michigan, US, and Santiago de Copostela, Spain. In Brazil’s Rio de Janeiro, for instance, free Ozempic even became a campaign promise when the mayor actively advocated the drug for weight loss and promised to make it available for free. “Rio will be a city where there will be no more fat people; everyone will be taking Ozempic at family clinics,” the mayor said while seeking re-election last year. “This is the first time I’ve seen weight loss drugs actually targeted for theft,” Issa Shain, Police chief in Dearborn, Michigan, told the media. But the drugs are not cheap and are seen as a luxury item. In India, people are spending as much as Rs 80,000 on a six-month course or scouring the black market for a shot. There are fears that this trend will continue to rise. The patent for semaglutide, the main ingredient of the Ozempic drug, will expire in 2026 in a number of countries, including India, China and Brazil. Only then will manufacturers in these countries be able to market generic and cheaper versions of the drug. Also Read:  I was a pregnant penguin, see my before-after pics. 66-yr-old’s Ozempic to Mounjaro journey In Brazil’s Rio de Janeiro, for instance, free Ozempic even became a campaign promise when the mayor actively advocated the drug for weight loss and promised to make it available for free. “Rio will be a city where there will be no more fat people; everyone will be taking Ozempic at family clinics,” the mayor said while seeking re-election last year. “This is the first time I’ve seen weight loss drugs actually targeted for theft,” Issa Shain, Police chief in Dearborn, Michigan, told the media. But the drugs are not cheap and are seen as a luxury item. In India, people are spending as much as Rs 80,000 on a six-month course or scouring the black market for a shot. There are fears that this trend will continue to rise. The patent for semaglutide, the main ingredient of the Ozempic drug, will expire in 2026 in a number of countries, including India, China and Brazil. Only then will manufacturers in these countries be able to market generic and cheaper versions of the drug. Also Read:  I was a pregnant penguin, see my before-after pics. 66-yr-old’s Ozempic to Mounjaro journey “This is the first time I’ve seen weight loss drugs actually targeted for theft,” Issa Shain, Police chief in Dearborn, Michigan, told the media. But the drugs are not cheap and are seen as a luxury item. In India, people are spending as much as Rs 80,000 on a six-month course or scouring the black market for a shot. There are fears that this trend will continue to rise. The patent for semaglutide, the main ingredient of the Ozempic drug, will expire in 2026 in a number of countries, including India, China and Brazil. Only then will manufacturers in these countries be able to market generic and cheaper versions of the drug. Also Read:  I was a pregnant penguin, see my before-after pics. 66-yr-old’s Ozempic to Mounjaro journey But the drugs are not cheap and are seen as a luxury item. In India, people are spending as much as Rs 80,000 on a six-month course or scouring the black market for a shot. There are fears that this trend will continue to rise. The patent for semaglutide, the main ingredient of the Ozempic drug, will expire in 2026 in a number of countries, including India, China and Brazil. Only then will manufacturers in these countries be able to market generic and cheaper versions of the drug. Also Read:  I was a pregnant penguin, see my before-after pics. 66-yr-old’s Ozempic to Mounjaro journey There are fears that this trend will continue to rise. The patent for semaglutide, the main ingredient of the Ozempic drug, will expire in 2026 in a number of countries, including India, China and Brazil. Only then will manufacturers in these countries be able to market generic and cheaper versions of the drug. (Edited by Sanya Mathur)","[('New', 'PROPN'), ('Delhi', 'PROPN'), (':', 'PUNCT'), ('Ozempic', 'PROPN'), ('is', 'AUX'), ('the', 'DET'), ('new', 'ADJ'), ('gold', 'NOUN'), ('for', 'ADP'), ('thieves', 'NOUN'), ('and', 'CCONJ'), ('armed', 'ADJ'), ('gangs', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('São', 'PROPN'), ('Paulo', 'PROPN'), (',', 'PUNCT'), ('Brazil', 'PROPN'), (',', 'PUNCT'), ('armed', 'ADJ'), ('robbers', 'NOUN'), ('are', 'AUX'), ('targeting', 'VERB'), ('pharmacies', 'NOUN'), ('in', 'ADP'), ('smash', 'NOUN'), ('-', 'PUNCT'), ('and', 'CCONJ'), ('-', 'PUNCT'), ('grabs', 'NOUN'), ('specifically', 'ADV'), ('for', 'ADP'), ('the', 'DET'), ('‘', 'PUNCT'), ('weight', 'NOUN'), ('-', 'PUNCT'), ('loss', 'NOUN'), ('’', 'PUNCT'), ('drug', 'NOUN'), ('that', 'PRON'), ('’s', 'AUX'), ('used', 'VERB'), ('to', 'PART'), ('treat', 'VERB'), ('type-2', 'PROPN'), ('diabetes', 'NOUN'), ('.', 'PUNCT'), ('Thieves', 'NOUN'), ('looking', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('a', 'DET'), ('quick', 'ADJ'), ('buck', 'NOUN'), ('are', 'AUX'), ('cashing', 'VERB'), ('in', 'ADP'), ('on', 'ADP'), ('the', 'DET'), ('growing', 'VERB'), ('demand', 'NOUN'), ('for', 'ADP'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('other', 'ADJ'), ('semaglutide', 'NOUN'), ('-', 'PUNCT'), ('based', 'VERB'), ('drugs', 'NOUN'), ('like', 'ADP'), ('Wegovy', 'PROPN'), ('and', 'CCONJ'), ('Saxenda', 'PROPN'), ('among', 'ADP'), ('people', 'NOUN'), ('who', 'PRON'), ('are', 'AUX'), ('convinced', 'ADJ'), ('that', 'SCONJ'), ('they', 'PRON'), ('are', 'AUX'), ('miracle', 'NOUN'), ('cures', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('\xa0 ', 'SPACE'), ('This', 'PRON'), ('is', 'AUX'), ('especially', 'ADV'), ('true', 'ADJ'), ('in', 'ADP'), ('Brazil', 'PROPN'), (',', 'PUNCT'), ('where', 'SCONJ'), ('body', 'NOUN'), ('image', 'NOUN'), ('is', 'AUX'), ('paramount', 'ADJ'), ('but', 'CCONJ'), ('obesity', 'NOUN'), ('is', 'AUX'), ('on', 'ADP'), ('the', 'DET'), ('rise', 'NOUN'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('report', 'NOUN'), ('in', 'ADP'), ('The', 'DET'), ('New', 'PROPN'), ('York', 'PROPN'), ('Times', 'PROPN'), ('.', 'PUNCT'), ('According', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('health', 'NOUN'), ('ministry', 'NOUN'), ('study', 'NOUN'), ('quoted', 'VERB'), ('in', 'ADP'), ('the', 'DET'), ('report', 'NOUN'), (',', 'PUNCT'), ('in', 'ADP'), ('Brazil', 'PROPN'), ('’s', 'PART'), ('largest', 'ADJ'), ('cities', 'NOUN'), (',', 'PUNCT'), ('obesity', 'NOUN'), ('increased', 'VERB'), ('to', 'ADP'), ('24', 'NUM'), ('percent', 'NOUN'), ('in', 'ADP'), ('2023', 'NUM'), ('from', 'ADP'), ('nearly', 'ADV'), ('12', 'NUM'), ('percent', 'NOUN'), ('in', 'ADP'), ('2006', 'NUM'), ('.', 'PUNCT'), ('\xa0 \t\t\t\t\t', 'SPACE'), ('Show', 'PROPN'), ('Full', 'ADJ'), ('Article', 'NOUN'), ('New', 'PROPN'), ('Delhi', 'PROPN'), (':', 'PUNCT'), ('Ozempic', 'PROPN'), ('is', 'AUX'), ('the', 'DET'), ('new', 'ADJ'), ('gold', 'NOUN'), ('for', 'ADP'), ('thieves', 'NOUN'), ('and', 'CCONJ'), ('armed', 'ADJ'), ('gangs', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('São', 'PROPN'), ('Paulo', 'PROPN'), (',', 'PUNCT'), ('Brazil', 'PROPN'), (',', 'PUNCT'), ('armed', 'ADJ'), ('robbers', 'NOUN'), ('are', 'AUX'), ('targeting', 'VERB'), ('pharmacies', 'NOUN'), ('in', 'ADP'), ('smash', 'NOUN'), ('-', 'PUNCT'), ('and', 'CCONJ'), ('-', 'PUNCT'), ('grabs', 'NOUN'), ('specifically', 'ADV'), ('for', 'ADP'), ('the', 'DET'), ('‘', 'PUNCT'), ('weight', 'NOUN'), ('-', 'PUNCT'), ('loss', 'NOUN'), ('’', 'PUNCT'), ('drug', 'NOUN'), ('that', 'PRON'), ('’s', 'AUX'), ('used', 'VERB'), ('to', 'PART'), ('treat', 'VERB'), ('type-2', 'PROPN'), ('diabetes', 'NOUN'), ('.', 'PUNCT'), ('Thieves', 'NOUN'), ('looking', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('a', 'DET'), ('quick', 'ADJ'), ('buck', 'NOUN'), ('are', 'AUX'), ('cashing', 'VERB'), ('in', 'ADP'), ('on', 'ADP'), ('the', 'DET'), ('growing', 'VERB'), ('demand', 'NOUN'), ('for', 'ADP'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('other', 'ADJ'), ('semaglutide', 'NOUN'), ('-', 'PUNCT'), ('based', 'VERB'), ('drugs', 'NOUN'), ('like', 'ADP'), ('Wegovy', 'PROPN'), ('and', 'CCONJ'), ('Saxenda', 'PROPN'), ('among', 'ADP'), ('people', 'NOUN'), ('who', 'PRON'), ('are', 'AUX'), ('convinced', 'ADJ'), ('that', 'SCONJ'), ('they', 'PRON'), ('are', 'AUX'), ('miracle', 'NOUN'), ('cures', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('\xa0 ', 'SPACE'), ('This', 'PRON'), ('is', 'AUX'), ('especially', 'ADV'), ('true', 'ADJ'), ('in', 'ADP'), ('Brazil', 'PROPN'), (',', 'PUNCT'), ('where', 'SCONJ'), ('body', 'NOUN'), ('image', 'NOUN'), ('is', 'AUX'), ('paramount', 'ADJ'), ('but', 'CCONJ'), ('obesity', 'NOUN'), ('is', 'AUX'), ('on', 'ADP'), ('the', 'DET'), ('rise', 'NOUN'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('report', 'NOUN'), ('in', 'ADP'), ('The', 'DET'), ('New', 'PROPN'), ('York', 'PROPN'), ('Times', 'PROPN'), ('.', 'PUNCT'), ('According', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('health', 'NOUN'), ('ministry', 'NOUN'), ('study', 'NOUN'), ('quoted', 'VERB'), ('in', 'ADP'), ('the', 'DET'), ('report', 'NOUN'), (',', 'PUNCT'), ('in', 'ADP'), ('Brazil', 'PROPN'), ('’s', 'PART'), ('largest', 'ADJ'), ('cities', 'NOUN'), (',', 'PUNCT'), ('obesity', 'NOUN'), ('increased', 'VERB'), ('to', 'ADP'), ('24', 'NUM'), ('percent', 'NOUN'), ('in', 'ADP'), ('2023', 'NUM'), ('from', 'ADP'), ('nearly', 'ADV'), ('12', 'NUM'), ('percent', 'NOUN'), ('in', 'ADP'), ('2006', 'NUM'), ('.', 'PUNCT'), ('\xa0 \t\t\t\t\t', 'SPACE'), ('Show', 'VERB'), ('Full', 'ADJ'), ('Article', 'NOUN'), ('Thieves', 'PROPN'), ('looking', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('a', 'DET'), ('quick', 'ADJ'), ('buck', 'NOUN'), ('are', 'AUX'), ('cashing', 'VERB'), ('in', 'ADP'), ('on', 'ADP'), ('the', 'DET'), ('growing', 'VERB'), ('demand', 'NOUN'), ('for', 'ADP'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('other', 'ADJ'), ('semaglutide', 'NOUN'), ('-', 'PUNCT'), ('based', 'VERB'), ('drugs', 'NOUN'), ('like', 'ADP'), ('Wegovy', 'PROPN'), ('and', 'CCONJ'), ('Saxenda', 'PROPN'), ('among', 'ADP'), ('people', 'NOUN'), ('who', 'PRON'), ('are', 'AUX'), ('convinced', 'ADJ'), ('that', 'SCONJ'), ('they', 'PRON'), ('are', 'AUX'), ('miracle', 'NOUN'), ('cures', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('This', 'PRON'), ('is', 'AUX'), ('especially', 'ADV'), ('true', 'ADJ'), ('in', 'ADP'), ('Brazil', 'PROPN'), (',', 'PUNCT'), ('where', 'SCONJ'), ('body', 'NOUN'), ('image', 'NOUN'), ('is', 'AUX'), ('paramount', 'ADJ'), ('but', 'CCONJ'), ('obesity', 'NOUN'), ('is', 'AUX'), ('on', 'ADP'), ('the', 'DET'), ('rise', 'NOUN'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('report', 'NOUN'), ('in', 'ADP'), ('The', 'DET'), ('New', 'PROPN'), ('York', 'PROPN'), ('Times', 'PROPN'), ('.', 'PUNCT'), ('According', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('health', 'NOUN'), ('ministry', 'NOUN'), ('study', 'NOUN'), ('quoted', 'VERB'), ('in', 'ADP'), ('the', 'DET'), ('report', 'NOUN'), (',', 'PUNCT'), ('in', 'ADP'), ('Brazil', 'PROPN'), ('’s', 'PART'), ('largest', 'ADJ'), ('cities', 'NOUN'), (',', 'PUNCT'), ('obesity', 'NOUN'), ('increased', 'VERB'), ('to', 'ADP'), ('24', 'NUM'), ('percent', 'NOUN'), ('in', 'ADP'), ('2023', 'NUM'), ('from', 'ADP'), ('nearly', 'ADV'), ('12', 'NUM'), ('percent', 'NOUN'), ('in', 'ADP'), ('2006', 'NUM'), ('.', 'PUNCT'), ('\xa0 \t\t\t\t\t', 'SPACE'), ('Show', 'VERB'), ('Full', 'ADJ'), ('Article', 'NOUN'), ('This', 'PRON'), ('is', 'AUX'), ('especially', 'ADV'), ('true', 'ADJ'), ('in', 'ADP'), ('Brazil', 'PROPN'), (',', 'PUNCT'), ('where', 'SCONJ'), ('body', 'NOUN'), ('image', 'NOUN'), ('is', 'AUX'), ('paramount', 'ADJ'), ('but', 'CCONJ'), ('obesity', 'NOUN'), ('is', 'AUX'), ('on', 'ADP'), ('the', 'DET'), ('rise', 'NOUN'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('report', 'NOUN'), ('in', 'ADP'), ('The', 'DET'), ('New', 'PROPN'), ('York', 'PROPN'), ('Times', 'PROPN'), ('.', 'PUNCT'), ('According', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('health', 'NOUN'), ('ministry', 'NOUN'), ('study', 'NOUN'), ('quoted', 'VERB'), ('in', 'ADP'), ('the', 'DET'), ('report', 'NOUN'), (',', 'PUNCT'), ('in', 'ADP'), ('Brazil', 'PROPN'), ('’s', 'PART'), ('largest', 'ADJ'), ('cities', 'NOUN'), (',', 'PUNCT'), ('obesity', 'NOUN'), ('increased', 'VERB'), ('to', 'ADP'), ('24', 'NUM'), ('percent', 'NOUN'), ('in', 'ADP'), ('2023', 'NUM'), ('from', 'ADP'), ('nearly', 'ADV'), ('12', 'NUM'), ('percent', 'NOUN'), ('in', 'ADP'), ('2006', 'NUM'), ('.', 'PUNCT'), ('An', 'DET'), ('NYT', 'PROPN'), ('analysis', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('São', 'PROPN'), ('Paulo', 'PROPN'), ('State', 'PROPN'), ('database', 'NOUN'), ('showed', 'VERB'), ('that', 'SCONJ'), ('theft', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('\xa0', 'SPACE'), ('has', 'AUX'), ('risen', 'VERB'), ('in', 'ADP'), ('the', 'DET'), ('last', 'ADJ'), ('three', 'NUM'), ('years', 'NOUN'), ('—', 'PUNCT'), ('from', 'ADP'), ('one', 'NUM'), ('incident', 'NOUN'), ('in', 'ADP'), ('2022', 'NUM'), ('when', 'SCONJ'), ('four', 'NUM'), ('boxes', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('were', 'AUX'), ('taken', 'VERB'), ('from', 'ADP'), ('a', 'DET'), ('single', 'ADJ'), ('drugstore', 'NOUN'), ('to', 'ADP'), ('18', 'NUM'), ('in', 'ADP'), ('2023', 'NUM'), ('and', 'CCONJ'), ('39', 'NUM'), ('in', 'ADP'), ('2024', 'NUM'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('The', 'DET'), ('wave', 'NOUN'), ('of', 'ADP'), ('thefts', 'NOUN'), ('began', 'VERB'), ('when', 'SCONJ'), ('social', 'ADJ'), ('media', 'NOUN'), ('started', 'VERB'), ('openly', 'ADV'), ('discussing', 'VERB'), ('the', 'DET'), ('drug', 'NOUN'), (',', 'PUNCT'), ('particularly', 'ADV'), ('as', 'SCONJ'), ('celebrity', 'NOUN'), ('and', 'CCONJ'), ('influencers', 'NOUN'), ('showcased', 'VERB'), ('dramatic', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Renata', 'PROPN'), ('Goncalves', 'PROPN'), (',', 'PUNCT'), ('head', 'NOUN'), ('of', 'ADP'), ('a', 'DET'), ('union', 'NOUN'), ('of', 'ADP'), ('pharmacists', 'NOUN'), ('in', 'ADP'), ('Sao', 'PROPN'), ('Paulo', 'PROPN'), (',', 'PUNCT'), ('told', 'VERB'), ('the', 'DET'), ('NYT', 'PROPN'), ('.', 'PUNCT'), ('The', 'DET'), ('desperation', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('is', 'AUX'), ('real', 'ADJ'), (',', 'PUNCT'), ('and', 'CCONJ'), ('world', 'NOUN'), ('over', 'ADV'), (',', 'PUNCT'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('is', 'AUX'), ('thriving', 'VERB'), ('.', 'PUNCT'), ('\xa0', 'SPACE'), ('Break', 'NOUN'), ('-', 'PUNCT'), ('ins', 'NOUN'), ('at', 'ADP'), ('pharmacies', 'NOUN'), ('have', 'AUX'), ('also', 'ADV'), ('been', 'AUX'), ('reported', 'VERB'), ('in', 'ADP'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('US', 'PROPN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('Santiago', 'PROPN'), ('de', 'X'), ('Copostela', 'PROPN'), (',', 'PUNCT'), ('Spain', 'PROPN'), ('.', 'PUNCT'), ('\xa0 ', 'SPACE'), ('In', 'ADP'), ('Brazil', 'PROPN'), ('’s', 'PART'), ('Rio', 'PROPN'), ('de', 'PROPN'), ('Janeiro', 'PROPN'), (',', 'PUNCT'), ('for', 'ADP'), ('instance', 'NOUN'), (',', 'PUNCT'), ('free', 'ADJ'), ('Ozempic', 'PROPN'), ('even', 'ADV'), ('became', 'VERB'), ('a', 'DET'), ('campaign', 'NOUN'), ('promise', 'NOUN'), ('when', 'SCONJ'), ('the', 'DET'), ('mayor', 'NOUN'), ('actively', 'ADV'), ('advocated', 'VERB'), ('the', 'DET'), ('drug', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('promised', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('it', 'PRON'), ('available', 'ADJ'), ('for', 'ADP'), ('free', 'ADJ'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('Rio', 'PROPN'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('city', 'NOUN'), ('where', 'SCONJ'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('no', 'DET'), ('more', 'ADV'), ('fat', 'ADJ'), ('people', 'NOUN'), (';', 'PUNCT'), ('everyone', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('taking', 'VERB'), ('Ozempic', 'PROPN'), ('at', 'ADP'), ('family', 'NOUN'), ('clinics', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('the', 'DET'), ('mayor', 'NOUN'), ('said', 'VERB'), ('while', 'SCONJ'), ('seeking', 'VERB'), ('re', 'NOUN'), ('-', 'NOUN'), ('election', 'NOUN'), ('last', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('This', 'PRON'), ('is', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('time', 'NOUN'), ('I', 'PRON'), ('’ve', 'AUX'), ('seen', 'VERB'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drugs', 'NOUN'), ('actually', 'ADV'), ('targeted', 'VERB'), ('for', 'ADP'), ('theft', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Issa', 'PROPN'), ('Shain', 'PROPN'), (',', 'PUNCT'), ('Police', 'PROPN'), ('chief', 'NOUN'), ('in', 'ADP'), ('Dearborn', 'PROPN'), (',', 'PUNCT'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('told', 'VERB'), ('the', 'DET'), ('media', 'NOUN'), ('.', 'PUNCT'), ('But', 'CCONJ'), ('the', 'DET'), ('drugs', 'NOUN'), ('are', 'AUX'), ('not', 'PART'), ('cheap', 'ADJ'), ('and', 'CCONJ'), ('are', 'AUX'), ('seen', 'VERB'), ('as', 'ADP'), ('a', 'DET'), ('luxury', 'NOUN'), ('item', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('India', 'PROPN'), (',', 'PUNCT'), ('people', 'NOUN'), ('are', 'AUX'), ('spending', 'VERB'), ('as', 'ADV'), ('much', 'ADV'), ('as', 'ADP'), ('Rs', 'NOUN'), ('80,000', 'NUM'), ('on', 'ADP'), ('a', 'DET'), ('six', 'NUM'), ('-', 'PUNCT'), ('month', 'NOUN'), ('course', 'NOUN'), ('or', 'CCONJ'), ('scouring', 'VERB'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('for', 'ADP'), ('a', 'DET'), ('shot', 'NOUN'), ('.', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('fears', 'NOUN'), ('that', 'SCONJ'), ('this', 'DET'), ('trend', 'NOUN'), ('will', 'AUX'), ('continue', 'VERB'), ('to', 'PART'), ('rise', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('patent', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('ingredient', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('Ozempic', 'PROPN'), ('drug', 'NOUN'), (',', 'PUNCT'), ('will', 'AUX'), ('expire', 'VERB'), ('in', 'ADP'), ('2026', 'NUM'), ('in', 'ADP'), ('a', 'DET'), ('number', 'NOUN'), ('of', 'ADP'), ('countries', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('India', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('.', 'PUNCT'), ('Only', 'ADV'), ('then', 'ADV'), ('will', 'AUX'), ('manufacturers', 'NOUN'), ('in', 'ADP'), ('these', 'DET'), ('countries', 'NOUN'), ('\xa0', 'SPACE'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('and', 'CCONJ'), ('cheaper', 'ADJ'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'PROPN'), (':', 'PUNCT'), (' ', 'SPACE'), ('I', 'PRON'), ('was', 'AUX'), ('a', 'DET'), ('pregnant', 'ADJ'), ('penguin', 'NOUN'), (',', 'PUNCT'), ('see', 'VERB'), ('my', 'PRON'), ('before', 'NOUN'), ('-', 'PUNCT'), ('after', 'ADP'), ('pics', 'NOUN'), ('.', 'PUNCT'), ('66', 'NUM'), ('-', 'PUNCT'), ('yr', 'NOUN'), ('-', 'PUNCT'), ('old', 'ADJ'), ('’s', 'PROPN'), ('Ozempic', 'PROPN'), ('to', 'ADP'), ('Mounjaro', 'PROPN'), ('journey', 'VERB'), ('An', 'DET'), ('NYT', 'PROPN'), ('analysis', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('São', 'PROPN'), ('Paulo', 'PROPN'), ('State', 'PROPN'), ('database', 'NOUN'), ('showed', 'VERB'), ('that', 'SCONJ'), ('theft', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('\xa0', 'SPACE'), ('has', 'AUX'), ('risen', 'VERB'), ('in', 'ADP'), ('the', 'DET'), ('last', 'ADJ'), ('three', 'NUM'), ('years', 'NOUN'), ('—', 'PUNCT'), ('from', 'ADP'), ('one', 'NUM'), ('incident', 'NOUN'), ('in', 'ADP'), ('2022', 'NUM'), ('when', 'SCONJ'), ('four', 'NUM'), ('boxes', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('were', 'AUX'), ('taken', 'VERB'), ('from', 'ADP'), ('a', 'DET'), ('single', 'ADJ'), ('drugstore', 'NOUN'), ('to', 'ADP'), ('18', 'NUM'), ('in', 'ADP'), ('2023', 'NUM'), ('and', 'CCONJ'), ('39', 'NUM'), ('in', 'ADP'), ('2024', 'NUM'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('The', 'DET'), ('wave', 'NOUN'), ('of', 'ADP'), ('thefts', 'NOUN'), ('began', 'VERB'), ('when', 'SCONJ'), ('social', 'ADJ'), ('media', 'NOUN'), ('started', 'VERB'), ('openly', 'ADV'), ('discussing', 'VERB'), ('the', 'DET'), ('drug', 'NOUN'), (',', 'PUNCT'), ('particularly', 'ADV'), ('as', 'SCONJ'), ('celebrity', 'NOUN'), ('and', 'CCONJ'), ('influencers', 'NOUN'), ('showcased', 'VERB'), ('dramatic', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Renata', 'PROPN'), ('Goncalves', 'PROPN'), (',', 'PUNCT'), ('head', 'NOUN'), ('of', 'ADP'), ('a', 'DET'), ('union', 'NOUN'), ('of', 'ADP'), ('pharmacists', 'NOUN'), ('in', 'ADP'), ('Sao', 'PROPN'), ('Paulo', 'PROPN'), (',', 'PUNCT'), ('told', 'VERB'), ('the', 'DET'), ('NYT', 'PROPN'), ('.', 'PUNCT'), ('The', 'DET'), ('desperation', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('is', 'AUX'), ('real', 'ADJ'), (',', 'PUNCT'), ('and', 'CCONJ'), ('world', 'NOUN'), ('over', 'ADV'), (',', 'PUNCT'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('is', 'AUX'), ('thriving', 'VERB'), ('.', 'PUNCT'), ('\xa0', 'SPACE'), ('Break', 'NOUN'), ('-', 'PUNCT'), ('ins', 'NOUN'), ('at', 'ADP'), ('pharmacies', 'NOUN'), ('have', 'AUX'), ('also', 'ADV'), ('been', 'AUX'), ('reported', 'VERB'), ('in', 'ADP'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('US', 'PROPN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('Santiago', 'PROPN'), ('de', 'X'), ('Copostela', 'PROPN'), (',', 'PUNCT'), ('Spain', 'PROPN'), ('.', 'PUNCT'), ('\xa0 ', 'SPACE'), ('In', 'ADP'), ('Brazil', 'PROPN'), ('’s', 'PART'), ('Rio', 'PROPN'), ('de', 'PROPN'), ('Janeiro', 'PROPN'), (',', 'PUNCT'), ('for', 'ADP'), ('instance', 'NOUN'), (',', 'PUNCT'), ('free', 'ADJ'), ('Ozempic', 'PROPN'), ('even', 'ADV'), ('became', 'VERB'), ('a', 'DET'), ('campaign', 'NOUN'), ('promise', 'NOUN'), ('when', 'SCONJ'), ('the', 'DET'), ('mayor', 'NOUN'), ('actively', 'ADV'), ('advocated', 'VERB'), ('the', 'DET'), ('drug', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('promised', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('it', 'PRON'), ('available', 'ADJ'), ('for', 'ADP'), ('free', 'ADJ'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('Rio', 'PROPN'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('city', 'NOUN'), ('where', 'SCONJ'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('no', 'DET'), ('more', 'ADV'), ('fat', 'ADJ'), ('people', 'NOUN'), (';', 'PUNCT'), ('everyone', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('taking', 'VERB'), ('Ozempic', 'PROPN'), ('at', 'ADP'), ('family', 'NOUN'), ('clinics', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('the', 'DET'), ('mayor', 'NOUN'), ('said', 'VERB'), ('while', 'SCONJ'), ('seeking', 'VERB'), ('re', 'NOUN'), ('-', 'NOUN'), ('election', 'NOUN'), ('last', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('This', 'PRON'), ('is', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('time', 'NOUN'), ('I', 'PRON'), ('’ve', 'AUX'), ('seen', 'VERB'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drugs', 'NOUN'), ('actually', 'ADV'), ('targeted', 'VERB'), ('for', 'ADP'), ('theft', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Issa', 'PROPN'), ('Shain', 'PROPN'), (',', 'PUNCT'), ('Police', 'PROPN'), ('chief', 'NOUN'), ('in', 'ADP'), ('Dearborn', 'PROPN'), (',', 'PUNCT'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('told', 'VERB'), ('the', 'DET'), ('media', 'NOUN'), ('.', 'PUNCT'), ('But', 'CCONJ'), ('the', 'DET'), ('drugs', 'NOUN'), ('are', 'AUX'), ('not', 'PART'), ('cheap', 'ADJ'), ('and', 'CCONJ'), ('are', 'AUX'), ('seen', 'VERB'), ('as', 'ADP'), ('a', 'DET'), ('luxury', 'NOUN'), ('item', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('India', 'PROPN'), (',', 'PUNCT'), ('people', 'NOUN'), ('are', 'AUX'), ('spending', 'VERB'), ('as', 'ADV'), ('much', 'ADV'), ('as', 'ADP'), ('Rs', 'NOUN'), ('80,000', 'NUM'), ('on', 'ADP'), ('a', 'DET'), ('six', 'NUM'), ('-', 'PUNCT'), ('month', 'NOUN'), ('course', 'NOUN'), ('or', 'CCONJ'), ('scouring', 'VERB'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('for', 'ADP'), ('a', 'DET'), ('shot', 'NOUN'), ('.', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('fears', 'NOUN'), ('that', 'SCONJ'), ('this', 'DET'), ('trend', 'NOUN'), ('will', 'AUX'), ('continue', 'VERB'), ('to', 'PART'), ('rise', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('patent', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('ingredient', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('Ozempic', 'PROPN'), ('drug', 'NOUN'), (',', 'PUNCT'), ('will', 'AUX'), ('expire', 'VERB'), ('in', 'ADP'), ('2026', 'NUM'), ('in', 'ADP'), ('a', 'DET'), ('number', 'NOUN'), ('of', 'ADP'), ('countries', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('India', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('.', 'PUNCT'), ('Only', 'ADV'), ('then', 'ADV'), ('will', 'AUX'), ('manufacturers', 'NOUN'), ('in', 'ADP'), ('these', 'DET'), ('countries', 'NOUN'), ('\xa0', 'SPACE'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('and', 'CCONJ'), ('cheaper', 'ADJ'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'PROPN'), (':', 'PUNCT'), (' ', 'SPACE'), ('I', 'PRON'), ('was', 'AUX'), ('a', 'DET'), ('pregnant', 'ADJ'), ('penguin', 'NOUN'), (',', 'PUNCT'), ('see', 'VERB'), ('my', 'PRON'), ('before', 'NOUN'), ('-', 'PUNCT'), ('after', 'ADP'), ('pics', 'NOUN'), ('.', 'PUNCT'), ('66', 'NUM'), ('-', 'PUNCT'), ('yr', 'NOUN'), ('-', 'PUNCT'), ('old', 'ADJ'), ('’s', 'PROPN'), ('Ozempic', 'PROPN'), ('to', 'ADP'), ('Mounjaro', 'PROPN'), ('journey', 'NOUN'), ('“', 'PUNCT'), ('The', 'DET'), ('wave', 'NOUN'), ('of', 'ADP'), ('thefts', 'NOUN'), ('began', 'VERB'), ('when', 'SCONJ'), ('social', 'ADJ'), ('media', 'NOUN'), ('started', 'VERB'), ('openly', 'ADV'), ('discussing', 'VERB'), ('the', 'DET'), ('drug', 'NOUN'), (',', 'PUNCT'), ('particularly', 'ADV'), ('as', 'SCONJ'), ('celebrity', 'NOUN'), ('and', 'CCONJ'), ('influencers', 'NOUN'), ('showcased', 'VERB'), ('dramatic', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Renata', 'PROPN'), ('Goncalves', 'PROPN'), (',', 'PUNCT'), ('head', 'NOUN'), ('of', 'ADP'), ('a', 'DET'), ('union', 'NOUN'), ('of', 'ADP'), ('pharmacists', 'NOUN'), ('in', 'ADP'), ('Sao', 'PROPN'), ('Paulo', 'PROPN'), (',', 'PUNCT'), ('told', 'VERB'), ('the', 'DET'), ('NYT', 'PROPN'), ('.', 'PUNCT'), ('The', 'DET'), ('desperation', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('is', 'AUX'), ('real', 'ADJ'), (',', 'PUNCT'), ('and', 'CCONJ'), ('world', 'NOUN'), ('over', 'ADV'), (',', 'PUNCT'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('is', 'AUX'), ('thriving', 'VERB'), ('.', 'PUNCT'), ('\xa0', 'SPACE'), ('Break', 'NOUN'), ('-', 'PUNCT'), ('ins', 'NOUN'), ('at', 'ADP'), ('pharmacies', 'NOUN'), ('have', 'AUX'), ('also', 'ADV'), ('been', 'AUX'), ('reported', 'VERB'), ('in', 'ADP'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('US', 'PROPN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('Santiago', 'PROPN'), ('de', 'X'), ('Copostela', 'PROPN'), (',', 'PUNCT'), ('Spain', 'PROPN'), ('.', 'PUNCT'), ('\xa0 ', 'SPACE'), ('In', 'ADP'), ('Brazil', 'PROPN'), ('’s', 'PART'), ('Rio', 'PROPN'), ('de', 'PROPN'), ('Janeiro', 'PROPN'), (',', 'PUNCT'), ('for', 'ADP'), ('instance', 'NOUN'), (',', 'PUNCT'), ('free', 'ADJ'), ('Ozempic', 'PROPN'), ('even', 'ADV'), ('became', 'VERB'), ('a', 'DET'), ('campaign', 'NOUN'), ('promise', 'NOUN'), ('when', 'SCONJ'), ('the', 'DET'), ('mayor', 'NOUN'), ('actively', 'ADV'), ('advocated', 'VERB'), ('the', 'DET'), ('drug', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('promised', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('it', 'PRON'), ('available', 'ADJ'), ('for', 'ADP'), ('free', 'ADJ'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('Rio', 'PROPN'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('city', 'NOUN'), ('where', 'SCONJ'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('no', 'DET'), ('more', 'ADV'), ('fat', 'ADJ'), ('people', 'NOUN'), (';', 'PUNCT'), ('everyone', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('taking', 'VERB'), ('Ozempic', 'PROPN'), ('at', 'ADP'), ('family', 'NOUN'), ('clinics', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('the', 'DET'), ('mayor', 'NOUN'), ('said', 'VERB'), ('while', 'SCONJ'), ('seeking', 'VERB'), ('re', 'NOUN'), ('-', 'NOUN'), ('election', 'NOUN'), ('last', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('This', 'PRON'), ('is', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('time', 'NOUN'), ('I', 'PRON'), ('’ve', 'AUX'), ('seen', 'VERB'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drugs', 'NOUN'), ('actually', 'ADV'), ('targeted', 'VERB'), ('for', 'ADP'), ('theft', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Issa', 'PROPN'), ('Shain', 'PROPN'), (',', 'PUNCT'), ('Police', 'PROPN'), ('chief', 'NOUN'), ('in', 'ADP'), ('Dearborn', 'PROPN'), (',', 'PUNCT'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('told', 'VERB'), ('the', 'DET'), ('media', 'NOUN'), ('.', 'PUNCT'), ('But', 'CCONJ'), ('the', 'DET'), ('drugs', 'NOUN'), ('are', 'AUX'), ('not', 'PART'), ('cheap', 'ADJ'), ('and', 'CCONJ'), ('are', 'AUX'), ('seen', 'VERB'), ('as', 'ADP'), ('a', 'DET'), ('luxury', 'NOUN'), ('item', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('India', 'PROPN'), (',', 'PUNCT'), ('people', 'NOUN'), ('are', 'AUX'), ('spending', 'VERB'), ('as', 'ADV'), ('much', 'ADV'), ('as', 'ADP'), ('Rs', 'NOUN'), ('80,000', 'NUM'), ('on', 'ADP'), ('a', 'DET'), ('six', 'NUM'), ('-', 'PUNCT'), ('month', 'NOUN'), ('course', 'NOUN'), ('or', 'CCONJ'), ('scouring', 'VERB'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('for', 'ADP'), ('a', 'DET'), ('shot', 'NOUN'), ('.', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('fears', 'NOUN'), ('that', 'SCONJ'), ('this', 'DET'), ('trend', 'NOUN'), ('will', 'AUX'), ('continue', 'VERB'), ('to', 'PART'), ('rise', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('patent', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('ingredient', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('Ozempic', 'PROPN'), ('drug', 'NOUN'), (',', 'PUNCT'), ('will', 'AUX'), ('expire', 'VERB'), ('in', 'ADP'), ('2026', 'NUM'), ('in', 'ADP'), ('a', 'DET'), ('number', 'NOUN'), ('of', 'ADP'), ('countries', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('India', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('.', 'PUNCT'), ('Only', 'ADV'), ('then', 'ADV'), ('will', 'AUX'), ('manufacturers', 'NOUN'), ('in', 'ADP'), ('these', 'DET'), ('countries', 'NOUN'), ('\xa0', 'SPACE'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('and', 'CCONJ'), ('cheaper', 'ADJ'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'PROPN'), (':', 'PUNCT'), (' ', 'SPACE'), ('I', 'PRON'), ('was', 'AUX'), ('a', 'DET'), ('pregnant', 'ADJ'), ('penguin', 'NOUN'), (',', 'PUNCT'), ('see', 'VERB'), ('my', 'PRON'), ('before', 'NOUN'), ('-', 'PUNCT'), ('after', 'ADP'), ('pics', 'NOUN'), ('.', 'PUNCT'), ('66', 'NUM'), ('-', 'PUNCT'), ('yr', 'NOUN'), ('-', 'PUNCT'), ('old', 'ADJ'), ('’s', 'PROPN'), ('Ozempic', 'PROPN'), ('to', 'ADP'), ('Mounjaro', 'PROPN'), ('journey', 'VERB'), ('The', 'DET'), ('desperation', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('is', 'AUX'), ('real', 'ADJ'), (',', 'PUNCT'), ('and', 'CCONJ'), ('world', 'NOUN'), ('over', 'ADV'), (',', 'PUNCT'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('is', 'AUX'), ('thriving', 'VERB'), ('.', 'PUNCT'), ('\xa0', 'SPACE'), ('Break', 'NOUN'), ('-', 'PUNCT'), ('ins', 'NOUN'), ('at', 'ADP'), ('pharmacies', 'NOUN'), ('have', 'AUX'), ('also', 'ADV'), ('been', 'AUX'), ('reported', 'VERB'), ('in', 'ADP'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('US', 'PROPN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('Santiago', 'PROPN'), ('de', 'X'), ('Copostela', 'PROPN'), (',', 'PUNCT'), ('Spain', 'PROPN'), ('.', 'PUNCT'), ('In', 'ADP'), ('Brazil', 'PROPN'), ('’s', 'PART'), ('Rio', 'PROPN'), ('de', 'PROPN'), ('Janeiro', 'PROPN'), (',', 'PUNCT'), ('for', 'ADP'), ('instance', 'NOUN'), (',', 'PUNCT'), ('free', 'ADJ'), ('Ozempic', 'PROPN'), ('even', 'ADV'), ('became', 'VERB'), ('a', 'DET'), ('campaign', 'NOUN'), ('promise', 'NOUN'), ('when', 'SCONJ'), ('the', 'DET'), ('mayor', 'NOUN'), ('actively', 'ADV'), ('advocated', 'VERB'), ('the', 'DET'), ('drug', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('promised', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('it', 'PRON'), ('available', 'ADJ'), ('for', 'ADP'), ('free', 'ADJ'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('Rio', 'PROPN'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('city', 'NOUN'), ('where', 'SCONJ'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('no', 'DET'), ('more', 'ADV'), ('fat', 'ADJ'), ('people', 'NOUN'), (';', 'PUNCT'), ('everyone', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('taking', 'VERB'), ('Ozempic', 'PROPN'), ('at', 'ADP'), ('family', 'NOUN'), ('clinics', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('the', 'DET'), ('mayor', 'NOUN'), ('said', 'VERB'), ('while', 'SCONJ'), ('seeking', 'VERB'), ('re', 'NOUN'), ('-', 'NOUN'), ('election', 'NOUN'), ('last', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('This', 'PRON'), ('is', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('time', 'NOUN'), ('I', 'PRON'), ('’ve', 'AUX'), ('seen', 'VERB'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drugs', 'NOUN'), ('actually', 'ADV'), ('targeted', 'VERB'), ('for', 'ADP'), ('theft', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Issa', 'PROPN'), ('Shain', 'PROPN'), (',', 'PUNCT'), ('Police', 'PROPN'), ('chief', 'NOUN'), ('in', 'ADP'), ('Dearborn', 'PROPN'), (',', 'PUNCT'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('told', 'VERB'), ('the', 'DET'), ('media', 'NOUN'), ('.', 'PUNCT'), ('But', 'CCONJ'), ('the', 'DET'), ('drugs', 'NOUN'), ('are', 'AUX'), ('not', 'PART'), ('cheap', 'ADJ'), ('and', 'CCONJ'), ('are', 'AUX'), ('seen', 'VERB'), ('as', 'ADP'), ('a', 'DET'), ('luxury', 'NOUN'), ('item', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('India', 'PROPN'), (',', 'PUNCT'), ('people', 'NOUN'), ('are', 'AUX'), ('spending', 'VERB'), ('as', 'ADV'), ('much', 'ADV'), ('as', 'ADP'), ('Rs', 'NOUN'), ('80,000', 'NUM'), ('on', 'ADP'), ('a', 'DET'), ('six', 'NUM'), ('-', 'PUNCT'), ('month', 'NOUN'), ('course', 'NOUN'), ('or', 'CCONJ'), ('scouring', 'VERB'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('for', 'ADP'), ('a', 'DET'), ('shot', 'NOUN'), ('.', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('fears', 'NOUN'), ('that', 'SCONJ'), ('this', 'DET'), ('trend', 'NOUN'), ('will', 'AUX'), ('continue', 'VERB'), ('to', 'PART'), ('rise', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('patent', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('ingredient', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('Ozempic', 'PROPN'), ('drug', 'NOUN'), (',', 'PUNCT'), ('will', 'AUX'), ('expire', 'VERB'), ('in', 'ADP'), ('2026', 'NUM'), ('in', 'ADP'), ('a', 'DET'), ('number', 'NOUN'), ('of', 'ADP'), ('countries', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('India', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('.', 'PUNCT'), ('Only', 'ADV'), ('then', 'ADV'), ('will', 'AUX'), ('manufacturers', 'NOUN'), ('in', 'ADP'), ('these', 'DET'), ('countries', 'NOUN'), ('\xa0', 'SPACE'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('and', 'CCONJ'), ('cheaper', 'ADJ'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'PROPN'), (':', 'PUNCT'), (' ', 'SPACE'), ('I', 'PRON'), ('was', 'AUX'), ('a', 'DET'), ('pregnant', 'ADJ'), ('penguin', 'NOUN'), (',', 'PUNCT'), ('see', 'VERB'), ('my', 'PRON'), ('before', 'NOUN'), ('-', 'PUNCT'), ('after', 'ADP'), ('pics', 'NOUN'), ('.', 'PUNCT'), ('66', 'NUM'), ('-', 'PUNCT'), ('yr', 'NOUN'), ('-', 'PUNCT'), ('old', 'ADJ'), ('’s', 'PROPN'), ('Ozempic', 'PROPN'), ('to', 'ADP'), ('Mounjaro', 'PROPN'), ('journey', 'NOUN'), ('In', 'ADP'), ('Brazil', 'PROPN'), ('’s', 'PART'), ('Rio', 'PROPN'), ('de', 'PROPN'), ('Janeiro', 'PROPN'), (',', 'PUNCT'), ('for', 'ADP'), ('instance', 'NOUN'), (',', 'PUNCT'), ('free', 'ADJ'), ('Ozempic', 'PROPN'), ('even', 'ADV'), ('became', 'VERB'), ('a', 'DET'), ('campaign', 'NOUN'), ('promise', 'NOUN'), ('when', 'SCONJ'), ('the', 'DET'), ('mayor', 'NOUN'), ('actively', 'ADV'), ('advocated', 'VERB'), ('the', 'DET'), ('drug', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('and', 'CCONJ'), ('promised', 'VERB'), ('to', 'PART'), ('make', 'VERB'), ('it', 'PRON'), ('available', 'ADJ'), ('for', 'ADP'), ('free', 'ADJ'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('Rio', 'PROPN'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('city', 'NOUN'), ('where', 'SCONJ'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('no', 'DET'), ('more', 'ADV'), ('fat', 'ADJ'), ('people', 'NOUN'), (';', 'PUNCT'), ('everyone', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('taking', 'VERB'), ('Ozempic', 'PROPN'), ('at', 'ADP'), ('family', 'NOUN'), ('clinics', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('the', 'DET'), ('mayor', 'NOUN'), ('said', 'VERB'), ('while', 'SCONJ'), ('seeking', 'VERB'), ('re', 'NOUN'), ('-', 'NOUN'), ('election', 'NOUN'), ('last', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('This', 'PRON'), ('is', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('time', 'NOUN'), ('I', 'PRON'), ('’ve', 'AUX'), ('seen', 'VERB'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drugs', 'NOUN'), ('actually', 'ADV'), ('targeted', 'VERB'), ('for', 'ADP'), ('theft', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Issa', 'PROPN'), ('Shain', 'PROPN'), (',', 'PUNCT'), ('Police', 'PROPN'), ('chief', 'NOUN'), ('in', 'ADP'), ('Dearborn', 'PROPN'), (',', 'PUNCT'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('told', 'VERB'), ('the', 'DET'), ('media', 'NOUN'), ('.', 'PUNCT'), ('But', 'CCONJ'), ('the', 'DET'), ('drugs', 'NOUN'), ('are', 'AUX'), ('not', 'PART'), ('cheap', 'ADJ'), ('and', 'CCONJ'), ('are', 'AUX'), ('seen', 'VERB'), ('as', 'ADP'), ('a', 'DET'), ('luxury', 'NOUN'), ('item', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('India', 'PROPN'), (',', 'PUNCT'), ('people', 'NOUN'), ('are', 'AUX'), ('spending', 'VERB'), ('as', 'ADV'), ('much', 'ADV'), ('as', 'ADP'), ('Rs', 'NOUN'), ('80,000', 'NUM'), ('on', 'ADP'), ('a', 'DET'), ('six', 'NUM'), ('-', 'PUNCT'), ('month', 'NOUN'), ('course', 'NOUN'), ('or', 'CCONJ'), ('scouring', 'VERB'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('for', 'ADP'), ('a', 'DET'), ('shot', 'NOUN'), ('.', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('fears', 'NOUN'), ('that', 'SCONJ'), ('this', 'DET'), ('trend', 'NOUN'), ('will', 'AUX'), ('continue', 'VERB'), ('to', 'PART'), ('rise', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('patent', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('ingredient', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('Ozempic', 'PROPN'), ('drug', 'NOUN'), (',', 'PUNCT'), ('will', 'AUX'), ('expire', 'VERB'), ('in', 'ADP'), ('2026', 'NUM'), ('in', 'ADP'), ('a', 'DET'), ('number', 'NOUN'), ('of', 'ADP'), ('countries', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('India', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('.', 'PUNCT'), ('Only', 'ADV'), ('then', 'ADV'), ('will', 'AUX'), ('manufacturers', 'NOUN'), ('in', 'ADP'), ('these', 'DET'), ('countries', 'NOUN'), ('\xa0', 'SPACE'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('and', 'CCONJ'), ('cheaper', 'ADJ'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'PROPN'), (':', 'PUNCT'), (' ', 'SPACE'), ('I', 'PRON'), ('was', 'AUX'), ('a', 'DET'), ('pregnant', 'ADJ'), ('penguin', 'NOUN'), (',', 'PUNCT'), ('see', 'VERB'), ('my', 'PRON'), ('before', 'NOUN'), ('-', 'PUNCT'), ('after', 'ADP'), ('pics', 'NOUN'), ('.', 'PUNCT'), ('66', 'NUM'), ('-', 'PUNCT'), ('yr', 'NOUN'), ('-', 'PUNCT'), ('old', 'ADJ'), ('’s', 'PROPN'), ('Ozempic', 'PROPN'), ('to', 'ADP'), ('Mounjaro', 'PROPN'), ('journey', 'NOUN'), ('“', 'PUNCT'), ('This', 'PRON'), ('is', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('time', 'NOUN'), ('I', 'PRON'), ('’ve', 'AUX'), ('seen', 'VERB'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drugs', 'NOUN'), ('actually', 'ADV'), ('targeted', 'VERB'), ('for', 'ADP'), ('theft', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('Issa', 'PROPN'), ('Shain', 'PROPN'), (',', 'PUNCT'), ('Police', 'PROPN'), ('chief', 'NOUN'), ('in', 'ADP'), ('Dearborn', 'PROPN'), (',', 'PUNCT'), ('Michigan', 'PROPN'), (',', 'PUNCT'), ('told', 'VERB'), ('the', 'DET'), ('media', 'NOUN'), ('.', 'PUNCT'), ('But', 'CCONJ'), ('the', 'DET'), ('drugs', 'NOUN'), ('are', 'AUX'), ('not', 'PART'), ('cheap', 'ADJ'), ('and', 'CCONJ'), ('are', 'AUX'), ('seen', 'VERB'), ('as', 'ADP'), ('a', 'DET'), ('luxury', 'NOUN'), ('item', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('India', 'PROPN'), (',', 'PUNCT'), ('people', 'NOUN'), ('are', 'AUX'), ('spending', 'VERB'), ('as', 'ADV'), ('much', 'ADV'), ('as', 'ADP'), ('Rs', 'NOUN'), ('80,000', 'NUM'), ('on', 'ADP'), ('a', 'DET'), ('six', 'NUM'), ('-', 'PUNCT'), ('month', 'NOUN'), ('course', 'NOUN'), ('or', 'CCONJ'), ('scouring', 'VERB'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('for', 'ADP'), ('a', 'DET'), ('shot', 'NOUN'), ('.', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('fears', 'NOUN'), ('that', 'SCONJ'), ('this', 'DET'), ('trend', 'NOUN'), ('will', 'AUX'), ('continue', 'VERB'), ('to', 'PART'), ('rise', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('patent', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('ingredient', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('Ozempic', 'PROPN'), ('drug', 'NOUN'), (',', 'PUNCT'), ('will', 'AUX'), ('expire', 'VERB'), ('in', 'ADP'), ('2026', 'NUM'), ('in', 'ADP'), ('a', 'DET'), ('number', 'NOUN'), ('of', 'ADP'), ('countries', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('India', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('.', 'PUNCT'), ('Only', 'ADV'), ('then', 'ADV'), ('will', 'AUX'), ('manufacturers', 'NOUN'), ('in', 'ADP'), ('these', 'DET'), ('countries', 'NOUN'), ('\xa0', 'SPACE'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('and', 'CCONJ'), ('cheaper', 'ADJ'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'PROPN'), (':', 'PUNCT'), (' ', 'SPACE'), ('I', 'PRON'), ('was', 'AUX'), ('a', 'DET'), ('pregnant', 'ADJ'), ('penguin', 'NOUN'), (',', 'PUNCT'), ('see', 'VERB'), ('my', 'PRON'), ('before', 'NOUN'), ('-', 'PUNCT'), ('after', 'ADP'), ('pics', 'NOUN'), ('.', 'PUNCT'), ('66', 'NUM'), ('-', 'PUNCT'), ('yr', 'NOUN'), ('-', 'PUNCT'), ('old', 'ADJ'), ('’s', 'PROPN'), ('Ozempic', 'PROPN'), ('to', 'ADP'), ('Mounjaro', 'PROPN'), ('journey', 'NOUN'), ('But', 'CCONJ'), ('the', 'DET'), ('drugs', 'NOUN'), ('are', 'AUX'), ('not', 'PART'), ('cheap', 'ADJ'), ('and', 'CCONJ'), ('are', 'AUX'), ('seen', 'VERB'), ('as', 'ADP'), ('a', 'DET'), ('luxury', 'NOUN'), ('item', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('India', 'PROPN'), (',', 'PUNCT'), ('people', 'NOUN'), ('are', 'AUX'), ('spending', 'VERB'), ('as', 'ADV'), ('much', 'ADV'), ('as', 'ADP'), ('Rs', 'NOUN'), ('80,000', 'NUM'), ('on', 'ADP'), ('a', 'DET'), ('six', 'NUM'), ('-', 'PUNCT'), ('month', 'NOUN'), ('course', 'NOUN'), ('or', 'CCONJ'), ('scouring', 'VERB'), ('the', 'DET'), ('black', 'ADJ'), ('market', 'NOUN'), ('for', 'ADP'), ('a', 'DET'), ('shot', 'NOUN'), ('.', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('fears', 'NOUN'), ('that', 'SCONJ'), ('this', 'DET'), ('trend', 'NOUN'), ('will', 'AUX'), ('continue', 'VERB'), ('to', 'PART'), ('rise', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('patent', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('ingredient', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('Ozempic', 'PROPN'), ('drug', 'NOUN'), (',', 'PUNCT'), ('will', 'AUX'), ('expire', 'VERB'), ('in', 'ADP'), ('2026', 'NUM'), ('in', 'ADP'), ('a', 'DET'), ('number', 'NOUN'), ('of', 'ADP'), ('countries', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('India', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('.', 'PUNCT'), ('Only', 'ADV'), ('then', 'ADV'), ('will', 'AUX'), ('manufacturers', 'NOUN'), ('in', 'ADP'), ('these', 'DET'), ('countries', 'NOUN'), ('\xa0', 'SPACE'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('and', 'CCONJ'), ('cheaper', 'ADJ'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'PROPN'), (':', 'PUNCT'), (' ', 'SPACE'), ('I', 'PRON'), ('was', 'AUX'), ('a', 'DET'), ('pregnant', 'ADJ'), ('penguin', 'NOUN'), (',', 'PUNCT'), ('see', 'VERB'), ('my', 'PRON'), ('before', 'NOUN'), ('-', 'PUNCT'), ('after', 'ADP'), ('pics', 'NOUN'), ('.', 'PUNCT'), ('66', 'NUM'), ('-', 'PUNCT'), ('yr', 'NOUN'), ('-', 'PUNCT'), ('old', 'ADJ'), ('’s', 'PROPN'), ('Ozempic', 'PROPN'), ('to', 'ADP'), ('Mounjaro', 'PROPN'), ('journey', 'NOUN'), ('There', 'PRON'), ('are', 'VERB'), ('fears', 'NOUN'), ('that', 'SCONJ'), ('this', 'DET'), ('trend', 'NOUN'), ('will', 'AUX'), ('continue', 'VERB'), ('to', 'PART'), ('rise', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('patent', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('main', 'ADJ'), ('ingredient', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('Ozempic', 'PROPN'), ('drug', 'NOUN'), (',', 'PUNCT'), ('will', 'AUX'), ('expire', 'VERB'), ('in', 'ADP'), ('2026', 'NUM'), ('in', 'ADP'), ('a', 'DET'), ('number', 'NOUN'), ('of', 'ADP'), ('countries', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('India', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('.', 'PUNCT'), ('Only', 'ADV'), ('then', 'ADV'), ('will', 'AUX'), ('manufacturers', 'NOUN'), ('in', 'ADP'), ('these', 'DET'), ('countries', 'NOUN'), ('\xa0', 'SPACE'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('and', 'CCONJ'), ('cheaper', 'ADJ'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('(', 'PUNCT'), ('Edited', 'VERB'), ('by', 'ADP'), ('Sanya', 'PROPN'), ('Mathur', 'PROPN'), (')', 'PUNCT')]","[('New Delhi', 'GPE'), ('São Paulo', 'GPE'), ('Brazil', 'GPE'), ('Wegovy', 'ORG'), ('Saxenda', 'PERSON'), ('Brazil', 'GPE'), ('The New York Times', 'ORG'), ('Brazil', 'GPE'), ('24 percent', 'PERCENT'), ('2023', 'DATE'), ('nearly 12 percent', 'PERCENT'), ('2006', 'DATE'), ('New Delhi', 'GPE'), ('São Paulo', 'GPE'), ('Brazil', 'GPE'), ('Wegovy', 'ORG'), ('Saxenda', 'PERSON'), ('Brazil', 'GPE'), ('The New York Times', 'ORG'), ('Brazil', 'GPE'), ('24 percent', 'PERCENT'), ('2023', 'DATE'), ('nearly 12 percent', 'PERCENT'), ('2006', 'DATE'), ('Wegovy', 'ORG'), ('Saxenda', 'PERSON'), ('Brazil', 'GPE'), ('The New York Times', 'ORG'), ('Brazil', 'GPE'), ('24 percent', 'PERCENT'), ('2023', 'DATE'), ('nearly 12 percent', 'PERCENT'), ('2006', 'DATE'), ('Brazil', 'GPE'), ('The New York Times', 'ORG'), ('Brazil', 'GPE'), ('24 percent', 'PERCENT'), ('2023', 'DATE'), ('nearly 12 percent', 'PERCENT'), ('2006', 'DATE'), ('NYT', 'ORG'), ('Ozempic', 'GPE'), ('the last three years', 'DATE'), ('one', 'CARDINAL'), ('2022', 'DATE'), ('four', 'CARDINAL'), ('Ozempic', 'GPE'), ('18', 'CARDINAL'), ('2023', 'DATE'), ('39', 'CARDINAL'), ('2024', 'DATE'), ('Renata Goncalves', 'ORG'), ('Sao Paulo', 'GPE'), ('NYT', 'ORG'), ('Michigan', 'GPE'), ('US', 'GPE'), ('Santiago de Copostela', 'ORG'), ('Spain', 'GPE'), ('Brazil', 'GPE'), ('last year', 'DATE'), ('first', 'ORDINAL'), ('Issa Shain', 'PERSON'), ('Dearborn', 'GPE'), ('Michigan', 'GPE'), ('India', 'GPE'), ('as much as Rs 80,000', 'CARDINAL'), ('six-month', 'DATE'), ('Ozempic', 'NORP'), ('2026', 'DATE'), ('India', 'GPE'), ('China', 'GPE'), ('Brazil', 'GPE'), ('66', 'CARDINAL'), ('’s Ozempic', 'ORG'), ('Mounjaro', 'PERSON'), ('NYT', 'ORG'), ('Ozempic', 'GPE'), ('the last three years', 'DATE'), ('one', 'CARDINAL'), ('2022', 'DATE'), ('four', 'CARDINAL'), ('Ozempic', 'GPE'), ('18', 'CARDINAL'), ('2023', 'DATE'), ('39', 'CARDINAL'), ('2024', 'DATE'), ('Renata Goncalves', 'ORG'), ('Sao Paulo', 'GPE'), ('NYT', 'ORG'), ('Michigan', 'GPE'), ('US', 'GPE'), ('Santiago de Copostela', 'ORG'), ('Spain', 'GPE'), ('Brazil', 'GPE'), ('last year', 'DATE'), ('first', 'ORDINAL'), ('Issa Shain', 'PERSON'), ('Dearborn', 'GPE'), ('Michigan', 'GPE'), ('India', 'GPE'), ('as much as Rs 80,000', 'CARDINAL'), ('six-month', 'DATE'), ('Ozempic', 'NORP'), ('2026', 'DATE'), ('India', 'GPE'), ('China', 'GPE'), ('Brazil', 'GPE'), ('66', 'CARDINAL'), ('’s Ozempic', 'ORG'), ('Mounjaro', 'PERSON'), ('Renata Goncalves', 'ORG'), ('Sao Paulo', 'GPE'), ('NYT', 'ORG'), ('Michigan', 'GPE'), ('US', 'GPE'), ('Santiago de Copostela', 'ORG'), ('Spain', 'GPE'), ('Brazil', 'GPE'), ('last year', 'DATE'), ('first', 'ORDINAL'), ('Issa Shain', 'PERSON'), ('Dearborn', 'GPE'), ('Michigan', 'GPE'), ('India', 'GPE'), ('as much as Rs 80,000', 'CARDINAL'), ('six-month', 'DATE'), ('Ozempic', 'NORP'), ('2026', 'DATE'), ('India', 'GPE'), ('China', 'GPE'), ('Brazil', 'GPE'), ('66', 'CARDINAL'), ('’s Ozempic', 'ORG'), ('Mounjaro', 'PERSON'), ('Michigan', 'GPE'), ('US', 'GPE'), ('Santiago de Copostela', 'ORG'), ('Spain', 'GPE'), ('Brazil', 'GPE'), ('last year', 'DATE'), ('first', 'ORDINAL'), ('Issa Shain', 'PERSON'), ('Dearborn', 'GPE'), ('Michigan', 'GPE'), ('India', 'GPE'), ('as much as Rs 80,000', 'CARDINAL'), ('six-month', 'DATE'), ('Ozempic', 'NORP'), ('2026', 'DATE'), ('India', 'GPE'), ('China', 'GPE'), ('Brazil', 'GPE'), ('66', 'CARDINAL'), ('’s Ozempic', 'ORG'), ('Mounjaro', 'PERSON'), ('Brazil', 'GPE'), ('last year', 'DATE'), ('first', 'ORDINAL'), ('Issa Shain', 'PERSON'), ('Dearborn', 'GPE'), ('Michigan', 'GPE'), ('India', 'GPE'), ('as much as Rs 80,000', 'CARDINAL'), ('six-month', 'DATE'), ('Ozempic', 'NORP'), ('2026', 'DATE'), ('India', 'GPE'), ('China', 'GPE'), ('Brazil', 'GPE'), ('66', 'CARDINAL'), ('’s Ozempic', 'ORG'), ('Mounjaro', 'PERSON'), ('first', 'ORDINAL'), ('Issa Shain', 'PERSON'), ('Dearborn', 'GPE'), ('Michigan', 'GPE'), ('India', 'GPE'), ('as much as Rs 80,000', 'CARDINAL'), ('six-month', 'DATE'), ('Ozempic', 'NORP'), ('2026', 'DATE'), ('India', 'GPE'), ('China', 'GPE'), ('Brazil', 'GPE'), ('66', 'CARDINAL'), ('’s Ozempic', 'ORG'), ('Mounjaro', 'PERSON'), ('India', 'GPE'), ('as much as Rs 80,000', 'CARDINAL'), ('six-month', 'DATE'), ('Ozempic', 'NORP'), ('2026', 'DATE'), ('India', 'GPE'), ('China', 'GPE'), ('Brazil', 'GPE'), ('66', 'CARDINAL'), ('’s Ozempic', 'ORG'), ('Mounjaro', 'PERSON'), ('Ozempic', 'NORP'), ('2026', 'DATE'), ('India', 'GPE'), ('China', 'GPE'), ('Brazil', 'GPE'), ('Sanya Mathur', 'PERSON')]","['New Delhi', 'São Paulo', 'Brazil', 'Wegovy', 'Saxenda', 'Brazil', 'The New York Times', 'Brazil', '24 percent', '2023', 'nearly 12 percent', '2006', 'New Delhi', 'São Paulo', 'Brazil', 'Wegovy', 'Saxenda', 'Brazil', 'The New York Times', 'Brazil', '24 percent', '2023', 'nearly 12 percent', '2006', 'Wegovy', 'Saxenda', 'Brazil', 'The New York Times', 'Brazil', '24 percent', '2023', 'nearly 12 percent', '2006', 'Brazil', 'The New York Times', 'Brazil', '24 percent', '2023', 'nearly 12 percent', '2006', 'NYT', 'Ozempic', 'the last three years', 'one', '2022', 'four', 'Ozempic', '18', '2023', '39', '2024', 'Renata Goncalves', 'Sao Paulo', 'NYT', 'Michigan', 'US', 'Santiago de Copostela', 'Spain', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'NYT', 'Ozempic', 'the last three years', 'one', '2022', 'four', 'Ozempic', '18', '2023', '39', '2024', 'Renata Goncalves', 'Sao Paulo', 'NYT', 'Michigan', 'US', 'Santiago de Copostela', 'Spain', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'Renata Goncalves', 'Sao Paulo', 'NYT', 'Michigan', 'US', 'Santiago de Copostela', 'Spain', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'Michigan', 'US', 'Santiago de Copostela', 'Spain', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'Ozempic', '2026', 'India', 'China', 'Brazil', 'Sanya Mathur']","['New Delhi', 'São Paulo', 'Brazil', 'Wegovy', 'Saxenda', 'Brazil', 'The New York Times', 'Brazil', '24 percent', '2023', 'nearly 12 percent', '2006', 'New Delhi', 'São Paulo', 'Brazil', 'Wegovy', 'Saxenda', 'Brazil', 'The New York Times', 'Brazil', '24 percent', '2023', 'nearly 12 percent', '2006', 'Wegovy', 'Saxenda', 'Brazil', 'The New York Times', 'Brazil', '24 percent', '2023', 'nearly 12 percent', '2006', 'Brazil', 'The New York Times', 'Brazil', '24 percent', '2023', 'nearly 12 percent', '2006', 'NYT', 'Ozempic', 'the last three years', 'One', '2022', 'four', 'Ozempic', '18', '2023', '39', '2024', 'Renata Goncalves', 'Sao Paulo', 'NYT', 'Michigan', 'US', 'Santiago de Copostela', 'Spain', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'NYT', 'Ozempic', 'the last three years', 'One', '2022', 'four', 'Ozempic', '18', '2023', '39', '2024', 'Renata Goncalves', 'Sao Paulo', 'NYT', 'Michigan', 'US', 'Santiago de Copostela', 'Spain', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'Renata Goncalves', 'Sao Paulo', 'NYT', 'Michigan', 'US', 'Santiago de Copostela', 'Spain', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'Michigan', 'US', 'Santiago de Copostela', 'Spain', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'Brazil', 'last year', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'first', 'Issa Shain', 'Dearborn', 'Michigan', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'India', 'as much as Rs 80,000', 'six-month', 'Ozempic', '2026', 'India', 'China', 'Brazil', '66', '’s Ozempic', 'Mounjaro', 'Ozempic', '2026', 'India', 'China', 'Brazil', 'Sanya Mathur']"
Ozempic made her sick until the Michigan woman found a loophole and lost 60 lbs | - The Times of India,https://timesofindia.indiatimes.com/life-style/health-fitness/weight-loss/ozempic-made-her-sick-until-the-michigan-woman-found-a-loophole-and-lost-60-lbs/articleshow/118456048.cms,"The TOI Lifestyle Desk is a dynamic team of dedicated journalists who, with unwavering passion and commitment, sift through the pulse of the nation to curate a vibrant tapestry of lifestyle news for The Times of India readers. At the TOI Lifestyle Desk, we go beyond the obvious, delving into the extraordinary. Consider us your lifestyle companion, providing a daily dose of inspiration and information. Whether you're seeking the latest fashion trends, travel escapades, culinary delights, or wellness tips, the TOI Lifestyle Desk is your one-stop destination for an enriching lifestyle experience.Read More Kareena's best wedding looks â10 new animal species discovered for the first time in 2024 10 birds that eat meat and other animals 9 reasons why pumpkin seed is a superfood 8 Indian wildlife destinations visitors are most excited about 10 health benefits of chewing cloves daily 10 wild animals known for their friendly nature 10 quotes to inspire and motivate you How to make Oats Omelette for a quick dinner","[('The', 'DET'), ('TOI', 'PROPN'), ('Lifestyle', 'PROPN'), ('Desk', 'PROPN'), ('is', 'AUX'), ('a', 'DET'), ('dynamic', 'ADJ'), ('team', 'NOUN'), ('of', 'ADP'), ('dedicated', 'ADJ'), ('journalists', 'NOUN'), ('who', 'PRON'), (',', 'PUNCT'), ('with', 'ADP'), ('unwavering', 'VERB'), ('passion', 'NOUN'), ('and', 'CCONJ'), ('commitment', 'NOUN'), (',', 'PUNCT'), ('sift', 'VERB'), ('through', 'ADP'), ('the', 'DET'), ('pulse', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('nation', 'NOUN'), ('to', 'PART'), ('curate', 'VERB'), ('a', 'DET'), ('vibrant', 'ADJ'), ('tapestry', 'NOUN'), ('of', 'ADP'), ('lifestyle', 'NOUN'), ('news', 'NOUN'), ('for', 'ADP'), ('The', 'DET'), ('Times', 'PROPN'), ('of', 'ADP'), ('India', 'PROPN'), ('readers', 'NOUN'), ('.', 'PUNCT'), ('At', 'ADP'), ('the', 'DET'), ('TOI', 'PROPN'), ('Lifestyle', 'PROPN'), ('Desk', 'PROPN'), (',', 'PUNCT'), ('we', 'PRON'), ('go', 'VERB'), ('beyond', 'ADP'), ('the', 'DET'), ('obvious', 'ADJ'), (',', 'PUNCT'), ('delving', 'VERB'), ('into', 'ADP'), ('the', 'DET'), ('extraordinary', 'ADJ'), ('.', 'PUNCT'), ('Consider', 'VERB'), ('us', 'PRON'), ('your', 'PRON'), ('lifestyle', 'NOUN'), ('companion', 'NOUN'), (',', 'PUNCT'), ('providing', 'VERB'), ('a', 'DET'), ('daily', 'ADJ'), ('dose', 'NOUN'), ('of', 'ADP'), ('inspiration', 'NOUN'), ('and', 'CCONJ'), ('information', 'NOUN'), ('.', 'PUNCT'), ('Whether', 'SCONJ'), ('you', 'PRON'), (""'re"", 'AUX'), ('seeking', 'VERB'), ('the', 'DET'), ('latest', 'ADJ'), ('fashion', 'NOUN'), ('trends', 'NOUN'), (',', 'PUNCT'), ('travel', 'NOUN'), ('escapades', 'NOUN'), (',', 'PUNCT'), ('culinary', 'PROPN'), ('delights', 'NOUN'), (',', 'PUNCT'), ('or', 'CCONJ'), ('wellness', 'NOUN'), ('tips', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('TOI', 'PROPN'), ('Lifestyle', 'PROPN'), ('Desk', 'PROPN'), ('is', 'AUX'), ('your', 'PRON'), ('one', 'NUM'), ('-', 'PUNCT'), ('stop', 'NOUN'), ('destination', 'NOUN'), ('for', 'ADP'), ('an', 'DET'), ('enriching', 'VERB'), ('lifestyle', 'NOUN'), ('experience', 'NOUN'), ('.', 'PUNCT'), ('Read', 'VERB'), ('More', 'ADJ'), ('Kareena', 'PROPN'), (""'s"", 'PART'), ('best', 'ADJ'), ('wedding', 'NOUN'), ('looks', 'VERB'), ('â\x80\x8b10', 'ADP'), ('new', 'ADJ'), ('animal', 'NOUN'), ('species', 'NOUN'), ('discovered', 'VERB'), ('for', 'ADP'), ('the', 'DET'), ('first', 'ADJ'), ('time', 'NOUN'), ('in', 'ADP'), ('2024', 'NUM'), ('10', 'NUM'), ('birds', 'NOUN'), ('that', 'PRON'), ('eat', 'VERB'), ('meat', 'NOUN'), ('and', 'CCONJ'), ('other', 'ADJ'), ('animals', 'NOUN'), ('9', 'NUM'), ('reasons', 'NOUN'), ('why', 'SCONJ'), ('pumpkin', 'NOUN'), ('seed', 'NOUN'), ('is', 'AUX'), ('a', 'DET'), ('superfood', 'NOUN'), ('8', 'NUM'), ('Indian', 'ADJ'), ('wildlife', 'NOUN'), ('destinations', 'NOUN'), ('visitors', 'NOUN'), ('are', 'AUX'), ('most', 'ADV'), ('excited', 'ADJ'), ('about', 'ADP'), ('10', 'NUM'), ('health', 'NOUN'), ('benefits', 'NOUN'), ('of', 'ADP'), ('chewing', 'VERB'), ('cloves', 'VERB'), ('daily', 'ADV'), ('10', 'NUM'), ('wild', 'ADJ'), ('animals', 'NOUN'), ('known', 'VERB'), ('for', 'ADP'), ('their', 'PRON'), ('friendly', 'ADJ'), ('nature', 'NOUN'), ('10', 'NUM'), ('quotes', 'NOUN'), ('to', 'PART'), ('inspire', 'VERB'), ('and', 'CCONJ'), ('motivate', 'VERB'), ('you', 'PRON'), ('How', 'SCONJ'), ('to', 'PART'), ('make', 'VERB'), ('Oats', 'PROPN'), ('Omelette', 'PROPN'), ('for', 'ADP'), ('a', 'DET'), ('quick', 'ADJ'), ('dinner', 'NOUN')]","[('The TOI Lifestyle Desk', 'ORG'), ('The Times of India', 'ORG'), ('the TOI Lifestyle Desk', 'FAC'), ('daily', 'DATE'), ('the TOI Lifestyle Desk', 'ORG'), ('one', 'CARDINAL'), ('Kareena', 'ORG'), ('first', 'ORDINAL'), ('2024', 'DATE'), ('9', 'CARDINAL'), ('8', 'CARDINAL'), ('Indian', 'NORP'), ('about 10', 'CARDINAL'), ('daily', 'DATE'), ('10', 'CARDINAL'), ('10', 'CARDINAL')]","['The TOI Lifestyle Desk', 'The Times of India', 'the TOI Lifestyle Desk', 'daily', 'the TOI Lifestyle Desk', 'one', 'Kareena', 'first', '2024', '9', '8', 'Indian', 'about 10', 'daily', '10', '10']","['The TOI Lifestyle Desk', 'The Times of India', 'The TOI Lifestyle Desk', 'daily', 'The TOI Lifestyle Desk', 'One', 'Kareena', 'first', '2024', '9', '8', 'Indian', 'about 10', 'daily', '10', '10']"
Ozempic May Reduce Bone Density; Know Other Possible Side Effects,https://www.ndtv.com/health/ozempic-may-reduce-bone-density-know-other-possible-side-effects-7586940,"Ozempic (semaglutide) is a prescription medication primarily used to manage type-2 diabetes. It lowers blood sugar levels in people with diabetes and also reduces heart disease risk in people with diabetes. In addition to its glucose-lowering effect, Ozempic has been associated with reduced appetite and weight loss. It has recently gained popularity and people across the world are using it for quick weight loss. However, it is not the safest and healthiest way to lose weight. Overuse of Ozempic is linked with several side effects. Recently, in an Instagram video, singer Avery revealed that she had been diagnosed with osteoporosis after taking Ozempic for a year for weight loss. In her video, she urged her Instagram followers not to ""make the same mistake."" A healthy diet with regular exercise can help with sustainable weight loss. However, the use of Ozempic may contribute to sudden weight loss which can cause a decrease in muscle mass, low bone density and poor metabolic rate. Some studies also suggest that overuse of this drug can make your bones brittle and increase the risk of fractures. ""There is very little direct evidence that suggests the link between Ozempic use and osteoporosis. Significant weight loss, however, does have an impact on bone density that could increase the risk of osteoporosis in the elderly. It is important to monitor bone health in any treatment of weight loss,"" says Dr. Vineet Kumar Surana, Consultant - Diabetes and Endocrinology at Manipal Hospital. ""For those who are planning to take or have already taken Ozempic, they should monitor their bone health,"" urged Dr. Kumar. He has further recommended the following tips for optimal bone health: As we already know, Ozempic contains an ingredient called semaglutide which is prescribed primarily for managing type-2 diabetes. It helps in regulating blood sugar levels and can lead to weight reduction. Semaglutide mimics the GLP-1 hormone which ultimately increases a feeling of fullness, and reduces appetite, leading to decreased calorie intake and weight loss.  (Dr. Vineet Kumar Surana, Consultant - Diabetes and Endocrinology Manipal Hospital, Dwarka) Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information. Track Latest News Live on NDTV.com and get news updates from India  and around the world","[('Ozempic', 'ADJ'), ('(', 'PUNCT'), ('semaglutide', 'NOUN'), (')', 'PUNCT'), ('is', 'AUX'), ('a', 'DET'), ('prescription', 'NOUN'), ('medication', 'NOUN'), ('primarily', 'ADV'), ('used', 'VERB'), ('to', 'PART'), ('manage', 'VERB'), ('type-2', 'NUM'), ('diabetes', 'NOUN'), ('.', 'PUNCT'), ('It', 'PRON'), ('lowers', 'VERB'), ('blood', 'NOUN'), ('sugar', 'NOUN'), ('levels', 'NOUN'), ('in', 'ADP'), ('people', 'NOUN'), ('with', 'ADP'), ('diabetes', 'NOUN'), ('and', 'CCONJ'), ('also', 'ADV'), ('reduces', 'VERB'), ('heart', 'NOUN'), ('disease', 'NOUN'), ('risk', 'NOUN'), ('in', 'ADP'), ('people', 'NOUN'), ('with', 'ADP'), ('diabetes', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('addition', 'NOUN'), ('to', 'ADP'), ('its', 'PRON'), ('glucose', 'NOUN'), ('-', 'PUNCT'), ('lowering', 'VERB'), ('effect', 'NOUN'), (',', 'PUNCT'), ('Ozempic', 'PROPN'), ('has', 'AUX'), ('been', 'AUX'), ('associated', 'VERB'), ('with', 'ADP'), ('reduced', 'VERB'), ('appetite', 'NOUN'), ('and', 'CCONJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('It', 'PRON'), ('has', 'AUX'), ('recently', 'ADV'), ('gained', 'VERB'), ('popularity', 'NOUN'), ('and', 'CCONJ'), ('people', 'NOUN'), ('across', 'ADP'), ('the', 'DET'), ('world', 'NOUN'), ('are', 'AUX'), ('using', 'VERB'), ('it', 'PRON'), ('for', 'ADP'), ('quick', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('However', 'ADV'), (',', 'PUNCT'), ('it', 'PRON'), ('is', 'AUX'), ('not', 'PART'), ('the', 'DET'), ('safest', 'ADJ'), ('and', 'CCONJ'), ('healthiest', 'ADJ'), ('way', 'NOUN'), ('to', 'PART'), ('lose', 'VERB'), ('weight', 'NOUN'), ('.', 'PUNCT'), ('Overuse', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('is', 'AUX'), ('linked', 'VERB'), ('with', 'ADP'), ('several', 'ADJ'), ('side', 'NOUN'), ('effects', 'NOUN'), ('.', 'PUNCT'), ('Recently', 'ADV'), (',', 'PUNCT'), ('in', 'ADP'), ('an', 'DET'), ('Instagram', 'PROPN'), ('video', 'NOUN'), (',', 'PUNCT'), ('singer', 'NOUN'), ('Avery', 'PROPN'), ('revealed', 'VERB'), ('that', 'SCONJ'), ('she', 'PRON'), ('had', 'AUX'), ('been', 'AUX'), ('diagnosed', 'VERB'), ('with', 'ADP'), ('osteoporosis', 'NOUN'), ('after', 'ADP'), ('taking', 'VERB'), ('Ozempic', 'PROPN'), ('for', 'ADP'), ('a', 'DET'), ('year', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('her', 'PRON'), ('video', 'NOUN'), (',', 'PUNCT'), ('she', 'PRON'), ('urged', 'VERB'), ('her', 'PRON'), ('Instagram', 'PROPN'), ('followers', 'NOUN'), ('not', 'PART'), ('to', 'PART'), ('""', 'PUNCT'), ('make', 'VERB'), ('the', 'DET'), ('same', 'ADJ'), ('mistake', 'NOUN'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('A', 'DET'), ('healthy', 'ADJ'), ('diet', 'NOUN'), ('with', 'ADP'), ('regular', 'ADJ'), ('exercise', 'NOUN'), ('can', 'AUX'), ('help', 'VERB'), ('with', 'ADP'), ('sustainable', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('However', 'ADV'), (',', 'PUNCT'), ('the', 'DET'), ('use', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), ('may', 'AUX'), ('contribute', 'VERB'), ('to', 'ADP'), ('sudden', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('which', 'PRON'), ('can', 'AUX'), ('cause', 'VERB'), ('a', 'DET'), ('decrease', 'NOUN'), ('in', 'ADP'), ('muscle', 'NOUN'), ('mass', 'PROPN'), (',', 'PUNCT'), ('low', 'ADJ'), ('bone', 'NOUN'), ('density', 'NOUN'), ('and', 'CCONJ'), ('poor', 'ADJ'), ('metabolic', 'NOUN'), ('rate', 'NOUN'), ('.', 'PUNCT'), ('Some', 'DET'), ('studies', 'NOUN'), ('also', 'ADV'), ('suggest', 'VERB'), ('that', 'SCONJ'), ('overuse', 'NOUN'), ('of', 'ADP'), ('this', 'DET'), ('drug', 'NOUN'), ('can', 'AUX'), ('make', 'VERB'), ('your', 'PRON'), ('bones', 'NOUN'), ('brittle', 'ADJ'), ('and', 'CCONJ'), ('increase', 'VERB'), ('the', 'DET'), ('risk', 'NOUN'), ('of', 'ADP'), ('fractures', 'NOUN'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('There', 'PRON'), ('is', 'VERB'), ('very', 'ADV'), ('little', 'ADJ'), ('direct', 'ADJ'), ('evidence', 'NOUN'), ('that', 'PRON'), ('suggests', 'VERB'), ('the', 'DET'), ('link', 'NOUN'), ('between', 'ADP'), ('Ozempic', 'PROPN'), ('use', 'NOUN'), ('and', 'CCONJ'), ('osteoporosis', 'NOUN'), ('.', 'PUNCT'), ('Significant', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('however', 'ADV'), (',', 'PUNCT'), ('does', 'AUX'), ('have', 'VERB'), ('an', 'DET'), ('impact', 'NOUN'), ('on', 'ADP'), ('bone', 'NOUN'), ('density', 'NOUN'), ('that', 'PRON'), ('could', 'AUX'), ('increase', 'VERB'), ('the', 'DET'), ('risk', 'NOUN'), ('of', 'ADP'), ('osteoporosis', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('elderly', 'ADJ'), ('.', 'PUNCT'), ('It', 'PRON'), ('is', 'AUX'), ('important', 'ADJ'), ('to', 'PART'), ('monitor', 'VERB'), ('bone', 'NOUN'), ('health', 'NOUN'), ('in', 'ADP'), ('any', 'DET'), ('treatment', 'NOUN'), ('of', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('says', 'VERB'), ('Dr.', 'PROPN'), ('Vineet', 'PROPN'), ('Kumar', 'PROPN'), ('Surana', 'PROPN'), (',', 'PUNCT'), ('Consultant', 'PROPN'), ('-', 'PUNCT'), ('Diabetes', 'PROPN'), ('and', 'CCONJ'), ('Endocrinology', 'PROPN'), ('at', 'ADP'), ('Manipal', 'PROPN'), ('Hospital', 'PROPN'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('For', 'ADP'), ('those', 'PRON'), ('who', 'PRON'), ('are', 'AUX'), ('planning', 'VERB'), ('to', 'PART'), ('take', 'VERB'), ('or', 'CCONJ'), ('have', 'AUX'), ('already', 'ADV'), ('taken', 'VERB'), ('Ozempic', 'PROPN'), (',', 'PUNCT'), ('they', 'PRON'), ('should', 'AUX'), ('monitor', 'VERB'), ('their', 'PRON'), ('bone', 'NOUN'), ('health', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('urged', 'VERB'), ('Dr.', 'PROPN'), ('Kumar', 'PROPN'), ('.', 'PUNCT'), ('He', 'PRON'), ('has', 'AUX'), ('further', 'ADV'), ('recommended', 'VERB'), ('the', 'DET'), ('following', 'ADJ'), ('tips', 'NOUN'), ('for', 'ADP'), ('optimal', 'ADJ'), ('bone', 'NOUN'), ('health', 'NOUN'), (':', 'PUNCT'), ('As', 'SCONJ'), ('we', 'PRON'), ('already', 'ADV'), ('know', 'VERB'), (',', 'PUNCT'), ('Ozempic', 'PROPN'), ('contains', 'VERB'), ('an', 'DET'), ('ingredient', 'NOUN'), ('called', 'VERB'), ('semaglutide', 'NOUN'), ('which', 'PRON'), ('is', 'AUX'), ('prescribed', 'VERB'), ('primarily', 'ADV'), ('for', 'ADP'), ('managing', 'VERB'), ('type-2', 'PROPN'), ('diabetes', 'NOUN'), ('.', 'PUNCT'), ('It', 'PRON'), ('helps', 'VERB'), ('in', 'ADP'), ('regulating', 'VERB'), ('blood', 'NOUN'), ('sugar', 'NOUN'), ('levels', 'NOUN'), ('and', 'CCONJ'), ('can', 'AUX'), ('lead', 'VERB'), ('to', 'ADP'), ('weight', 'NOUN'), ('reduction', 'NOUN'), ('.', 'PUNCT'), ('Semaglutide', 'NOUN'), ('mimics', 'VERB'), ('the', 'DET'), ('GLP-1', 'PROPN'), ('hormone', 'NOUN'), ('which', 'PRON'), ('ultimately', 'ADV'), ('increases', 'VERB'), ('a', 'DET'), ('feeling', 'NOUN'), ('of', 'ADP'), ('fullness', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('reduces', 'VERB'), ('appetite', 'NOUN'), (',', 'PUNCT'), ('leading', 'VERB'), ('to', 'ADP'), ('decreased', 'VERB'), ('calorie', 'NOUN'), ('intake', 'NOUN'), ('and', 'CCONJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), (' ', 'SPACE'), ('(', 'PUNCT'), ('Dr.', 'PROPN'), ('Vineet', 'PROPN'), ('Kumar', 'PROPN'), ('Surana', 'PROPN'), (',', 'PUNCT'), ('Consultant', 'PROPN'), ('-', 'PUNCT'), ('Diabetes', 'PROPN'), ('and', 'CCONJ'), ('Endocrinology', 'PROPN'), ('Manipal', 'PROPN'), ('Hospital', 'PROPN'), (',', 'PUNCT'), ('Dwarka', 'PROPN'), (')', 'PUNCT'), ('Disclaimer', 'PROPN'), (':', 'PUNCT'), ('This', 'DET'), ('content', 'NOUN'), ('including', 'VERB'), ('advice', 'NOUN'), ('provides', 'VERB'), ('generic', 'ADJ'), ('information', 'NOUN'), ('only', 'ADV'), ('.', 'PUNCT'), ('It', 'PRON'), ('is', 'AUX'), ('in', 'ADP'), ('no', 'DET'), ('way', 'NOUN'), ('a', 'DET'), ('substitute', 'NOUN'), ('for', 'ADP'), ('a', 'DET'), ('qualified', 'ADJ'), ('medical', 'ADJ'), ('opinion', 'NOUN'), ('.', 'PUNCT'), ('Always', 'ADV'), ('consult', 'VERB'), ('a', 'DET'), ('specialist', 'NOUN'), ('or', 'CCONJ'), ('your', 'PRON'), ('own', 'ADJ'), ('doctor', 'NOUN'), ('for', 'ADP'), ('more', 'ADJ'), ('information', 'NOUN'), ('.', 'PUNCT'), ('NDTV', 'PROPN'), ('does', 'AUX'), ('not', 'PART'), ('claim', 'VERB'), ('responsibility', 'NOUN'), ('for', 'ADP'), ('this', 'DET'), ('information', 'NOUN'), ('.', 'PUNCT'), ('Track', 'PROPN'), ('Latest', 'PROPN'), ('News', 'PROPN'), ('Live', 'VERB'), ('on', 'ADP'), ('NDTV.com', 'PROPN'), ('and', 'CCONJ'), ('get', 'VERB'), ('news', 'NOUN'), ('updates', 'NOUN'), ('from', 'ADP'), ('India', 'PROPN'), (' ', 'SPACE'), ('and', 'CCONJ'), ('around', 'ADP'), ('the', 'DET'), ('world', 'NOUN')]","[('Ozempic', 'GPE'), ('Overuse of Ozempic', 'ORG'), ('Instagram', 'ORG'), ('Avery', 'ORG'), ('a year', 'DATE'), ('Instagram', 'NORP'), ('Ozempic', 'GPE'), ('Vineet Kumar Surana', 'PERSON'), ('Manipal Hospital', 'ORG'), ('Ozempic', 'GPE'), ('Kumar', 'PERSON'), ('Ozempic', 'ORG'), ('GLP-1', 'LOC'), ('Vineet Kumar Surana', 'PERSON'), ('NDTV', 'ORG'), ('Track Latest News Live on NDTV.com', 'ORG'), ('India', 'GPE')]","['Ozempic', 'Overuse of Ozempic', 'Instagram', 'Avery', 'a year', 'Instagram', 'Ozempic', 'Vineet Kumar Surana', 'Manipal Hospital', 'Ozempic', 'Kumar', 'Ozempic', 'GLP-1', 'Vineet Kumar Surana', 'NDTV', 'Track Latest News Live on NDTV.com', 'India']","['Ozempic', 'Overuse of Ozempic', 'Instagram', 'Avery', 'a year', 'Instagram', 'Ozempic', 'Vineet Kumar Surana', 'Manipal Hospital', 'Ozempic', 'Kumar', 'Ozempic', 'GLP-1', 'Vineet Kumar Surana', 'NDTV', 'Track Latest News Live on NDTV.com', 'India']"
Will Natco and Dr. Reddy's bet on weight-loss drug Ozempic's copy pay off? | Company Business News,https://www.livemint.com/companies/will-natco-and-dr-reddys-bet-on-weight-loss-drug-ozempics-copy-pay-off-11739886055094.html,"Also Read | Natco Pharma Q3 Results 2025: Profit Falls by 37.47% YoY       However, the companies are set to lose exclusivity on distribution of the drug in January 2026. Dr. Reddy’s, which has profited the most from the drug’s sales, and Natco, which led the launch and will see its share of the total Revlimid market grow to 33% by March 2025, will be the most impacted next year, according to analysts.        While Natco is expecting robust growth from Revlimid sales in FY26, as its market share increases to 33%, brokerage ICICI Direct Research expects a 50-60% drop in profits in FY27, following the waning of Revlimid.        Dr. Reddy’s, whose Ebitda surged from  ₹5,140 crore in FY22 to  ₹8,301 crore in FY24, significantly profiting from Revlimid sales, is also facing a market share loss in Revlimid. Also Read | Dr. Reddy’s to focus on complex products for growth to offset Revlimid loss       Now, both companies are eyeing another blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under brand names Ozempic and Wegovy, to stave off the Revlimid cliff.        “Semaglutide is the next thing which will drive growth for the Indian generic pharma companies, considering the opportunity is almost $22 billion globally, and demand has not been met entirely because there is a shortage at the innovator end,"" Amey Chalke, pharma research analyst at JM Financial Institutional Securities told Mint.        The exact market for Semaglutide is estimated to be much larger than $28-29 billion, Chalke said.  The golden opportunityNatco has secured first-to-file exclusivity under Paragraph IV for all strengths of Wegovy and key strengths of Ozempic, the Semaglutide pen. This means that if the company clears all legal and regulatory hurdles, it will have a 180-day exclusivity to market generic variants of the drug. Also Read | Dr Reddy's Labs Q3 Results: Profit grows 2% YoY to  ₹1413 crore; revenue up 16%       In October, Natco’s partner Mylan settled a US patent litigation with innovator Novo Nordisk for generic Ozempic (to be outsourced from Stelis) which registered about $9 billion sales in the US in calendar year 2023, according to ICICI Direct Research. While the US patent for the Semaglutide expires in FY31, the India patent expires next year, and the company is geared for an India launch.        “If we get all regulatory clearances on time for Semaglutide, we will be able to launch it 1HFY26,"" a Natco spokesperson told Mint in an emailed response.        Dr. Reddy’s is eyeing a Canada launch in January 2026. “I believe we are positioned well to get approval for that period of time,"" Dr. Reddy’s CEO Erez Israeli said in an earnings call in January. “Normally, between the time that you submit the product to the Canadian authorities, until you get approval, is 12 to 14 months…So what you're going to see is probably the sequence in which people will get approval, and we hope to be the first one in the pack,"" he added.        But that’s not all. The pharma major is also looking at India and Brazil as well as other emerging markets where the product is in demand.        “At present, we at JM Financial Institutional Research see Dr. Reddy’s as one of first few generic filers for semaglutide globally,"" Chalke said.  Is it enough? JM Financials estimates that Dr. Reddy’s could clock $100-150 million in Semaglutide sales if they launch in 3-4 markets next year.        On the other hand, the brokerage is anticipating $700 million from Revlimid sales in the US for the company in the coming year, before loss of exclusivity.        Dr. Reddy’s has some other products and strategies in place to offset the drop in Revlimid sales. The company is looking at the launch of biosimilar Abatacept in the US by the end of FY27. ““Abatacept is a $3-4 billion product in the US, if Dr. Reddy’s is the only company to launch that product for at least one year, their sales could be upward of $100 million for that product,"" Chalke said.        Together, Semaglutide and Abatacept may be able to substantially offset the Revlimid loss, the analyst said.        The company also has the recently-acquired nicotine replacement therapy (NRT) portfolio from Haleon plc in Europe, as an additional growth driver.        Natco Pharma has some other key first-to-file products in the pipeline, including Risdiplam Oral Solution for spinal muscular atrophy and breast cancer drug Olaparib, although the timelines for these are yet to be defined.        Analysts are divided on the company’s prospects, though.        “There are products in the pipeline, but there will be a one or two-year gap in between, where the base will be much lower, the profits will be much lower,"" an analyst who requested anonymity told Mint.        In a research note dated 14 February, ICICI Direct analysts said: “We continue to have faith in Natco’s ability to focus on blockbusters which are capable of generating robust cash flows for 3-5 years' horizon before they fade."" On the other hand, Nuvama analysts said that while the next couple of quarters could witness robust growth due to Revlimid, this is not sustainable in the future.        “We also note an impressive US launch pipeline, but uncertainty persists around launch and approval timelines. Break-even in the agrochem business in FY26 and the GLP-1 opportunity in India are triggers that can help Natco offset part of the gRevlimid hit in FY27 and beyond,"" the Nuvama analysts said in a note dated 13 February.        Natco believes there will be a drop in earnings in FY27. “That's the elephant in the room, [we] have to accept that earnings will drop in ‘27 March,"" Nannapaneni told investors in an earnings call last week.       There is no dearth of competition when it comes to Semaglutide, with leading generics makers jumping in. Sun Pharma has already undertaken clinical trials for Semaglutide, while Biocon signed an exclusive licensing and supply agreement for Semaglutide commercialization in Brazil with Biomm last year.        Domestically, innovators Eli Lilly and Novo Nordisk have also indicated potential launches. While Novo Nordisk hasn’t clarified a timeline, Eli Lilly has announced that it will launch its weight loss drug Tirzepatide in India in 2025 at competitive pricing. Indian pharma companies like Dr. Reddy’s, Natco, Cipla, Sun Pharma, Zydus and Aurobindo Pharma have cashed in on generic versions of the $8 billion blockbuster drug distributed in restricted quantities in the US since March 2022, per agreements with innovator Celgene’s parent company Bristol Myers Squibb. Also Read | Natco Pharma Q3 Results 2025: Profit Falls by 37.47% YoY However, the companies are set to lose exclusivity on distribution of the drug in January 2026. Dr. Reddy’s, which has profited the most from the drug’s sales, and Natco, which led the launch and will see its share of the total Revlimid market grow to 33% by March 2025, will be the most impacted next year, according to analysts. While Natco is expecting robust growth from Revlimid sales in FY26, as its market share increases to 33%, brokerage ICICI Direct Research expects a 50-60% drop in profits in FY27, following the waning of Revlimid. Dr. Reddy’s, whose Ebitda surged from  ₹5,140 crore in FY22 to  ₹8,301 crore in FY24, significantly profiting from Revlimid sales, is also facing a market share loss in Revlimid. Also Read | Dr. Reddy’s to focus on complex products for growth to offset Revlimid loss Now, both companies are eyeing another blockbuster drug–Novo Nordisk’s breakout star Semaglutide, sold under brand names Ozempic and Wegovy, to stave off the Revlimid cliff. “Semaglutide is the next thing which will drive growth for the Indian generic pharma companies, considering the opportunity is almost $22 billion globally, and demand has not been met entirely because there is a shortage at the innovator end,"" Amey Chalke, pharma research analyst at JM Financial Institutional Securities told Mint. The exact market for Semaglutide is estimated to be much larger than $28-29 billion, Chalke said. The golden opportunityNatco has secured first-to-file exclusivity under Paragraph IV for all strengths of Wegovy and key strengths of Ozempic, the Semaglutide pen. This means that if the company clears all legal and regulatory hurdles, it will have a 180-day exclusivity to market generic variants of the drug. Also Read | Dr Reddy's Labs Q3 Results: Profit grows 2% YoY to  ₹1413 crore; revenue up 16%       In October, Natco’s partner Mylan settled a US patent litigation with innovator Novo Nordisk for generic Ozempic (to be outsourced from Stelis) which registered about $9 billion sales in the US in calendar year 2023, according to ICICI Direct Research. While the US patent for the Semaglutide expires in FY31, the India patent expires next year, and the company is geared for an India launch.        “If we get all regulatory clearances on time for Semaglutide, we will be able to launch it 1HFY26,"" a Natco spokesperson told Mint in an emailed response.        Dr. Reddy’s is eyeing a Canada launch in January 2026. “I believe we are positioned well to get approval for that period of time,"" Dr. Reddy’s CEO Erez Israeli said in an earnings call in January. “Normally, between the time that you submit the product to the Canadian authorities, until you get approval, is 12 to 14 months…So what you're going to see is probably the sequence in which people will get approval, and we hope to be the first one in the pack,"" he added.        But that’s not all. The pharma major is also looking at India and Brazil as well as other emerging markets where the product is in demand.        “At present, we at JM Financial Institutional Research see Dr. Reddy’s as one of first few generic filers for semaglutide globally,"" Chalke said.  Is it enough? JM Financials estimates that Dr. Reddy’s could clock $100-150 million in Semaglutide sales if they launch in 3-4 markets next year.        On the other hand, the brokerage is anticipating $700 million from Revlimid sales in the US for the company in the coming year, before loss of exclusivity.        Dr. Reddy’s has some other products and strategies in place to offset the drop in Revlimid sales. The company is looking at the launch of biosimilar Abatacept in the US by the end of FY27. ““Abatacept is a $3-4 billion product in the US, if Dr. Reddy’s is the only company to launch that product for at least one year, their sales could be upward of $100 million for that product,"" Chalke said.        Together, Semaglutide and Abatacept may be able to substantially offset the Revlimid loss, the analyst said.        The company also has the recently-acquired nicotine replacement therapy (NRT) portfolio from Haleon plc in Europe, as an additional growth driver.        Natco Pharma has some other key first-to-file products in the pipeline, including Risdiplam Oral Solution for spinal muscular atrophy and breast cancer drug Olaparib, although the timelines for these are yet to be defined.        Analysts are divided on the company’s prospects, though.        “There are products in the pipeline, but there will be a one or two-year gap in between, where the base will be much lower, the profits will be much lower,"" an analyst who requested anonymity told Mint.        In a research note dated 14 February, ICICI Direct analysts said: “We continue to have faith in Natco’s ability to focus on blockbusters which are capable of generating robust cash flows for 3-5 years' horizon before they fade."" On the other hand, Nuvama analysts said that while the next couple of quarters could witness robust growth due to Revlimid, this is not sustainable in the future.        “We also note an impressive US launch pipeline, but uncertainty persists around launch and approval timelines. Break-even in the agrochem business in FY26 and the GLP-1 opportunity in India are triggers that can help Natco offset part of the gRevlimid hit in FY27 and beyond,"" the Nuvama analysts said in a note dated 13 February.        Natco believes there will be a drop in earnings in FY27. “That's the elephant in the room, [we] have to accept that earnings will drop in ‘27 March,"" Nannapaneni told investors in an earnings call last week.       There is no dearth of competition when it comes to Semaglutide, with leading generics makers jumping in. Sun Pharma has already undertaken clinical trials for Semaglutide, while Biocon signed an exclusive licensing and supply agreement for Semaglutide commercialization in Brazil with Biomm last year.        Domestically, innovators Eli Lilly and Novo Nordisk have also indicated potential launches. While Novo Nordisk hasn’t clarified a timeline, Eli Lilly has announced that it will launch its weight loss drug Tirzepatide in India in 2025 at competitive pricing. Natco has secured first-to-file exclusivity under Paragraph IV for all strengths of Wegovy and key strengths of Ozempic, the Semaglutide pen. This means that if the company clears all legal and regulatory hurdles, it will have a 180-day exclusivity to market generic variants of the drug. Also Read | Dr Reddy's Labs Q3 Results: Profit grows 2% YoY to  ₹1413 crore; revenue up 16% In October, Natco’s partner Mylan settled a US patent litigation with innovator Novo Nordisk for generic Ozempic (to be outsourced from Stelis) which registered about $9 billion sales in the US in calendar year 2023, according to ICICI Direct Research. While the US patent for the Semaglutide expires in FY31, the India patent expires next year, and the company is geared for an India launch. “If we get all regulatory clearances on time for Semaglutide, we will be able to launch it 1HFY26,"" a Natco spokesperson told Mint in an emailed response. Dr. Reddy’s is eyeing a Canada launch in January 2026. “I believe we are positioned well to get approval for that period of time,"" Dr. Reddy’s CEO Erez Israeli said in an earnings call in January. “Normally, between the time that you submit the product to the Canadian authorities, until you get approval, is 12 to 14 months…So what you're going to see is probably the sequence in which people will get approval, and we hope to be the first one in the pack,"" he added. But that’s not all. The pharma major is also looking at India and Brazil as well as other emerging markets where the product is in demand. “At present, we at JM Financial Institutional Research see Dr. Reddy’s as one of first few generic filers for semaglutide globally,"" Chalke said. Is it enough? JM Financials estimates that Dr. Reddy’s could clock $100-150 million in Semaglutide sales if they launch in 3-4 markets next year.        On the other hand, the brokerage is anticipating $700 million from Revlimid sales in the US for the company in the coming year, before loss of exclusivity.        Dr. Reddy’s has some other products and strategies in place to offset the drop in Revlimid sales. The company is looking at the launch of biosimilar Abatacept in the US by the end of FY27. ““Abatacept is a $3-4 billion product in the US, if Dr. Reddy’s is the only company to launch that product for at least one year, their sales could be upward of $100 million for that product,"" Chalke said.        Together, Semaglutide and Abatacept may be able to substantially offset the Revlimid loss, the analyst said.        The company also has the recently-acquired nicotine replacement therapy (NRT) portfolio from Haleon plc in Europe, as an additional growth driver.        Natco Pharma has some other key first-to-file products in the pipeline, including Risdiplam Oral Solution for spinal muscular atrophy and breast cancer drug Olaparib, although the timelines for these are yet to be defined.        Analysts are divided on the company’s prospects, though.        “There are products in the pipeline, but there will be a one or two-year gap in between, where the base will be much lower, the profits will be much lower,"" an analyst who requested anonymity told Mint.        In a research note dated 14 February, ICICI Direct analysts said: “We continue to have faith in Natco’s ability to focus on blockbusters which are capable of generating robust cash flows for 3-5 years' horizon before they fade."" On the other hand, Nuvama analysts said that while the next couple of quarters could witness robust growth due to Revlimid, this is not sustainable in the future.        “We also note an impressive US launch pipeline, but uncertainty persists around launch and approval timelines. Break-even in the agrochem business in FY26 and the GLP-1 opportunity in India are triggers that can help Natco offset part of the gRevlimid hit in FY27 and beyond,"" the Nuvama analysts said in a note dated 13 February.        Natco believes there will be a drop in earnings in FY27. “That's the elephant in the room, [we] have to accept that earnings will drop in ‘27 March,"" Nannapaneni told investors in an earnings call last week.       There is no dearth of competition when it comes to Semaglutide, with leading generics makers jumping in. Sun Pharma has already undertaken clinical trials for Semaglutide, while Biocon signed an exclusive licensing and supply agreement for Semaglutide commercialization in Brazil with Biomm last year.        Domestically, innovators Eli Lilly and Novo Nordisk have also indicated potential launches. While Novo Nordisk hasn’t clarified a timeline, Eli Lilly has announced that it will launch its weight loss drug Tirzepatide in India in 2025 at competitive pricing. JM Financials estimates that Dr. Reddy’s could clock $100-150 million in Semaglutide sales if they launch in 3-4 markets next year. On the other hand, the brokerage is anticipating $700 million from Revlimid sales in the US for the company in the coming year, before loss of exclusivity. Dr. Reddy’s has some other products and strategies in place to offset the drop in Revlimid sales. The company is looking at the launch of biosimilar Abatacept in the US by the end of FY27. ““Abatacept is a $3-4 billion product in the US, if Dr. Reddy’s is the only company to launch that product for at least one year, their sales could be upward of $100 million for that product,"" Chalke said. Together, Semaglutide and Abatacept may be able to substantially offset the Revlimid loss, the analyst said. The company also has the recently-acquired nicotine replacement therapy (NRT) portfolio from Haleon plc in Europe, as an additional growth driver. Natco Pharma has some other key first-to-file products in the pipeline, including Risdiplam Oral Solution for spinal muscular atrophy and breast cancer drug Olaparib, although the timelines for these are yet to be defined. Analysts are divided on the company’s prospects, though. “There are products in the pipeline, but there will be a one or two-year gap in between, where the base will be much lower, the profits will be much lower,"" an analyst who requested anonymity told Mint. In a research note dated 14 February, ICICI Direct analysts said: “We continue to have faith in Natco’s ability to focus on blockbusters which are capable of generating robust cash flows for 3-5 years' horizon before they fade."" On the other hand, Nuvama analysts said that while the next couple of quarters could witness robust growth due to Revlimid, this is not sustainable in the future. “We also note an impressive US launch pipeline, but uncertainty persists around launch and approval timelines. Break-even in the agrochem business in FY26 and the GLP-1 opportunity in India are triggers that can help Natco offset part of the gRevlimid hit in FY27 and beyond,"" the Nuvama analysts said in a note dated 13 February. Natco believes there will be a drop in earnings in FY27. “That's the elephant in the room, [we] have to accept that earnings will drop in ‘27 March,"" Nannapaneni told investors in an earnings call last week. There is no dearth of competition when it comes to Semaglutide, with leading generics makers jumping in. Sun Pharma has already undertaken clinical trials for Semaglutide, while Biocon signed an exclusive licensing and supply agreement for Semaglutide commercialization in Brazil with Biomm last year. Domestically, innovators Eli Lilly and Novo Nordisk have also indicated potential launches. While Novo Nordisk hasn’t clarified a timeline, Eli Lilly has announced that it will launch its weight loss drug Tirzepatide in India in 2025 at competitive pricing.","[('Also', 'ADV'), ('Read', 'VERB'), ('|', 'ADV'), ('Natco', 'PROPN'), ('Pharma', 'PROPN'), ('Q3', 'PROPN'), ('Results', 'VERB'), ('2025', 'NUM'), (':', 'PUNCT'), ('Profit', 'NOUN'), ('Falls', 'PROPN'), ('by', 'ADP'), ('37.47', 'NUM'), ('%', 'NOUN'), ('YoY', 'NOUN'), ('      ', 'SPACE'), ('However', 'ADV'), (',', 'PUNCT'), ('the', 'DET'), ('companies', 'NOUN'), ('are', 'AUX'), ('set', 'VERB'), ('to', 'PART'), ('lose', 'VERB'), ('exclusivity', 'NOUN'), ('on', 'ADP'), ('distribution', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('in', 'ADP'), ('January', 'PROPN'), ('2026', 'NUM'), ('.', 'PUNCT'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PUNCT'), (',', 'PUNCT'), ('which', 'PRON'), ('has', 'AUX'), ('profited', 'VERB'), ('the', 'DET'), ('most', 'ADJ'), ('from', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('’s', 'PART'), ('sales', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('Natco', 'PROPN'), (',', 'PUNCT'), ('which', 'PRON'), ('led', 'VERB'), ('the', 'DET'), ('launch', 'NOUN'), ('and', 'CCONJ'), ('will', 'AUX'), ('see', 'VERB'), ('its', 'PRON'), ('share', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('total', 'ADJ'), ('Revlimid', 'PROPN'), ('market', 'NOUN'), ('grow', 'VERB'), ('to', 'ADP'), ('33', 'NUM'), ('%', 'NOUN'), ('by', 'ADP'), ('March', 'PROPN'), ('2025', 'NUM'), (',', 'PUNCT'), ('will', 'AUX'), ('be', 'AUX'), ('the', 'PRON'), ('most', 'ADV'), ('impacted', 'VERB'), ('next', 'ADJ'), ('year', 'NOUN'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('analysts', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('While', 'SCONJ'), ('Natco', 'PROPN'), ('is', 'AUX'), ('expecting', 'VERB'), ('robust', 'ADJ'), ('growth', 'NOUN'), ('from', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('in', 'ADP'), ('FY26', 'PROPN'), (',', 'PUNCT'), ('as', 'SCONJ'), ('its', 'PRON'), ('market', 'NOUN'), ('share', 'NOUN'), ('increases', 'VERB'), ('to', 'ADP'), ('33', 'NUM'), ('%', 'NOUN'), (',', 'PUNCT'), ('brokerage', 'NOUN'), ('ICICI', 'NOUN'), ('Direct', 'PROPN'), ('Research', 'PROPN'), ('expects', 'VERB'), ('a', 'DET'), ('50', 'NUM'), ('-', 'SYM'), ('60', 'NUM'), ('%', 'NOUN'), ('drop', 'NOUN'), ('in', 'ADP'), ('profits', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), (',', 'PUNCT'), ('following', 'VERB'), ('the', 'DET'), ('waning', 'NOUN'), ('of', 'ADP'), ('Revlimid', 'PROPN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PUNCT'), (',', 'PUNCT'), ('whose', 'DET'), ('Ebitda', 'PROPN'), ('surged', 'VERB'), ('from', 'ADP'), (' ', 'SPACE'), ('₹', 'PROPN'), ('5,140', 'NUM'), ('crore', 'NOUN'), ('in', 'ADP'), ('FY22', 'PROPN'), ('to', 'PART'), (' ', 'SPACE'), ('₹', 'PROPN'), ('8,301', 'NUM'), ('crore', 'NOUN'), ('in', 'ADP'), ('FY24', 'PROPN'), (',', 'PUNCT'), ('significantly', 'ADV'), ('profiting', 'ADJ'), ('from', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), (',', 'PUNCT'), ('is', 'AUX'), ('also', 'ADV'), ('facing', 'VERB'), ('a', 'DET'), ('market', 'NOUN'), ('share', 'NOUN'), ('loss', 'NOUN'), ('in', 'ADP'), ('Revlimid', 'PROPN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'VERB'), ('|', 'ADV'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'AUX'), ('to', 'PART'), ('focus', 'VERB'), ('on', 'ADP'), ('complex', 'ADJ'), ('products', 'NOUN'), ('for', 'ADP'), ('growth', 'NOUN'), ('to', 'PART'), ('offset', 'VERB'), ('Revlimid', 'PROPN'), ('loss', 'NOUN'), ('      ', 'SPACE'), ('Now', 'ADV'), (',', 'PUNCT'), ('both', 'DET'), ('companies', 'NOUN'), ('are', 'AUX'), ('eyeing', 'VERB'), ('another', 'DET'), ('blockbuster', 'ADJ'), ('drug', 'NOUN'), ('–', 'PUNCT'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('’s', 'PART'), ('breakout', 'PROPN'), ('star', 'PROPN'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('sold', 'VERB'), ('under', 'ADP'), ('brand', 'NOUN'), ('names', 'NOUN'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), (',', 'PUNCT'), ('to', 'PART'), ('stave', 'VERB'), ('off', 'ADP'), ('the', 'DET'), ('Revlimid', 'PROPN'), ('cliff', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('Semaglutide', 'PROPN'), ('is', 'AUX'), ('the', 'DET'), ('next', 'ADJ'), ('thing', 'NOUN'), ('which', 'PRON'), ('will', 'AUX'), ('drive', 'VERB'), ('growth', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('Indian', 'ADJ'), ('generic', 'ADJ'), ('pharma', 'NOUN'), ('companies', 'NOUN'), (',', 'PUNCT'), ('considering', 'VERB'), ('the', 'DET'), ('opportunity', 'NOUN'), ('is', 'AUX'), ('almost', 'ADV'), ('$', 'SYM'), ('22', 'NUM'), ('billion', 'NUM'), ('globally', 'ADV'), (',', 'PUNCT'), ('and', 'CCONJ'), ('demand', 'NOUN'), ('has', 'AUX'), ('not', 'PART'), ('been', 'AUX'), ('met', 'VERB'), ('entirely', 'ADV'), ('because', 'SCONJ'), ('there', 'PRON'), ('is', 'VERB'), ('a', 'DET'), ('shortage', 'NOUN'), ('at', 'ADP'), ('the', 'DET'), ('innovator', 'NOUN'), ('end', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Amey', 'PROPN'), ('Chalke', 'PROPN'), (',', 'PUNCT'), ('pharma', 'PROPN'), ('research', 'NOUN'), ('analyst', 'NOUN'), ('at', 'ADP'), ('JM', 'PROPN'), ('Financial', 'PROPN'), ('Institutional', 'PROPN'), ('Securities', 'PROPN'), ('told', 'VERB'), ('Mint', 'PROPN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('The', 'DET'), ('exact', 'ADJ'), ('market', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), ('is', 'AUX'), ('estimated', 'VERB'), ('to', 'PART'), ('be', 'AUX'), ('much', 'ADV'), ('larger', 'ADJ'), ('than', 'ADP'), ('$', 'SYM'), ('28', 'NUM'), ('-', 'SYM'), ('29', 'NUM'), ('billion', 'NUM'), (',', 'PUNCT'), ('Chalke', 'PROPN'), ('said', 'VERB'), ('.', 'PUNCT'), ('\xa0 ', 'SPACE'), ('The', 'DET'), ('golden', 'ADJ'), ('opportunityNatco', 'PROPN'), ('has', 'AUX'), ('secured', 'VERB'), ('first', 'ADJ'), ('-', 'PUNCT'), ('to', 'ADP'), ('-', 'PUNCT'), ('file', 'NOUN'), ('exclusivity', 'NOUN'), ('under', 'ADP'), ('Paragraph', 'PROPN'), ('IV', 'PROPN'), ('for', 'ADP'), ('all', 'DET'), ('strengths', 'NOUN'), ('of', 'ADP'), ('Wegovy', 'PROPN'), ('and', 'CCONJ'), ('key', 'ADJ'), ('strengths', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('Semaglutide', 'PROPN'), ('pen', 'NOUN'), ('.', 'PUNCT'), ('This', 'PRON'), ('means', 'VERB'), ('that', 'SCONJ'), ('if', 'SCONJ'), ('the', 'DET'), ('company', 'NOUN'), ('clears', 'VERB'), ('all', 'DET'), ('legal', 'ADJ'), ('and', 'CCONJ'), ('regulatory', 'ADJ'), ('hurdles', 'NOUN'), (',', 'PUNCT'), ('it', 'PRON'), ('will', 'AUX'), ('have', 'VERB'), ('a', 'DET'), ('180', 'NUM'), ('-', 'PUNCT'), ('day', 'NOUN'), ('exclusivity', 'NOUN'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('variants', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'VERB'), ('|', 'NOUN'), ('Dr', 'PROPN'), ('Reddy', 'PROPN'), (""'s"", 'PART'), ('Labs', 'PROPN'), ('Q3', 'PROPN'), ('Results', 'NOUN'), (':', 'PUNCT'), ('Profit', 'NOUN'), ('grows', 'VERB'), ('2', 'NUM'), ('%', 'NOUN'), ('YoY', 'NOUN'), ('to', 'PART'), (' ', 'SPACE'), ('₹', 'PROPN'), ('1413', 'NUM'), ('crore', 'NOUN'), (';', 'PUNCT'), ('revenue', 'NOUN'), ('up', 'ADP'), ('16', 'NUM'), ('%', 'NOUN'), ('      ', 'SPACE'), ('In', 'ADP'), ('October', 'PROPN'), (',', 'PUNCT'), ('Natco', 'PROPN'), ('’s', 'PART'), ('partner', 'NOUN'), ('Mylan', 'PROPN'), ('settled', 'VERB'), ('a', 'DET'), ('US', 'PROPN'), ('patent', 'NOUN'), ('litigation', 'NOUN'), ('with', 'ADP'), ('innovator', 'NOUN'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('for', 'ADP'), ('generic', 'ADJ'), ('Ozempic', 'PROPN'), ('(', 'PUNCT'), ('to', 'PART'), ('be', 'AUX'), ('outsourced', 'VERB'), ('from', 'ADP'), ('Stelis', 'PROPN'), (')', 'PUNCT'), ('which', 'PRON'), ('registered', 'VERB'), ('about', 'ADP'), ('$', 'SYM'), ('9', 'NUM'), ('billion', 'NUM'), ('sales', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('in', 'ADP'), ('calendar', 'NOUN'), ('year', 'NOUN'), ('2023', 'NUM'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('ICICI', 'PROPN'), ('Direct', 'PROPN'), ('Research', 'PROPN'), ('.', 'PUNCT'), ('While', 'SCONJ'), ('the', 'DET'), ('US', 'PROPN'), ('patent', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('Semaglutide', 'PROPN'), ('expires', 'VERB'), ('in', 'ADP'), ('FY31', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('India', 'PROPN'), ('patent', 'NOUN'), ('expires', 'VERB'), ('next', 'ADJ'), ('year', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('the', 'DET'), ('company', 'NOUN'), ('is', 'AUX'), ('geared', 'VERB'), ('for', 'ADP'), ('an', 'DET'), ('India', 'PROPN'), ('launch', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('If', 'SCONJ'), ('we', 'PRON'), ('get', 'VERB'), ('all', 'DET'), ('regulatory', 'ADJ'), ('clearances', 'NOUN'), ('on', 'ADP'), ('time', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('we', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('launch', 'VERB'), ('it', 'PRON'), ('1HFY26', 'NUM'), (',', 'PUNCT'), ('""', 'PUNCT'), ('a', 'DET'), ('Natco', 'PROPN'), ('spokesperson', 'NOUN'), ('told', 'VERB'), ('Mint', 'PROPN'), ('in', 'ADP'), ('an', 'DET'), ('emailed', 'ADJ'), ('response', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('is', 'AUX'), ('eyeing', 'VERB'), ('a', 'DET'), ('Canada', 'PROPN'), ('launch', 'NOUN'), ('in', 'ADP'), ('January', 'PROPN'), ('2026', 'NUM'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('I', 'PRON'), ('believe', 'VERB'), ('we', 'PRON'), ('are', 'AUX'), ('positioned', 'VERB'), ('well', 'ADV'), ('to', 'PART'), ('get', 'VERB'), ('approval', 'NOUN'), ('for', 'ADP'), ('that', 'DET'), ('period', 'NOUN'), ('of', 'ADP'), ('time', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('CEO', 'PROPN'), ('Erez', 'PROPN'), ('Israeli', 'PROPN'), ('said', 'VERB'), ('in', 'ADP'), ('an', 'DET'), ('earnings', 'NOUN'), ('call', 'NOUN'), ('in', 'ADP'), ('January', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('Normally', 'ADV'), (',', 'PUNCT'), ('between', 'ADP'), ('the', 'DET'), ('time', 'NOUN'), ('that', 'PRON'), ('you', 'PRON'), ('submit', 'VERB'), ('the', 'DET'), ('product', 'NOUN'), ('to', 'ADP'), ('the', 'DET'), ('Canadian', 'ADJ'), ('authorities', 'NOUN'), (',', 'PUNCT'), ('until', 'SCONJ'), ('you', 'PRON'), ('get', 'VERB'), ('approval', 'NOUN'), (',', 'PUNCT'), ('is', 'AUX'), ('12', 'NUM'), ('to', 'PART'), ('14', 'NUM'), ('months', 'NOUN'), ('…', 'PUNCT'), ('So', 'ADV'), ('what', 'PRON'), ('you', 'PRON'), (""'re"", 'AUX'), ('going', 'VERB'), ('to', 'PART'), ('see', 'VERB'), ('is', 'AUX'), ('probably', 'ADV'), ('the', 'DET'), ('sequence', 'NOUN'), ('in', 'ADP'), ('which', 'PRON'), ('people', 'NOUN'), ('will', 'AUX'), ('get', 'VERB'), ('approval', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('we', 'PRON'), ('hope', 'VERB'), ('to', 'PART'), ('be', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('one', 'NUM'), ('in', 'ADP'), ('the', 'DET'), ('pack', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('he', 'PRON'), ('added', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('But', 'CCONJ'), ('that', 'PRON'), ('’s', 'VERB'), ('not', 'PART'), ('all', 'PRON'), ('.', 'PUNCT'), ('The', 'DET'), ('pharma', 'NOUN'), ('major', 'NOUN'), ('is', 'AUX'), ('also', 'ADV'), ('looking', 'VERB'), ('at', 'ADP'), ('India', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('as', 'ADV'), ('well', 'ADV'), ('as', 'ADP'), ('other', 'ADJ'), ('emerging', 'VERB'), ('markets', 'NOUN'), ('where', 'SCONJ'), ('the', 'DET'), ('product', 'NOUN'), ('is', 'AUX'), ('in', 'ADP'), ('demand', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('At', 'ADP'), ('present', 'NOUN'), (',', 'PUNCT'), ('we', 'PRON'), ('at', 'ADP'), ('JM', 'PROPN'), ('Financial', 'PROPN'), ('Institutional', 'PROPN'), ('Research', 'PROPN'), ('see', 'VERB'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PUNCT'), ('as', 'ADP'), ('one', 'NUM'), ('of', 'ADP'), ('first', 'ADJ'), ('few', 'ADJ'), ('generic', 'ADJ'), ('filers', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), ('globally', 'ADV'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Chalke', 'PROPN'), ('said', 'VERB'), ('.', 'PUNCT'), ('\xa0 ', 'SPACE'), ('Is', 'AUX'), ('it', 'PRON'), ('enough', 'ADJ'), ('?', 'PUNCT'), ('\xa0', 'SPACE'), ('JM', 'PROPN'), ('Financials', 'NOUN'), ('estimates', 'VERB'), ('that', 'SCONJ'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('could', 'AUX'), ('clock', 'VERB'), ('$', 'SYM'), ('100', 'NUM'), ('-', 'SYM'), ('150', 'NUM'), ('million', 'NUM'), ('in', 'ADP'), ('Semaglutide', 'PROPN'), ('sales', 'NOUN'), ('if', 'SCONJ'), ('they', 'PRON'), ('launch', 'VERB'), ('in', 'ADP'), ('3', 'NUM'), ('-', 'SYM'), ('4', 'NUM'), ('markets', 'NOUN'), ('next', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('On', 'ADP'), ('the', 'DET'), ('other', 'ADJ'), ('hand', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('brokerage', 'NOUN'), ('is', 'AUX'), ('anticipating', 'VERB'), ('$', 'SYM'), ('700', 'NUM'), ('million', 'NUM'), ('from', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('for', 'ADP'), ('the', 'DET'), ('company', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('coming', 'VERB'), ('year', 'NOUN'), (',', 'PUNCT'), ('before', 'ADP'), ('loss', 'NOUN'), ('of', 'ADP'), ('exclusivity', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('has', 'VERB'), ('some', 'DET'), ('other', 'ADJ'), ('products', 'NOUN'), ('and', 'CCONJ'), ('strategies', 'NOUN'), ('in', 'ADP'), ('place', 'NOUN'), ('to', 'PART'), ('offset', 'VERB'), ('the', 'DET'), ('drop', 'NOUN'), ('in', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('company', 'NOUN'), ('is', 'AUX'), ('looking', 'VERB'), ('at', 'ADP'), ('the', 'DET'), ('launch', 'NOUN'), ('of', 'ADP'), ('biosimilar', 'ADJ'), ('Abatacept', 'PROPN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('by', 'ADP'), ('the', 'DET'), ('end', 'NOUN'), ('of', 'ADP'), ('FY27', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('“', 'PUNCT'), ('Abatacept', 'PROPN'), ('is', 'AUX'), ('a', 'DET'), ('$', 'SYM'), ('3', 'NUM'), ('-', 'SYM'), ('4', 'NUM'), ('billion', 'NUM'), ('product', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), (',', 'PUNCT'), ('if', 'SCONJ'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('is', 'AUX'), ('the', 'DET'), ('only', 'ADJ'), ('company', 'NOUN'), ('to', 'PART'), ('launch', 'VERB'), ('that', 'DET'), ('product', 'NOUN'), ('for', 'ADP'), ('at', 'ADV'), ('least', 'ADV'), ('one', 'NUM'), ('year', 'NOUN'), (',', 'PUNCT'), ('their', 'PRON'), ('sales', 'NOUN'), ('could', 'AUX'), ('be', 'AUX'), ('upward', 'ADV'), ('of', 'ADP'), ('$', 'SYM'), ('100', 'NUM'), ('million', 'NUM'), ('for', 'ADP'), ('that', 'DET'), ('product', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Chalke', 'PROPN'), ('said', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Together', 'ADV'), (',', 'PUNCT'), ('Semaglutide', 'PROPN'), ('and', 'CCONJ'), ('Abatacept', 'PROPN'), ('may', 'AUX'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('substantially', 'ADV'), ('offset', 'VERB'), ('the', 'DET'), ('Revlimid', 'PROPN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('analyst', 'NOUN'), ('said', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('The', 'DET'), ('company', 'NOUN'), ('also', 'ADV'), ('has', 'VERB'), ('the', 'DET'), ('recently', 'ADV'), ('-', 'PUNCT'), ('acquired', 'VERB'), ('nicotine', 'NOUN'), ('replacement', 'NOUN'), ('therapy', 'NOUN'), ('(', 'PUNCT'), ('NRT', 'PROPN'), (')', 'PUNCT'), ('portfolio', 'NOUN'), ('from', 'ADP'), ('Haleon', 'PROPN'), ('plc', 'PROPN'), ('in', 'ADP'), ('Europe', 'PROPN'), (',', 'PUNCT'), ('as', 'ADP'), ('an', 'DET'), ('additional', 'ADJ'), ('growth', 'NOUN'), ('driver', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Natco', 'PROPN'), ('Pharma', 'PROPN'), ('has', 'VERB'), ('some', 'DET'), ('other', 'ADJ'), ('key', 'ADJ'), ('first', 'ADJ'), ('-', 'PUNCT'), ('to', 'ADP'), ('-', 'PUNCT'), ('file', 'NOUN'), ('products', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('Risdiplam', 'PROPN'), ('Oral', 'PROPN'), ('Solution', 'PROPN'), ('for', 'ADP'), ('spinal', 'ADJ'), ('muscular', 'ADJ'), ('atrophy', 'NOUN'), ('and', 'CCONJ'), ('breast', 'NOUN'), ('cancer', 'NOUN'), ('drug', 'NOUN'), ('Olaparib', 'PROPN'), (',', 'PUNCT'), ('although', 'SCONJ'), ('the', 'DET'), ('timelines', 'NOUN'), ('for', 'ADP'), ('these', 'PRON'), ('are', 'AUX'), ('yet', 'ADV'), ('to', 'PART'), ('be', 'AUX'), ('defined', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Analysts', 'NOUN'), ('are', 'AUX'), ('divided', 'VERB'), ('on', 'ADP'), ('the', 'DET'), ('company', 'NOUN'), ('’s', 'PART'), ('prospects', 'NOUN'), (',', 'PUNCT'), ('though', 'ADV'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('products', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('one', 'NUM'), ('or', 'CCONJ'), ('two', 'NUM'), ('-', 'PUNCT'), ('year', 'NOUN'), ('gap', 'NOUN'), ('in', 'ADP'), ('between', 'ADP'), (',', 'PUNCT'), ('where', 'SCONJ'), ('the', 'DET'), ('base', 'NOUN'), ('will', 'AUX'), ('be', 'AUX'), ('much', 'ADV'), ('lower', 'ADJ'), (',', 'PUNCT'), ('the', 'DET'), ('profits', 'NOUN'), ('will', 'AUX'), ('be', 'AUX'), ('much', 'ADV'), ('lower', 'ADJ'), (',', 'PUNCT'), ('""', 'PUNCT'), ('an', 'DET'), ('analyst', 'NOUN'), ('who', 'PRON'), ('requested', 'VERB'), ('anonymity', 'NOUN'), ('told', 'VERB'), ('Mint', 'PROPN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('In', 'ADP'), ('a', 'DET'), ('research', 'NOUN'), ('note', 'NOUN'), ('dated', 'VERB'), ('14', 'NUM'), ('February', 'PROPN'), (',', 'PUNCT'), ('ICICI', 'PROPN'), ('Direct', 'ADJ'), ('analysts', 'NOUN'), ('said', 'VERB'), (':', 'PUNCT'), ('“', 'PUNCT'), ('We', 'PRON'), ('continue', 'VERB'), ('to', 'PART'), ('have', 'VERB'), ('faith', 'NOUN'), ('in', 'ADP'), ('Natco', 'PROPN'), ('’s', 'PART'), ('ability', 'NOUN'), ('to', 'PART'), ('focus', 'VERB'), ('on', 'ADP'), ('blockbusters', 'NOUN'), ('which', 'PRON'), ('are', 'AUX'), ('capable', 'ADJ'), ('of', 'ADP'), ('generating', 'VERB'), ('robust', 'ADJ'), ('cash', 'NOUN'), ('flows', 'VERB'), ('for', 'ADP'), ('3', 'NUM'), ('-', 'SYM'), ('5', 'NUM'), ('years', 'NOUN'), (""'"", 'PART'), ('horizon', 'NOUN'), ('before', 'SCONJ'), ('they', 'PRON'), ('fade', 'VERB'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('On', 'ADP'), ('the', 'DET'), ('other', 'ADJ'), ('hand', 'NOUN'), (',', 'PUNCT'), ('Nuvama', 'PROPN'), ('analysts', 'NOUN'), ('said', 'VERB'), ('that', 'SCONJ'), ('while', 'SCONJ'), ('the', 'DET'), ('next', 'ADJ'), ('couple', 'NOUN'), ('of', 'ADP'), ('quarters', 'NOUN'), ('could', 'AUX'), ('witness', 'VERB'), ('robust', 'ADJ'), ('growth', 'NOUN'), ('due', 'ADP'), ('to', 'ADP'), ('Revlimid', 'PROPN'), (',', 'PUNCT'), ('this', 'PRON'), ('is', 'AUX'), ('not', 'PART'), ('sustainable', 'ADJ'), ('in', 'ADP'), ('the', 'DET'), ('future', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('We', 'PRON'), ('also', 'ADV'), ('note', 'VERB'), ('an', 'DET'), ('impressive', 'ADJ'), ('US', 'PROPN'), ('launch', 'NOUN'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('uncertainty', 'NOUN'), ('persists', 'VERB'), ('around', 'ADP'), ('launch', 'NOUN'), ('and', 'CCONJ'), ('approval', 'NOUN'), ('timelines', 'NOUN'), ('.', 'PUNCT'), ('Break', 'VERB'), ('-', 'PUNCT'), ('even', 'ADV'), ('in', 'ADP'), ('the', 'DET'), ('agrochem', 'NOUN'), ('business', 'NOUN'), ('in', 'ADP'), ('FY26', 'PROPN'), ('and', 'CCONJ'), ('the', 'DET'), ('GLP-1', 'PROPN'), ('opportunity', 'NOUN'), ('in', 'ADP'), ('India', 'PROPN'), ('are', 'AUX'), ('triggers', 'NOUN'), ('that', 'PRON'), ('can', 'AUX'), ('help', 'VERB'), ('Natco', 'PROPN'), ('offset', 'VERB'), ('part', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('gRevlimid', 'PROPN'), ('hit', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), ('and', 'CCONJ'), ('beyond', 'ADP'), (',', 'PUNCT'), ('""', 'PUNCT'), ('the', 'DET'), ('Nuvama', 'PROPN'), ('analysts', 'NOUN'), ('said', 'VERB'), ('in', 'ADP'), ('a', 'DET'), ('note', 'NOUN'), ('dated', 'VERB'), ('13', 'NUM'), ('February', 'PROPN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Natco', 'PROPN'), ('believes', 'VERB'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('drop', 'NOUN'), ('in', 'ADP'), ('earnings', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('That', 'PRON'), (""'s"", 'AUX'), ('the', 'DET'), ('elephant', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('room', 'NOUN'), (',', 'PUNCT'), ('[', 'X'), ('we', 'PRON'), (']', 'PUNCT'), ('have', 'VERB'), ('to', 'PART'), ('accept', 'VERB'), ('that', 'SCONJ'), ('earnings', 'NOUN'), ('will', 'AUX'), ('drop', 'VERB'), ('in', 'ADP'), ('‘', 'PUNCT'), ('27', 'NUM'), ('March', 'PROPN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Nannapaneni', 'PROPN'), ('told', 'VERB'), ('investors', 'NOUN'), ('in', 'ADP'), ('an', 'DET'), ('earnings', 'NOUN'), ('call', 'NOUN'), ('last', 'ADJ'), ('week', 'NOUN'), ('.', 'PUNCT'), ('      ', 'SPACE'), ('There', 'PRON'), ('is', 'VERB'), ('no', 'DET'), ('dearth', 'NOUN'), ('of', 'ADP'), ('competition', 'NOUN'), ('when', 'SCONJ'), ('it', 'PRON'), ('comes', 'VERB'), ('to', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('with', 'ADP'), ('leading', 'VERB'), ('generics', 'NOUN'), ('makers', 'NOUN'), ('jumping', 'VERB'), ('in', 'ADP'), ('.', 'PUNCT'), ('Sun', 'PROPN'), ('Pharma', 'PROPN'), ('has', 'AUX'), ('already', 'ADV'), ('undertaken', 'VERB'), ('clinical', 'ADJ'), ('trials', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('while', 'SCONJ'), ('Biocon', 'PROPN'), ('signed', 'VERB'), ('an', 'DET'), ('exclusive', 'ADJ'), ('licensing', 'NOUN'), ('and', 'CCONJ'), ('supply', 'NOUN'), ('agreement', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), ('commercialization', 'NOUN'), ('in', 'ADP'), ('Brazil', 'PROPN'), ('with', 'ADP'), ('Biomm', 'PROPN'), ('last', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Domestically', 'ADV'), (',', 'PUNCT'), ('innovators', 'X'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), ('and', 'CCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('have', 'AUX'), ('also', 'ADV'), ('indicated', 'VERB'), ('potential', 'ADJ'), ('launches', 'NOUN'), ('.', 'PUNCT'), ('While', 'SCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('has', 'AUX'), ('n’t', 'PART'), ('clarified', 'VERB'), ('a', 'DET'), ('timeline', 'NOUN'), (',', 'PUNCT'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), ('has', 'AUX'), ('announced', 'VERB'), ('that', 'SCONJ'), ('it', 'PRON'), ('will', 'AUX'), ('launch', 'VERB'), ('its', 'PRON'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drug', 'NOUN'), ('Tirzepatide', 'PROPN'), ('in', 'ADP'), ('India', 'PROPN'), ('in', 'ADP'), ('2025', 'NUM'), ('at', 'ADP'), ('competitive', 'ADJ'), ('pricing', 'NOUN'), ('.', 'PUNCT'), ('Indian', 'ADJ'), ('pharma', 'NOUN'), ('companies', 'NOUN'), ('like', 'ADP'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PUNCT'), (',', 'PUNCT'), ('Natco', 'PROPN'), (',', 'PUNCT'), ('Cipla', 'PROPN'), (',', 'PUNCT'), ('Sun', 'PROPN'), ('Pharma', 'PROPN'), (',', 'PUNCT'), ('Zydus', 'PROPN'), ('and', 'CCONJ'), ('Aurobindo', 'PROPN'), ('Pharma', 'PROPN'), ('have', 'AUX'), ('cashed', 'VERB'), ('in', 'ADP'), ('on', 'ADP'), ('generic', 'ADJ'), ('versions', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('$', 'SYM'), ('8', 'NUM'), ('billion', 'NUM'), ('blockbuster', 'ADJ'), ('drug', 'NOUN'), ('distributed', 'VERB'), ('in', 'ADP'), ('restricted', 'VERB'), ('quantities', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('since', 'SCONJ'), ('March', 'PROPN'), ('2022', 'NUM'), (',', 'PUNCT'), ('per', 'ADP'), ('agreements', 'NOUN'), ('with', 'ADP'), ('innovator', 'PROPN'), ('Celgene', 'PROPN'), ('’s', 'PART'), ('parent', 'NOUN'), ('company', 'NOUN'), ('Bristol', 'PROPN'), ('Myers', 'PROPN'), ('Squibb', 'PROPN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'VERB'), ('|', 'ADV'), ('Natco', 'PROPN'), ('Pharma', 'PROPN'), ('Q3', 'PROPN'), ('Results', 'VERB'), ('2025', 'NUM'), (':', 'PUNCT'), ('Profit', 'NOUN'), ('Falls', 'PROPN'), ('by', 'ADP'), ('37.47', 'NUM'), ('%', 'NOUN'), ('YoY', 'NOUN'), ('However', 'ADV'), (',', 'PUNCT'), ('the', 'DET'), ('companies', 'NOUN'), ('are', 'AUX'), ('set', 'VERB'), ('to', 'PART'), ('lose', 'VERB'), ('exclusivity', 'NOUN'), ('on', 'ADP'), ('distribution', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('in', 'ADP'), ('January', 'PROPN'), ('2026', 'NUM'), ('.', 'PUNCT'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PUNCT'), (',', 'PUNCT'), ('which', 'PRON'), ('has', 'AUX'), ('profited', 'VERB'), ('the', 'DET'), ('most', 'ADJ'), ('from', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('’s', 'PART'), ('sales', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('Natco', 'PROPN'), (',', 'PUNCT'), ('which', 'PRON'), ('led', 'VERB'), ('the', 'DET'), ('launch', 'NOUN'), ('and', 'CCONJ'), ('will', 'AUX'), ('see', 'VERB'), ('its', 'PRON'), ('share', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('total', 'ADJ'), ('Revlimid', 'PROPN'), ('market', 'NOUN'), ('grow', 'VERB'), ('to', 'ADP'), ('33', 'NUM'), ('%', 'NOUN'), ('by', 'ADP'), ('March', 'PROPN'), ('2025', 'NUM'), (',', 'PUNCT'), ('will', 'AUX'), ('be', 'AUX'), ('the', 'PRON'), ('most', 'ADV'), ('impacted', 'VERB'), ('next', 'ADJ'), ('year', 'NOUN'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('analysts', 'NOUN'), ('.', 'PUNCT'), ('While', 'SCONJ'), ('Natco', 'PROPN'), ('is', 'AUX'), ('expecting', 'VERB'), ('robust', 'ADJ'), ('growth', 'NOUN'), ('from', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('in', 'ADP'), ('FY26', 'PROPN'), (',', 'PUNCT'), ('as', 'SCONJ'), ('its', 'PRON'), ('market', 'NOUN'), ('share', 'NOUN'), ('increases', 'VERB'), ('to', 'ADP'), ('33', 'NUM'), ('%', 'NOUN'), (',', 'PUNCT'), ('brokerage', 'NOUN'), ('ICICI', 'NOUN'), ('Direct', 'PROPN'), ('Research', 'PROPN'), ('expects', 'VERB'), ('a', 'DET'), ('50', 'NUM'), ('-', 'SYM'), ('60', 'NUM'), ('%', 'NOUN'), ('drop', 'NOUN'), ('in', 'ADP'), ('profits', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), (',', 'PUNCT'), ('following', 'VERB'), ('the', 'DET'), ('waning', 'NOUN'), ('of', 'ADP'), ('Revlimid', 'PROPN'), ('.', 'PUNCT'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PUNCT'), (',', 'PUNCT'), ('whose', 'DET'), ('Ebitda', 'PROPN'), ('surged', 'VERB'), ('from', 'ADP'), (' ', 'SPACE'), ('₹', 'PROPN'), ('5,140', 'NUM'), ('crore', 'NOUN'), ('in', 'ADP'), ('FY22', 'PROPN'), ('to', 'PART'), (' ', 'SPACE'), ('₹', 'PROPN'), ('8,301', 'NUM'), ('crore', 'NOUN'), ('in', 'ADP'), ('FY24', 'PROPN'), (',', 'PUNCT'), ('significantly', 'ADV'), ('profiting', 'ADJ'), ('from', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), (',', 'PUNCT'), ('is', 'AUX'), ('also', 'ADV'), ('facing', 'VERB'), ('a', 'DET'), ('market', 'NOUN'), ('share', 'NOUN'), ('loss', 'NOUN'), ('in', 'ADP'), ('Revlimid', 'PROPN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'VERB'), ('|', 'ADV'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'AUX'), ('to', 'PART'), ('focus', 'VERB'), ('on', 'ADP'), ('complex', 'ADJ'), ('products', 'NOUN'), ('for', 'ADP'), ('growth', 'NOUN'), ('to', 'PART'), ('offset', 'VERB'), ('Revlimid', 'PROPN'), ('loss', 'NOUN'), ('Now', 'ADV'), (',', 'PUNCT'), ('both', 'DET'), ('companies', 'NOUN'), ('are', 'AUX'), ('eyeing', 'VERB'), ('another', 'DET'), ('blockbuster', 'ADJ'), ('drug', 'NOUN'), ('–', 'PUNCT'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('’s', 'PART'), ('breakout', 'PROPN'), ('star', 'PROPN'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('sold', 'VERB'), ('under', 'ADP'), ('brand', 'NOUN'), ('names', 'NOUN'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), (',', 'PUNCT'), ('to', 'PART'), ('stave', 'VERB'), ('off', 'ADP'), ('the', 'DET'), ('Revlimid', 'PROPN'), ('cliff', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('Semaglutide', 'PROPN'), ('is', 'AUX'), ('the', 'DET'), ('next', 'ADJ'), ('thing', 'NOUN'), ('which', 'PRON'), ('will', 'AUX'), ('drive', 'VERB'), ('growth', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('Indian', 'ADJ'), ('generic', 'ADJ'), ('pharma', 'NOUN'), ('companies', 'NOUN'), (',', 'PUNCT'), ('considering', 'VERB'), ('the', 'DET'), ('opportunity', 'NOUN'), ('is', 'AUX'), ('almost', 'ADV'), ('$', 'SYM'), ('22', 'NUM'), ('billion', 'NUM'), ('globally', 'ADV'), (',', 'PUNCT'), ('and', 'CCONJ'), ('demand', 'NOUN'), ('has', 'AUX'), ('not', 'PART'), ('been', 'AUX'), ('met', 'VERB'), ('entirely', 'ADV'), ('because', 'SCONJ'), ('there', 'PRON'), ('is', 'VERB'), ('a', 'DET'), ('shortage', 'NOUN'), ('at', 'ADP'), ('the', 'DET'), ('innovator', 'NOUN'), ('end', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Amey', 'PROPN'), ('Chalke', 'PROPN'), (',', 'PUNCT'), ('pharma', 'PROPN'), ('research', 'NOUN'), ('analyst', 'NOUN'), ('at', 'ADP'), ('JM', 'PROPN'), ('Financial', 'PROPN'), ('Institutional', 'PROPN'), ('Securities', 'PROPN'), ('told', 'VERB'), ('Mint', 'PROPN'), ('.', 'PUNCT'), ('The', 'DET'), ('exact', 'ADJ'), ('market', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), ('is', 'AUX'), ('estimated', 'VERB'), ('to', 'PART'), ('be', 'AUX'), ('much', 'ADV'), ('larger', 'ADJ'), ('than', 'ADP'), ('$', 'SYM'), ('28', 'NUM'), ('-', 'SYM'), ('29', 'NUM'), ('billion', 'NUM'), (',', 'PUNCT'), ('Chalke', 'PROPN'), ('said', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('golden', 'ADJ'), ('opportunityNatco', 'PROPN'), ('has', 'AUX'), ('secured', 'VERB'), ('first', 'ADJ'), ('-', 'PUNCT'), ('to', 'ADP'), ('-', 'PUNCT'), ('file', 'NOUN'), ('exclusivity', 'NOUN'), ('under', 'ADP'), ('Paragraph', 'PROPN'), ('IV', 'PROPN'), ('for', 'ADP'), ('all', 'DET'), ('strengths', 'NOUN'), ('of', 'ADP'), ('Wegovy', 'PROPN'), ('and', 'CCONJ'), ('key', 'ADJ'), ('strengths', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('Semaglutide', 'PROPN'), ('pen', 'NOUN'), ('.', 'PUNCT'), ('This', 'PRON'), ('means', 'VERB'), ('that', 'SCONJ'), ('if', 'SCONJ'), ('the', 'DET'), ('company', 'NOUN'), ('clears', 'VERB'), ('all', 'DET'), ('legal', 'ADJ'), ('and', 'CCONJ'), ('regulatory', 'ADJ'), ('hurdles', 'NOUN'), (',', 'PUNCT'), ('it', 'PRON'), ('will', 'AUX'), ('have', 'VERB'), ('a', 'DET'), ('180', 'NUM'), ('-', 'PUNCT'), ('day', 'NOUN'), ('exclusivity', 'NOUN'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('variants', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'VERB'), ('|', 'NOUN'), ('Dr', 'PROPN'), ('Reddy', 'PROPN'), (""'s"", 'PART'), ('Labs', 'PROPN'), ('Q3', 'PROPN'), ('Results', 'NOUN'), (':', 'PUNCT'), ('Profit', 'NOUN'), ('grows', 'VERB'), ('2', 'NUM'), ('%', 'NOUN'), ('YoY', 'NOUN'), ('to', 'PART'), (' ', 'SPACE'), ('₹', 'PROPN'), ('1413', 'NUM'), ('crore', 'NOUN'), (';', 'PUNCT'), ('revenue', 'NOUN'), ('up', 'ADP'), ('16', 'NUM'), ('%', 'NOUN'), ('      ', 'SPACE'), ('In', 'ADP'), ('October', 'PROPN'), (',', 'PUNCT'), ('Natco', 'PROPN'), ('’s', 'PART'), ('partner', 'NOUN'), ('Mylan', 'PROPN'), ('settled', 'VERB'), ('a', 'DET'), ('US', 'PROPN'), ('patent', 'NOUN'), ('litigation', 'NOUN'), ('with', 'ADP'), ('innovator', 'NOUN'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('for', 'ADP'), ('generic', 'ADJ'), ('Ozempic', 'PROPN'), ('(', 'PUNCT'), ('to', 'PART'), ('be', 'AUX'), ('outsourced', 'VERB'), ('from', 'ADP'), ('Stelis', 'PROPN'), (')', 'PUNCT'), ('which', 'PRON'), ('registered', 'VERB'), ('about', 'ADP'), ('$', 'SYM'), ('9', 'NUM'), ('billion', 'NUM'), ('sales', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('in', 'ADP'), ('calendar', 'NOUN'), ('year', 'NOUN'), ('2023', 'NUM'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('ICICI', 'PROPN'), ('Direct', 'PROPN'), ('Research', 'PROPN'), ('.', 'PUNCT'), ('While', 'SCONJ'), ('the', 'DET'), ('US', 'PROPN'), ('patent', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('Semaglutide', 'PROPN'), ('expires', 'VERB'), ('in', 'ADP'), ('FY31', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('India', 'PROPN'), ('patent', 'NOUN'), ('expires', 'VERB'), ('next', 'ADJ'), ('year', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('the', 'DET'), ('company', 'NOUN'), ('is', 'AUX'), ('geared', 'VERB'), ('for', 'ADP'), ('an', 'DET'), ('India', 'PROPN'), ('launch', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('If', 'SCONJ'), ('we', 'PRON'), ('get', 'VERB'), ('all', 'DET'), ('regulatory', 'ADJ'), ('clearances', 'NOUN'), ('on', 'ADP'), ('time', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('we', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('launch', 'VERB'), ('it', 'PRON'), ('1HFY26', 'NUM'), (',', 'PUNCT'), ('""', 'PUNCT'), ('a', 'DET'), ('Natco', 'PROPN'), ('spokesperson', 'NOUN'), ('told', 'VERB'), ('Mint', 'PROPN'), ('in', 'ADP'), ('an', 'DET'), ('emailed', 'ADJ'), ('response', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('is', 'AUX'), ('eyeing', 'VERB'), ('a', 'DET'), ('Canada', 'PROPN'), ('launch', 'NOUN'), ('in', 'ADP'), ('January', 'PROPN'), ('2026', 'NUM'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('I', 'PRON'), ('believe', 'VERB'), ('we', 'PRON'), ('are', 'AUX'), ('positioned', 'VERB'), ('well', 'ADV'), ('to', 'PART'), ('get', 'VERB'), ('approval', 'NOUN'), ('for', 'ADP'), ('that', 'DET'), ('period', 'NOUN'), ('of', 'ADP'), ('time', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('CEO', 'PROPN'), ('Erez', 'PROPN'), ('Israeli', 'PROPN'), ('said', 'VERB'), ('in', 'ADP'), ('an', 'DET'), ('earnings', 'NOUN'), ('call', 'NOUN'), ('in', 'ADP'), ('January', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('Normally', 'ADV'), (',', 'PUNCT'), ('between', 'ADP'), ('the', 'DET'), ('time', 'NOUN'), ('that', 'PRON'), ('you', 'PRON'), ('submit', 'VERB'), ('the', 'DET'), ('product', 'NOUN'), ('to', 'ADP'), ('the', 'DET'), ('Canadian', 'ADJ'), ('authorities', 'NOUN'), (',', 'PUNCT'), ('until', 'SCONJ'), ('you', 'PRON'), ('get', 'VERB'), ('approval', 'NOUN'), (',', 'PUNCT'), ('is', 'AUX'), ('12', 'NUM'), ('to', 'PART'), ('14', 'NUM'), ('months', 'NOUN'), ('…', 'PUNCT'), ('So', 'ADV'), ('what', 'PRON'), ('you', 'PRON'), (""'re"", 'AUX'), ('going', 'VERB'), ('to', 'PART'), ('see', 'VERB'), ('is', 'AUX'), ('probably', 'ADV'), ('the', 'DET'), ('sequence', 'NOUN'), ('in', 'ADP'), ('which', 'PRON'), ('people', 'NOUN'), ('will', 'AUX'), ('get', 'VERB'), ('approval', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('we', 'PRON'), ('hope', 'VERB'), ('to', 'PART'), ('be', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('one', 'NUM'), ('in', 'ADP'), ('the', 'DET'), ('pack', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('he', 'PRON'), ('added', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('But', 'CCONJ'), ('that', 'PRON'), ('’s', 'VERB'), ('not', 'PART'), ('all', 'PRON'), ('.', 'PUNCT'), ('The', 'DET'), ('pharma', 'NOUN'), ('major', 'NOUN'), ('is', 'AUX'), ('also', 'ADV'), ('looking', 'VERB'), ('at', 'ADP'), ('India', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('as', 'ADV'), ('well', 'ADV'), ('as', 'ADP'), ('other', 'ADJ'), ('emerging', 'VERB'), ('markets', 'NOUN'), ('where', 'SCONJ'), ('the', 'DET'), ('product', 'NOUN'), ('is', 'AUX'), ('in', 'ADP'), ('demand', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('At', 'ADP'), ('present', 'NOUN'), (',', 'PUNCT'), ('we', 'PRON'), ('at', 'ADP'), ('JM', 'PROPN'), ('Financial', 'PROPN'), ('Institutional', 'PROPN'), ('Research', 'PROPN'), ('see', 'VERB'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PUNCT'), ('as', 'ADP'), ('one', 'NUM'), ('of', 'ADP'), ('first', 'ADJ'), ('few', 'ADJ'), ('generic', 'ADJ'), ('filers', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), ('globally', 'ADV'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Chalke', 'PROPN'), ('said', 'VERB'), ('.', 'PUNCT'), ('\xa0 ', 'SPACE'), ('Is', 'AUX'), ('it', 'PRON'), ('enough', 'ADJ'), ('?', 'PUNCT'), ('\xa0', 'SPACE'), ('JM', 'PROPN'), ('Financials', 'NOUN'), ('estimates', 'VERB'), ('that', 'SCONJ'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('could', 'AUX'), ('clock', 'VERB'), ('$', 'SYM'), ('100', 'NUM'), ('-', 'SYM'), ('150', 'NUM'), ('million', 'NUM'), ('in', 'ADP'), ('Semaglutide', 'PROPN'), ('sales', 'NOUN'), ('if', 'SCONJ'), ('they', 'PRON'), ('launch', 'VERB'), ('in', 'ADP'), ('3', 'NUM'), ('-', 'SYM'), ('4', 'NUM'), ('markets', 'NOUN'), ('next', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('On', 'ADP'), ('the', 'DET'), ('other', 'ADJ'), ('hand', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('brokerage', 'NOUN'), ('is', 'AUX'), ('anticipating', 'VERB'), ('$', 'SYM'), ('700', 'NUM'), ('million', 'NUM'), ('from', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('for', 'ADP'), ('the', 'DET'), ('company', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('coming', 'VERB'), ('year', 'NOUN'), (',', 'PUNCT'), ('before', 'ADP'), ('loss', 'NOUN'), ('of', 'ADP'), ('exclusivity', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('has', 'VERB'), ('some', 'DET'), ('other', 'ADJ'), ('products', 'NOUN'), ('and', 'CCONJ'), ('strategies', 'NOUN'), ('in', 'ADP'), ('place', 'NOUN'), ('to', 'PART'), ('offset', 'VERB'), ('the', 'DET'), ('drop', 'NOUN'), ('in', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('company', 'NOUN'), ('is', 'AUX'), ('looking', 'VERB'), ('at', 'ADP'), ('the', 'DET'), ('launch', 'NOUN'), ('of', 'ADP'), ('biosimilar', 'ADJ'), ('Abatacept', 'PROPN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('by', 'ADP'), ('the', 'DET'), ('end', 'NOUN'), ('of', 'ADP'), ('FY27', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('“', 'PUNCT'), ('Abatacept', 'PROPN'), ('is', 'AUX'), ('a', 'DET'), ('$', 'SYM'), ('3', 'NUM'), ('-', 'SYM'), ('4', 'NUM'), ('billion', 'NUM'), ('product', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), (',', 'PUNCT'), ('if', 'SCONJ'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('is', 'AUX'), ('the', 'DET'), ('only', 'ADJ'), ('company', 'NOUN'), ('to', 'PART'), ('launch', 'VERB'), ('that', 'DET'), ('product', 'NOUN'), ('for', 'ADP'), ('at', 'ADV'), ('least', 'ADV'), ('one', 'NUM'), ('year', 'NOUN'), (',', 'PUNCT'), ('their', 'PRON'), ('sales', 'NOUN'), ('could', 'AUX'), ('be', 'AUX'), ('upward', 'ADV'), ('of', 'ADP'), ('$', 'SYM'), ('100', 'NUM'), ('million', 'NUM'), ('for', 'ADP'), ('that', 'DET'), ('product', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Chalke', 'PROPN'), ('said', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Together', 'ADV'), (',', 'PUNCT'), ('Semaglutide', 'PROPN'), ('and', 'CCONJ'), ('Abatacept', 'PROPN'), ('may', 'AUX'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('substantially', 'ADV'), ('offset', 'VERB'), ('the', 'DET'), ('Revlimid', 'PROPN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('analyst', 'NOUN'), ('said', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('The', 'DET'), ('company', 'NOUN'), ('also', 'ADV'), ('has', 'VERB'), ('the', 'DET'), ('recently', 'ADV'), ('-', 'PUNCT'), ('acquired', 'VERB'), ('nicotine', 'NOUN'), ('replacement', 'NOUN'), ('therapy', 'NOUN'), ('(', 'PUNCT'), ('NRT', 'PROPN'), (')', 'PUNCT'), ('portfolio', 'NOUN'), ('from', 'ADP'), ('Haleon', 'PROPN'), ('plc', 'PROPN'), ('in', 'ADP'), ('Europe', 'PROPN'), (',', 'PUNCT'), ('as', 'ADP'), ('an', 'DET'), ('additional', 'ADJ'), ('growth', 'NOUN'), ('driver', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Natco', 'PROPN'), ('Pharma', 'PROPN'), ('has', 'VERB'), ('some', 'DET'), ('other', 'ADJ'), ('key', 'ADJ'), ('first', 'ADJ'), ('-', 'PUNCT'), ('to', 'ADP'), ('-', 'PUNCT'), ('file', 'NOUN'), ('products', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('Risdiplam', 'PROPN'), ('Oral', 'PROPN'), ('Solution', 'PROPN'), ('for', 'ADP'), ('spinal', 'ADJ'), ('muscular', 'ADJ'), ('atrophy', 'NOUN'), ('and', 'CCONJ'), ('breast', 'NOUN'), ('cancer', 'NOUN'), ('drug', 'NOUN'), ('Olaparib', 'PROPN'), (',', 'PUNCT'), ('although', 'SCONJ'), ('the', 'DET'), ('timelines', 'NOUN'), ('for', 'ADP'), ('these', 'PRON'), ('are', 'AUX'), ('yet', 'ADV'), ('to', 'PART'), ('be', 'AUX'), ('defined', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Analysts', 'NOUN'), ('are', 'AUX'), ('divided', 'VERB'), ('on', 'ADP'), ('the', 'DET'), ('company', 'NOUN'), ('’s', 'PART'), ('prospects', 'NOUN'), (',', 'PUNCT'), ('though', 'ADV'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('products', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('one', 'NUM'), ('or', 'CCONJ'), ('two', 'NUM'), ('-', 'PUNCT'), ('year', 'NOUN'), ('gap', 'NOUN'), ('in', 'ADP'), ('between', 'ADP'), (',', 'PUNCT'), ('where', 'SCONJ'), ('the', 'DET'), ('base', 'NOUN'), ('will', 'AUX'), ('be', 'AUX'), ('much', 'ADV'), ('lower', 'ADJ'), (',', 'PUNCT'), ('the', 'DET'), ('profits', 'NOUN'), ('will', 'AUX'), ('be', 'AUX'), ('much', 'ADV'), ('lower', 'ADJ'), (',', 'PUNCT'), ('""', 'PUNCT'), ('an', 'DET'), ('analyst', 'NOUN'), ('who', 'PRON'), ('requested', 'VERB'), ('anonymity', 'NOUN'), ('told', 'VERB'), ('Mint', 'PROPN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('In', 'ADP'), ('a', 'DET'), ('research', 'NOUN'), ('note', 'NOUN'), ('dated', 'VERB'), ('14', 'NUM'), ('February', 'PROPN'), (',', 'PUNCT'), ('ICICI', 'PROPN'), ('Direct', 'ADJ'), ('analysts', 'NOUN'), ('said', 'VERB'), (':', 'PUNCT'), ('“', 'PUNCT'), ('We', 'PRON'), ('continue', 'VERB'), ('to', 'PART'), ('have', 'VERB'), ('faith', 'NOUN'), ('in', 'ADP'), ('Natco', 'PROPN'), ('’s', 'PART'), ('ability', 'NOUN'), ('to', 'PART'), ('focus', 'VERB'), ('on', 'ADP'), ('blockbusters', 'NOUN'), ('which', 'PRON'), ('are', 'AUX'), ('capable', 'ADJ'), ('of', 'ADP'), ('generating', 'VERB'), ('robust', 'ADJ'), ('cash', 'NOUN'), ('flows', 'VERB'), ('for', 'ADP'), ('3', 'NUM'), ('-', 'SYM'), ('5', 'NUM'), ('years', 'NOUN'), (""'"", 'PART'), ('horizon', 'NOUN'), ('before', 'SCONJ'), ('they', 'PRON'), ('fade', 'VERB'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('On', 'ADP'), ('the', 'DET'), ('other', 'ADJ'), ('hand', 'NOUN'), (',', 'PUNCT'), ('Nuvama', 'PROPN'), ('analysts', 'NOUN'), ('said', 'VERB'), ('that', 'SCONJ'), ('while', 'SCONJ'), ('the', 'DET'), ('next', 'ADJ'), ('couple', 'NOUN'), ('of', 'ADP'), ('quarters', 'NOUN'), ('could', 'AUX'), ('witness', 'VERB'), ('robust', 'ADJ'), ('growth', 'NOUN'), ('due', 'ADP'), ('to', 'ADP'), ('Revlimid', 'PROPN'), (',', 'PUNCT'), ('this', 'PRON'), ('is', 'AUX'), ('not', 'PART'), ('sustainable', 'ADJ'), ('in', 'ADP'), ('the', 'DET'), ('future', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('We', 'PRON'), ('also', 'ADV'), ('note', 'VERB'), ('an', 'DET'), ('impressive', 'ADJ'), ('US', 'PROPN'), ('launch', 'NOUN'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('uncertainty', 'NOUN'), ('persists', 'VERB'), ('around', 'ADP'), ('launch', 'NOUN'), ('and', 'CCONJ'), ('approval', 'NOUN'), ('timelines', 'NOUN'), ('.', 'PUNCT'), ('Break', 'VERB'), ('-', 'PUNCT'), ('even', 'ADV'), ('in', 'ADP'), ('the', 'DET'), ('agrochem', 'NOUN'), ('business', 'NOUN'), ('in', 'ADP'), ('FY26', 'PROPN'), ('and', 'CCONJ'), ('the', 'DET'), ('GLP-1', 'PROPN'), ('opportunity', 'NOUN'), ('in', 'ADP'), ('India', 'PROPN'), ('are', 'AUX'), ('triggers', 'NOUN'), ('that', 'PRON'), ('can', 'AUX'), ('help', 'VERB'), ('Natco', 'PROPN'), ('offset', 'VERB'), ('part', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('gRevlimid', 'PROPN'), ('hit', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), ('and', 'CCONJ'), ('beyond', 'ADP'), (',', 'PUNCT'), ('""', 'PUNCT'), ('the', 'DET'), ('Nuvama', 'PROPN'), ('analysts', 'NOUN'), ('said', 'VERB'), ('in', 'ADP'), ('a', 'DET'), ('note', 'NOUN'), ('dated', 'VERB'), ('13', 'NUM'), ('February', 'PROPN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Natco', 'PROPN'), ('believes', 'VERB'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('drop', 'NOUN'), ('in', 'ADP'), ('earnings', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('That', 'PRON'), (""'s"", 'AUX'), ('the', 'DET'), ('elephant', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('room', 'NOUN'), (',', 'PUNCT'), ('[', 'X'), ('we', 'PRON'), (']', 'PUNCT'), ('have', 'VERB'), ('to', 'PART'), ('accept', 'VERB'), ('that', 'SCONJ'), ('earnings', 'NOUN'), ('will', 'AUX'), ('drop', 'VERB'), ('in', 'ADP'), ('‘', 'PUNCT'), ('27', 'NUM'), ('March', 'PROPN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Nannapaneni', 'PROPN'), ('told', 'VERB'), ('investors', 'NOUN'), ('in', 'ADP'), ('an', 'DET'), ('earnings', 'NOUN'), ('call', 'NOUN'), ('last', 'ADJ'), ('week', 'NOUN'), ('.', 'PUNCT'), ('      ', 'SPACE'), ('There', 'PRON'), ('is', 'VERB'), ('no', 'DET'), ('dearth', 'NOUN'), ('of', 'ADP'), ('competition', 'NOUN'), ('when', 'SCONJ'), ('it', 'PRON'), ('comes', 'VERB'), ('to', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('with', 'ADP'), ('leading', 'VERB'), ('generics', 'NOUN'), ('makers', 'NOUN'), ('jumping', 'VERB'), ('in', 'ADP'), ('.', 'PUNCT'), ('Sun', 'PROPN'), ('Pharma', 'PROPN'), ('has', 'AUX'), ('already', 'ADV'), ('undertaken', 'VERB'), ('clinical', 'ADJ'), ('trials', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('while', 'SCONJ'), ('Biocon', 'PROPN'), ('signed', 'VERB'), ('an', 'DET'), ('exclusive', 'ADJ'), ('licensing', 'NOUN'), ('and', 'CCONJ'), ('supply', 'NOUN'), ('agreement', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), ('commercialization', 'NOUN'), ('in', 'ADP'), ('Brazil', 'PROPN'), ('with', 'ADP'), ('Biomm', 'PROPN'), ('last', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Domestically', 'ADV'), (',', 'PUNCT'), ('innovators', 'X'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), ('and', 'CCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('have', 'AUX'), ('also', 'ADV'), ('indicated', 'VERB'), ('potential', 'ADJ'), ('launches', 'NOUN'), ('.', 'PUNCT'), ('While', 'SCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('has', 'AUX'), ('n’t', 'PART'), ('clarified', 'VERB'), ('a', 'DET'), ('timeline', 'NOUN'), (',', 'PUNCT'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), ('has', 'AUX'), ('announced', 'VERB'), ('that', 'SCONJ'), ('it', 'PRON'), ('will', 'AUX'), ('launch', 'VERB'), ('its', 'PRON'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drug', 'NOUN'), ('Tirzepatide', 'PROPN'), ('in', 'ADP'), ('India', 'PROPN'), ('in', 'ADP'), ('2025', 'NUM'), ('at', 'ADP'), ('competitive', 'ADJ'), ('pricing', 'NOUN'), ('.', 'PUNCT'), ('Natco', 'PROPN'), ('has', 'AUX'), ('secured', 'VERB'), ('first', 'ADJ'), ('-', 'PUNCT'), ('to', 'ADP'), ('-', 'PUNCT'), ('file', 'NOUN'), ('exclusivity', 'NOUN'), ('under', 'ADP'), ('Paragraph', 'PROPN'), ('IV', 'PROPN'), ('for', 'ADP'), ('all', 'DET'), ('strengths', 'NOUN'), ('of', 'ADP'), ('Wegovy', 'PROPN'), ('and', 'CCONJ'), ('key', 'ADJ'), ('strengths', 'NOUN'), ('of', 'ADP'), ('Ozempic', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('Semaglutide', 'PROPN'), ('pen', 'NOUN'), ('.', 'PUNCT'), ('This', 'PRON'), ('means', 'VERB'), ('that', 'SCONJ'), ('if', 'SCONJ'), ('the', 'DET'), ('company', 'NOUN'), ('clears', 'VERB'), ('all', 'DET'), ('legal', 'ADJ'), ('and', 'CCONJ'), ('regulatory', 'ADJ'), ('hurdles', 'NOUN'), (',', 'PUNCT'), ('it', 'PRON'), ('will', 'AUX'), ('have', 'VERB'), ('a', 'DET'), ('180', 'NUM'), ('-', 'PUNCT'), ('day', 'NOUN'), ('exclusivity', 'NOUN'), ('to', 'PART'), ('market', 'VERB'), ('generic', 'ADJ'), ('variants', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('drug', 'NOUN'), ('.', 'PUNCT'), ('Also', 'ADV'), ('Read', 'VERB'), ('|', 'NOUN'), ('Dr', 'PROPN'), ('Reddy', 'PROPN'), (""'s"", 'PART'), ('Labs', 'PROPN'), ('Q3', 'PROPN'), ('Results', 'NOUN'), (':', 'PUNCT'), ('Profit', 'NOUN'), ('grows', 'VERB'), ('2', 'NUM'), ('%', 'NOUN'), ('YoY', 'NOUN'), ('to', 'PART'), (' ', 'SPACE'), ('₹', 'PROPN'), ('1413', 'NUM'), ('crore', 'NOUN'), (';', 'PUNCT'), ('revenue', 'NOUN'), ('up', 'ADP'), ('16', 'NUM'), ('%', 'NOUN'), ('In', 'ADP'), ('October', 'PROPN'), (',', 'PUNCT'), ('Natco', 'PROPN'), ('’s', 'PART'), ('partner', 'NOUN'), ('Mylan', 'PROPN'), ('settled', 'VERB'), ('a', 'DET'), ('US', 'PROPN'), ('patent', 'NOUN'), ('litigation', 'NOUN'), ('with', 'ADP'), ('innovator', 'NOUN'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('for', 'ADP'), ('generic', 'ADJ'), ('Ozempic', 'PROPN'), ('(', 'PUNCT'), ('to', 'PART'), ('be', 'AUX'), ('outsourced', 'VERB'), ('from', 'ADP'), ('Stelis', 'PROPN'), (')', 'PUNCT'), ('which', 'PRON'), ('registered', 'VERB'), ('about', 'ADP'), ('$', 'SYM'), ('9', 'NUM'), ('billion', 'NUM'), ('sales', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('in', 'ADP'), ('calendar', 'NOUN'), ('year', 'NOUN'), ('2023', 'NUM'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('ICICI', 'PROPN'), ('Direct', 'PROPN'), ('Research', 'PROPN'), ('.', 'PUNCT'), ('While', 'SCONJ'), ('the', 'DET'), ('US', 'PROPN'), ('patent', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('Semaglutide', 'PROPN'), ('expires', 'VERB'), ('in', 'ADP'), ('FY31', 'PROPN'), (',', 'PUNCT'), ('the', 'DET'), ('India', 'PROPN'), ('patent', 'NOUN'), ('expires', 'VERB'), ('next', 'ADJ'), ('year', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('the', 'DET'), ('company', 'NOUN'), ('is', 'AUX'), ('geared', 'VERB'), ('for', 'ADP'), ('an', 'DET'), ('India', 'PROPN'), ('launch', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('If', 'SCONJ'), ('we', 'PRON'), ('get', 'VERB'), ('all', 'DET'), ('regulatory', 'ADJ'), ('clearances', 'NOUN'), ('on', 'ADP'), ('time', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('we', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('launch', 'VERB'), ('it', 'PRON'), ('1HFY26', 'NUM'), (',', 'PUNCT'), ('""', 'PUNCT'), ('a', 'DET'), ('Natco', 'PROPN'), ('spokesperson', 'NOUN'), ('told', 'VERB'), ('Mint', 'PROPN'), ('in', 'ADP'), ('an', 'DET'), ('emailed', 'ADJ'), ('response', 'NOUN'), ('.', 'PUNCT'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('is', 'AUX'), ('eyeing', 'VERB'), ('a', 'DET'), ('Canada', 'PROPN'), ('launch', 'NOUN'), ('in', 'ADP'), ('January', 'PROPN'), ('2026', 'NUM'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('I', 'PRON'), ('believe', 'VERB'), ('we', 'PRON'), ('are', 'AUX'), ('positioned', 'VERB'), ('well', 'ADV'), ('to', 'PART'), ('get', 'VERB'), ('approval', 'NOUN'), ('for', 'ADP'), ('that', 'DET'), ('period', 'NOUN'), ('of', 'ADP'), ('time', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('CEO', 'PROPN'), ('Erez', 'PROPN'), ('Israeli', 'PROPN'), ('said', 'VERB'), ('in', 'ADP'), ('an', 'DET'), ('earnings', 'NOUN'), ('call', 'NOUN'), ('in', 'ADP'), ('January', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('Normally', 'ADV'), (',', 'PUNCT'), ('between', 'ADP'), ('the', 'DET'), ('time', 'NOUN'), ('that', 'PRON'), ('you', 'PRON'), ('submit', 'VERB'), ('the', 'DET'), ('product', 'NOUN'), ('to', 'ADP'), ('the', 'DET'), ('Canadian', 'ADJ'), ('authorities', 'NOUN'), (',', 'PUNCT'), ('until', 'SCONJ'), ('you', 'PRON'), ('get', 'VERB'), ('approval', 'NOUN'), (',', 'PUNCT'), ('is', 'AUX'), ('12', 'NUM'), ('to', 'PART'), ('14', 'NUM'), ('months', 'NOUN'), ('…', 'PUNCT'), ('So', 'ADV'), ('what', 'PRON'), ('you', 'PRON'), (""'re"", 'AUX'), ('going', 'VERB'), ('to', 'PART'), ('see', 'VERB'), ('is', 'AUX'), ('probably', 'ADV'), ('the', 'DET'), ('sequence', 'NOUN'), ('in', 'ADP'), ('which', 'PRON'), ('people', 'NOUN'), ('will', 'AUX'), ('get', 'VERB'), ('approval', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('we', 'PRON'), ('hope', 'VERB'), ('to', 'PART'), ('be', 'AUX'), ('the', 'DET'), ('first', 'ADJ'), ('one', 'NUM'), ('in', 'ADP'), ('the', 'DET'), ('pack', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('he', 'PRON'), ('added', 'VERB'), ('.', 'PUNCT'), ('But', 'CCONJ'), ('that', 'PRON'), ('’s', 'VERB'), ('not', 'PART'), ('all', 'PRON'), ('.', 'PUNCT'), ('The', 'DET'), ('pharma', 'NOUN'), ('major', 'NOUN'), ('is', 'AUX'), ('also', 'ADV'), ('looking', 'VERB'), ('at', 'ADP'), ('India', 'PROPN'), ('and', 'CCONJ'), ('Brazil', 'PROPN'), ('as', 'ADV'), ('well', 'ADV'), ('as', 'ADP'), ('other', 'ADJ'), ('emerging', 'VERB'), ('markets', 'NOUN'), ('where', 'SCONJ'), ('the', 'DET'), ('product', 'NOUN'), ('is', 'AUX'), ('in', 'ADP'), ('demand', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('At', 'ADP'), ('present', 'NOUN'), (',', 'PUNCT'), ('we', 'PRON'), ('at', 'ADP'), ('JM', 'PROPN'), ('Financial', 'PROPN'), ('Institutional', 'PROPN'), ('Research', 'PROPN'), ('see', 'VERB'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PUNCT'), ('as', 'ADP'), ('one', 'NUM'), ('of', 'ADP'), ('first', 'ADJ'), ('few', 'ADJ'), ('generic', 'ADJ'), ('filers', 'NOUN'), ('for', 'ADP'), ('semaglutide', 'NOUN'), ('globally', 'ADV'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Chalke', 'PROPN'), ('said', 'VERB'), ('.', 'PUNCT'), ('Is', 'AUX'), ('it', 'PRON'), ('enough', 'ADJ'), ('?', 'PUNCT'), ('\xa0', 'SPACE'), ('JM', 'PROPN'), ('Financials', 'NOUN'), ('estimates', 'VERB'), ('that', 'SCONJ'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('could', 'AUX'), ('clock', 'VERB'), ('$', 'SYM'), ('100', 'NUM'), ('-', 'SYM'), ('150', 'NUM'), ('million', 'NUM'), ('in', 'ADP'), ('Semaglutide', 'PROPN'), ('sales', 'NOUN'), ('if', 'SCONJ'), ('they', 'PRON'), ('launch', 'VERB'), ('in', 'ADP'), ('3', 'NUM'), ('-', 'SYM'), ('4', 'NUM'), ('markets', 'NOUN'), ('next', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('On', 'ADP'), ('the', 'DET'), ('other', 'ADJ'), ('hand', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('brokerage', 'NOUN'), ('is', 'AUX'), ('anticipating', 'VERB'), ('$', 'SYM'), ('700', 'NUM'), ('million', 'NUM'), ('from', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('for', 'ADP'), ('the', 'DET'), ('company', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('coming', 'VERB'), ('year', 'NOUN'), (',', 'PUNCT'), ('before', 'ADP'), ('loss', 'NOUN'), ('of', 'ADP'), ('exclusivity', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('has', 'VERB'), ('some', 'DET'), ('other', 'ADJ'), ('products', 'NOUN'), ('and', 'CCONJ'), ('strategies', 'NOUN'), ('in', 'ADP'), ('place', 'NOUN'), ('to', 'PART'), ('offset', 'VERB'), ('the', 'DET'), ('drop', 'NOUN'), ('in', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('company', 'NOUN'), ('is', 'AUX'), ('looking', 'VERB'), ('at', 'ADP'), ('the', 'DET'), ('launch', 'NOUN'), ('of', 'ADP'), ('biosimilar', 'ADJ'), ('Abatacept', 'PROPN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('by', 'ADP'), ('the', 'DET'), ('end', 'NOUN'), ('of', 'ADP'), ('FY27', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('“', 'PUNCT'), ('Abatacept', 'PROPN'), ('is', 'AUX'), ('a', 'DET'), ('$', 'SYM'), ('3', 'NUM'), ('-', 'SYM'), ('4', 'NUM'), ('billion', 'NUM'), ('product', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), (',', 'PUNCT'), ('if', 'SCONJ'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('is', 'AUX'), ('the', 'DET'), ('only', 'ADJ'), ('company', 'NOUN'), ('to', 'PART'), ('launch', 'VERB'), ('that', 'DET'), ('product', 'NOUN'), ('for', 'ADP'), ('at', 'ADV'), ('least', 'ADV'), ('one', 'NUM'), ('year', 'NOUN'), (',', 'PUNCT'), ('their', 'PRON'), ('sales', 'NOUN'), ('could', 'AUX'), ('be', 'AUX'), ('upward', 'ADV'), ('of', 'ADP'), ('$', 'SYM'), ('100', 'NUM'), ('million', 'NUM'), ('for', 'ADP'), ('that', 'DET'), ('product', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Chalke', 'PROPN'), ('said', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Together', 'ADV'), (',', 'PUNCT'), ('Semaglutide', 'PROPN'), ('and', 'CCONJ'), ('Abatacept', 'PROPN'), ('may', 'AUX'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('substantially', 'ADV'), ('offset', 'VERB'), ('the', 'DET'), ('Revlimid', 'PROPN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('analyst', 'NOUN'), ('said', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('The', 'DET'), ('company', 'NOUN'), ('also', 'ADV'), ('has', 'VERB'), ('the', 'DET'), ('recently', 'ADV'), ('-', 'PUNCT'), ('acquired', 'VERB'), ('nicotine', 'NOUN'), ('replacement', 'NOUN'), ('therapy', 'NOUN'), ('(', 'PUNCT'), ('NRT', 'PROPN'), (')', 'PUNCT'), ('portfolio', 'NOUN'), ('from', 'ADP'), ('Haleon', 'PROPN'), ('plc', 'PROPN'), ('in', 'ADP'), ('Europe', 'PROPN'), (',', 'PUNCT'), ('as', 'ADP'), ('an', 'DET'), ('additional', 'ADJ'), ('growth', 'NOUN'), ('driver', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Natco', 'PROPN'), ('Pharma', 'PROPN'), ('has', 'VERB'), ('some', 'DET'), ('other', 'ADJ'), ('key', 'ADJ'), ('first', 'ADJ'), ('-', 'PUNCT'), ('to', 'ADP'), ('-', 'PUNCT'), ('file', 'NOUN'), ('products', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('Risdiplam', 'PROPN'), ('Oral', 'PROPN'), ('Solution', 'PROPN'), ('for', 'ADP'), ('spinal', 'ADJ'), ('muscular', 'ADJ'), ('atrophy', 'NOUN'), ('and', 'CCONJ'), ('breast', 'NOUN'), ('cancer', 'NOUN'), ('drug', 'NOUN'), ('Olaparib', 'PROPN'), (',', 'PUNCT'), ('although', 'SCONJ'), ('the', 'DET'), ('timelines', 'NOUN'), ('for', 'ADP'), ('these', 'PRON'), ('are', 'AUX'), ('yet', 'ADV'), ('to', 'PART'), ('be', 'AUX'), ('defined', 'VERB'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Analysts', 'NOUN'), ('are', 'AUX'), ('divided', 'VERB'), ('on', 'ADP'), ('the', 'DET'), ('company', 'NOUN'), ('’s', 'PART'), ('prospects', 'NOUN'), (',', 'PUNCT'), ('though', 'ADV'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('products', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('one', 'NUM'), ('or', 'CCONJ'), ('two', 'NUM'), ('-', 'PUNCT'), ('year', 'NOUN'), ('gap', 'NOUN'), ('in', 'ADP'), ('between', 'ADP'), (',', 'PUNCT'), ('where', 'SCONJ'), ('the', 'DET'), ('base', 'NOUN'), ('will', 'AUX'), ('be', 'AUX'), ('much', 'ADV'), ('lower', 'ADJ'), (',', 'PUNCT'), ('the', 'DET'), ('profits', 'NOUN'), ('will', 'AUX'), ('be', 'AUX'), ('much', 'ADV'), ('lower', 'ADJ'), (',', 'PUNCT'), ('""', 'PUNCT'), ('an', 'DET'), ('analyst', 'NOUN'), ('who', 'PRON'), ('requested', 'VERB'), ('anonymity', 'NOUN'), ('told', 'VERB'), ('Mint', 'PROPN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('In', 'ADP'), ('a', 'DET'), ('research', 'NOUN'), ('note', 'NOUN'), ('dated', 'VERB'), ('14', 'NUM'), ('February', 'PROPN'), (',', 'PUNCT'), ('ICICI', 'PROPN'), ('Direct', 'ADJ'), ('analysts', 'NOUN'), ('said', 'VERB'), (':', 'PUNCT'), ('“', 'PUNCT'), ('We', 'PRON'), ('continue', 'VERB'), ('to', 'PART'), ('have', 'VERB'), ('faith', 'NOUN'), ('in', 'ADP'), ('Natco', 'PROPN'), ('’s', 'PART'), ('ability', 'NOUN'), ('to', 'PART'), ('focus', 'VERB'), ('on', 'ADP'), ('blockbusters', 'NOUN'), ('which', 'PRON'), ('are', 'AUX'), ('capable', 'ADJ'), ('of', 'ADP'), ('generating', 'VERB'), ('robust', 'ADJ'), ('cash', 'NOUN'), ('flows', 'VERB'), ('for', 'ADP'), ('3', 'NUM'), ('-', 'SYM'), ('5', 'NUM'), ('years', 'NOUN'), (""'"", 'PART'), ('horizon', 'NOUN'), ('before', 'SCONJ'), ('they', 'PRON'), ('fade', 'VERB'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('On', 'ADP'), ('the', 'DET'), ('other', 'ADJ'), ('hand', 'NOUN'), (',', 'PUNCT'), ('Nuvama', 'PROPN'), ('analysts', 'NOUN'), ('said', 'VERB'), ('that', 'SCONJ'), ('while', 'SCONJ'), ('the', 'DET'), ('next', 'ADJ'), ('couple', 'NOUN'), ('of', 'ADP'), ('quarters', 'NOUN'), ('could', 'AUX'), ('witness', 'VERB'), ('robust', 'ADJ'), ('growth', 'NOUN'), ('due', 'ADP'), ('to', 'ADP'), ('Revlimid', 'PROPN'), (',', 'PUNCT'), ('this', 'PRON'), ('is', 'AUX'), ('not', 'PART'), ('sustainable', 'ADJ'), ('in', 'ADP'), ('the', 'DET'), ('future', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('“', 'PUNCT'), ('We', 'PRON'), ('also', 'ADV'), ('note', 'VERB'), ('an', 'DET'), ('impressive', 'ADJ'), ('US', 'PROPN'), ('launch', 'NOUN'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('uncertainty', 'NOUN'), ('persists', 'VERB'), ('around', 'ADP'), ('launch', 'NOUN'), ('and', 'CCONJ'), ('approval', 'NOUN'), ('timelines', 'NOUN'), ('.', 'PUNCT'), ('Break', 'VERB'), ('-', 'PUNCT'), ('even', 'ADV'), ('in', 'ADP'), ('the', 'DET'), ('agrochem', 'NOUN'), ('business', 'NOUN'), ('in', 'ADP'), ('FY26', 'PROPN'), ('and', 'CCONJ'), ('the', 'DET'), ('GLP-1', 'PROPN'), ('opportunity', 'NOUN'), ('in', 'ADP'), ('India', 'PROPN'), ('are', 'AUX'), ('triggers', 'NOUN'), ('that', 'PRON'), ('can', 'AUX'), ('help', 'VERB'), ('Natco', 'PROPN'), ('offset', 'VERB'), ('part', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('gRevlimid', 'PROPN'), ('hit', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), ('and', 'CCONJ'), ('beyond', 'ADP'), (',', 'PUNCT'), ('""', 'PUNCT'), ('the', 'DET'), ('Nuvama', 'PROPN'), ('analysts', 'NOUN'), ('said', 'VERB'), ('in', 'ADP'), ('a', 'DET'), ('note', 'NOUN'), ('dated', 'VERB'), ('13', 'NUM'), ('February', 'PROPN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Natco', 'PROPN'), ('believes', 'VERB'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('drop', 'NOUN'), ('in', 'ADP'), ('earnings', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('That', 'PRON'), (""'s"", 'AUX'), ('the', 'DET'), ('elephant', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('room', 'NOUN'), (',', 'PUNCT'), ('[', 'X'), ('we', 'PRON'), (']', 'PUNCT'), ('have', 'VERB'), ('to', 'PART'), ('accept', 'VERB'), ('that', 'SCONJ'), ('earnings', 'NOUN'), ('will', 'AUX'), ('drop', 'VERB'), ('in', 'ADP'), ('‘', 'PUNCT'), ('27', 'NUM'), ('March', 'PROPN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Nannapaneni', 'PROPN'), ('told', 'VERB'), ('investors', 'NOUN'), ('in', 'ADP'), ('an', 'DET'), ('earnings', 'NOUN'), ('call', 'NOUN'), ('last', 'ADJ'), ('week', 'NOUN'), ('.', 'PUNCT'), ('      ', 'SPACE'), ('There', 'PRON'), ('is', 'VERB'), ('no', 'DET'), ('dearth', 'NOUN'), ('of', 'ADP'), ('competition', 'NOUN'), ('when', 'SCONJ'), ('it', 'PRON'), ('comes', 'VERB'), ('to', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('with', 'ADP'), ('leading', 'VERB'), ('generics', 'NOUN'), ('makers', 'NOUN'), ('jumping', 'VERB'), ('in', 'ADP'), ('.', 'PUNCT'), ('Sun', 'PROPN'), ('Pharma', 'PROPN'), ('has', 'AUX'), ('already', 'ADV'), ('undertaken', 'VERB'), ('clinical', 'ADJ'), ('trials', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('while', 'SCONJ'), ('Biocon', 'PROPN'), ('signed', 'VERB'), ('an', 'DET'), ('exclusive', 'ADJ'), ('licensing', 'NOUN'), ('and', 'CCONJ'), ('supply', 'NOUN'), ('agreement', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), ('commercialization', 'NOUN'), ('in', 'ADP'), ('Brazil', 'PROPN'), ('with', 'ADP'), ('Biomm', 'PROPN'), ('last', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('\xa0       ', 'SPACE'), ('Domestically', 'ADV'), (',', 'PUNCT'), ('innovators', 'X'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), ('and', 'CCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('have', 'AUX'), ('also', 'ADV'), ('indicated', 'VERB'), ('potential', 'ADJ'), ('launches', 'NOUN'), ('.', 'PUNCT'), ('While', 'SCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('has', 'AUX'), ('n’t', 'PART'), ('clarified', 'VERB'), ('a', 'DET'), ('timeline', 'NOUN'), (',', 'PUNCT'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), ('has', 'AUX'), ('announced', 'VERB'), ('that', 'SCONJ'), ('it', 'PRON'), ('will', 'AUX'), ('launch', 'VERB'), ('its', 'PRON'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drug', 'NOUN'), ('Tirzepatide', 'PROPN'), ('in', 'ADP'), ('India', 'PROPN'), ('in', 'ADP'), ('2025', 'NUM'), ('at', 'ADP'), ('competitive', 'ADJ'), ('pricing', 'NOUN'), ('.', 'PUNCT'), ('JM', 'PROPN'), ('Financials', 'PROPN'), ('estimates', 'VERB'), ('that', 'SCONJ'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('could', 'AUX'), ('clock', 'VERB'), ('$', 'SYM'), ('100', 'NUM'), ('-', 'SYM'), ('150', 'NUM'), ('million', 'NUM'), ('in', 'ADP'), ('Semaglutide', 'PROPN'), ('sales', 'NOUN'), ('if', 'SCONJ'), ('they', 'PRON'), ('launch', 'VERB'), ('in', 'ADP'), ('3', 'NUM'), ('-', 'SYM'), ('4', 'NUM'), ('markets', 'NOUN'), ('next', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('On', 'ADP'), ('the', 'DET'), ('other', 'ADJ'), ('hand', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('brokerage', 'NOUN'), ('is', 'AUX'), ('anticipating', 'VERB'), ('$', 'SYM'), ('700', 'NUM'), ('million', 'NUM'), ('from', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('for', 'ADP'), ('the', 'DET'), ('company', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('coming', 'VERB'), ('year', 'NOUN'), (',', 'PUNCT'), ('before', 'ADP'), ('loss', 'NOUN'), ('of', 'ADP'), ('exclusivity', 'NOUN'), ('.', 'PUNCT'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('has', 'VERB'), ('some', 'DET'), ('other', 'ADJ'), ('products', 'NOUN'), ('and', 'CCONJ'), ('strategies', 'NOUN'), ('in', 'ADP'), ('place', 'NOUN'), ('to', 'PART'), ('offset', 'VERB'), ('the', 'DET'), ('drop', 'NOUN'), ('in', 'ADP'), ('Revlimid', 'PROPN'), ('sales', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('company', 'NOUN'), ('is', 'AUX'), ('looking', 'VERB'), ('at', 'ADP'), ('the', 'DET'), ('launch', 'NOUN'), ('of', 'ADP'), ('biosimilar', 'ADJ'), ('Abatacept', 'PROPN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), ('by', 'ADP'), ('the', 'DET'), ('end', 'NOUN'), ('of', 'ADP'), ('FY27', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('“', 'PUNCT'), ('Abatacept', 'PROPN'), ('is', 'AUX'), ('a', 'DET'), ('$', 'SYM'), ('3', 'NUM'), ('-', 'SYM'), ('4', 'NUM'), ('billion', 'NUM'), ('product', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('US', 'PROPN'), (',', 'PUNCT'), ('if', 'SCONJ'), ('Dr.', 'PROPN'), ('Reddy', 'PROPN'), ('’s', 'PART'), ('is', 'AUX'), ('the', 'DET'), ('only', 'ADJ'), ('company', 'NOUN'), ('to', 'PART'), ('launch', 'VERB'), ('that', 'DET'), ('product', 'NOUN'), ('for', 'ADP'), ('at', 'ADV'), ('least', 'ADV'), ('one', 'NUM'), ('year', 'NOUN'), (',', 'PUNCT'), ('their', 'PRON'), ('sales', 'NOUN'), ('could', 'AUX'), ('be', 'AUX'), ('upward', 'ADV'), ('of', 'ADP'), ('$', 'SYM'), ('100', 'NUM'), ('million', 'NUM'), ('for', 'ADP'), ('that', 'DET'), ('product', 'NOUN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Chalke', 'PROPN'), ('said', 'VERB'), ('.', 'PUNCT'), ('Together', 'ADV'), (',', 'PUNCT'), ('Semaglutide', 'PROPN'), ('and', 'CCONJ'), ('Abatacept', 'PROPN'), ('may', 'AUX'), ('be', 'AUX'), ('able', 'ADJ'), ('to', 'PART'), ('substantially', 'ADV'), ('offset', 'VERB'), ('the', 'DET'), ('Revlimid', 'PROPN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('analyst', 'NOUN'), ('said', 'VERB'), ('.', 'PUNCT'), ('The', 'DET'), ('company', 'NOUN'), ('also', 'ADV'), ('has', 'VERB'), ('the', 'DET'), ('recently', 'ADV'), ('-', 'PUNCT'), ('acquired', 'VERB'), ('nicotine', 'NOUN'), ('replacement', 'NOUN'), ('therapy', 'NOUN'), ('(', 'PUNCT'), ('NRT', 'PROPN'), (')', 'PUNCT'), ('portfolio', 'NOUN'), ('from', 'ADP'), ('Haleon', 'PROPN'), ('plc', 'PROPN'), ('in', 'ADP'), ('Europe', 'PROPN'), (',', 'PUNCT'), ('as', 'ADP'), ('an', 'DET'), ('additional', 'ADJ'), ('growth', 'NOUN'), ('driver', 'NOUN'), ('.', 'PUNCT'), ('Natco', 'PROPN'), ('Pharma', 'PROPN'), ('has', 'VERB'), ('some', 'DET'), ('other', 'ADJ'), ('key', 'ADJ'), ('first', 'ADJ'), ('-', 'PUNCT'), ('to', 'ADP'), ('-', 'PUNCT'), ('file', 'NOUN'), ('products', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('including', 'VERB'), ('Risdiplam', 'PROPN'), ('Oral', 'PROPN'), ('Solution', 'PROPN'), ('for', 'ADP'), ('spinal', 'ADJ'), ('muscular', 'ADJ'), ('atrophy', 'NOUN'), ('and', 'CCONJ'), ('breast', 'NOUN'), ('cancer', 'NOUN'), ('drug', 'NOUN'), ('Olaparib', 'PROPN'), (',', 'PUNCT'), ('although', 'SCONJ'), ('the', 'DET'), ('timelines', 'NOUN'), ('for', 'ADP'), ('these', 'PRON'), ('are', 'AUX'), ('yet', 'ADV'), ('to', 'PART'), ('be', 'AUX'), ('defined', 'VERB'), ('.', 'PUNCT'), ('Analysts', 'NOUN'), ('are', 'AUX'), ('divided', 'VERB'), ('on', 'ADP'), ('the', 'DET'), ('company', 'NOUN'), ('’s', 'PART'), ('prospects', 'NOUN'), (',', 'PUNCT'), ('though', 'ADV'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('There', 'PRON'), ('are', 'VERB'), ('products', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('one', 'NUM'), ('or', 'CCONJ'), ('two', 'NUM'), ('-', 'PUNCT'), ('year', 'NOUN'), ('gap', 'NOUN'), ('in', 'ADP'), ('between', 'ADP'), (',', 'PUNCT'), ('where', 'SCONJ'), ('the', 'DET'), ('base', 'NOUN'), ('will', 'AUX'), ('be', 'AUX'), ('much', 'ADV'), ('lower', 'ADJ'), (',', 'PUNCT'), ('the', 'DET'), ('profits', 'NOUN'), ('will', 'AUX'), ('be', 'AUX'), ('much', 'ADV'), ('lower', 'ADJ'), (',', 'PUNCT'), ('""', 'PUNCT'), ('an', 'DET'), ('analyst', 'NOUN'), ('who', 'PRON'), ('requested', 'VERB'), ('anonymity', 'NOUN'), ('told', 'VERB'), ('Mint', 'PROPN'), ('.', 'PUNCT'), ('In', 'ADP'), ('a', 'DET'), ('research', 'NOUN'), ('note', 'NOUN'), ('dated', 'VERB'), ('14', 'NUM'), ('February', 'PROPN'), (',', 'PUNCT'), ('ICICI', 'PROPN'), ('Direct', 'ADJ'), ('analysts', 'NOUN'), ('said', 'VERB'), (':', 'PUNCT'), ('“', 'PUNCT'), ('We', 'PRON'), ('continue', 'VERB'), ('to', 'PART'), ('have', 'VERB'), ('faith', 'NOUN'), ('in', 'ADP'), ('Natco', 'PROPN'), ('’s', 'PART'), ('ability', 'NOUN'), ('to', 'PART'), ('focus', 'VERB'), ('on', 'ADP'), ('blockbusters', 'NOUN'), ('which', 'PRON'), ('are', 'AUX'), ('capable', 'ADJ'), ('of', 'ADP'), ('generating', 'VERB'), ('robust', 'ADJ'), ('cash', 'NOUN'), ('flows', 'VERB'), ('for', 'ADP'), ('3', 'NUM'), ('-', 'SYM'), ('5', 'NUM'), ('years', 'NOUN'), (""'"", 'PART'), ('horizon', 'NOUN'), ('before', 'SCONJ'), ('they', 'PRON'), ('fade', 'VERB'), ('.', 'PUNCT'), ('""', 'PUNCT'), ('On', 'ADP'), ('the', 'DET'), ('other', 'ADJ'), ('hand', 'NOUN'), (',', 'PUNCT'), ('Nuvama', 'PROPN'), ('analysts', 'NOUN'), ('said', 'VERB'), ('that', 'SCONJ'), ('while', 'SCONJ'), ('the', 'DET'), ('next', 'ADJ'), ('couple', 'NOUN'), ('of', 'ADP'), ('quarters', 'NOUN'), ('could', 'AUX'), ('witness', 'VERB'), ('robust', 'ADJ'), ('growth', 'NOUN'), ('due', 'ADP'), ('to', 'ADP'), ('Revlimid', 'PROPN'), (',', 'PUNCT'), ('this', 'PRON'), ('is', 'AUX'), ('not', 'PART'), ('sustainable', 'ADJ'), ('in', 'ADP'), ('the', 'DET'), ('future', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('We', 'PRON'), ('also', 'ADV'), ('note', 'VERB'), ('an', 'DET'), ('impressive', 'ADJ'), ('US', 'PROPN'), ('launch', 'NOUN'), ('pipeline', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('uncertainty', 'NOUN'), ('persists', 'VERB'), ('around', 'ADP'), ('launch', 'NOUN'), ('and', 'CCONJ'), ('approval', 'NOUN'), ('timelines', 'NOUN'), ('.', 'PUNCT'), ('Break', 'VERB'), ('-', 'PUNCT'), ('even', 'ADV'), ('in', 'ADP'), ('the', 'DET'), ('agrochem', 'NOUN'), ('business', 'NOUN'), ('in', 'ADP'), ('FY26', 'PROPN'), ('and', 'CCONJ'), ('the', 'DET'), ('GLP-1', 'PROPN'), ('opportunity', 'NOUN'), ('in', 'ADP'), ('India', 'PROPN'), ('are', 'AUX'), ('triggers', 'NOUN'), ('that', 'PRON'), ('can', 'AUX'), ('help', 'VERB'), ('Natco', 'PROPN'), ('offset', 'VERB'), ('part', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('gRevlimid', 'PROPN'), ('hit', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), ('and', 'CCONJ'), ('beyond', 'ADP'), (',', 'PUNCT'), ('""', 'PUNCT'), ('the', 'DET'), ('Nuvama', 'PROPN'), ('analysts', 'NOUN'), ('said', 'VERB'), ('in', 'ADP'), ('a', 'DET'), ('note', 'NOUN'), ('dated', 'VERB'), ('13', 'NUM'), ('February', 'PROPN'), ('.', 'PUNCT'), ('Natco', 'PROPN'), ('believes', 'VERB'), ('there', 'PRON'), ('will', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('drop', 'NOUN'), ('in', 'ADP'), ('earnings', 'NOUN'), ('in', 'ADP'), ('FY27', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('That', 'PRON'), (""'s"", 'AUX'), ('the', 'DET'), ('elephant', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('room', 'NOUN'), (',', 'PUNCT'), ('[', 'X'), ('we', 'PRON'), (']', 'PUNCT'), ('have', 'VERB'), ('to', 'PART'), ('accept', 'VERB'), ('that', 'SCONJ'), ('earnings', 'NOUN'), ('will', 'AUX'), ('drop', 'VERB'), ('in', 'ADP'), ('‘', 'PUNCT'), ('27', 'NUM'), ('March', 'PROPN'), (',', 'PUNCT'), ('""', 'PUNCT'), ('Nannapaneni', 'PROPN'), ('told', 'VERB'), ('investors', 'NOUN'), ('in', 'ADP'), ('an', 'DET'), ('earnings', 'NOUN'), ('call', 'NOUN'), ('last', 'ADJ'), ('week', 'NOUN'), ('.', 'PUNCT'), ('There', 'PRON'), ('is', 'VERB'), ('no', 'DET'), ('dearth', 'NOUN'), ('of', 'ADP'), ('competition', 'NOUN'), ('when', 'SCONJ'), ('it', 'PRON'), ('comes', 'VERB'), ('to', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('with', 'ADP'), ('leading', 'VERB'), ('generics', 'NOUN'), ('makers', 'NOUN'), ('jumping', 'VERB'), ('in', 'ADP'), ('.', 'PUNCT'), ('Sun', 'PROPN'), ('Pharma', 'PROPN'), ('has', 'AUX'), ('already', 'ADV'), ('undertaken', 'VERB'), ('clinical', 'ADJ'), ('trials', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), (',', 'PUNCT'), ('while', 'SCONJ'), ('Biocon', 'PROPN'), ('signed', 'VERB'), ('an', 'DET'), ('exclusive', 'ADJ'), ('licensing', 'NOUN'), ('and', 'CCONJ'), ('supply', 'NOUN'), ('agreement', 'NOUN'), ('for', 'ADP'), ('Semaglutide', 'PROPN'), ('commercialization', 'NOUN'), ('in', 'ADP'), ('Brazil', 'PROPN'), ('with', 'ADP'), ('Biomm', 'PROPN'), ('last', 'ADJ'), ('year', 'NOUN'), ('.', 'PUNCT'), ('Domestically', 'ADV'), (',', 'PUNCT'), ('innovators', 'X'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), ('and', 'CCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('have', 'AUX'), ('also', 'ADV'), ('indicated', 'VERB'), ('potential', 'ADJ'), ('launches', 'NOUN'), ('.', 'PUNCT'), ('While', 'SCONJ'), ('Novo', 'PROPN'), ('Nordisk', 'PROPN'), ('has', 'AUX'), ('n’t', 'PART'), ('clarified', 'VERB'), ('a', 'DET'), ('timeline', 'NOUN'), (',', 'PUNCT'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), ('has', 'AUX'), ('announced', 'VERB'), ('that', 'SCONJ'), ('it', 'PRON'), ('will', 'AUX'), ('launch', 'VERB'), ('its', 'PRON'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('drug', 'NOUN'), ('Tirzepatide', 'PROPN'), ('in', 'ADP'), ('India', 'PROPN'), ('in', 'ADP'), ('2025', 'NUM'), ('at', 'ADP'), ('competitive', 'ADJ'), ('pricing', 'NOUN'), ('.', 'PUNCT')]","[('Natco Pharma Q3 Results', 'PERSON'), ('2025', 'DATE'), ('Profit Falls', 'ORG'), ('37.47%', 'PERCENT'), ('YoY       However', 'ORG'), ('January 2026', 'DATE'), ('Reddy’s', 'PERSON'), ('Natco', 'ORG'), ('Revlimid', 'PERSON'), ('33%', 'PERCENT'), ('March 2025', 'DATE'), ('next year', 'DATE'), ('Natco', 'WORK_OF_ART'), ('Revlimid', 'PERSON'), ('FY26', 'GPE'), ('33%', 'PERCENT'), ('ICICI Direct Research', 'ORG'), ('50-60%', 'PERCENT'), ('Revlimid', 'PERSON'), ('Reddy’s', 'PERSON'), ('Ebitda', 'PERSON'), ('5,140', 'MONEY'), ('8,301', 'MONEY'), ('Revlimid', 'PERSON'), ('Revlimid', 'GPE'), ('Reddy', 'PERSON'), ('Revlimid', 'PERSON'), ('Novo Nordisk’s', 'PERSON'), ('Semaglutide', 'WORK_OF_ART'), ('Ozempic', 'ORG'), ('Wegovy', 'ORG'), ('Revlimid', 'PERSON'), ('Semaglutide', 'WORK_OF_ART'), ('Indian', 'NORP'), ('almost $22 billion', 'MONEY'), ('Amey Chalke', 'PERSON'), ('JM Financial Institutional Securities', 'ORG'), ('Mint', 'PERSON'), ('Semaglutide', 'PERSON'), ('larger than $28-29 billion', 'MONEY'), ('Chalke', 'ORG'), ('first', 'ORDINAL'), ('Paragraph IV', 'ORG'), ('Wegovy', 'ORG'), ('Ozempic', 'GPE'), ('Semaglutide', 'PERSON'), ('180-day', 'DATE'), ('Reddy', 'ORG'), ('Labs Q3 Results:', 'PERSON'), ('2%', 'PERCENT'), ('YoY', 'ORG'), ('1413', 'MONEY'), ('16%', 'PERCENT'), ('October', 'DATE'), ('Natco', 'ORG'), ('Mylan', 'ORG'), ('US', 'GPE'), ('Novo Nordisk', 'PERSON'), ('Stelis', 'ORG'), ('about $9 billion', 'MONEY'), ('US', 'GPE'), ('calendar year 2023', 'DATE'), ('ICICI Direct Research', 'ORG'), ('US', 'GPE'), ('Semaglutide', 'PERSON'), ('India', 'GPE'), ('next year', 'DATE'), ('India', 'GPE'), ('Semaglutide', 'PERSON'), ('1HFY26', 'CARDINAL'), ('Natco', 'WORK_OF_ART'), ('Mint', 'ORG'), ('Reddy’s', 'PERSON'), ('Canada', 'GPE'), ('January 2026', 'DATE'), ('Reddy', 'PERSON'), ('Erez Israeli', 'PERSON'), ('January', 'DATE'), ('Canadian', 'NORP'), ('12 to 14 months', 'DATE'), ('first', 'ORDINAL'), ('India', 'GPE'), ('Brazil', 'GPE'), ('JM Financial Institutional Research', 'ORG'), ('Reddy', 'PERSON'), ('one', 'CARDINAL'), ('first', 'ORDINAL'), ('Chalke', 'ORG'), ('JM Financials', 'ORG'), ('Reddy', 'PERSON'), ('100', 'MONEY'), ('Semaglutide', 'WORK_OF_ART'), ('3', 'CARDINAL'), ('next year', 'DATE'), ('$700 million', 'MONEY'), ('Revlimid', 'PERSON'), ('US', 'GPE'), ('the coming year', 'DATE'), ('Reddy’s', 'PERSON'), ('Revlimid', 'PERSON'), ('Abatacept', 'PRODUCT'), ('US', 'GPE'), ('the end of FY27', 'DATE'), ('$3-4 billion', 'MONEY'), ('US', 'GPE'), ('Reddy’s', 'PERSON'), ('at least one year', 'DATE'), ('$100 million', 'MONEY'), ('Chalke', 'ORG'), ('Semaglutide', 'PERSON'), ('Abatacept', 'PERSON'), ('Revlimid', 'PERSON'), ('NRT', 'ORG'), ('Haleon plc', 'ORG'), ('Europe', 'LOC'), ('Natco Pharma', 'PERSON'), ('first', 'ORDINAL'), ('Risdiplam Oral Solution', 'ORG'), ('Olaparib', 'PERSON'), ('one', 'CARDINAL'), ('two-year', 'DATE'), ('Mint', 'ORG'), ('14 February', 'DATE'), ('Natco', 'WORK_OF_ART'), (""3-5 years'"", 'DATE'), ('Nuvama', 'PERSON'), ('the next couple of quarters', 'DATE'), ('Revlimid', 'PERSON'), ('US', 'GPE'), ('FY26', 'GPE'), ('GLP-1', 'LOC'), ('India', 'GPE'), ('Natco', 'WORK_OF_ART'), ('gRevlimid', 'NORP'), ('Nuvama', 'PERSON'), ('13 February', 'DATE'), ('Natco', 'WORK_OF_ART'), ('27 March', 'DATE'), ('Nannapaneni', 'ORG'), ('last week', 'DATE'), ('Semaglutide', 'PERSON'), ('Sun Pharma', 'PERSON'), ('Semaglutide', 'WORK_OF_ART'), ('Biocon', 'ORG'), ('Semaglutide', 'PRODUCT'), ('Brazil', 'GPE'), ('Biomm', 'GPE'), ('last year', 'DATE'), ('Eli Lilly', 'ORG'), ('Novo Nordisk', 'PERSON'), ('Novo Nordisk', 'PERSON'), ('Eli Lilly', 'ORG'), ('Tirzepatide', 'GPE'), ('India', 'GPE'), ('2025', 'DATE'), ('Indian', 'NORP'), ('Reddy’s', 'PERSON'), ('Natco', 'ORG'), ('Cipla', 'ORG'), ('Sun Pharma', 'PERSON'), ('Zydus', 'GPE'), ('Aurobindo Pharma', 'PERSON'), ('$8 billion', 'MONEY'), ('US', 'GPE'), ('March 2022', 'DATE'), ('Celgene', 'PERSON'), ('Bristol Myers Squibb', 'ORG'), ('Natco Pharma Q3 Results', 'PERSON'), ('2025', 'DATE'), ('Profit Falls', 'ORG'), ('37.47%', 'PERCENT'), ('YoY', 'ORG'), ('January 2026', 'DATE'), ('Reddy’s', 'PERSON'), ('Natco', 'ORG'), ('Revlimid', 'PERSON'), ('33%', 'PERCENT'), ('March 2025', 'DATE'), ('next year', 'DATE'), ('Natco', 'PERSON'), ('Revlimid', 'PERSON'), ('FY26', 'GPE'), ('33%', 'PERCENT'), ('ICICI Direct Research', 'ORG'), ('50-60%', 'PERCENT'), ('Revlimid', 'PERSON'), ('Reddy’s', 'PERSON'), ('Ebitda', 'PERSON'), ('5,140', 'MONEY'), ('8,301', 'MONEY'), ('Revlimid', 'PERSON'), ('Revlimid', 'GPE'), ('Reddy', 'PERSON'), ('Revlimid', 'PERSON'), ('Novo Nordisk’s', 'PERSON'), ('Semaglutide', 'WORK_OF_ART'), ('Ozempic', 'ORG'), ('Wegovy', 'ORG'), ('Revlimid', 'PERSON'), ('Semaglutide', 'WORK_OF_ART'), ('Indian', 'NORP'), ('almost $22 billion', 'MONEY'), ('Amey Chalke', 'PERSON'), ('JM Financial Institutional Securities', 'ORG'), ('Mint', 'PERSON'), ('Semaglutide', 'PERSON'), ('larger than $28-29 billion', 'MONEY'), ('Chalke', 'ORG'), ('first', 'ORDINAL'), ('Paragraph IV', 'ORG'), ('Wegovy', 'ORG'), ('Ozempic', 'GPE'), ('Semaglutide', 'PERSON'), ('180-day', 'DATE'), ('Reddy', 'ORG'), ('Labs Q3 Results:', 'PERSON'), ('2%', 'PERCENT'), ('YoY', 'ORG'), ('1413', 'MONEY'), ('16%', 'PERCENT'), ('October', 'DATE'), ('Natco', 'ORG'), ('Mylan', 'ORG'), ('US', 'GPE'), ('Novo Nordisk', 'PERSON'), ('Stelis', 'ORG'), ('about $9 billion', 'MONEY'), ('US', 'GPE'), ('calendar year 2023', 'DATE'), ('ICICI Direct Research', 'ORG'), ('US', 'GPE'), ('Semaglutide', 'PERSON'), ('India', 'GPE'), ('next year', 'DATE'), ('India', 'GPE'), ('Semaglutide', 'PERSON'), ('1HFY26', 'CARDINAL'), ('Natco', 'WORK_OF_ART'), ('Mint', 'ORG'), ('Reddy’s', 'PERSON'), ('Canada', 'GPE'), ('January 2026', 'DATE'), ('Reddy', 'PERSON'), ('Erez Israeli', 'PERSON'), ('January', 'DATE'), ('Canadian', 'NORP'), ('12 to 14 months', 'DATE'), ('first', 'ORDINAL'), ('India', 'GPE'), ('Brazil', 'GPE'), ('JM Financial Institutional Research', 'ORG'), ('Reddy', 'PERSON'), ('one', 'CARDINAL'), ('first', 'ORDINAL'), ('Chalke', 'ORG'), ('JM Financials', 'ORG'), ('Reddy', 'PERSON'), ('100', 'MONEY'), ('Semaglutide', 'WORK_OF_ART'), ('3', 'CARDINAL'), ('next year', 'DATE'), ('$700 million', 'MONEY'), ('Revlimid', 'PERSON'), ('US', 'GPE'), ('the coming year', 'DATE'), ('Reddy’s', 'PERSON'), ('Revlimid', 'PERSON'), ('Abatacept', 'PRODUCT'), ('US', 'GPE'), ('the end of FY27', 'DATE'), ('$3-4 billion', 'MONEY'), ('US', 'GPE'), ('Reddy’s', 'PERSON'), ('at least one year', 'DATE'), ('$100 million', 'MONEY'), ('Chalke', 'ORG'), ('Semaglutide', 'PERSON'), ('Abatacept', 'PERSON'), ('Revlimid', 'PERSON'), ('NRT', 'ORG'), ('Haleon plc', 'ORG'), ('Europe', 'LOC'), ('Natco Pharma', 'PERSON'), ('first', 'ORDINAL'), ('Risdiplam Oral Solution', 'ORG'), ('Olaparib', 'PERSON'), ('one', 'CARDINAL'), ('two-year', 'DATE'), ('Mint', 'ORG'), ('14 February', 'DATE'), ('Natco', 'WORK_OF_ART'), (""3-5 years'"", 'DATE'), ('Nuvama', 'PERSON'), ('the next couple of quarters', 'DATE'), ('Revlimid', 'PERSON'), ('US', 'GPE'), ('FY26', 'GPE'), ('GLP-1', 'LOC'), ('India', 'GPE'), ('Natco', 'WORK_OF_ART'), ('gRevlimid', 'NORP'), ('Nuvama', 'PERSON'), ('13 February', 'DATE'), ('Natco', 'WORK_OF_ART'), ('27 March', 'DATE'), ('Nannapaneni', 'ORG'), ('last week', 'DATE'), ('Semaglutide', 'PERSON'), ('Sun Pharma', 'PERSON'), ('Semaglutide', 'WORK_OF_ART'), ('Biocon', 'ORG'), ('Semaglutide', 'PRODUCT'), ('Brazil', 'GPE'), ('Biomm', 'GPE'), ('last year', 'DATE'), ('Eli Lilly', 'ORG'), ('Novo Nordisk', 'PERSON'), ('Novo Nordisk', 'PERSON'), ('Eli Lilly', 'ORG'), ('Tirzepatide', 'GPE'), ('India', 'GPE'), ('2025', 'DATE'), ('Natco', 'ORG'), ('first', 'ORDINAL'), ('Paragraph IV', 'ORG'), ('Wegovy', 'ORG'), ('Ozempic', 'GPE'), ('Semaglutide', 'PERSON'), ('180-day', 'DATE'), ('Reddy', 'ORG'), ('Labs Q3 Results:', 'PERSON'), ('2%', 'PERCENT'), ('YoY', 'ORG'), ('1413', 'MONEY'), ('16%', 'PERCENT'), ('October', 'DATE'), ('Natco', 'ORG'), ('Mylan', 'ORG'), ('US', 'GPE'), ('Novo Nordisk', 'PERSON'), ('Stelis', 'ORG'), ('about $9 billion', 'MONEY'), ('US', 'GPE'), ('calendar year 2023', 'DATE'), ('ICICI Direct Research', 'ORG'), ('US', 'GPE'), ('Semaglutide', 'PERSON'), ('India', 'GPE'), ('next year', 'DATE'), ('India', 'GPE'), ('Semaglutide', 'PERSON'), ('1HFY26', 'CARDINAL'), ('Natco', 'WORK_OF_ART'), ('Mint', 'ORG'), ('Reddy’s', 'PERSON'), ('Canada', 'GPE'), ('January 2026', 'DATE'), ('Reddy', 'PERSON'), ('Erez Israeli', 'PERSON'), ('January', 'DATE'), ('Canadian', 'NORP'), ('12 to 14 months', 'DATE'), ('first', 'ORDINAL'), ('India', 'GPE'), ('Brazil', 'GPE'), ('JM Financial Institutional Research', 'ORG'), ('Reddy', 'PERSON'), ('one', 'CARDINAL'), ('first', 'ORDINAL'), ('Chalke', 'ORG'), ('JM Financials', 'ORG'), ('Reddy', 'PERSON'), ('100', 'MONEY'), ('Semaglutide', 'WORK_OF_ART'), ('3', 'CARDINAL'), ('next year', 'DATE'), ('$700 million', 'MONEY'), ('Revlimid', 'PERSON'), ('US', 'GPE'), ('the coming year', 'DATE'), ('Reddy’s', 'PERSON'), ('Revlimid', 'PERSON'), ('Abatacept', 'PRODUCT'), ('US', 'GPE'), ('the end of FY27', 'DATE'), ('$3-4 billion', 'MONEY'), ('US', 'GPE'), ('Reddy’s', 'PERSON'), ('at least one year', 'DATE'), ('$100 million', 'MONEY'), ('Chalke', 'ORG'), ('Semaglutide', 'PERSON'), ('Abatacept', 'PERSON'), ('Revlimid', 'PERSON'), ('NRT', 'ORG'), ('Haleon plc', 'ORG'), ('Europe', 'LOC'), ('Natco Pharma', 'PERSON'), ('first', 'ORDINAL'), ('Risdiplam Oral Solution', 'ORG'), ('Olaparib', 'PERSON'), ('one', 'CARDINAL'), ('two-year', 'DATE'), ('Mint', 'ORG'), ('14 February', 'DATE'), ('Natco', 'WORK_OF_ART'), (""3-5 years'"", 'DATE'), ('Nuvama', 'PERSON'), ('the next couple of quarters', 'DATE'), ('Revlimid', 'PERSON'), ('US', 'GPE'), ('FY26', 'GPE'), ('GLP-1', 'LOC'), ('India', 'GPE'), ('Natco', 'WORK_OF_ART'), ('gRevlimid', 'NORP'), ('Nuvama', 'PERSON'), ('13 February', 'DATE'), ('Natco', 'WORK_OF_ART'), ('27 March', 'DATE'), ('Nannapaneni', 'ORG'), ('last week', 'DATE'), ('Semaglutide', 'PERSON'), ('Sun Pharma', 'PERSON'), ('Semaglutide', 'WORK_OF_ART'), ('Biocon', 'ORG'), ('Semaglutide', 'PRODUCT'), ('Brazil', 'GPE'), ('Biomm', 'GPE'), ('last year', 'DATE'), ('Eli Lilly', 'ORG'), ('Novo Nordisk', 'PERSON'), ('Novo Nordisk', 'PERSON'), ('Eli Lilly', 'ORG'), ('Tirzepatide', 'GPE'), ('India', 'GPE'), ('2025', 'DATE'), ('JM Financials', 'ORG'), ('Reddy', 'PERSON'), ('100', 'MONEY'), ('Semaglutide', 'WORK_OF_ART'), ('3', 'CARDINAL'), ('next year', 'DATE'), ('$700 million', 'MONEY'), ('Revlimid', 'PERSON'), ('US', 'GPE'), ('the coming year', 'DATE'), ('Reddy’s', 'PERSON'), ('Revlimid', 'PERSON'), ('Abatacept', 'PRODUCT'), ('US', 'GPE'), ('the end of FY27', 'DATE'), ('$3-4 billion', 'MONEY'), ('US', 'GPE'), ('Reddy’s', 'PERSON'), ('at least one year', 'DATE'), ('$100 million', 'MONEY'), ('Chalke', 'ORG'), ('Semaglutide', 'PERSON'), ('Abatacept', 'PERSON'), ('Revlimid', 'PERSON'), ('NRT', 'ORG'), ('Haleon plc', 'ORG'), ('Europe', 'LOC'), ('Natco Pharma', 'PERSON'), ('first', 'ORDINAL'), ('Risdiplam Oral Solution', 'ORG'), ('Olaparib', 'PERSON'), ('one', 'CARDINAL'), ('two-year', 'DATE'), ('Mint', 'ORG'), ('14 February', 'DATE'), ('Natco', 'WORK_OF_ART'), (""3-5 years'"", 'DATE'), ('Nuvama', 'PERSON'), ('the next couple of quarters', 'DATE'), ('Revlimid', 'PERSON'), ('US', 'GPE'), ('FY26', 'GPE'), ('GLP-1', 'LOC'), ('India', 'GPE'), ('Natco', 'WORK_OF_ART'), ('gRevlimid', 'NORP'), ('Nuvama', 'PERSON'), ('13 February', 'DATE'), ('Natco', 'WORK_OF_ART'), ('27 March', 'DATE'), ('Nannapaneni', 'ORG'), ('last week', 'DATE'), ('Semaglutide', 'PERSON'), ('Sun Pharma', 'PERSON'), ('Semaglutide', 'WORK_OF_ART'), ('Biocon', 'ORG'), ('Semaglutide', 'PRODUCT'), ('Brazil', 'GPE'), ('Biomm', 'GPE'), ('last year', 'DATE'), ('Eli Lilly', 'ORG'), ('Novo Nordisk', 'PERSON'), ('Novo Nordisk', 'PERSON'), ('Eli Lilly', 'ORG'), ('Tirzepatide', 'GPE'), ('India', 'GPE'), ('2025', 'DATE')]","['Natco Pharma Q3 Results', '2025', 'Profit Falls', '37.47%', 'YoY       However', 'January 2026', 'Reddy’s', 'Natco', 'Revlimid', '33%', 'March 2025', 'next year', 'Natco', 'Revlimid', 'FY26', '33%', 'ICICI Direct Research', '50-60%', 'Revlimid', 'Reddy’s', 'Ebitda', '5,140', '8,301', 'Revlimid', 'Revlimid', 'Reddy', 'Revlimid', 'Novo Nordisk’s', 'Semaglutide', 'Ozempic', 'Wegovy', 'Revlimid', 'Semaglutide', 'Indian', 'almost $22 billion', 'Amey Chalke', 'JM Financial Institutional Securities', 'Mint', 'Semaglutide', 'larger than $28-29 billion', 'Chalke', 'first', 'Paragraph IV', 'Wegovy', 'Ozempic', 'Semaglutide', '180-day', 'Reddy', 'Labs Q3 Results:', '2%', 'YoY', '1413', '16%', 'October', 'Natco', 'Mylan', 'US', 'Novo Nordisk', 'Stelis', 'about $9 billion', 'US', 'calendar year 2023', 'ICICI Direct Research', 'US', 'Semaglutide', 'India', 'next year', 'India', 'Semaglutide', '1HFY26', 'Natco', 'Mint', 'Reddy’s', 'Canada', 'January 2026', 'Reddy', 'Erez Israeli', 'January', 'Canadian', '12 to 14 months', 'first', 'India', 'Brazil', 'JM Financial Institutional Research', 'Reddy', 'one', 'first', 'Chalke', 'JM Financials', 'Reddy', '100', 'Semaglutide', '3', 'next year', '$700 million', 'Revlimid', 'US', 'the coming year', 'Reddy’s', 'Revlimid', 'Abatacept', 'US', 'the end of FY27', '$3-4 billion', 'US', 'Reddy’s', 'at least one year', '$100 million', 'Chalke', 'Semaglutide', 'Abatacept', 'Revlimid', 'NRT', 'Haleon plc', 'Europe', 'Natco Pharma', 'first', 'Risdiplam Oral Solution', 'Olaparib', 'one', 'two-year', 'Mint', '14 February', 'Natco', ""3-5 years'"", 'Nuvama', 'the next couple of quarters', 'Revlimid', 'US', 'FY26', 'GLP-1', 'India', 'Natco', 'gRevlimid', 'Nuvama', '13 February', 'Natco', '27 March', 'Nannapaneni', 'last week', 'Semaglutide', 'Sun Pharma', 'Semaglutide', 'Biocon', 'Semaglutide', 'Brazil', 'Biomm', 'last year', 'Eli Lilly', 'Novo Nordisk', 'Novo Nordisk', 'Eli Lilly', 'Tirzepatide', 'India', '2025', 'Indian', 'Reddy’s', 'Natco', 'Cipla', 'Sun Pharma', 'Zydus', 'Aurobindo Pharma', '$8 billion', 'US', 'March 2022', 'Celgene', 'Bristol Myers Squibb', 'Natco Pharma Q3 Results', '2025', 'Profit Falls', '37.47%', 'YoY', 'January 2026', 'Reddy’s', 'Natco', 'Revlimid', '33%', 'March 2025', 'next year', 'Natco', 'Revlimid', 'FY26', '33%', 'ICICI Direct Research', '50-60%', 'Revlimid', 'Reddy’s', 'Ebitda', '5,140', '8,301', 'Revlimid', 'Revlimid', 'Reddy', 'Revlimid', 'Novo Nordisk’s', 'Semaglutide', 'Ozempic', 'Wegovy', 'Revlimid', 'Semaglutide', 'Indian', 'almost $22 billion', 'Amey Chalke', 'JM Financial Institutional Securities', 'Mint', 'Semaglutide', 'larger than $28-29 billion', 'Chalke', 'first', 'Paragraph IV', 'Wegovy', 'Ozempic', 'Semaglutide', '180-day', 'Reddy', 'Labs Q3 Results:', '2%', 'YoY', '1413', '16%', 'October', 'Natco', 'Mylan', 'US', 'Novo Nordisk', 'Stelis', 'about $9 billion', 'US', 'calendar year 2023', 'ICICI Direct Research', 'US', 'Semaglutide', 'India', 'next year', 'India', 'Semaglutide', '1HFY26', 'Natco', 'Mint', 'Reddy’s', 'Canada', 'January 2026', 'Reddy', 'Erez Israeli', 'January', 'Canadian', '12 to 14 months', 'first', 'India', 'Brazil', 'JM Financial Institutional Research', 'Reddy', 'one', 'first', 'Chalke', 'JM Financials', 'Reddy', '100', 'Semaglutide', '3', 'next year', '$700 million', 'Revlimid', 'US', 'the coming year', 'Reddy’s', 'Revlimid', 'Abatacept', 'US', 'the end of FY27', '$3-4 billion', 'US', 'Reddy’s', 'at least one year', '$100 million', 'Chalke', 'Semaglutide', 'Abatacept', 'Revlimid', 'NRT', 'Haleon plc', 'Europe', 'Natco Pharma', 'first', 'Risdiplam Oral Solution', 'Olaparib', 'one', 'two-year', 'Mint', '14 February', 'Natco', ""3-5 years'"", 'Nuvama', 'the next couple of quarters', 'Revlimid', 'US', 'FY26', 'GLP-1', 'India', 'Natco', 'gRevlimid', 'Nuvama', '13 February', 'Natco', '27 March', 'Nannapaneni', 'last week', 'Semaglutide', 'Sun Pharma', 'Semaglutide', 'Biocon', 'Semaglutide', 'Brazil', 'Biomm', 'last year', 'Eli Lilly', 'Novo Nordisk', 'Novo Nordisk', 'Eli Lilly', 'Tirzepatide', 'India', '2025', 'Natco', 'first', 'Paragraph IV', 'Wegovy', 'Ozempic', 'Semaglutide', '180-day', 'Reddy', 'Labs Q3 Results:', '2%', 'YoY', '1413', '16%', 'October', 'Natco', 'Mylan', 'US', 'Novo Nordisk', 'Stelis', 'about $9 billion', 'US', 'calendar year 2023', 'ICICI Direct Research', 'US', 'Semaglutide', 'India', 'next year', 'India', 'Semaglutide', '1HFY26', 'Natco', 'Mint', 'Reddy’s', 'Canada', 'January 2026', 'Reddy', 'Erez Israeli', 'January', 'Canadian', '12 to 14 months', 'first', 'India', 'Brazil', 'JM Financial Institutional Research', 'Reddy', 'one', 'first', 'Chalke', 'JM Financials', 'Reddy', '100', 'Semaglutide', '3', 'next year', '$700 million', 'Revlimid', 'US', 'the coming year', 'Reddy’s', 'Revlimid', 'Abatacept', 'US', 'the end of FY27', '$3-4 billion', 'US', 'Reddy’s', 'at least one year', '$100 million', 'Chalke', 'Semaglutide', 'Abatacept', 'Revlimid', 'NRT', 'Haleon plc', 'Europe', 'Natco Pharma', 'first', 'Risdiplam Oral Solution', 'Olaparib', 'one', 'two-year', 'Mint', '14 February', 'Natco', ""3-5 years'"", 'Nuvama', 'the next couple of quarters', 'Revlimid', 'US', 'FY26', 'GLP-1', 'India', 'Natco', 'gRevlimid', 'Nuvama', '13 February', 'Natco', '27 March', 'Nannapaneni', 'last week', 'Semaglutide', 'Sun Pharma', 'Semaglutide', 'Biocon', 'Semaglutide', 'Brazil', 'Biomm', 'last year', 'Eli Lilly', 'Novo Nordisk', 'Novo Nordisk', 'Eli Lilly', 'Tirzepatide', 'India', '2025', 'JM Financials', 'Reddy', '100', 'Semaglutide', '3', 'next year', '$700 million', 'Revlimid', 'US', 'the coming year', 'Reddy’s', 'Revlimid', 'Abatacept', 'US', 'the end of FY27', '$3-4 billion', 'US', 'Reddy’s', 'at least one year', '$100 million', 'Chalke', 'Semaglutide', 'Abatacept', 'Revlimid', 'NRT', 'Haleon plc', 'Europe', 'Natco Pharma', 'first', 'Risdiplam Oral Solution', 'Olaparib', 'one', 'two-year', 'Mint', '14 February', 'Natco', ""3-5 years'"", 'Nuvama', 'the next couple of quarters', 'Revlimid', 'US', 'FY26', 'GLP-1', 'India', 'Natco', 'gRevlimid', 'Nuvama', '13 February', 'Natco', '27 March', 'Nannapaneni', 'last week', 'Semaglutide', 'Sun Pharma', 'Semaglutide', 'Biocon', 'Semaglutide', 'Brazil', 'Biomm', 'last year', 'Eli Lilly', 'Novo Nordisk', 'Novo Nordisk', 'Eli Lilly', 'Tirzepatide', 'India', '2025']","['Natco Pharma Q3 Results', '2025', 'Profit Falls', '37.47%', 'YoY       However', 'January 2026', 'Reddy’s', 'Natco', 'Revlimid', '33%', 'March 2025', 'next year', 'Natco', 'Revlimid', 'FY26', '33%', 'ICICI Direct Research', '50-60%', 'Revlimid', 'Reddy’s', 'Ebitda', '5,140', '8,301', 'Revlimid', 'Revlimid', 'Reddy', 'Revlimid', 'Novo Nordisk’s', 'Semaglutide', 'Ozempic', 'Wegovy', 'Revlimid', 'Semaglutide', 'Indian', 'almost $22 billion', 'Amey Chalke', 'JM Financial Institutional Securities', 'Mint', 'Semaglutide', 'larger than $28-29 billion', 'Chalke', 'first', 'Paragraph IV', 'Wegovy', 'Ozempic', 'Semaglutide', '180-day', 'Reddy', 'Labs Q3 Results:', '2', 'YoY', '1413', '16%', 'October', 'Natco', 'Mylan', 'US', 'Novo Nordisk', 'Stelis', 'about $9 billion', 'US', 'calendar year 2023', 'ICICI Direct Research', 'US', 'Semaglutide', 'India', 'next year', 'India', 'Semaglutide', '1HFY26', 'Natco', 'Mint', 'Reddy’s', 'Canada', 'January 2026', 'Reddy', 'Erez Israeli', 'January', 'Canadian', '12 to 14 months', 'first', 'India', 'Brazil', 'JM Financial Institutional Research', 'Reddy', 'One', 'first', 'Chalke', 'JM Financials', 'Reddy', '100', 'Semaglutide', '3', 'next year', '$700 million', 'Revlimid', 'US', 'the coming year', 'Reddy’s', 'Revlimid', 'Abatacept', 'US', 'the end of FY27', '$3-4 billion', 'US', 'Reddy’s', 'at least one year', '$100 million', 'Chalke', 'Semaglutide', 'Abatacept', 'Revlimid', 'NRT', 'Haleon plc', 'Europe', 'Natco Pharma', 'first', 'Risdiplam Oral Solution', 'Olaparib', 'One', 'two-year', 'Mint', '14 February', 'Natco', ""3-5 years'"", 'Nuvama', 'the next couple of quarters', 'Revlimid', 'US', 'FY26', 'GLP-1', 'India', 'Natco', 'gRevlimid', 'Nuvama', '13 February', 'Natco', '27 March', 'Nannapaneni', 'last week', 'Semaglutide', 'Sun Pharma', 'Semaglutide', 'Biocon', 'Semaglutide', 'Brazil', 'Biomm', 'last year', 'Eli Lilly', 'Novo Nordisk', 'Novo Nordisk', 'Eli Lilly', 'Tirzepatide', 'India', '2025', 'Indian', 'Reddy’s', 'Natco', 'Cipla', 'Sun Pharma', 'Zydus', 'Aurobindo Pharma', '$8 billion', 'US', 'March 2022', 'Celgene', 'Bristol Myers Squibb', 'Natco Pharma Q3 Results', '2025', 'Profit Falls', '37.47%', 'YoY', 'January 2026', 'Reddy’s', 'Natco', 'Revlimid', '33%', 'March 2025', 'next year', 'Natco', 'Revlimid', 'FY26', '33%', 'ICICI Direct Research', '50-60%', 'Revlimid', 'Reddy’s', 'Ebitda', '5,140', '8,301', 'Revlimid', 'Revlimid', 'Reddy', 'Revlimid', 'Novo Nordisk’s', 'Semaglutide', 'Ozempic', 'Wegovy', 'Revlimid', 'Semaglutide', 'Indian', 'almost $22 billion', 'Amey Chalke', 'JM Financial Institutional Securities', 'Mint', 'Semaglutide', 'larger than $28-29 billion', 'Chalke', 'first', 'Paragraph IV', 'Wegovy', 'Ozempic', 'Semaglutide', '180-day', 'Reddy', 'Labs Q3 Results:', '2', 'YoY', '1413', '16%', 'October', 'Natco', 'Mylan', 'US', 'Novo Nordisk', 'Stelis', 'about $9 billion', 'US', 'calendar year 2023', 'ICICI Direct Research', 'US', 'Semaglutide', 'India', 'next year', 'India', 'Semaglutide', '1HFY26', 'Natco', 'Mint', 'Reddy’s', 'Canada', 'January 2026', 'Reddy', 'Erez Israeli', 'January', 'Canadian', '12 to 14 months', 'first', 'India', 'Brazil', 'JM Financial Institutional Research', 'Reddy', 'One', 'first', 'Chalke', 'JM Financials', 'Reddy', '100', 'Semaglutide', '3', 'next year', '$700 million', 'Revlimid', 'US', 'the coming year', 'Reddy’s', 'Revlimid', 'Abatacept', 'US', 'the end of FY27', '$3-4 billion', 'US', 'Reddy’s', 'at least one year', '$100 million', 'Chalke', 'Semaglutide', 'Abatacept', 'Revlimid', 'NRT', 'Haleon plc', 'Europe', 'Natco Pharma', 'first', 'Risdiplam Oral Solution', 'Olaparib', 'One', 'two-year', 'Mint', '14 February', 'Natco', ""3-5 years'"", 'Nuvama', 'the next couple of quarters', 'Revlimid', 'US', 'FY26', 'GLP-1', 'India', 'Natco', 'gRevlimid', 'Nuvama', '13 February', 'Natco', '27 March', 'Nannapaneni', 'last week', 'Semaglutide', 'Sun Pharma', 'Semaglutide', 'Biocon', 'Semaglutide', 'Brazil', 'Biomm', 'last year', 'Eli Lilly', 'Novo Nordisk', 'Novo Nordisk', 'Eli Lilly', 'Tirzepatide', 'India', '2025', 'Natco', 'first', 'Paragraph IV', 'Wegovy', 'Ozempic', 'Semaglutide', '180-day', 'Reddy', 'Labs Q3 Results:', '2', 'YoY', '1413', '16%', 'October', 'Natco', 'Mylan', 'US', 'Novo Nordisk', 'Stelis', 'about $9 billion', 'US', 'calendar year 2023', 'ICICI Direct Research', 'US', 'Semaglutide', 'India', 'next year', 'India', 'Semaglutide', '1HFY26', 'Natco', 'Mint', 'Reddy’s', 'Canada', 'January 2026', 'Reddy', 'Erez Israeli', 'January', 'Canadian', '12 to 14 months', 'first', 'India', 'Brazil', 'JM Financial Institutional Research', 'Reddy', 'One', 'first', 'Chalke', 'JM Financials', 'Reddy', '100', 'Semaglutide', '3', 'next year', '$700 million', 'Revlimid', 'US', 'the coming year', 'Reddy’s', 'Revlimid', 'Abatacept', 'US', 'the end of FY27', '$3-4 billion', 'US', 'Reddy’s', 'at least one year', '$100 million', 'Chalke', 'Semaglutide', 'Abatacept', 'Revlimid', 'NRT', 'Haleon plc', 'Europe', 'Natco Pharma', 'first', 'Risdiplam Oral Solution', 'Olaparib', 'One', 'two-year', 'Mint', '14 February', 'Natco', ""3-5 years'"", 'Nuvama', 'the next couple of quarters', 'Revlimid', 'US', 'FY26', 'GLP-1', 'India', 'Natco', 'gRevlimid', 'Nuvama', '13 February', 'Natco', '27 March', 'Nannapaneni', 'last week', 'Semaglutide', 'Sun Pharma', 'Semaglutide', 'Biocon', 'Semaglutide', 'Brazil', 'Biomm', 'last year', 'Eli Lilly', 'Novo Nordisk', 'Novo Nordisk', 'Eli Lilly', 'Tirzepatide', 'India', '2025', 'JM Financials', 'Reddy', '100', 'Semaglutide', '3', 'next year', '$700 million', 'Revlimid', 'US', 'the coming year', 'Reddy’s', 'Revlimid', 'Abatacept', 'US', 'the end of FY27', '$3-4 billion', 'US', 'Reddy’s', 'at least one year', '$100 million', 'Chalke', 'Semaglutide', 'Abatacept', 'Revlimid', 'NRT', 'Haleon plc', 'Europe', 'Natco Pharma', 'first', 'Risdiplam Oral Solution', 'Olaparib', 'One', 'two-year', 'Mint', '14 February', 'Natco', ""3-5 years'"", 'Nuvama', 'the next couple of quarters', 'Revlimid', 'US', 'FY26', 'GLP-1', 'India', 'Natco', 'gRevlimid', 'Nuvama', '13 February', 'Natco', '27 March', 'Nannapaneni', 'last week', 'Semaglutide', 'Sun Pharma', 'Semaglutide', 'Biocon', 'Semaglutide', 'Brazil', 'Biomm', 'last year', 'Eli Lilly', 'Novo Nordisk', 'Novo Nordisk', 'Eli Lilly', 'Tirzepatide', 'India', '2025']"
New Study Points to Using Ozempic to Treat Addiction | Psychology Today,https://www.psychologytoday.com/intl/blog/navigating-addiction-recovery/202502/new-study-points-to-using-ozempic-to-treat-addiction,"Reviewed by Davia Sills GLP-1 agonist medications such as Ozempic have been game changers in the treatment of obesity and diabetes. Recently, a new study found evidence that Ozempic may be a promising medicine for individuals with alcohol use disorders. This investigation, one of the first clinical trials focused on a population with alcohol use disorders, expands other research exploring the impact of GLP-1 agonists on alcohol and tobacco use among individuals with obesity or diabetes who were being treated with these medications. GLP-1 (also known as glucagon-like peptide 1) is a hormone that is produced by the digestive system and in parts of the brain after we eat. GLP-1 agonist medicines such as Ozempic and Wegovy mimic this hormone’s effects, letting the body know that you’ve eaten enough. The powerful weight loss effects of these medicines have led individuals who take them to achieve a 15 percent reduction in their body weight, on average. Addiction scientists took an interest in GLP-1 agonists after some people who were taking them for weight loss noted that in addition to suppressing their appetite, the medication also seemed to reduce their desire to drink alcohol and/or smoke. Though the reasons these medicines had this effect are not yet well understood, we can make some assumptions based on the way they work on appetite. We know that GLP-1 reduces dopamine (the brain’s pleasure chemical). When a person has food in front of them that they normally really like, such as a piece of cake, without the usual amount of dopamine released, they won’t feel as “excited” in anticipation of enjoying the cake. Without a strong urge, desire, or craving for the cake, they become less likely to want it. If the same process is happening in relation to alcohol and drugs, then GLP-1 agonists may reduce the desire to use them. Research is currently in the early stages. So far, we’ve learned from preliminary study results that those with obesity or diabetes who take GLP-1 agonist medications show reductions in alcohol and tobacco consumption. To date, there have been two randomized clinical trials (this is the “gold standard” type of research study for testing the effectiveness of a drug) evaluating a GLP-1 agonist for treating alcohol use disorder. The first study did not find reductions in heavy alcohol use after 26 weeks of medication treatment, except among those who had both obesity and an alcohol use disorder. The newest study published earlier this month found that among adults with alcohol use disorders, weekly low-dose semaglutide given over 9 weeks effectively reduced alcohol cravings and use when compared to a placebo. Clinical trials evaluating these medicines for tobacco cessation have found mixed results, with one showing positive effects of a GLP-agonist (exenatide) when taken in combination with nicotine replacement therapy and two trials showing no effects. More studies are needed to understand how well these medicines work to reduce alcohol and drug use, for whom they work best, and at what doses. Though more research is needed, the promise of these medicines is important for two reasons: 1. Since GLP-1 agonists act on brain circuits that are generally tied to reward and pleasure, both from food and drugs, it is possible that these medicines may be therapeutic for individuals who are addicted to more than one type of substance (i.e., polysubstance use or addiction). Currently, all the FDA-approved medicines for addictions are for a specific type of substance use disorder, but we don’t have any such options for addictions to multiple substances. 2. The stigma around addiction as a reflection of poor choices or flawed morals remains in our society. The promise of widely used and known medications such as Ozempic as potential treatment options to help people change their use of alcohol and drugs can help shift the conversation about addiction as an illness. This is an essential step towards helping people access much-needed treatments for this condition without shame and stigma as barriers. Based on what is currently known about GLP-1 agonist medications for addiction: 1. Some treatment providers may opt to prescribe them “off-label” to help someone overcome the addiction. Here’s what this means: Though not FDA-approved for this indication, some prescribing healthcare providers may feel that the research to date is compelling enough to warrant the use of these medications to treat addictions. Off-label prescribing is not at all an uncommon practice. The prescriber relies on their clinical judgment, in conjunction with the patient’s willingness to take a medicine that is not FDA-approved for the condition it’s being prescribed for, with a good understanding of the potential risks and benefits of doing so. 2. Research is in the early stages. It is important to be aware of the stage of research we’re currently in with GLP-1 agonists for addiction. With support for accelerated research currently in place from the National Institutes of Health, we are positioned to have scientifically based guidance on their use for addiction treatment a few years from now. In the meantime, we know that these medicines have promise, but we have a limited understanding of their safety, effectiveness, and ideal dosing for individuals with substance use disorders before more randomized clinical trials are conducted. More FDA-approved and unapproved (but promising) medication treatments to address substance misuse and addiction are covered in greater depth in my recently released book, Addiction: What Everyone Needs to Know.","[('Reviewed', 'VERB'), ('by', 'ADP'), ('Davia', 'PROPN'), ('Sills', 'PROPN'), ('GLP-1', 'PROPN'), ('agonist', 'NOUN'), ('medications', 'NOUN'), ('such', 'ADJ'), ('as', 'ADP'), ('Ozempic', 'PROPN'), ('have', 'AUX'), ('been', 'AUX'), ('game', 'NOUN'), ('changers', 'NOUN'), ('in', 'ADP'), ('the', 'DET'), ('treatment', 'NOUN'), ('of', 'ADP'), ('obesity', 'NOUN'), ('and', 'CCONJ'), ('diabetes', 'NOUN'), ('.', 'PUNCT'), ('Recently', 'ADV'), (',', 'PUNCT'), ('a', 'DET'), ('new', 'ADJ'), ('study', 'NOUN'), ('found', 'VERB'), ('evidence', 'NOUN'), ('that', 'SCONJ'), ('Ozempic', 'PROPN'), ('may', 'AUX'), ('be', 'AUX'), ('a', 'DET'), ('promising', 'ADJ'), ('medicine', 'NOUN'), ('for', 'ADP'), ('individuals', 'NOUN'), ('with', 'ADP'), ('alcohol', 'NOUN'), ('use', 'NOUN'), ('disorders', 'NOUN'), ('.', 'PUNCT'), ('This', 'DET'), ('investigation', 'NOUN'), (',', 'PUNCT'), ('one', 'NUM'), ('of', 'ADP'), ('the', 'DET'), ('first', 'ADJ'), ('clinical', 'ADJ'), ('trials', 'NOUN'), ('focused', 'VERB'), ('on', 'ADP'), ('a', 'DET'), ('population', 'NOUN'), ('with', 'ADP'), ('alcohol', 'NOUN'), ('use', 'NOUN'), ('disorders', 'NOUN'), (',', 'PUNCT'), ('expands', 'VERB'), ('other', 'ADJ'), ('research', 'NOUN'), ('exploring', 'VERB'), ('the', 'DET'), ('impact', 'NOUN'), ('of', 'ADP'), ('GLP-1', 'PROPN'), ('agonists', 'NOUN'), ('on', 'ADP'), ('alcohol', 'NOUN'), ('and', 'CCONJ'), ('tobacco', 'NOUN'), ('use', 'NOUN'), ('among', 'ADP'), ('individuals', 'NOUN'), ('with', 'ADP'), ('obesity', 'NOUN'), ('or', 'CCONJ'), ('diabetes', 'NOUN'), ('who', 'PRON'), ('were', 'AUX'), ('being', 'AUX'), ('treated', 'VERB'), ('with', 'ADP'), ('these', 'DET'), ('medications', 'NOUN'), ('.', 'PUNCT'), ('GLP-1', 'PROPN'), ('(', 'PUNCT'), ('also', 'ADV'), ('known', 'VERB'), ('as', 'ADP'), ('glucagon', 'NOUN'), ('-', 'PUNCT'), ('like', 'ADJ'), ('peptide', 'NOUN'), ('1', 'NUM'), (')', 'PUNCT'), ('is', 'AUX'), ('a', 'DET'), ('hormone', 'NOUN'), ('that', 'PRON'), ('is', 'AUX'), ('produced', 'VERB'), ('by', 'ADP'), ('the', 'DET'), ('digestive', 'ADJ'), ('system', 'NOUN'), ('and', 'CCONJ'), ('in', 'ADP'), ('parts', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('brain', 'NOUN'), ('after', 'SCONJ'), ('we', 'PRON'), ('eat', 'VERB'), ('.', 'PUNCT'), ('GLP-1', 'PROPN'), ('agonist', 'NOUN'), ('medicines', 'NOUN'), ('such', 'ADJ'), ('as', 'ADP'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), ('mimic', 'NOUN'), ('this', 'DET'), ('hormone', 'NOUN'), ('’s', 'PART'), ('effects', 'NOUN'), (',', 'PUNCT'), ('letting', 'VERB'), ('the', 'DET'), ('body', 'NOUN'), ('know', 'VERB'), ('that', 'SCONJ'), ('you', 'PRON'), ('’ve', 'AUX'), ('eaten', 'VERB'), ('enough', 'ADV'), ('.', 'PUNCT'), ('The', 'DET'), ('powerful', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('effects', 'NOUN'), ('of', 'ADP'), ('these', 'DET'), ('medicines', 'NOUN'), ('have', 'AUX'), ('led', 'VERB'), ('individuals', 'NOUN'), ('who', 'PRON'), ('take', 'VERB'), ('them', 'PRON'), ('to', 'PART'), ('achieve', 'VERB'), ('a', 'DET'), ('15', 'NUM'), ('percent', 'NOUN'), ('reduction', 'NOUN'), ('in', 'ADP'), ('their', 'PRON'), ('body', 'NOUN'), ('weight', 'NOUN'), (',', 'PUNCT'), ('on', 'ADP'), ('average', 'ADJ'), ('.', 'PUNCT'), ('Addiction', 'NOUN'), ('scientists', 'NOUN'), ('took', 'VERB'), ('an', 'DET'), ('interest', 'NOUN'), ('in', 'ADP'), ('GLP-1', 'PROPN'), ('agonists', 'NOUN'), ('after', 'SCONJ'), ('some', 'DET'), ('people', 'NOUN'), ('who', 'PRON'), ('were', 'AUX'), ('taking', 'VERB'), ('them', 'PRON'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('noted', 'VERB'), ('that', 'SCONJ'), ('in', 'ADP'), ('addition', 'NOUN'), ('to', 'ADP'), ('suppressing', 'VERB'), ('their', 'PRON'), ('appetite', 'NOUN'), (',', 'PUNCT'), ('the', 'DET'), ('medication', 'NOUN'), ('also', 'ADV'), ('seemed', 'VERB'), ('to', 'PART'), ('reduce', 'VERB'), ('their', 'PRON'), ('desire', 'NOUN'), ('to', 'PART'), ('drink', 'VERB'), ('alcohol', 'NOUN'), ('and/or', 'CCONJ'), ('smoke', 'NOUN'), ('.', 'PUNCT'), ('Though', 'SCONJ'), ('the', 'DET'), ('reasons', 'NOUN'), ('these', 'DET'), ('medicines', 'NOUN'), ('had', 'VERB'), ('this', 'DET'), ('effect', 'NOUN'), ('are', 'AUX'), ('not', 'PART'), ('yet', 'ADV'), ('well', 'ADV'), ('understood', 'VERB'), (',', 'PUNCT'), ('we', 'PRON'), ('can', 'AUX'), ('make', 'VERB'), ('some', 'DET'), ('assumptions', 'NOUN'), ('based', 'VERB'), ('on', 'ADP'), ('the', 'DET'), ('way', 'NOUN'), ('they', 'PRON'), ('work', 'VERB'), ('on', 'ADP'), ('appetite', 'NOUN'), ('.', 'PUNCT'), ('We', 'PRON'), ('know', 'VERB'), ('that', 'SCONJ'), ('GLP-1', 'PROPN'), ('reduces', 'VERB'), ('dopamine', 'NOUN'), ('(', 'PUNCT'), ('the', 'DET'), ('brain', 'NOUN'), ('’s', 'PART'), ('pleasure', 'NOUN'), ('chemical', 'NOUN'), (')', 'PUNCT'), ('.', 'PUNCT'), ('When', 'SCONJ'), ('a', 'DET'), ('person', 'NOUN'), ('has', 'VERB'), ('food', 'NOUN'), ('in', 'ADP'), ('front', 'NOUN'), ('of', 'ADP'), ('them', 'PRON'), ('that', 'SCONJ'), ('they', 'PRON'), ('normally', 'ADV'), ('really', 'ADV'), ('like', 'INTJ'), (',', 'PUNCT'), ('such', 'ADJ'), ('as', 'ADP'), ('a', 'DET'), ('piece', 'NOUN'), ('of', 'ADP'), ('cake', 'NOUN'), (',', 'PUNCT'), ('without', 'ADP'), ('the', 'DET'), ('usual', 'ADJ'), ('amount', 'NOUN'), ('of', 'ADP'), ('dopamine', 'NOUN'), ('released', 'VERB'), (',', 'PUNCT'), ('they', 'PRON'), ('wo', 'AUX'), ('n’t', 'PART'), ('feel', 'VERB'), ('as', 'ADP'), ('“', 'PUNCT'), ('excited', 'ADJ'), ('”', 'PUNCT'), ('in', 'ADP'), ('anticipation', 'NOUN'), ('of', 'ADP'), ('enjoying', 'VERB'), ('the', 'DET'), ('cake', 'NOUN'), ('.', 'PUNCT'), ('Without', 'ADP'), ('a', 'DET'), ('strong', 'ADJ'), ('urge', 'NOUN'), (',', 'PUNCT'), ('desire', 'NOUN'), (',', 'PUNCT'), ('or', 'CCONJ'), ('craving', 'VERB'), ('for', 'ADP'), ('the', 'DET'), ('cake', 'NOUN'), (',', 'PUNCT'), ('they', 'PRON'), ('become', 'VERB'), ('less', 'ADV'), ('likely', 'ADJ'), ('to', 'PART'), ('want', 'VERB'), ('it', 'PRON'), ('.', 'PUNCT'), ('If', 'SCONJ'), ('the', 'DET'), ('same', 'ADJ'), ('process', 'NOUN'), ('is', 'AUX'), ('happening', 'VERB'), ('in', 'ADP'), ('relation', 'NOUN'), ('to', 'ADP'), ('alcohol', 'NOUN'), ('and', 'CCONJ'), ('drugs', 'NOUN'), (',', 'PUNCT'), ('then', 'ADV'), ('GLP-1', 'PROPN'), ('agonists', 'NOUN'), ('may', 'AUX'), ('reduce', 'VERB'), ('the', 'DET'), ('desire', 'NOUN'), ('to', 'PART'), ('use', 'VERB'), ('them', 'PRON'), ('.', 'PUNCT'), ('Research', 'NOUN'), ('is', 'AUX'), ('currently', 'ADV'), ('in', 'ADP'), ('the', 'DET'), ('early', 'ADJ'), ('stages', 'NOUN'), ('.', 'PUNCT'), ('So', 'ADV'), ('far', 'ADV'), (',', 'PUNCT'), ('we', 'PRON'), ('’ve', 'AUX'), ('learned', 'VERB'), ('from', 'ADP'), ('preliminary', 'ADJ'), ('study', 'NOUN'), ('results', 'NOUN'), ('that', 'SCONJ'), ('those', 'PRON'), ('with', 'ADP'), ('obesity', 'NOUN'), ('or', 'CCONJ'), ('diabetes', 'NOUN'), ('who', 'PRON'), ('take', 'VERB'), ('GLP-1', 'PROPN'), ('agonist', 'NOUN'), ('medications', 'NOUN'), ('show', 'VERB'), ('reductions', 'NOUN'), ('in', 'ADP'), ('alcohol', 'NOUN'), ('and', 'CCONJ'), ('tobacco', 'NOUN'), ('consumption', 'NOUN'), ('.', 'PUNCT'), ('To', 'ADP'), ('date', 'NOUN'), (',', 'PUNCT'), ('there', 'PRON'), ('have', 'AUX'), ('been', 'AUX'), ('two', 'NUM'), ('randomized', 'VERB'), ('clinical', 'ADJ'), ('trials', 'NOUN'), ('(', 'PUNCT'), ('this', 'PRON'), ('is', 'AUX'), ('the', 'DET'), ('“', 'PUNCT'), ('gold', 'ADJ'), ('standard', 'NOUN'), ('”', 'PUNCT'), ('type', 'NOUN'), ('of', 'ADP'), ('research', 'NOUN'), ('study', 'NOUN'), ('for', 'ADP'), ('testing', 'VERB'), ('the', 'DET'), ('effectiveness', 'NOUN'), ('of', 'ADP'), ('a', 'DET'), ('drug', 'NOUN'), (')', 'PUNCT'), ('evaluating', 'VERB'), ('a', 'DET'), ('GLP-1', 'PROPN'), ('agonist', 'NOUN'), ('for', 'ADP'), ('treating', 'VERB'), ('alcohol', 'NOUN'), ('use', 'NOUN'), ('disorder', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('first', 'ADJ'), ('study', 'NOUN'), ('did', 'AUX'), ('not', 'PART'), ('find', 'VERB'), ('reductions', 'NOUN'), ('in', 'ADP'), ('heavy', 'ADJ'), ('alcohol', 'NOUN'), ('use', 'NOUN'), ('after', 'ADP'), ('26', 'NUM'), ('weeks', 'NOUN'), ('of', 'ADP'), ('medication', 'NOUN'), ('treatment', 'NOUN'), (',', 'PUNCT'), ('except', 'SCONJ'), ('among', 'ADP'), ('those', 'PRON'), ('who', 'PRON'), ('had', 'VERB'), ('both', 'CCONJ'), ('obesity', 'NOUN'), ('and', 'CCONJ'), ('an', 'DET'), ('alcohol', 'NOUN'), ('use', 'NOUN'), ('disorder', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('newest', 'ADJ'), ('study', 'NOUN'), ('published', 'VERB'), ('earlier', 'ADV'), ('this', 'DET'), ('month', 'NOUN'), ('found', 'VERB'), ('that', 'SCONJ'), ('among', 'ADP'), ('adults', 'NOUN'), ('with', 'ADP'), ('alcohol', 'NOUN'), ('use', 'NOUN'), ('disorders', 'NOUN'), (',', 'PUNCT'), ('weekly', 'ADJ'), ('low', 'ADJ'), ('-', 'PUNCT'), ('dose', 'NOUN'), ('semaglutide', 'NOUN'), ('given', 'VERB'), ('over', 'ADP'), ('9', 'NUM'), ('weeks', 'NOUN'), ('effectively', 'ADV'), ('reduced', 'VERB'), ('alcohol', 'NOUN'), ('cravings', 'NOUN'), ('and', 'CCONJ'), ('use', 'NOUN'), ('when', 'SCONJ'), ('compared', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('placebo', 'NOUN'), ('.', 'PUNCT'), ('Clinical', 'ADJ'), ('trials', 'NOUN'), ('evaluating', 'VERB'), ('these', 'DET'), ('medicines', 'NOUN'), ('for', 'ADP'), ('tobacco', 'NOUN'), ('cessation', 'NOUN'), ('have', 'AUX'), ('found', 'VERB'), ('mixed', 'ADJ'), ('results', 'NOUN'), (',', 'PUNCT'), ('with', 'ADP'), ('one', 'NUM'), ('showing', 'VERB'), ('positive', 'ADJ'), ('effects', 'NOUN'), ('of', 'ADP'), ('a', 'DET'), ('GLP', 'PROPN'), ('-', 'PUNCT'), ('agonist', 'NOUN'), ('(', 'PUNCT'), ('exenatide', 'ADV'), (')', 'PUNCT'), ('when', 'SCONJ'), ('taken', 'VERB'), ('in', 'ADP'), ('combination', 'NOUN'), ('with', 'ADP'), ('nicotine', 'NOUN'), ('replacement', 'NOUN'), ('therapy', 'NOUN'), ('and', 'CCONJ'), ('two', 'NUM'), ('trials', 'NOUN'), ('showing', 'VERB'), ('no', 'DET'), ('effects', 'NOUN'), ('.', 'PUNCT'), ('More', 'ADJ'), ('studies', 'NOUN'), ('are', 'AUX'), ('needed', 'VERB'), ('to', 'PART'), ('understand', 'VERB'), ('how', 'SCONJ'), ('well', 'ADV'), ('these', 'DET'), ('medicines', 'NOUN'), ('work', 'VERB'), ('to', 'PART'), ('reduce', 'VERB'), ('alcohol', 'NOUN'), ('and', 'CCONJ'), ('drug', 'NOUN'), ('use', 'NOUN'), (',', 'PUNCT'), ('for', 'ADP'), ('whom', 'PRON'), ('they', 'PRON'), ('work', 'VERB'), ('best', 'ADV'), (',', 'PUNCT'), ('and', 'CCONJ'), ('at', 'ADP'), ('what', 'PRON'), ('doses', 'NOUN'), ('.', 'PUNCT'), ('Though', 'SCONJ'), ('more', 'ADJ'), ('research', 'NOUN'), ('is', 'AUX'), ('needed', 'VERB'), (',', 'PUNCT'), ('the', 'DET'), ('promise', 'NOUN'), ('of', 'ADP'), ('these', 'DET'), ('medicines', 'NOUN'), ('is', 'AUX'), ('important', 'ADJ'), ('for', 'ADP'), ('two', 'NUM'), ('reasons', 'NOUN'), (':', 'PUNCT'), ('1', 'X'), ('.', 'PUNCT'), ('Since', 'SCONJ'), ('GLP-1', 'PROPN'), ('agonists', 'NOUN'), ('act', 'VERB'), ('on', 'ADP'), ('brain', 'NOUN'), ('circuits', 'NOUN'), ('that', 'PRON'), ('are', 'AUX'), ('generally', 'ADV'), ('tied', 'VERB'), ('to', 'PART'), ('reward', 'VERB'), ('and', 'CCONJ'), ('pleasure', 'NOUN'), (',', 'PUNCT'), ('both', 'PRON'), ('from', 'ADP'), ('food', 'NOUN'), ('and', 'CCONJ'), ('drugs', 'NOUN'), (',', 'PUNCT'), ('it', 'PRON'), ('is', 'AUX'), ('possible', 'ADJ'), ('that', 'SCONJ'), ('these', 'DET'), ('medicines', 'NOUN'), ('may', 'AUX'), ('be', 'AUX'), ('therapeutic', 'ADJ'), ('for', 'ADP'), ('individuals', 'NOUN'), ('who', 'PRON'), ('are', 'AUX'), ('addicted', 'ADJ'), ('to', 'ADP'), ('more', 'ADJ'), ('than', 'ADP'), ('one', 'NUM'), ('type', 'NOUN'), ('of', 'ADP'), ('substance', 'NOUN'), ('(', 'PUNCT'), ('i.e.', 'X'), (',', 'PUNCT'), ('polysubstance', 'NOUN'), ('use', 'NOUN'), ('or', 'CCONJ'), ('addiction', 'NOUN'), (')', 'PUNCT'), ('.', 'PUNCT'), ('Currently', 'ADV'), (',', 'PUNCT'), ('all', 'DET'), ('the', 'DET'), ('FDA', 'PROPN'), ('-', 'PUNCT'), ('approved', 'VERB'), ('medicines', 'NOUN'), ('for', 'ADP'), ('addictions', 'NOUN'), ('are', 'AUX'), ('for', 'ADP'), ('a', 'DET'), ('specific', 'ADJ'), ('type', 'NOUN'), ('of', 'ADP'), ('substance', 'NOUN'), ('use', 'NOUN'), ('disorder', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('we', 'PRON'), ('do', 'AUX'), ('n’t', 'PART'), ('have', 'VERB'), ('any', 'DET'), ('such', 'ADJ'), ('options', 'NOUN'), ('for', 'ADP'), ('addictions', 'NOUN'), ('to', 'ADP'), ('multiple', 'ADJ'), ('substances', 'NOUN'), ('.', 'PUNCT'), ('2', 'X'), ('.', 'X'), ('The', 'DET'), ('stigma', 'NOUN'), ('around', 'ADP'), ('addiction', 'NOUN'), ('as', 'ADP'), ('a', 'DET'), ('reflection', 'NOUN'), ('of', 'ADP'), ('poor', 'ADJ'), ('choices', 'NOUN'), ('or', 'CCONJ'), ('flawed', 'ADJ'), ('morals', 'NOUN'), ('remains', 'VERB'), ('in', 'ADP'), ('our', 'PRON'), ('society', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('promise', 'NOUN'), ('of', 'ADP'), ('widely', 'ADV'), ('used', 'VERB'), ('and', 'CCONJ'), ('known', 'ADJ'), ('medications', 'NOUN'), ('such', 'ADJ'), ('as', 'ADP'), ('Ozempic', 'PROPN'), ('as', 'ADP'), ('potential', 'ADJ'), ('treatment', 'NOUN'), ('options', 'NOUN'), ('to', 'PART'), ('help', 'VERB'), ('people', 'NOUN'), ('change', 'VERB'), ('their', 'PRON'), ('use', 'NOUN'), ('of', 'ADP'), ('alcohol', 'NOUN'), ('and', 'CCONJ'), ('drugs', 'NOUN'), ('can', 'AUX'), ('help', 'VERB'), ('shift', 'VERB'), ('the', 'DET'), ('conversation', 'NOUN'), ('about', 'ADP'), ('addiction', 'NOUN'), ('as', 'ADP'), ('an', 'DET'), ('illness', 'NOUN'), ('.', 'PUNCT'), ('This', 'PRON'), ('is', 'AUX'), ('an', 'DET'), ('essential', 'ADJ'), ('step', 'NOUN'), ('towards', 'ADP'), ('helping', 'VERB'), ('people', 'NOUN'), ('access', 'VERB'), ('much', 'ADV'), ('-', 'PUNCT'), ('needed', 'VERB'), ('treatments', 'NOUN'), ('for', 'ADP'), ('this', 'DET'), ('condition', 'NOUN'), ('without', 'ADP'), ('shame', 'NOUN'), ('and', 'CCONJ'), ('stigma', 'NOUN'), ('as', 'ADP'), ('barriers', 'NOUN'), ('.', 'PUNCT'), ('Based', 'VERB'), ('on', 'ADP'), ('what', 'PRON'), ('is', 'AUX'), ('currently', 'ADV'), ('known', 'VERB'), ('about', 'ADP'), ('GLP-1', 'PROPN'), ('agonist', 'NOUN'), ('medications', 'NOUN'), ('for', 'ADP'), ('addiction', 'NOUN'), (':', 'PUNCT'), ('1', 'X'), ('.', 'PUNCT'), ('Some', 'DET'), ('treatment', 'NOUN'), ('providers', 'NOUN'), ('may', 'AUX'), ('opt', 'VERB'), ('to', 'PART'), ('prescribe', 'VERB'), ('them', 'PRON'), ('“', 'PUNCT'), ('off', 'ADP'), ('-', 'PUNCT'), ('label', 'NOUN'), ('”', 'PUNCT'), ('to', 'PART'), ('help', 'VERB'), ('someone', 'PRON'), ('overcome', 'VERB'), ('the', 'DET'), ('addiction', 'NOUN'), ('.', 'PUNCT'), ('Here', 'ADV'), ('’s', 'PUNCT'), ('what', 'PRON'), ('this', 'PRON'), ('means', 'VERB'), (':', 'PUNCT'), ('Though', 'SCONJ'), ('not', 'PART'), ('FDA', 'PROPN'), ('-', 'PUNCT'), ('approved', 'VERB'), ('for', 'ADP'), ('this', 'DET'), ('indication', 'NOUN'), (',', 'PUNCT'), ('some', 'DET'), ('prescribing', 'VERB'), ('healthcare', 'NOUN'), ('providers', 'NOUN'), ('may', 'AUX'), ('feel', 'VERB'), ('that', 'SCONJ'), ('the', 'DET'), ('research', 'NOUN'), ('to', 'ADP'), ('date', 'NOUN'), ('is', 'AUX'), ('compelling', 'ADJ'), ('enough', 'ADV'), ('to', 'PART'), ('warrant', 'VERB'), ('the', 'DET'), ('use', 'NOUN'), ('of', 'ADP'), ('these', 'DET'), ('medications', 'NOUN'), ('to', 'PART'), ('treat', 'VERB'), ('addictions', 'NOUN'), ('.', 'PUNCT'), ('Off', 'ADJ'), ('-', 'PUNCT'), ('label', 'NOUN'), ('prescribing', 'NOUN'), ('is', 'AUX'), ('not', 'PART'), ('at', 'ADV'), ('all', 'ADV'), ('an', 'DET'), ('uncommon', 'ADJ'), ('practice', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('prescriber', 'NOUN'), ('relies', 'VERB'), ('on', 'ADP'), ('their', 'PRON'), ('clinical', 'ADJ'), ('judgment', 'NOUN'), (',', 'PUNCT'), ('in', 'ADP'), ('conjunction', 'NOUN'), ('with', 'ADP'), ('the', 'DET'), ('patient', 'NOUN'), ('’s', 'PART'), ('willingness', 'NOUN'), ('to', 'PART'), ('take', 'VERB'), ('a', 'DET'), ('medicine', 'NOUN'), ('that', 'PRON'), ('is', 'AUX'), ('not', 'PART'), ('FDA', 'PROPN'), ('-', 'PUNCT'), ('approved', 'VERB'), ('for', 'ADP'), ('the', 'DET'), ('condition', 'NOUN'), ('it', 'PRON'), ('’s', 'AUX'), ('being', 'AUX'), ('prescribed', 'VERB'), ('for', 'ADP'), (',', 'PUNCT'), ('with', 'ADP'), ('a', 'DET'), ('good', 'ADJ'), ('understanding', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('potential', 'ADJ'), ('risks', 'NOUN'), ('and', 'CCONJ'), ('benefits', 'NOUN'), ('of', 'ADP'), ('doing', 'VERB'), ('so', 'ADV'), ('.', 'PUNCT'), ('2', 'X'), ('.', 'X'), ('Research', 'NOUN'), ('is', 'AUX'), ('in', 'ADP'), ('the', 'DET'), ('early', 'ADJ'), ('stages', 'NOUN'), ('.', 'PUNCT'), ('It', 'PRON'), ('is', 'AUX'), ('important', 'ADJ'), ('to', 'PART'), ('be', 'AUX'), ('aware', 'ADJ'), ('of', 'ADP'), ('the', 'DET'), ('stage', 'NOUN'), ('of', 'ADP'), ('research', 'NOUN'), ('we', 'PRON'), ('’re', 'VERB'), ('currently', 'ADV'), ('in', 'ADV'), ('with', 'ADP'), ('GLP-1', 'PROPN'), ('agonists', 'NOUN'), ('for', 'ADP'), ('addiction', 'NOUN'), ('.', 'PUNCT'), ('With', 'ADP'), ('support', 'NOUN'), ('for', 'ADP'), ('accelerated', 'ADJ'), ('research', 'NOUN'), ('currently', 'ADV'), ('in', 'ADP'), ('place', 'NOUN'), ('from', 'ADP'), ('the', 'DET'), ('National', 'PROPN'), ('Institutes', 'PROPN'), ('of', 'ADP'), ('Health', 'PROPN'), (',', 'PUNCT'), ('we', 'PRON'), ('are', 'AUX'), ('positioned', 'VERB'), ('to', 'PART'), ('have', 'VERB'), ('scientifically', 'ADV'), ('based', 'VERB'), ('guidance', 'NOUN'), ('on', 'ADP'), ('their', 'PRON'), ('use', 'NOUN'), ('for', 'ADP'), ('addiction', 'NOUN'), ('treatment', 'NOUN'), ('a', 'DET'), ('few', 'ADJ'), ('years', 'NOUN'), ('from', 'ADP'), ('now', 'ADV'), ('.', 'PUNCT'), ('In', 'ADP'), ('the', 'DET'), ('meantime', 'NOUN'), (',', 'PUNCT'), ('we', 'PRON'), ('know', 'VERB'), ('that', 'SCONJ'), ('these', 'DET'), ('medicines', 'NOUN'), ('have', 'AUX'), ('promise', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('we', 'PRON'), ('have', 'VERB'), ('a', 'DET'), ('limited', 'ADJ'), ('understanding', 'NOUN'), ('of', 'ADP'), ('their', 'PRON'), ('safety', 'NOUN'), (',', 'PUNCT'), ('effectiveness', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('ideal', 'ADJ'), ('dosing', 'NOUN'), ('for', 'ADP'), ('individuals', 'NOUN'), ('with', 'ADP'), ('substance', 'NOUN'), ('use', 'NOUN'), ('disorders', 'NOUN'), ('before', 'SCONJ'), ('more', 'ADV'), ('randomized', 'ADJ'), ('clinical', 'ADJ'), ('trials', 'NOUN'), ('are', 'AUX'), ('conducted', 'VERB'), ('.', 'PUNCT'), ('More', 'ADJ'), ('FDA', 'PROPN'), ('-', 'PUNCT'), ('approved', 'VERB'), ('and', 'CCONJ'), ('unapproved', 'ADJ'), ('(', 'PUNCT'), ('but', 'CCONJ'), ('promising', 'ADJ'), (')', 'PUNCT'), ('medication', 'NOUN'), ('treatments', 'NOUN'), ('to', 'PART'), ('address', 'VERB'), ('substance', 'NOUN'), ('misuse', 'NOUN'), ('and', 'CCONJ'), ('addiction', 'NOUN'), ('are', 'AUX'), ('covered', 'VERB'), ('in', 'ADP'), ('greater', 'ADJ'), ('depth', 'NOUN'), ('in', 'ADP'), ('my', 'PRON'), ('recently', 'ADV'), ('released', 'VERB'), ('book', 'NOUN'), (',', 'PUNCT'), ('Addiction', 'NOUN'), (':', 'PUNCT'), ('What', 'PRON'), ('Everyone', 'PRON'), ('Needs', 'VERB'), ('to', 'PART'), ('Know', 'VERB'), ('.', 'PUNCT')]","[('Sills GLP-1', 'LOC'), ('Ozempic', 'ORG'), ('Ozempic', 'GPE'), ('one', 'CARDINAL'), ('first', 'ORDINAL'), ('GLP-1', 'ORG'), ('GLP-1', 'PERSON'), ('1', 'CARDINAL'), ('Ozempic', 'ORG'), ('Wegovy', 'PERSON'), ('15 percent', 'PERCENT'), ('GLP-1', 'ORG'), ('GLP-1', 'ORG'), ('GLP-1', 'ORG'), ('GLP-1', 'PERSON'), ('two', 'CARDINAL'), ('GLP-1', 'ORG'), ('first', 'ORDINAL'), ('26 weeks', 'DATE'), ('earlier this month', 'DATE'), ('weekly', 'DATE'), ('9 weeks', 'DATE'), ('GLP', 'ORG'), ('two', 'CARDINAL'), ('two', 'CARDINAL'), ('1', 'CARDINAL'), ('GLP-1', 'PERSON'), ('more than one', 'CARDINAL'), ('FDA', 'ORG'), ('2.', 'CARDINAL'), ('Ozempic', 'ORG'), ('GLP-1', 'ORG'), ('1', 'CARDINAL'), ('FDA', 'ORG'), ('FDA', 'ORG'), ('2', 'CARDINAL'), ('GLP-1', 'ORG'), ('the National Institutes of Health', 'ORG'), ('a few years from now', 'DATE'), ('FDA', 'ORG')]","['Sills GLP-1', 'Ozempic', 'Ozempic', 'one', 'first', 'GLP-1', 'GLP-1', '1', 'Ozempic', 'Wegovy', '15 percent', 'GLP-1', 'GLP-1', 'GLP-1', 'GLP-1', 'two', 'GLP-1', 'first', '26 weeks', 'earlier this month', 'weekly', '9 weeks', 'GLP', 'two', 'two', '1', 'GLP-1', 'more than one', 'FDA', '2.', 'Ozempic', 'GLP-1', '1', 'FDA', 'FDA', '2', 'GLP-1', 'the National Institutes of Health', 'a few years from now', 'FDA']","['Sills GLP-1', 'Ozempic', 'Ozempic', 'One', 'first', 'GLP-1', 'GLP-1', '1', 'Ozempic', 'Wegovy', '15 percent', 'GLP-1', 'GLP-1', 'GLP-1', 'GLP-1', 'two', 'GLP-1', 'first', '26 weeks', 'earlier this month', 'weekly', '9 weeks', 'GLP', 'two', 'two', '1', 'GLP-1', 'more than one', 'FDA', '2', 'Ozempic', 'GLP-1', '1', 'FDA', 'FDA', '2', 'GLP-1', 'the National Institutes of Health', 'a few years from now', 'FDA']"
Hims & Hers shares fall after FDA says semaglutide no longer in shortage,https://www.cnbc.com/2025/02/21/hims-hers-shares-fall-after-fda-says-semaglutide-no-longer-in-shortage.html,"      Global Business and Financial News, Stock Quotes, and Market Data       and Analysis. Data also provided by","[('      ', 'SPACE'), ('Global', 'PROPN'), ('Business', 'PROPN'), ('and', 'CCONJ'), ('Financial', 'PROPN'), ('News', 'PROPN'), (',', 'PUNCT'), ('Stock', 'PROPN'), ('Quotes', 'PROPN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('Market', 'PROPN'), ('Data', 'PROPN'), ('      ', 'SPACE'), ('and', 'CCONJ'), ('Analysis', 'NOUN'), ('.', 'PUNCT'), ('Data', 'NOUN'), ('also', 'ADV'), ('provided', 'VERB'), ('by', 'ADP')]","[('Global Business and Financial News', 'ORG'), ('Market Data       and', 'ORG'), ('Analysis', 'ORG')]","['Global Business and Financial News', 'Market Data       and', 'Analysis']","['Global Business and Financial News', 'Market Data       and', 'Analysis']"
The weight-loss drugs being tested in 2025: will they beat Ozempic?,https://www.nature.com/articles/d41586-025-00376-w,"You can also search for this author in PubMed  Google Scholar An ongoing trial of Zepbound (tirzepatide) is testing effects on heart disease in people with obesity and diabetes.Credit: Shelby Knowles/Bloomberg via Getty As appetite for blockbuster weight-loss drugs grows worldwide, scientists are developing the next crop of medications that, they hope, will improve the performance of these drugs and offer benefits beyond weight loss. “It’s going to be another year where, every week, there’s going to be something really cool,” says Daniel Drucker, an endocrinologist at the University of Toronto in Canada. New obesity definition sidelines BMI to focus on health New obesity definition sidelines BMI to focus on health Drug makers are building on the success of medications such as Ozempic and Wegovy, which contain the active ingredient semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. These drugs mimic the hormone GLP-1, helping to regulate blood-sugar levels and appetite. But most of these medications are costly, require weekly injections and need to be taken long-term to prevent weight regain. These are some of the issues that companies hope alternative drugs will address. Nature looks at the weight-loss medicines being tested in 2025 and what they have to offer. Tirzepatide — sold as Mounjaro and Zepbound and given by injection — mimics GLP-1 and another hormone called gastric inhibitory polypeptide (GIP), which is involved in fat metabolism. In trial results published in November, it helped participants to lose up to 20% of their body weight over 72 weeks and reduced the risk of diabetes, compared with a placebo. People taking semaglutide for 68 weeks lose up to 15% of their body weight. Participants who took tirzepatide also had a beneficial reduction in heart weight and in fat surrounding the heart, improved mobility and lower blood pressure and inflammation compared with people on a placebo. One trial expected to conclude in 2025 is examining tirzepatide’s effects on heart disease in people with obesity and diabetes. Retatrutide, which has not yet received regulatory approval for weight loss, activates receptors for GLP-1, GIP and glucagon, a hormone that regulates blood sugar levels. Developed by Eli Lilly in Indianapolis, Indiana, it has shown even more promising results than tirzepatide and semaglutide, with trial participants losing an average of 24% of their body weight over 11 months. The drug also helped to reduce blood-sugar levels in people with diabetes, and it’s now being tested in phase III trials that are expected to conclude by 2026. Anti-obesity drug has life-changing benefits for arthritis Anti-obesity drug has life-changing benefits for arthritis Researchers are excited about combination therapies such as retatrutide, says Beverly Tchang, an endocrinologist at Weill Cornell Medicine in New York City, who notes that obesity’s complexity makes targeting multiple pathways the most promising approach. Orforglipron, an oral small-molecule drug candidate also developed by Eli Lilly, showed similar results to GLP-1 injections in rodents, and led to a weight loss of about 10% over 26 weeks in people with obesity, improving blood pressure and levels of circulating fatty molecules. Like Ozempic, orforglipron is a GLP-1 receptor agonist, but whereas Ozempic requires injection, orforglipron comes as a daily pill. Lilly expects to complete phase III trials in 2025, and orforglipron could receive US regulatory approval in 2026, according to Lilly’s chief executive Dave Ricks. “The wild card is the oral small molecules,” says Randy Seeley, an obesity specialist at the University of Michigan Medical School in Ann Arbor. Many companies are working on this approach, because pills might be more appealing and cost-effective than injections, but progress has been slower than expected owing to dosing challenges, he says. “If one of them finally breaks through, it has the ability to alter the landscape pretty considerably.” Biopharmaceutical company Amgen in Thousand Oaks, California, is planning a phase III trial of its drug candidate MariTide, which activates GLP-1 receptors while reducing GIP’s activity. The medication can be taken monthly by injection and resulted in an average weight loss of up to 20% over 52 weeks, according to data released by the company. Unlike other treatments, MariTide has shown the ability to maintain weight loss for several months after the last dose. When people stop taking semaglutide or tirzepatide, they tend to regain weight quickly, but that doesn’t seem to happen with MariTide, which might encourage more people to have the treatment, says Seeley, who consults for and receives funding from Amgen and other companies developing obesity drugs. or Nature 638, 591-592 (2025) doi: https://doi.org/10.1038/d41586-025-00376-w Reprints and permissions Dozens of new obesity drugs are coming: these are the ones to watch News Feature 12 FEB 25 A comprehensive spatio-cellular map of the human hypothalamus Article 05 FEB 25 Obesity drugs: huge study identifies new health risks News 20 JAN 25 Rare genetic disorder treated in womb for the first time News 20 FEB 25 Plasmodium blood stage development requires the chromatin remodeller Snf2L Article 19 FEB 25 Human-correlated genetic models identify precision therapy for liver cancer Article 19 FEB 25 The School of Science and Engineering (SSE) at The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen) sincerely invites applications for mul... Shenzhen, China The Chinese University of Hong Kong, Shenzhen (CUHK Shenzhen) The School of Science and Engineering (SSE) at The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen) sincerely invites applications for mul... Shenzhen, China The Chinese University of Hong Kong, Shenzhen (CUHK Shenzhen) We seek outstanding applicants for full-time tenure-track/tenured faculty positions. Positions are available for both junior and senior-level. Shenzhen, Guangdong, China Southern University of Science and Technology (Biomedical Engineering) Qiushi Chair Professor; Qiushi Distinguished Scholar; ZJU 100 Young Researcher; Distinguished researcher No. 3, Qingchun East Road, Hangzhou, Zhejiang (CN) Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine SLS invites applications for multiple tenure-track/tenured faculty positions at all academic ranks. Hangzhou, Zhejiang, China School of Life Sciences, Westlake University","[('You', 'PRON'), ('can', 'AUX'), ('also', 'ADV'), ('search', 'VERB'), ('for', 'ADP'), ('this', 'DET'), ('author', 'NOUN'), ('in', 'ADP'), ('PubMed', 'PROPN'), ('\xa0', 'SPACE'), ('Google', 'PROPN'), ('Scholar', 'PROPN'), ('An', 'DET'), ('ongoing', 'ADJ'), ('trial', 'NOUN'), ('of', 'ADP'), ('Zepbound', 'PROPN'), ('(', 'PUNCT'), ('tirzepatide', 'NOUN'), (')', 'PUNCT'), ('is', 'AUX'), ('testing', 'VERB'), ('effects', 'NOUN'), ('on', 'ADP'), ('heart', 'NOUN'), ('disease', 'NOUN'), ('in', 'ADP'), ('people', 'NOUN'), ('with', 'ADP'), ('obesity', 'NOUN'), ('and', 'CCONJ'), ('diabetes', 'NOUN'), ('.', 'PUNCT'), ('Credit', 'NOUN'), (':', 'PUNCT'), ('Shelby', 'PROPN'), ('Knowles', 'PROPN'), ('/', 'SYM'), ('Bloomberg', 'PROPN'), ('via', 'ADP'), ('Getty', 'PROPN'), ('As', 'SCONJ'), ('appetite', 'NOUN'), ('for', 'ADP'), ('blockbuster', 'ADJ'), ('weight', 'NOUN'), ('-', 'PUNCT'), ('loss', 'NOUN'), ('drugs', 'NOUN'), ('grows', 'VERB'), ('worldwide', 'ADV'), (',', 'PUNCT'), ('scientists', 'NOUN'), ('are', 'AUX'), ('developing', 'VERB'), ('the', 'DET'), ('next', 'ADJ'), ('crop', 'NOUN'), ('of', 'ADP'), ('medications', 'NOUN'), ('that', 'PRON'), (',', 'PUNCT'), ('they', 'PRON'), ('hope', 'VERB'), (',', 'PUNCT'), ('will', 'AUX'), ('improve', 'VERB'), ('the', 'DET'), ('performance', 'NOUN'), ('of', 'ADP'), ('these', 'DET'), ('drugs', 'NOUN'), ('and', 'CCONJ'), ('offer', 'VERB'), ('benefits', 'NOUN'), ('beyond', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('It', 'PRON'), ('’s', 'AUX'), ('going', 'VERB'), ('to', 'PART'), ('be', 'AUX'), ('another', 'DET'), ('year', 'NOUN'), ('where', 'SCONJ'), (',', 'PUNCT'), ('every', 'DET'), ('week', 'NOUN'), (',', 'PUNCT'), ('there', 'PRON'), ('’s', 'AUX'), ('going', 'VERB'), ('to', 'PART'), ('be', 'AUX'), ('something', 'PRON'), ('really', 'ADV'), ('cool', 'ADJ'), (',', 'PUNCT'), ('”', 'PUNCT'), ('says', 'VERB'), ('Daniel', 'PROPN'), ('Drucker', 'PROPN'), (',', 'PUNCT'), ('an', 'DET'), ('endocrinologist', 'NOUN'), ('at', 'ADP'), ('the', 'DET'), ('University', 'PROPN'), ('of', 'ADP'), ('Toronto', 'PROPN'), ('in', 'ADP'), ('Canada', 'PROPN'), ('.', 'PUNCT'), ('New', 'ADJ'), ('obesity', 'NOUN'), ('definition', 'NOUN'), ('sidelines', 'VERB'), ('BMI', 'PROPN'), ('to', 'PART'), ('focus', 'VERB'), ('on', 'ADP'), ('health', 'NOUN'), ('New', 'ADJ'), ('obesity', 'NOUN'), ('definition', 'NOUN'), ('sidelines', 'VERB'), ('BMI', 'PROPN'), ('to', 'PART'), ('focus', 'VERB'), ('on', 'ADP'), ('health', 'NOUN'), ('Drug', 'NOUN'), ('makers', 'NOUN'), ('are', 'AUX'), ('building', 'VERB'), ('on', 'ADP'), ('the', 'DET'), ('success', 'NOUN'), ('of', 'ADP'), ('medications', 'NOUN'), ('such', 'ADJ'), ('as', 'ADP'), ('Ozempic', 'PROPN'), ('and', 'CCONJ'), ('Wegovy', 'PROPN'), (',', 'PUNCT'), ('which', 'PRON'), ('contain', 'VERB'), ('the', 'DET'), ('active', 'ADJ'), ('ingredient', 'NOUN'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('a', 'DET'), ('glucagon', 'NOUN'), ('-', 'PUNCT'), ('like', 'ADJ'), ('peptide-1', 'PROPN'), ('(', 'PUNCT'), ('GLP-1', 'PROPN'), (')', 'PUNCT'), ('receptor', 'NOUN'), ('agonist', 'NOUN'), ('.', 'PUNCT'), ('These', 'DET'), ('drugs', 'NOUN'), ('mimic', 'VERB'), ('the', 'DET'), ('hormone', 'NOUN'), ('GLP-1', 'PROPN'), (',', 'PUNCT'), ('helping', 'VERB'), ('to', 'PART'), ('regulate', 'VERB'), ('blood', 'NOUN'), ('-', 'PUNCT'), ('sugar', 'NOUN'), ('levels', 'NOUN'), ('and', 'CCONJ'), ('appetite', 'NOUN'), ('.', 'PUNCT'), ('But', 'CCONJ'), ('most', 'ADJ'), ('of', 'ADP'), ('these', 'DET'), ('medications', 'NOUN'), ('are', 'AUX'), ('costly', 'ADJ'), (',', 'PUNCT'), ('require', 'VERB'), ('weekly', 'ADJ'), ('injections', 'NOUN'), ('and', 'CCONJ'), ('need', 'VERB'), ('to', 'PART'), ('be', 'AUX'), ('taken', 'VERB'), ('long', 'ADJ'), ('-', 'PUNCT'), ('term', 'NOUN'), ('to', 'PART'), ('prevent', 'VERB'), ('weight', 'NOUN'), ('regain', 'NOUN'), ('.', 'PUNCT'), ('These', 'PRON'), ('are', 'AUX'), ('some', 'PRON'), ('of', 'ADP'), ('the', 'DET'), ('issues', 'NOUN'), ('that', 'PRON'), ('companies', 'NOUN'), ('hope', 'VERB'), ('alternative', 'ADJ'), ('drugs', 'NOUN'), ('will', 'AUX'), ('address', 'VERB'), ('.', 'PUNCT'), ('Nature', 'NOUN'), ('looks', 'VERB'), ('at', 'ADP'), ('the', 'DET'), ('weight', 'NOUN'), ('-', 'PUNCT'), ('loss', 'NOUN'), ('medicines', 'NOUN'), ('being', 'AUX'), ('tested', 'VERB'), ('in', 'ADP'), ('2025', 'NUM'), ('and', 'CCONJ'), ('what', 'PRON'), ('they', 'PRON'), ('have', 'VERB'), ('to', 'PART'), ('offer', 'VERB'), ('.', 'PUNCT'), ('Tirzepatide', 'NOUN'), ('—', 'PUNCT'), ('sold', 'VERB'), ('as', 'ADP'), ('Mounjaro', 'PROPN'), ('and', 'CCONJ'), ('Zepbound', 'PROPN'), ('and', 'CCONJ'), ('given', 'VERB'), ('by', 'ADP'), ('injection', 'NOUN'), ('—', 'PUNCT'), ('mimics', 'NOUN'), ('GLP-1', 'PROPN'), ('and', 'CCONJ'), ('another', 'DET'), ('hormone', 'NOUN'), ('called', 'VERB'), ('gastric', 'ADJ'), ('inhibitory', 'PROPN'), ('polypeptide', 'PROPN'), ('(', 'PUNCT'), ('GIP', 'PROPN'), (')', 'PUNCT'), (',', 'PUNCT'), ('which', 'PRON'), ('is', 'AUX'), ('involved', 'VERB'), ('in', 'ADP'), ('fat', 'ADJ'), ('metabolism', 'NOUN'), ('.', 'PUNCT'), ('In', 'ADP'), ('trial', 'NOUN'), ('results', 'NOUN'), ('published', 'VERB'), ('in', 'ADP'), ('November', 'PROPN'), (',', 'PUNCT'), ('it', 'PRON'), ('helped', 'VERB'), ('participants', 'NOUN'), ('to', 'PART'), ('lose', 'VERB'), ('up', 'ADP'), ('to', 'PART'), ('20', 'NUM'), ('%', 'NOUN'), ('of', 'ADP'), ('their', 'PRON'), ('body', 'NOUN'), ('weight', 'NOUN'), ('over', 'ADP'), ('72', 'NUM'), ('weeks', 'NOUN'), ('and', 'CCONJ'), ('reduced', 'VERB'), ('the', 'DET'), ('risk', 'NOUN'), ('of', 'ADP'), ('diabetes', 'NOUN'), (',', 'PUNCT'), ('compared', 'VERB'), ('with', 'ADP'), ('a', 'DET'), ('placebo', 'NOUN'), ('.', 'PUNCT'), ('People', 'NOUN'), ('taking', 'VERB'), ('semaglutide', 'NOUN'), ('for', 'ADP'), ('68', 'NUM'), ('weeks', 'NOUN'), ('lose', 'VERB'), ('up', 'ADP'), ('to', 'PART'), ('15', 'NUM'), ('%', 'NOUN'), ('of', 'ADP'), ('their', 'PRON'), ('body', 'NOUN'), ('weight', 'NOUN'), ('.', 'PUNCT'), ('Participants', 'NOUN'), ('who', 'PRON'), ('took', 'VERB'), ('tirzepatide', 'NOUN'), ('also', 'ADV'), ('had', 'VERB'), ('a', 'DET'), ('beneficial', 'ADJ'), ('reduction', 'NOUN'), ('in', 'ADP'), ('heart', 'NOUN'), ('weight', 'NOUN'), ('and', 'CCONJ'), ('in', 'ADP'), ('fat', 'NOUN'), ('surrounding', 'VERB'), ('the', 'DET'), ('heart', 'NOUN'), (',', 'PUNCT'), ('improved', 'VERB'), ('mobility', 'NOUN'), ('and', 'CCONJ'), ('lower', 'ADJ'), ('blood', 'NOUN'), ('pressure', 'NOUN'), ('and', 'CCONJ'), ('inflammation', 'NOUN'), ('compared', 'VERB'), ('with', 'ADP'), ('people', 'NOUN'), ('on', 'ADP'), ('a', 'DET'), ('placebo', 'NOUN'), ('.', 'PUNCT'), ('One', 'NUM'), ('trial', 'NOUN'), ('expected', 'VERB'), ('to', 'PART'), ('conclude', 'VERB'), ('in', 'ADP'), ('2025', 'NUM'), ('is', 'AUX'), ('examining', 'VERB'), ('tirzepatide', 'NOUN'), ('’s', 'PART'), ('effects', 'NOUN'), ('on', 'ADP'), ('heart', 'NOUN'), ('disease', 'NOUN'), ('in', 'ADP'), ('people', 'NOUN'), ('with', 'ADP'), ('obesity', 'NOUN'), ('and', 'CCONJ'), ('diabetes', 'NOUN'), ('.', 'PUNCT'), ('Retatrutide', 'PROPN'), (',', 'PUNCT'), ('which', 'PRON'), ('has', 'AUX'), ('not', 'PART'), ('yet', 'ADV'), ('received', 'VERB'), ('regulatory', 'ADJ'), ('approval', 'NOUN'), ('for', 'ADP'), ('weight', 'NOUN'), ('loss', 'NOUN'), (',', 'PUNCT'), ('activates', 'VERB'), ('receptors', 'NOUN'), ('for', 'ADP'), ('GLP-1', 'PROPN'), (',', 'PUNCT'), ('GIP', 'PROPN'), ('and', 'CCONJ'), ('glucagon', 'PROPN'), (',', 'PUNCT'), ('a', 'DET'), ('hormone', 'NOUN'), ('that', 'PRON'), ('regulates', 'VERB'), ('blood', 'NOUN'), ('sugar', 'NOUN'), ('levels', 'NOUN'), ('.', 'PUNCT'), ('Developed', 'VERB'), ('by', 'ADP'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), ('in', 'ADP'), ('Indianapolis', 'PROPN'), (',', 'PUNCT'), ('Indiana', 'PROPN'), (',', 'PUNCT'), ('it', 'PRON'), ('has', 'AUX'), ('shown', 'VERB'), ('even', 'ADV'), ('more', 'ADV'), ('promising', 'ADJ'), ('results', 'NOUN'), ('than', 'ADP'), ('tirzepatide', 'NOUN'), ('and', 'CCONJ'), ('semaglutide', 'NOUN'), (',', 'PUNCT'), ('with', 'ADP'), ('trial', 'NOUN'), ('participants', 'NOUN'), ('losing', 'VERB'), ('an', 'DET'), ('average', 'NOUN'), ('of', 'ADP'), ('24', 'NUM'), ('%', 'NOUN'), ('of', 'ADP'), ('their', 'PRON'), ('body', 'NOUN'), ('weight', 'NOUN'), ('over', 'ADP'), ('11', 'NUM'), ('months', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('drug', 'NOUN'), ('also', 'ADV'), ('helped', 'VERB'), ('to', 'PART'), ('reduce', 'VERB'), ('blood', 'NOUN'), ('-', 'PUNCT'), ('sugar', 'NOUN'), ('levels', 'NOUN'), ('in', 'ADP'), ('people', 'NOUN'), ('with', 'ADP'), ('diabetes', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('it', 'PRON'), ('’s', 'AUX'), ('now', 'ADV'), ('being', 'AUX'), ('tested', 'VERB'), ('in', 'ADP'), ('phase', 'NOUN'), ('III', 'PROPN'), ('trials', 'NOUN'), ('that', 'PRON'), ('are', 'AUX'), ('expected', 'VERB'), ('to', 'PART'), ('conclude', 'VERB'), ('by', 'ADP'), ('2026', 'NUM'), ('.', 'PUNCT'), ('Anti', 'ADJ'), ('-', 'ADJ'), ('obesity', 'ADJ'), ('drug', 'NOUN'), ('has', 'VERB'), ('life', 'NOUN'), ('-', 'PUNCT'), ('changing', 'VERB'), ('benefits', 'NOUN'), ('for', 'ADP'), ('arthritis', 'NOUN'), ('Anti', 'PROPN'), ('-', 'ADJ'), ('obesity', 'ADJ'), ('drug', 'NOUN'), ('has', 'VERB'), ('life', 'NOUN'), ('-', 'PUNCT'), ('changing', 'VERB'), ('benefits', 'NOUN'), ('for', 'ADP'), ('arthritis', 'NOUN'), ('Researchers', 'NOUN'), ('are', 'AUX'), ('excited', 'ADJ'), ('about', 'ADP'), ('combination', 'NOUN'), ('therapies', 'NOUN'), ('such', 'ADJ'), ('as', 'ADP'), ('retatrutide', 'NOUN'), (',', 'PUNCT'), ('says', 'VERB'), ('Beverly', 'PROPN'), ('Tchang', 'PROPN'), (',', 'PUNCT'), ('an', 'DET'), ('endocrinologist', 'NOUN'), ('at', 'ADP'), ('Weill', 'PROPN'), ('Cornell', 'PROPN'), ('Medicine', 'PROPN'), ('in', 'ADP'), ('New', 'PROPN'), ('York', 'PROPN'), ('City', 'PROPN'), (',', 'PUNCT'), ('who', 'PRON'), ('notes', 'VERB'), ('that', 'SCONJ'), ('obesity', 'NOUN'), ('’s', 'PART'), ('complexity', 'NOUN'), ('makes', 'VERB'), ('targeting', 'VERB'), ('multiple', 'ADJ'), ('pathways', 'NOUN'), ('the', 'DET'), ('most', 'ADV'), ('promising', 'ADJ'), ('approach', 'NOUN'), ('.', 'PUNCT'), ('Orforglipron', 'PROPN'), (',', 'PUNCT'), ('an', 'DET'), ('oral', 'ADJ'), ('small', 'ADJ'), ('-', 'PUNCT'), ('molecule', 'NOUN'), ('drug', 'NOUN'), ('candidate', 'NOUN'), ('also', 'ADV'), ('developed', 'VERB'), ('by', 'ADP'), ('Eli', 'PROPN'), ('Lilly', 'PROPN'), (',', 'PUNCT'), ('showed', 'VERB'), ('similar', 'ADJ'), ('results', 'NOUN'), ('to', 'ADP'), ('GLP-1', 'PROPN'), ('injections', 'NOUN'), ('in', 'ADP'), ('rodents', 'NOUN'), (',', 'PUNCT'), ('and', 'CCONJ'), ('led', 'VERB'), ('to', 'ADP'), ('a', 'DET'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('of', 'ADP'), ('about', 'ADV'), ('10', 'NUM'), ('%', 'NOUN'), ('over', 'ADP'), ('26', 'NUM'), ('weeks', 'NOUN'), ('in', 'ADP'), ('people', 'NOUN'), ('with', 'ADP'), ('obesity', 'NOUN'), (',', 'PUNCT'), ('improving', 'VERB'), ('blood', 'NOUN'), ('pressure', 'NOUN'), ('and', 'CCONJ'), ('levels', 'NOUN'), ('of', 'ADP'), ('circulating', 'VERB'), ('fatty', 'ADJ'), ('molecules', 'NOUN'), ('.', 'PUNCT'), ('Like', 'ADP'), ('Ozempic', 'PROPN'), (',', 'PUNCT'), ('orforglipron', 'PROPN'), ('is', 'AUX'), ('a', 'DET'), ('GLP-1', 'PROPN'), ('receptor', 'NOUN'), ('agonist', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('whereas', 'SCONJ'), ('Ozempic', 'PROPN'), ('requires', 'VERB'), ('injection', 'NOUN'), (',', 'PUNCT'), ('orforglipron', 'PROPN'), ('comes', 'VERB'), ('as', 'ADP'), ('a', 'DET'), ('daily', 'ADJ'), ('pill', 'NOUN'), ('.', 'PUNCT'), ('Lilly', 'PROPN'), ('expects', 'VERB'), ('to', 'PART'), ('complete', 'VERB'), ('phase', 'NOUN'), ('III', 'PROPN'), ('trials', 'NOUN'), ('in', 'ADP'), ('2025', 'NUM'), (',', 'PUNCT'), ('and', 'CCONJ'), ('orforglipron', 'PROPN'), ('could', 'AUX'), ('receive', 'VERB'), ('US', 'PROPN'), ('regulatory', 'ADJ'), ('approval', 'NOUN'), ('in', 'ADP'), ('2026', 'NUM'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('Lilly', 'PROPN'), ('’s', 'PART'), ('chief', 'ADJ'), ('executive', 'NOUN'), ('Dave', 'PROPN'), ('Ricks', 'PROPN'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('The', 'DET'), ('wild', 'ADJ'), ('card', 'NOUN'), ('is', 'AUX'), ('the', 'DET'), ('oral', 'ADJ'), ('small', 'ADJ'), ('molecules', 'NOUN'), (',', 'PUNCT'), ('”', 'PUNCT'), ('says', 'VERB'), ('Randy', 'PROPN'), ('Seeley', 'PROPN'), (',', 'PUNCT'), ('an', 'DET'), ('obesity', 'NOUN'), ('specialist', 'NOUN'), ('at', 'ADP'), ('the', 'DET'), ('University', 'PROPN'), ('of', 'ADP'), ('Michigan', 'PROPN'), ('Medical', 'PROPN'), ('School', 'PROPN'), ('in', 'ADP'), ('Ann', 'PROPN'), ('Arbor', 'PROPN'), ('.', 'PUNCT'), ('Many', 'ADJ'), ('companies', 'NOUN'), ('are', 'AUX'), ('working', 'VERB'), ('on', 'ADP'), ('this', 'DET'), ('approach', 'NOUN'), (',', 'PUNCT'), ('because', 'SCONJ'), ('pills', 'NOUN'), ('might', 'AUX'), ('be', 'AUX'), ('more', 'ADV'), ('appealing', 'ADJ'), ('and', 'CCONJ'), ('cost', 'NOUN'), ('-', 'PUNCT'), ('effective', 'ADJ'), ('than', 'ADP'), ('injections', 'NOUN'), (',', 'PUNCT'), ('but', 'CCONJ'), ('progress', 'NOUN'), ('has', 'AUX'), ('been', 'AUX'), ('slower', 'ADJ'), ('than', 'SCONJ'), ('expected', 'VERB'), ('owing', 'VERB'), ('to', 'ADP'), ('dosing', 'ADJ'), ('challenges', 'NOUN'), (',', 'PUNCT'), ('he', 'PRON'), ('says', 'VERB'), ('.', 'PUNCT'), ('“', 'PUNCT'), ('If', 'SCONJ'), ('one', 'NUM'), ('of', 'ADP'), ('them', 'PRON'), ('finally', 'ADV'), ('breaks', 'VERB'), ('through', 'ADP'), (',', 'PUNCT'), ('it', 'PRON'), ('has', 'VERB'), ('the', 'DET'), ('ability', 'NOUN'), ('to', 'PART'), ('alter', 'VERB'), ('the', 'DET'), ('landscape', 'NOUN'), ('pretty', 'ADV'), ('considerably', 'ADV'), ('.', 'PUNCT'), ('”', 'PUNCT'), ('Biopharmaceutical', 'ADJ'), ('company', 'NOUN'), ('Amgen', 'PROPN'), ('in', 'ADP'), ('Thousand', 'PROPN'), ('Oaks', 'PROPN'), (',', 'PUNCT'), ('California', 'PROPN'), (',', 'PUNCT'), ('is', 'AUX'), ('planning', 'VERB'), ('a', 'DET'), ('phase', 'NOUN'), ('III', 'PROPN'), ('trial', 'NOUN'), ('of', 'ADP'), ('its', 'PRON'), ('drug', 'NOUN'), ('candidate', 'NOUN'), ('MariTide', 'PROPN'), (',', 'PUNCT'), ('which', 'PRON'), ('activates', 'VERB'), ('GLP-1', 'PROPN'), ('receptors', 'NOUN'), ('while', 'SCONJ'), ('reducing', 'VERB'), ('GIP', 'PROPN'), ('’s', 'PART'), ('activity', 'NOUN'), ('.', 'PUNCT'), ('The', 'DET'), ('medication', 'NOUN'), ('can', 'AUX'), ('be', 'AUX'), ('taken', 'VERB'), ('monthly', 'ADV'), ('by', 'ADP'), ('injection', 'NOUN'), ('and', 'CCONJ'), ('resulted', 'VERB'), ('in', 'ADP'), ('an', 'DET'), ('average', 'ADJ'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('of', 'ADP'), ('up', 'ADP'), ('to', 'PART'), ('20', 'NUM'), ('%', 'NOUN'), ('over', 'ADP'), ('52', 'NUM'), ('weeks', 'NOUN'), (',', 'PUNCT'), ('according', 'VERB'), ('to', 'ADP'), ('data', 'NOUN'), ('released', 'VERB'), ('by', 'ADP'), ('the', 'DET'), ('company', 'NOUN'), ('.', 'PUNCT'), ('Unlike', 'ADP'), ('other', 'ADJ'), ('treatments', 'NOUN'), (',', 'PUNCT'), ('MariTide', 'PROPN'), ('has', 'AUX'), ('shown', 'VERB'), ('the', 'DET'), ('ability', 'NOUN'), ('to', 'PART'), ('maintain', 'VERB'), ('weight', 'NOUN'), ('loss', 'NOUN'), ('for', 'ADP'), ('several', 'ADJ'), ('months', 'NOUN'), ('after', 'ADP'), ('the', 'DET'), ('last', 'ADJ'), ('dose', 'NOUN'), ('.', 'PUNCT'), ('When', 'SCONJ'), ('people', 'NOUN'), ('stop', 'VERB'), ('taking', 'VERB'), ('semaglutide', 'NOUN'), ('or', 'CCONJ'), ('tirzepatide', 'NOUN'), (',', 'PUNCT'), ('they', 'PRON'), ('tend', 'VERB'), ('to', 'PART'), ('regain', 'VERB'), ('weight', 'NOUN'), ('quickly', 'ADV'), (',', 'PUNCT'), ('but', 'CCONJ'), ('that', 'PRON'), ('does', 'AUX'), ('n’t', 'PART'), ('seem', 'VERB'), ('to', 'PART'), ('happen', 'VERB'), ('with', 'ADP'), ('MariTide', 'PROPN'), (',', 'PUNCT'), ('which', 'PRON'), ('might', 'AUX'), ('encourage', 'VERB'), ('more', 'ADJ'), ('people', 'NOUN'), ('to', 'PART'), ('have', 'VERB'), ('the', 'DET'), ('treatment', 'NOUN'), (',', 'PUNCT'), ('says', 'VERB'), ('Seeley', 'PROPN'), (',', 'PUNCT'), ('who', 'PRON'), ('consults', 'VERB'), ('for', 'ADP'), ('and', 'CCONJ'), ('receives', 'VERB'), ('funding', 'NOUN'), ('from', 'ADP'), ('Amgen', 'PROPN'), ('and', 'CCONJ'), ('other', 'ADJ'), ('companies', 'NOUN'), ('developing', 'VERB'), ('obesity', 'NOUN'), ('drugs', 'NOUN'), ('.', 'PUNCT'), ('or', 'CCONJ'), ('Nature', 'NOUN'), ('638', 'NUM'), (',', 'PUNCT'), ('591', 'NUM'), ('-', 'SYM'), ('592', 'NUM'), ('(', 'PUNCT'), ('2025', 'NUM'), (')', 'PUNCT'), ('doi', 'PROPN'), (':', 'PUNCT'), ('https://doi.org/10.1038/d41586-025-00376-w', 'PROPN'), ('Reprints', 'NOUN'), ('and', 'CCONJ'), ('permissions', 'NOUN'), ('Dozens', 'NOUN'), ('of', 'ADP'), ('new', 'ADJ'), ('obesity', 'NOUN'), ('drugs', 'NOUN'), ('are', 'AUX'), ('coming', 'VERB'), (':', 'PUNCT'), ('these', 'PRON'), ('are', 'AUX'), ('the', 'DET'), ('ones', 'NOUN'), ('to', 'PART'), ('watch', 'VERB'), ('News', 'PROPN'), ('Feature', 'PROPN'), ('12', 'NUM'), ('FEB', 'PROPN'), ('25', 'NUM'), ('A', 'DET'), ('comprehensive', 'ADJ'), ('spatio', 'NOUN'), ('-', 'PUNCT'), ('cellular', 'ADJ'), ('map', 'NOUN'), ('of', 'ADP'), ('the', 'DET'), ('human', 'ADJ'), ('hypothalamus', 'ADJ'), ('Article', 'NOUN'), ('05', 'NUM'), ('FEB', 'PROPN'), ('25', 'NUM'), ('Obesity', 'PROPN'), ('drugs', 'NOUN'), (':', 'PUNCT'), ('huge', 'ADJ'), ('study', 'NOUN'), ('identifies', 'VERB'), ('new', 'ADJ'), ('health', 'NOUN'), ('risks', 'NOUN'), ('News', 'PROPN'), ('20', 'NUM'), ('JAN', 'PROPN'), ('25', 'NUM'), ('Rare', 'ADJ'), ('genetic', 'ADJ'), ('disorder', 'NOUN'), ('treated', 'VERB'), ('in', 'ADP'), ('womb', 'NOUN'), ('for', 'ADP'), ('the', 'DET'), ('first', 'ADJ'), ('time', 'NOUN'), ('News', 'PROPN'), ('20', 'NUM'), ('FEB', 'PROPN'), ('25', 'NUM'), ('Plasmodium', 'PROPN'), ('blood', 'NOUN'), ('stage', 'NOUN'), ('development', 'NOUN'), ('requires', 'VERB'), ('the', 'DET'), ('chromatin', 'ADJ'), ('remodeller', 'NOUN'), ('Snf2L', 'PROPN'), ('Article', 'NOUN'), ('19', 'NUM'), ('FEB', 'PROPN'), ('25', 'NUM'), ('Human', 'PROPN'), ('-', 'PUNCT'), ('correlated', 'VERB'), ('genetic', 'ADJ'), ('models', 'NOUN'), ('identify', 'VERB'), ('precision', 'NOUN'), ('therapy', 'NOUN'), ('for', 'ADP'), ('liver', 'NOUN'), ('cancer', 'NOUN'), ('Article', 'NOUN'), ('19', 'NUM'), ('FEB', 'PROPN'), ('25', 'NUM'), ('The', 'DET'), ('School', 'PROPN'), ('of', 'ADP'), ('Science', 'PROPN'), ('and', 'CCONJ'), ('Engineering', 'PROPN'), ('(', 'PUNCT'), ('SSE', 'PROPN'), (')', 'PUNCT'), ('at', 'ADP'), ('The', 'DET'), ('Chinese', 'PROPN'), ('University', 'PROPN'), ('of', 'ADP'), ('Hong', 'PROPN'), ('Kong', 'PROPN'), (',', 'PUNCT'), ('Shenzhen', 'PROPN'), ('(', 'PUNCT'), ('CUHK', 'PROPN'), ('-', 'PUNCT'), ('Shenzhen', 'PROPN'), (')', 'PUNCT'), ('sincerely', 'ADV'), ('invites', 'VERB'), ('applications', 'NOUN'), ('for', 'ADP'), ('mul', 'PROPN'), ('...', 'PUNCT'), ('Shenzhen', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('The', 'DET'), ('Chinese', 'PROPN'), ('University', 'PROPN'), ('of', 'ADP'), ('Hong', 'PROPN'), ('Kong', 'PROPN'), (',', 'PUNCT'), ('Shenzhen', 'PROPN'), ('(', 'PUNCT'), ('CUHK', 'PROPN'), ('Shenzhen', 'PROPN'), (')', 'PUNCT'), ('The', 'DET'), ('School', 'PROPN'), ('of', 'ADP'), ('Science', 'PROPN'), ('and', 'CCONJ'), ('Engineering', 'PROPN'), ('(', 'PUNCT'), ('SSE', 'PROPN'), (')', 'PUNCT'), ('at', 'ADP'), ('The', 'DET'), ('Chinese', 'PROPN'), ('University', 'PROPN'), ('of', 'ADP'), ('Hong', 'PROPN'), ('Kong', 'PROPN'), (',', 'PUNCT'), ('Shenzhen', 'PROPN'), ('(', 'PUNCT'), ('CUHK', 'PROPN'), ('-', 'PUNCT'), ('Shenzhen', 'PROPN'), (')', 'PUNCT'), ('sincerely', 'ADV'), ('invites', 'VERB'), ('applications', 'NOUN'), ('for', 'ADP'), ('mul', 'PROPN'), ('...', 'PUNCT'), ('Shenzhen', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('The', 'DET'), ('Chinese', 'PROPN'), ('University', 'PROPN'), ('of', 'ADP'), ('Hong', 'PROPN'), ('Kong', 'PROPN'), (',', 'PUNCT'), ('Shenzhen', 'PROPN'), ('(', 'PUNCT'), ('CUHK', 'PROPN'), ('Shenzhen', 'PROPN'), (')', 'PUNCT'), ('We', 'PRON'), ('seek', 'VERB'), ('outstanding', 'ADJ'), ('applicants', 'NOUN'), ('for', 'ADP'), ('full', 'ADJ'), ('-', 'PUNCT'), ('time', 'NOUN'), ('tenure', 'NOUN'), ('-', 'PUNCT'), ('track', 'NOUN'), ('/', 'SYM'), ('tenured', 'VERB'), ('faculty', 'NOUN'), ('positions', 'NOUN'), ('.', 'PUNCT'), ('Positions', 'NOUN'), ('are', 'AUX'), ('available', 'ADJ'), ('for', 'ADP'), ('both', 'CCONJ'), ('junior', 'ADJ'), ('and', 'CCONJ'), ('senior', 'ADJ'), ('-', 'PUNCT'), ('level', 'NOUN'), ('.', 'PUNCT'), ('Shenzhen', 'PROPN'), (',', 'PUNCT'), ('Guangdong', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('Southern', 'PROPN'), ('University', 'PROPN'), ('of', 'ADP'), ('Science', 'PROPN'), ('and', 'CCONJ'), ('Technology', 'PROPN'), ('(', 'PUNCT'), ('Biomedical', 'PROPN'), ('Engineering', 'PROPN'), (')', 'PUNCT'), ('Qiushi', 'PROPN'), ('Chair', 'PROPN'), ('Professor', 'PROPN'), (';', 'PUNCT'), ('Qiushi', 'PROPN'), ('Distinguished', 'PROPN'), ('Scholar', 'PROPN'), (';', 'PUNCT'), ('ZJU', 'PROPN'), ('100', 'NUM'), ('Young', 'PROPN'), ('Researcher', 'PROPN'), (';', 'PUNCT'), ('Distinguished', 'PROPN'), ('researcher', 'NOUN'), ('No', 'NOUN'), ('.', 'NOUN'), ('3', 'NUM'), (',', 'PUNCT'), ('Qingchun', 'PROPN'), ('East', 'PROPN'), ('Road', 'PROPN'), (',', 'PUNCT'), ('Hangzhou', 'PROPN'), (',', 'PUNCT'), ('Zhejiang', 'PROPN'), ('(', 'PUNCT'), ('CN', 'PROPN'), (')', 'PUNCT'), ('Sir', 'PROPN'), ('Run', 'PROPN'), ('Run', 'PROPN'), ('Shaw', 'PROPN'), ('Hospital', 'PROPN'), ('Affiliated', 'VERB'), ('with', 'ADP'), ('Zhejiang', 'PROPN'), ('University', 'PROPN'), ('School', 'PROPN'), ('of', 'ADP'), ('Medicine', 'PROPN'), ('SLS', 'PROPN'), ('invites', 'VERB'), ('applications', 'NOUN'), ('for', 'ADP'), ('multiple', 'ADJ'), ('tenure', 'NOUN'), ('-', 'PUNCT'), ('track', 'NOUN'), ('/', 'SYM'), ('tenured', 'VERB'), ('faculty', 'NOUN'), ('positions', 'NOUN'), ('at', 'ADP'), ('all', 'DET'), ('academic', 'ADJ'), ('ranks', 'NOUN'), ('.', 'PUNCT'), ('Hangzhou', 'PROPN'), (',', 'PUNCT'), ('Zhejiang', 'PROPN'), (',', 'PUNCT'), ('China', 'PROPN'), ('School', 'PROPN'), ('of', 'ADP'), ('Life', 'PROPN'), ('Sciences', 'PROPN'), (',', 'PUNCT'), ('Westlake', 'PROPN'), ('University', 'PROPN')]","[('PubMed', 'ORG'), ('Zepbound', 'GPE'), ('Shelby Knowles/Bloomberg', 'PERSON'), ('another year', 'DATE'), ('every week', 'DATE'), ('Daniel Drucker', 'PERSON'), ('the University of Toronto', 'ORG'), ('Canada', 'GPE'), ('BMI', 'ORG'), ('BMI', 'ORG'), ('Ozempic', 'ORG'), ('Wegovy', 'ORG'), ('weekly', 'DATE'), ('2025', 'DATE'), ('Mounjaro', 'PERSON'), ('Zepbound', 'PERSON'), ('GLP-1', 'PERSON'), ('GIP', 'ORG'), ('November', 'DATE'), ('up to 20%', 'PERCENT'), ('72 weeks', 'DATE'), ('68 weeks', 'DATE'), ('up to 15%', 'PERCENT'), ('One', 'CARDINAL'), ('2025', 'DATE'), ('Retatrutide', 'ORG'), ('GLP-1', 'ORG'), ('GIP', 'ORG'), ('glucagon', 'ORG'), ('Eli Lilly', 'ORG'), ('Indianapolis', 'GPE'), ('Indiana', 'GPE'), ('24%', 'PERCENT'), ('11 months', 'DATE'), ('2026', 'DATE'), ('Beverly Tchang', 'PERSON'), ('Weill Cornell Medicine', 'ORG'), ('New York City', 'GPE'), ('Orforglipron', 'ORG'), ('Eli Lilly', 'ORG'), ('about 10%', 'PERCENT'), ('26 weeks', 'DATE'), ('orforglipron', 'ORG'), ('GLP-1', 'ORG'), ('daily', 'DATE'), ('Lilly', 'ORG'), ('2025', 'DATE'), ('orforglipron', 'ORG'), ('US', 'GPE'), ('2026', 'DATE'), ('Lilly', 'ORG'), ('Dave Ricks', 'PERSON'), ('Randy Seeley', 'PERSON'), ('the University of Michigan Medical School', 'ORG'), ('Ann Arbor', 'GPE'), ('one', 'CARDINAL'), ('Amgen', 'ORG'), ('Thousand Oaks', 'GPE'), ('California', 'GPE'), ('MariTide', 'PRODUCT'), ('GLP-1', 'ORG'), ('GIP', 'ORG'), ('monthly', 'DATE'), ('up to 20%', 'PERCENT'), ('52 weeks', 'DATE'), ('MariTide', 'ORG'), ('several months', 'DATE'), ('MariTide', 'ORG'), ('Seeley', 'PERSON'), ('Amgen', 'ORG'), ('638', 'CARDINAL'), ('591', 'CARDINAL'), ('2025', 'DATE'), ('Dozens', 'CARDINAL'), ('News Feature', 'ORG'), ('12', 'CARDINAL'), ('Article 05 FEB 25 Obesity', 'LAW'), ('first', 'ORDINAL'), ('20', 'CARDINAL'), ('Plasmodium', 'ORG'), ('Article 19 FEB 25 Human', 'LAW'), ('Article 19', 'LAW'), ('The School of Science and Engineering', 'ORG'), ('SSE', 'ORG'), ('The Chinese University of Hong Kong', 'ORG'), ('Shenzhen', 'GPE'), ('Shenzhen', 'GPE'), ('China', 'GPE'), ('The Chinese University of Hong Kong', 'ORG'), ('Shenzhen', 'GPE'), ('The School of Science and Engineering', 'ORG'), ('SSE', 'ORG'), ('The Chinese University of Hong Kong', 'ORG'), ('Shenzhen', 'GPE'), ('Shenzhen', 'GPE'), ('China', 'GPE'), ('The Chinese University of Hong Kong', 'ORG'), ('Shenzhen', 'GPE'), ('Shenzhen', 'GPE'), ('Guangdong', 'GPE'), ('China Southern University of Science and Technology (Biomedical Engineering', 'ORG'), ('Qiushi Chair', 'ORG'), ('Qiushi', 'ORG'), ('100', 'CARDINAL'), ('3', 'CARDINAL'), ('Qingchun', 'GPE'), ('East Road', 'GPE'), ('Hangzhou', 'GPE'), ('Zhejiang', 'GPE'), ('Run Run Shaw Hospital', 'PERSON'), ('Zhejiang University School of Medicine SLS', 'ORG'), ('Hangzhou', 'GPE'), ('Zhejiang', 'GPE'), ('China School of Life Sciences, Westlake University', 'ORG')]","['PubMed', 'Zepbound', 'Shelby Knowles/Bloomberg', 'another year', 'every week', 'Daniel Drucker', 'the University of Toronto', 'Canada', 'BMI', 'BMI', 'Ozempic', 'Wegovy', 'weekly', '2025', 'Mounjaro', 'Zepbound', 'GLP-1', 'GIP', 'November', 'up to 20%', '72 weeks', '68 weeks', 'up to 15%', 'One', '2025', 'Retatrutide', 'GLP-1', 'GIP', 'glucagon', 'Eli Lilly', 'Indianapolis', 'Indiana', '24%', '11 months', '2026', 'Beverly Tchang', 'Weill Cornell Medicine', 'New York City', 'Orforglipron', 'Eli Lilly', 'about 10%', '26 weeks', 'orforglipron', 'GLP-1', 'daily', 'Lilly', '2025', 'orforglipron', 'US', '2026', 'Lilly', 'Dave Ricks', 'Randy Seeley', 'the University of Michigan Medical School', 'Ann Arbor', 'one', 'Amgen', 'Thousand Oaks', 'California', 'MariTide', 'GLP-1', 'GIP', 'monthly', 'up to 20%', '52 weeks', 'MariTide', 'several months', 'MariTide', 'Seeley', 'Amgen', '638', '591', '2025', 'Dozens', 'News Feature', '12', 'Article 05 FEB 25 Obesity', 'first', '20', 'Plasmodium', 'Article 19 FEB 25 Human', 'Article 19', 'The School of Science and Engineering', 'SSE', 'The Chinese University of Hong Kong', 'Shenzhen', 'Shenzhen', 'China', 'The Chinese University of Hong Kong', 'Shenzhen', 'The School of Science and Engineering', 'SSE', 'The Chinese University of Hong Kong', 'Shenzhen', 'Shenzhen', 'China', 'The Chinese University of Hong Kong', 'Shenzhen', 'Shenzhen', 'Guangdong', 'China Southern University of Science and Technology (Biomedical Engineering', 'Qiushi Chair', 'Qiushi', '100', '3', 'Qingchun', 'East Road', 'Hangzhou', 'Zhejiang', 'Run Run Shaw Hospital', 'Zhejiang University School of Medicine SLS', 'Hangzhou', 'Zhejiang', 'China School of Life Sciences, Westlake University']","['PubMed', 'Zepbound', 'Shelby Knowles/Bloomberg', 'another year', 'every week', 'Daniel Drucker', 'the University of Toronto', 'Canada', 'BMI', 'BMI', 'Ozempic', 'Wegovy', 'weekly', '2025', 'Mounjaro', 'Zepbound', 'GLP-1', 'GIP', 'November', 'up to 20%', '72 weeks', '68 weeks', 'up to 15%', 'One', '2025', 'Retatrutide', 'GLP-1', 'GIP', 'glucagon', 'Eli Lilly', 'Indianapolis', 'Indian', '24%', '11 months', '2026', 'Beverly Tchang', 'Weill Cornell Medicine', 'New York City', 'Orforglipron', 'Eli Lilly', 'about 10', '26 weeks', 'Orforglipron', 'GLP-1', 'daily', 'Lilly', '2025', 'Orforglipron', 'US', '2026', 'Lilly', 'Dave Ricks', 'Randy Seeley', 'the University of Michigan Medical School', 'Ann Arbor', 'One', 'Amgen', 'Thousand Oaks', 'California', 'MariTide', 'GLP-1', 'GIP', 'monthly', 'up to 20%', '52 weeks', 'MariTide', 'several months', 'MariTide', 'Seeley', 'Amgen', '638', '591', '2025', 'Dozens', 'News Feature', '12', 'Article 05 FEB 25 Obesity', 'first', '20', 'Plasmodium', 'Article 19 FEB 25 Human', 'Article 19', 'The School of Science and Engineering', 'SSE', 'The Chinese University of Hong Kong', 'Shenzhen', 'Shenzhen', 'China', 'The Chinese University of Hong Kong', 'Shenzhen', 'The School of Science and Engineering', 'SSE', 'The Chinese University of Hong Kong', 'Shenzhen', 'Shenzhen', 'China', 'The Chinese University of Hong Kong', 'Shenzhen', 'Shenzhen', 'Guangdong', 'China Southern University of Science and Technology (Biomedical Engineering', 'Qiushi Chair', 'Qiushi', '100', '3', 'Qingchun', 'East Road', 'Hangzhou', 'Zhejiang', 'Run Run Shaw Hospital', 'Zhejiang University School of Medicine SLS', 'Hangzhou', 'Zhejiang', 'China School of Life Sciences, Westlake University']"
